0001193125-24-081994.txt : 20240329 0001193125-24-081994.hdr.sgml : 20240329 20240329151402 ACCESSION NUMBER: 0001193125-24-081994 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 106 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vincerx Pharma, Inc. CENTRAL INDEX KEY: 0001796129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 833197402 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39244 FILM NUMBER: 24803883 BUSINESS ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-800-6676 MAIL ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: Vincera Pharma, Inc. DATE OF NAME CHANGE: 20201223 FORMER COMPANY: FORMER CONFORMED NAME: LifeSci Acquisition Corp. DATE OF NAME CHANGE: 20191206 10-K 1 d739497d10k.htm 10-K 10-K
Table of Contents
falseFY0001796129CA 0001796129 2023-12-31 0001796129 2022-12-31 0001796129 2022-01-01 2022-12-31 0001796129 2023-01-01 2023-12-31 0001796129 2021-01-01 2021-01-05 0001796129 2020-12-23 2020-12-23 0001796129 2023-01-31 0001796129 2021-01-01 2021-12-31 0001796129 2023-06-30 0001796129 2024-03-26 0001796129 2020-12-31 0001796129 2022-06-04 2022-06-04 0001796129 2022-07-01 2022-07-31 0001796129 2023-10-01 2023-12-31 0001796129 2021-12-31 0001796129 srt:RestatementAdjustmentMember 2022-04-01 2022-06-30 0001796129 srt:RestatementAdjustmentMember 2023-07-01 2023-09-30 0001796129 srt:RestatementAdjustmentMember 2023-04-01 2023-06-30 0001796129 srt:RestatementAdjustmentMember 2023-01-01 2023-03-31 0001796129 srt:RestatementAdjustmentMember 2022-10-01 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-07-01 2022-09-30 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceTwoMember 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceOneMember 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceThreeMember 2023-12-31 0001796129 srt:MaximumMember 2023-12-31 0001796129 srt:MinimumMember 2023-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-12-31 0001796129 vinc:PrivateWarrantMember 2023-12-31 0001796129 us-gaap:PrivatePlacementMember 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:LifesciHoldingsLlcMember 2023-12-31 0001796129 vinc:PrivateWarrantMember us-gaap:CommonStockMember 2023-12-31 0001796129 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel2Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel1Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001796129 us-gaap:DomesticCountryMember 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001796129 us-gaap:ComputerEquipmentMember 2023-12-31 0001796129 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001796129 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001796129 us-gaap:OtherCurrentAssetsMember 2023-12-31 0001796129 us-gaap:DebtSecuritiesMember vinc:MarketableSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001796129 us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0001796129 us-gaap:ComputerEquipmentMember srt:MinimumMember 2023-12-31 0001796129 us-gaap:ComputerEquipmentMember srt:MaximumMember 2023-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001796129 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001796129 vinc:OptionOutstandingMember 2022-01-01 2022-12-31 0001796129 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestructuringChargesMember 2022-01-01 2022-12-31 0001796129 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001796129 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-01 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001796129 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2022-01-01 2022-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-12-31 0001796129 vinc:PrivateWarrantMember 2022-01-01 2022-12-31 0001796129 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-01-01 2022-12-31 0001796129 srt:MaximumMember 2022-12-31 2022-12-31 0001796129 srt:MinimumMember 2022-12-31 2022-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2021-05-31 0001796129 us-gaap:RestrictedStockMember 2020-05-31 0001796129 us-gaap:RestrictedStockMember vinc:VinceraPharmaMember 2020-05-31 2020-05-31 0001796129 us-gaap:RestrictedStockMember 2020-05-31 2020-05-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2020-05-31 2020-05-31 0001796129 us-gaap:RestrictedStockMember 2019-07-31 2019-07-31 0001796129 us-gaap:RestrictedStockMember 2019-07-01 2019-08-31 0001796129 vinc:PrivateWarrantMember 2021-12-31 0001796129 vinc:PublicWarrantMember 2021-12-31 0001796129 vinc:PrivateWarrantMember 2021-01-01 2021-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001796129 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceThreeMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceTwoMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceOneMember 2023-01-01 2023-12-31 0001796129 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001796129 vinc:OptionOutstandingMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestructuringChargesMember 2023-01-01 2023-12-31 0001796129 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001796129 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001796129 vinc:PrivateWarrantMember 2023-01-01 2023-12-31 0001796129 vinc:PublicWarrantMember 2023-01-01 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-01-01 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-01-01 2023-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001796129 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2023-01-01 2023-12-31 0001796129 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001796129 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2023-01-01 2023-12-31 0001796129 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2023-01-01 2023-12-31 0001796129 us-gaap:OtherAssetsMember 2023-01-01 2023-12-31 0001796129 vinc:CurrentAssetMember 2023-01-01 2023-12-31 0001796129 vinc:ShareBasedPaymentsMember 2023-01-01 2023-12-31 0001796129 vinc:TwentyThousandTwentyPlanMember 2023-01-31 0001796129 vinc:PublicWarrantMember 2023-01-31 0001796129 vinc:PrivateWarrantMember 2023-01-31 0001796129 vinc:PrivateWarrantMember vinc:LifesciHoldingsLlcMember 2023-01-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-01-31 0001796129 vinc:PrivateWarrantMember us-gaap:CommonStockMember 2023-01-31 0001796129 us-gaap:OtherCurrentAssetsMember 2023-01-31 0001796129 vinc:PublicWarrantMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001796129 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001796129 us-gaap:ComputerEquipmentMember 2022-12-31 0001796129 us-gaap:OtherCurrentAssetsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-12-31 0001796129 us-gaap:RetainedEarningsMember 2021-12-31 0001796129 us-gaap:CommonStockMember 2021-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001796129 us-gaap:RestrictedStockMember 2021-12-31 0001796129 us-gaap:RestrictedStockMember 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001796129 us-gaap:RetainedEarningsMember 2022-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001796129 us-gaap:CommonStockMember 2022-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2021-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2022-12-31 0001796129 us-gaap:CommonStockMember 2023-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001796129 us-gaap:RetainedEarningsMember 2023-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 iso4217:USD xbrli:shares utr:Day xbrli:pure utr:Year iso4217:EUR utr:Month iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-K
 
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
 
  
 
 
to
 
 
  
 
Commission file number
001-39244
 
 
Vincerx Pharma, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 
 
Delaware
  
83-3197402
(State or Other Jurisdiction of
Incorporation or Organization)
  
(I.R.S. Employer
Identification No.)
260 Sheridan Avenue, Suite 400
Palo Alto,
CA
  
94306
(Address of principal executive offices)
  
(Zip Code)
Registrant’s telephone number, including area code: (650)
800-6676
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
  
VINC
  
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
None.
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large Accelerated Filer   ☐    Accelerated Filer   ☐
Non-Accelerated Filer
   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b). ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). Yes ☐ No ☒
The aggregate market value of common stock held by
non-affiliates
(based on the closing sale price on The Nasdaq Capital Market on June 30, 2023) was approximately $
23.0
million.
As of March
26
, 2024, there were 21,413,389 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120 days of December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form
10-K.
 
 
 

Table of Contents

TABLE OF CONTENTS

 

Forward-Looking Statements

     1  

Summary Risk Factors

     4  

PART I

     6  

ITEM 1.

  

Business

      6  

ITEM 1A.

  

Risk Factors

      31  

ITEM 1B.

  

Unresolved Staff Comments

      66  

ITEM 1C.

  

Cybersecurity

      66  

ITEM 2.

  

Properties

      68  

ITEM 3.

  

Legal Proceedings

      68  

ITEM 4.

  

Mine Safety Disclosures

      68  

PART II

     69  

ITEM 5.

  

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

      69  

ITEM 6.

  

[Reserved]

      69  

ITEM 7.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

      69  

ITEM 7A.

  

Quantitative and Qualitative Disclosures About Market Risk

      80  

ITEM 8.

  

Financial Statements and Supplementary Data

      81  

ITEM 9.

  

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

      108  

ITEM 9A.

  

Controls and Procedures

      108  

ITEM 9B.

  

Other Information

      109  

ITEM 9C.

  

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

      109  

PART III

     110  

ITEM 10.

  

Directors, Executive Officers and Corporate Governance

      110  

ITEM 11.

  

Executive Compensation

      110  

ITEM 12.

  

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

      110  

ITEM 13.

  

Certain Relationships and Related Transactions, and Director Independence

      111  

ITEM 14.

  

Principal Accountant Fees and Services

      111  

PART IV

     112  

ITEM 15.

  

Exhibit and Financial Statement Schedules

      112  

ITEM 16.

  

Form 10-K Summary

      114  

SIGNATURES

     115  

 

i

Table of Contents

Forward-Looking Statements

This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. When used in this report, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “forecast,” “goal,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “seeks,” “suggests,” “scheduled,” “target,” or “will,” and similar expressions are intended to identify forward-looking statements, and include but are not limited to:

 

  •  

our future financial and business performance;

 

  •  

strategic plans for our business and product candidates;

 

  •  

the attributes of, and our ability to develop or commercialize, our product candidates;

 

  •  

the strength of our pipeline, product candidates, VersAptx platform and management team;

 

  •  

the expected results and timing of clinical trials and nonclinical studies;

 

  •  

our ability to comply with the terms of the Bayer License Agreement;

 

  •  

our future capital requirements and sufficiency of available cash, including our expected cash runway, timing of those requirements, and sources and uses of cash;

 

  •  

our ability to obtain funding for our operations and continue as a going concern;

 

  •  

developments and expectations relating to our competitors and industry;

 

  •  

our expectations regarding our ability to obtain, develop, and maintain intellectual property protection and not infringe on the rights of others;

 

  •  

our ability to retain key scientific or management personnel;

 

  •  

our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;

 

  •  

the outcome of any known and unknown litigation and regulatory proceedings;

 

  •  

our business, expansion plans, and opportunities; and

 

  •  

changes in applicable laws or regulations.

These statements are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statements, including the following:

 

  •  

risks associated with preclinical or clinical development and trials, including clinical trials conducted prior to our in-licensing;

 

  •  

risks related to the rollout of our business and the timing of expected business and product development milestones;

 

  •  

changes in the assumptions underlying our expectations regarding our future business or business model;

 

  •  

our ability to develop, manufacture, and commercialize product candidates;

 

  •  

our ability to raise capital and continue as a going concern;

 

  •  

general economic, financial, legal, political, and business conditions and changes in domestic and foreign markets;

 

  •  

changes in applicable laws or regulations, including the impact of the Inflation Reduction Act of 2022 and potential legislation restricting the use of foreign third-party service providers;

 

1

Table of Contents
  •  

the impact of natural disasters, including climate change, and the impact of health pandemics and epidemics on our business;

 

  •  

the size and growth potential of the markets for our products, and our ability to compete in those markets;

 

  •  

market acceptance of our planned products;

 

  •  

the effects of other economic, business, or competitive factors, including the impact of inflation and the wars in Ukraine and Israel; and

 

  •  

other risks and uncertainties set forth in this report in the section entitled “Risk Factors.”

Given these and other risks and uncertainties described in this report, you should not place undue reliance on these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expected. These risks and uncertainties include, but are not limited to, those risks discussed in Item 1A of this report. These forward-looking statements made by us in this report speak only as of the date of this report. Except as required under the federal securities laws and rules and regulations of the Securities and Exchange Commission (the “SEC”), we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our definitive proxy statement for the 2024 Annual Meeting of Stockholders, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC.

You should read this report completely and with the understanding that our actual future results, levels of activity, and performance as well as other events and circumstances may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Frequently Used Terms

Unless the context indicates otherwise, references in this report to the “Company,” “Vincerx,” “we,” “us,” “our,” and similar terms refer to Vincerx Pharma, Inc. (f/k/a Vincera Pharma, Inc. f/k/a LifeSci Acquisition Corp.) and its consolidated subsidiaries. References to “LSAC” refer to our predecessor company prior to the consummation of the Business Combination (as defined below). Additional terms frequently used in this report include the following:

 

  •  

“ADC” means antibody-drug conjugate.

 

  •  

“Affordable Care Act” means the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act.

 

  •  

“AML” means acute myeloid leukemia.

 

  •  

“ANDA” means an abbreviated new drug application.

 

  •  

“Bayer License Agreement” means that certain License Agreement, dated October 7, 2020, by and among Legacy Vincera Pharma, Bayer Aktiengesellschaft, and Bayer Intellectual Property GmbH.

 

  •  

“BLA” means a biologics license application.

 

  •  

“BPCIA” means the Biologics Price Competition and Innovation Act of 2009.

 

  •  

“Business Combination” means the Merger and the other transactions described in the Merger Agreement.

 

2

Table of Contents
  •  

“Bylaws” means our amended and restated bylaws.

 

  •  

“CDK” means cyclin-dependent kinase.

 

  •  

“CDX” means cell-derived xenograft.

 

  •  

“Certificate of Incorporation” means our second amended and restated certificate of incorporation, as amended.

 

  •  

“cGMP” means current Good Manufacturing Practice.

 

  •  

“CLL” means chronic lymphocytic leukemia.

 

  •  

“common stock” means our common stock, $0.0001 par value per share.

 

  •  

“CPT” means camptothecin.

 

  •  

“DLBCL” means diffuse large B-cell lymphoma.

 

  •  

“DH-DLBCL” means double-hit DLBCL (i.e., DLBCL characterized by translocations of MYC and BCL-2).

 

  •  

“Earnout Shares” means certain rights to common stock after the closing of the Business Combination that Legacy Holders may be entitled to receive pursuant to the Merger Agreement.

 

  •  

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

  •  

“FDA” means the U.S. Food and Drug Administration.

 

  •  

“FDCA” means the Federal Food, Drug and Cosmetic Act.

 

  •  

“GAAP” means accounting principles generally accepted in the United States of America.

 

  •  

“HER2” means human epidermal growth factor receptor 2.

 

  •  

“IL3RA” means Interleukin 3 receptor subunit alpha.

 

  •  

“HIPAA” means the Health Insurance Portability and Accountability Act.

 

  •  

“IND” means an investigational new drug application.

 

  •  

“JOBS Act” means the Jumpstart Our Business Startups Act of 2012.

 

  •  

“KSPi” means kinesin spindle protein inhibitor.

 

  •  

“Legacy Holders” means the stockholders of Legacy Vincera Pharma immediately prior to the Business Combination.

 

  •  

“Legacy Vincera Pharma” means Vincera Pharma, Inc. prior to the consummation of the Business Combination, which changed its name to VNRX Corp. following the Business Combination.

 

  •  

“Legacy Vincera Pharma Common Stock” means Legacy Vincera Pharma common stock, par value $0.0001 per share.

 

  •  

“MCL” means mantle cell lymphoma.

 

  •  

“MCL1” means a protein coding gene.

 

  •  

“Merger” means the merger of Merger Sub with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving as the surviving company and as a wholly-owned subsidiary of LSAC, which occurred on December 23, 2020.

 

  •  

“Merger Agreement” means that certain Merger Agreement, dated September 25, 2020, by and among LSAC, Merger Sub, Legacy Vincera Pharma and Raquel E. Izumi, as the representative of the Legacy Holders.

 

  •  

“Merger Sub” means LifeSci Acquisition Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LSAC at the time of the Business Combination.

 

3

Table of Contents
  •  

“MYC” means a family of regulator genes and proto-oncogenes that code for transcription factors.

 

  •  

“NDA” means a new drug application.

 

  •  

“public warrants” means warrants originally issued in the initial public offering of LSAC, which were redeemed in April 2021.

 

  •  

“private warrants” means the warrants issued simultaneously with the closing of the initial public offering of LSAC in a private placement to LifeSci Holdings LLC and Rosedale Park, LLC and the warrants issued pursuant to Section 8.6 of the Merger Agreement.

 

  •  

“P-TEFb/CDK9” means positive transcription elongation factor beta/cyclin-dependent kinase 9.

 

  •  

“Securities Act” means the Securities Act of 1933, as amended.

 

  •  

“SMDC” means small molecule drug conjugate.

 

  •  

“USPTO” means the United States Patent and Trademark Office.

 

  •  

“Warrant Agreement” means that certain Warrant Agreement, dated March 5, 2020, between LSAC and the Continental Stock Transfer & Trust Company.

Vincerx®, Vincerx Pharma®, the Vincerx Wings logo design, CellTrapper®, and VersAptx™ are our trademarks or registered trademarks. This report also contains trademarks and trade names that are the property of their respective owners.

Summary Risk Factors

Our business is subject to numerous risks and uncertainties that could affect our ability to successfully implement our business strategy and affect our financial results. You should carefully consider all of the information in this report and, in particular, the following principal risks and all of the other specific factors described in Item 1A of this report, “Risk Factors,” before deciding whether to invest in our company.

 

  •  

We rely on the Bayer License Agreement to provide rights to the core intellectual property relating to all of our current product candidates, which agreement imposes significant payment and other obligations on us. Any failure by us to perform our obligations under the Bayer License Agreement could give Bayer AG (“Bayer”) the right to terminate or seek other remedies under the agreement, and any termination or loss of important rights under the Bayer License Agreement would significantly and adversely affect our ability to develop and commercialize VIP236, VIP943, VIP924, enitociclib, the VersAptx platform, and our other current product candidates and technologies that incorporate such intellectual property, raise capital, or continue our operations.

 

  •  

We are substantially dependent on the success of VIP236, VIP943, and enitociclib, our lead product candidates. If we are unable to complete development of, obtain approval for, and commercialize these lead product candidates in a timely manner, our business will be harmed.

 

  •  

We are at an early stage in development efforts for our product candidates, and we may not be able to successfully develop, manufacture, complete clinical trials and commercialize our product candidates on a timely basis or at all.

 

  •  

Our long-term prospects depend in part upon discovering, developing, manufacturing, and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.

 

  •  

Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials.

 

  •  

Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in subsequent or final data.

 

4

Table of Contents
  •  

We have incurred net losses since inception and expect to continue to incur significant net losses for the foreseeable future, and there can be no assurance we will be able to raise capital.

 

  •  

We require substantial capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and drug development programs or future commercialization efforts and may not be able to continue as a going concern.

 

  •  

Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.

 

  •  

If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.

 

  •  

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

 

  •  

We may expend our limited resources to pursue a particular product candidate, target, or indication and fail to capitalize on product candidates, targets, or indications that may be more profitable or for which there is a greater likelihood of success.

 

  •  

Clinical trials are expensive, time consuming, subject to enrollment and other delays, and may be required to continue beyond our available funding, and we cannot be certain that we will be able to raise sufficient funds to successfully complete the development, clinical trials, and commercialization of any of our product candidates currently in preclinical and clinical development, should they succeed.

 

  •  

Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and prospects.

 

  •  

Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations, including those under the Inflation Reduction Act of 2022.

 

  •  

We are at an early stage of development as a company, and our limited operating history may make it difficult to evaluate our ability to succeed.

 

  •  

The Bayer License Agreement obligates us to make significant milestone and royalty payments, some of which will be triggered prior to the commercialization of any of our product candidates, and we may not be able to raise additional capital or enter into strategic alliances at levels sufficient to pay these amounts when due.

 

  •  

We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.

 

  •  

Our current or future product candidates may cause adverse events, toxicities, or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential, or result in significant negative consequences.

 

5

Table of Contents

PART I

 

ITEM 1.

Business.

Corporate History and Background

We were initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. From the time of our formation to the time of the consummation of the Business Combination, our name was “LifeSci Acquisition Corp.”

On September 25, 2020, we entered into the Merger Agreement. At the effective time of the Merger, each share of Legacy Vincera Pharma Common Stock, other than any Dissenting Shares (as defined in the Merger Agreement), was canceled and the Legacy Holders received (i) 0.570895 shares of our common stock, for each share of Legacy Vincera Pharma Common Stock held by them immediately prior to the effective time of the Merger and (ii) the right to receive Earnout Shares under certain conditions following the closing of the Business Combination.

The Legacy Holders are entitled to receive Earnout Shares after the closing of the Business Combination if the daily volume-weighted average price of our common stock equals or exceeds the following prices for any 20 trading days within any 30 trading-day period (the “Trading Period”), following the closing of the Business Combination: (1) during any Trading Period prior to the forty-two (42) month anniversary of the closing of the Business Combination, upon achievement of a daily volume-weighted average price of at least $20.00 per share, such number of shares of our common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share (as defined in the Merger Agreement); (2) during any Trading Period prior to the six year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $35.00 per share, such number of shares of our common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; and (3) during any Trading Period prior to the eight year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $45.00 per share, such number of shares of our common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share. A total of 90.6% (rounded to the nearest whole share) of the Earnout Shares then earned and issuable shall be issued to the Legacy Holders on a pro-rata basis based on the percentage of the number of shares of Legacy Vincera Pharma Common Stock owned by them immediately prior to the closing of the Business Combination, and the remaining Earnout Shares that would otherwise have been issuable shall not be issuable to the Legacy Holders but in lieu thereof the number of authorized shares available for issuance under the Vincerx Pharma, Inc. 2020 Stock Incentive Plan shall be automatically increased by an equivalent number of shares of our common stock.

Overview

We are a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer.

We have a versatile and adaptable, next generation bioconjugation platform, called VersAptx. The modular nature of this innovative platform allows us to combine targeting, linker, and payload technologies to develop bespoke bioconjugates to address different cancer biologies. The VersAptx platform has the following features:

 

  •  

Antibodies and small molecules that target different tumor antigens, including non-internalizing targets

 

  •  

Linkers designed to:

 

  •  

reduce non-specific release of the payload

 

  •  

cleave intracellularly or extracellularly

 

  •  

conjugate to single or multiple payloads

 

6

Table of Contents
  •  

Payloads designed to:

 

  •  

reduce permeability using our CellTrapper™ technology to ensure accumulation in cancer cells

 

  •  

increase permeability with low efflux for release in the TME.

The VersAptx platform allows us to optimize these technologies to a specific target and develop bioconjugates designed to address the safety and efficacy challenges of first-generation bioconjugates.

The following graphic summarizes our diverse pipeline:

 

LOGO

Our accomplished management team, with collective experience of over 120 years in oncology, brings a proven track record in successful drug development, approvals, and value creation. Drawing talent from leading companies such as Pharmacyclics LLC, Acerta Pharma LLC, AstraZeneca plc, Bayer AG, Amgen Inc., Genentech Inc., Eli Lilly and Company, and Johnson & Johnson Inc, they have significantly contributed to multiple drug approvals and blockbuster exits, including the $7B acquisition of Acerta Pharma’s Calquence® by AstraZeneca and the $975M Imbruvica® partnership between Janssen Pharmaceuticals (now J&J Innovative Medicine) and Pharmacyclics.

We believe our diverse pipeline including our next-generation VersAptx platform and our management team position us to successfully develop paradigm-shifting therapies for patients.

Strategy

Our goal is to become a leading biopharmaceutical company by developing differentiated and novel therapies that are safe, effective, and well-tolerated. We seek to accomplish this goal through the implementation of the following strategy:

 

  •  

Progress VIP943, VIP236, and enitociclib through clinical development and proof-of concept

 

  •  

Progress VIP924 to an IND application in late 2025 or early 2026

 

  •  

Leverage our next-generation VersAptx platform to expand our pipeline and collaborate with other companies to develop unique, safe, and effective ADCs and SMDCs

 

  •  

Form strategic partnerships/collaborations to maximize the potential of our pipeline and VersAptx platform

 

7

Table of Contents

Our ability to achieve these goals and strategies will be dependent on a number of factors as described in the section titled “Risk Factors.”

Our Value Proposition

The VersAptx Platform

The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. The modular nature of this platform allows us to combine different targeting, linker, and payload technologies to develop unique ADCs and SMDCs that address the safety and efficacy challenges of first-generation bioconjugates.

The VersAptx platform has the following features:

Targets. We use antibodies or small molecules to target different tumor antigens. Currently, we have disclosed the following hematologic and solid tumor targets:

 

  •  

CD123: A protein mainly produced by activated T-cells and expressed at high levels in AML, classical Hodgkin lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), and MDS. Targeting CD123 allows for selective destruction of cancer cells while sparing normal cells, potentially minimizing side effects.

 

  •  

CXCR5: A receptor that regulates chemotaxis, germinal center formation, and plasma and memory B-cell differentiation and is highly expressed on the tumor cells of DLBCL, FL, MCL, and CLL. The specific expression pattern of CXCR5 prevents general effects on the B-cell population commonly observed with other compounds in this disease area. Targeting CXCR5 can also address the issue of cancer cell masking, by preventing homing into lymphatic systems (e.g., lymph nodes), keeping the cells exposed to the treatment.

 

  •  

αvß3: A small molecule integrin binder and well-established target in solid tumors. αvß3 is found on tumor cells and in the TME and is overexpressed in advanced and metastatic solid tumors. High expression of αvß3 is commonly associated with poor survival prognosis.

 

  •  

CD33: CD33 is a cell surface protein primarily found in myeloid cells and plays a crucial role in regulating immune cell activity. This protein is particularly intriguing as a target for ADCs due to its prevalence in malignant AML cells. CD33 is a validated target in AML as a monotherapy and could also prove to be safe and efficacious when combined with VIP943 by effectively targeting nearly all malignant AML cells in patients.

Linkers. Linkers designed to reduce non-specific release of the payload, cleave intracellularly or extracellularly, and conjugate to single or multiple payloads. Currently, we have disclosed the following linker technologies:

 

  •  

Legumain Linker: A novel linker that cleaves specifically by legumain, a protein that is present and overactive inside cancer cells. The stability and mechanism of action of this linker allows for targeted payload release within tumor cells after internalization.

 

  •  

Neutrophil Elastase Linker: A novel linker that selectively cleaves in the TME by neutrophil elastase, a protein highly expressed in the TME of advanced and metastatic solid tumors and associated with poor survival. Neutrophil elastase retains its structural integrity while circulating in the body and avoids cleavage in non-target tissues, allowing for a targeted payload release inside the TME.

Payloads. Highly potent and optimized payloads, designed to address common challenges in their class. Currently, we have disclosed the following payloads:

 

  •  

Optimized Camptothecin (CPT): Designed to have (i) high permeability, so it can efficiently enter cancer cells, and (ii) low efflux, so it stays in the cancer cell to inhibit topoisomerase 1—causing

 

8

Table of Contents
 

DNA damage and cell death. Camptothecins are an established payload class. The structural optimization of our camptothecin is designed to address the issue of transporter effect, a common resistance mechanism seen in this payload class.

 

  •  

Kinesin Spindle Protein Inhibitor (KSPi): This highly potent and selective KSPi payload specifically targets the kinesin spindle protein, a protein that is essential for mitotic spindle formation and only expressed during cell division. This novel payload is designed to allow us to only target dividing cells while sparing healthy cells, effectively circumventing common side effects associated with other payload classes.

CellTrapper. Our proprietary CellTrapper technology is designed to reduce payload cellular permeability, so the released payload accumulates within the target cell. This accumulation enables precise targeting of transiently expressed KSP, thereby inducing cell death. Moreover, the inability of the released payload to diffuse through membranes ensures non-target cells remain unaffected.

Beyond the technologies described above, our research and development team continues to work on new undisclosed bioconjugation technologies for solid tumor and hematologic indications.

Improving the Safety and Efficacy of Bioconjugates

The full potential of bioconjugates has been hindered by many challenges, such as payload damage of non-dividing/non-target cells, premature payload release, and unspecific cellular uptake, each of which can result in severe adverse effects including myelosuppression, infections, and hepatotoxicity. The adaptable and modular nature of our VersAptx platform allows us to combine different targeting, linker, and payload technologies to develop unique bioconjugates, such as those in our current product pipeline, that are designed to address the safety and efficacy challenges of existing bioconjugates. Our technological advancements have been demonstrated in preclinical studies, including the following comparisons to FDA-approved bioconjugates:

 

  •  

At the American Society of Hematology (ASH) 2022 Annual Meeting, we presented preclinical data demonstrating how our legumain linker + KSPi payload with CellTrapper effector chemistry improved the safety and efficacy of Mylotarg®1 (gemtuzumab-ozogamycin), the only marketed ADC for AML.

 

  •  

At the American Association for Cancer Research (AACR) 2023 Annual Meeting, we presented preclinical data for VIP236, our SMDC, demonstrating improved efficacy in patient- and cell line-derived gastric cancer models compared with ENHERTU®2, a marketed ADC for HER2+ solid tumors.

 

  •  

At the ASH 2023 Annual Meeting, we presented preclinical data for VIP924 demonstrating superior efficacy and safety compared with Polivy®3 and Zynlonta®4, two marketed ADCs for B-cell lymphoma.

 

  •  

Recently, we demonstrated in a preclinical study the ability of our legumain linker + KSPi payload with CellTrapper effector chemistry to enhance the potency of TRODELVY®5 and ENHERTU, two marketed ADCs, by conjugating TRODELVY’s TROP2 and ENHERTU’s HER2 antibodies with our effector chemistry. The results of this study, shown in the table below, demonstrated a significant improvement in the potency of both drugs, with TRODELVY potency amplified by a factor of 20 and ENHERTU potency by a factor of 8.

 

1 

Mylotarg™ is a trademark owned by Pfizer Inc.

2 

ENHERTU® is a trademark owned by Daiichi Sankyo, Inc. and AstraZeneca LP

3 

Polivy® is a trademark owned by Genentech USA, Inc.

4 

Zynlonta® is a trademark owned by ADC Therapeutics SA

5 

TRODELVY® is a trademark owned by Gilead Sciences, Inc.

 

9

Table of Contents

 

LOGO

These preclinical studies underscore the potential of the VersAptx platform in developing safer and more efficacious treatment options in hematological malignancies and solid tumors.

Our Product Candidates

Antibody Drug Conjugate: VIP943 (CD123-KSPi)

VIP943 is a potential best-in-class anti-CD123 ADC created with our VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with our CellTrapper technology. CD123 is a protein predominantly produced by activated T-cells. In diseases like AML, B-cell acute lymphoblastic leukemia (B-ALL), classical Hodgkin lymphoma, and MDS, CD123 is expressed at elevated levels, particularly in peripheral blasts and leukemic stem cells. By employing an anti-CD123 antibody, VIP943 can selectively target cells expressing CD123 while minimizing impact on healthy cells. Our VIP943 effector chemistry (legumain linker + KSPi payload with CellTrapper) is designed to deliver improved efficacy and safety, allowing us to prolong patients’ treatment duration and thereby effectively target the leukemic stem cells accountable for disease relapse.

Preclinical Results

On-target selectivity and activity assays show our KSPi payload is highly selective for the kinesin spindle protein target, Eg5, versus other members of the related KIF super family. This on-target activity translates to cell cycle arrest at the G2/M phase of mitosis, resulting in cell death in AML cell lines. In vitro cytotoxicity assays show that most hematologic cell lines (n=56) are sensitive to KSPi and that DNA alterations (including common AML mutations such as TP53) did not reduce its cytotoxicity. Nonhuman primate safety and toxicokinetic studies show that repeat dosing of VIP943 in cynomolgus monkeys has good overall tolerability without the myelosuppression and hepatotoxicity seen with other ADCs. This is consistent with the favorable safety profile seen to date in the VIP943 Phase 1 dose-escalation study.

At the American Society of Hematology (ASH) 2022 Annual Meeting, we presented data for VIP943 demonstrating in monkeys the benefit of our VIP943 effector chemistry. In this safety study, we compared VIP943 to Mylotarg (gemtuzumab-ozogamycin; FDA approved ADC for AML), and to Mylotarg’s anti-CD33 monoclonal antibody combined with our VIP943 effector chemistry (legumain linker + KSPi payload with CellTrapper). Following a single dose of each test agent (n=2 per group), the Mylotarg group showed a significant drop in platelet and red blood cell counts with insufficient recovery, along with a continuous decrease in white blood cells and lymphocyte. Mylotarg-treated animals also exhibited critical decreases in hemoglobin and hematocrit, indicating adverse effects. In contrast, the ADCs with our VIP943 effector chemistry showed no impact on the number of platelets or red blood cell populations. Mylotarg also led to increased liver enzymes, severely elevated total bilirubin (signifying liver toxicity), and an extreme rise in urea nitrogen (indicating kidney toxicity). These adverse events prompted euthanasia for one Mylotarg-treated monkey, while another died on

 

10

Table of Contents

day 13. In contrast, no animals treated with ADCs using our VIP943 effector chemistry died, and all were healthy after the study’s conclusion.

 

LOGO

LOGO

 

The data presented at ASH also included results of an efficacy study in a MOLM-13 mouse model, which showed that VIP943 had superior efficacy as compared with Mylotarg. In that study, VIP943 achieved tumor regression after 2 cycles, while Mylotarg resulted in disease progression in all treated mice.

 

LOGO

 

** P<0.01, *** P<0.001 vs vehicle

   

LOGO

 

* Measured at day 10

Clinical Studies

VIP943 is in a Phase 1 dose-escalation study treating patients with relapsed/refractory AML, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia who have exhausted standard therapeutic options (NCT06034275).

In September 2023, we dosed the first patient in this study. To date, we have completed dosing two cohorts and enrollment in the third cohort has started, with a total of 9 patients dosed in the study. The preliminary pharmacokinetic data from the first two cohorts show low levels of unconjugated payload in circulation, aligning with preclinical findings in nonhuman primates. Early safety data is also promising, with no patients showing dose-limiting toxicities in cohorts 1 and 2. We expect to release more details regarding the preliminary dose escalation study data on or around the 2024 European Hematology Association (EHA) Annual Meeting in June 2024.

Potential Clinical Path

We expect to expand into additional CD123-positive indications, including TP53 mutated AML, as safety and efficacy data are generated.

 

11

Table of Contents

Antibody Drug Conjugate: VIP924 (CXCR5-KSPi)

VIP924 is a first-in-class anti-CXCR5 ADC created with our VersAptx platform and shares the same effector chemistry as VIP943 (legumain linker + KSPi payload with CellTrapper). CXCR5 governs crucial processes including chemotaxis, germinal center formation, and differentiation of plasma and memory B-cells. It is highly expressed on tumor cells of DLBCL, FL, MCL and CLL. As with VIP943, our VIP924 effector chemistry is designed to reduce non-specific release and uptake of the payload and ensure payload accumulation in cancer cells.

Preclinical Results

In preclinical studies, VIP924 induced sustained tumor regression in MCL and DLBCL models, including ibrutinib-refractory MCL cell-derived models, with only 1 or 2 doses.

 

VIP924 Is Active in Ibrutinib-Refractory MCL

In Vivo Model

 

LOGO

 

  •   Ibrutinib-refractory MCL CDX CXCR5+ REC-1 model (inset)

 

  •   VIP924 achieved complete remission after 2 doses

 

  ****

P=0.0001 vs vehicle. Tumor volumes on day 26.

Single Dose of VIP924 in DLBCL In Vivo Model Achieved Durable Complete Regressions

 

LOGO

 

  •   Complete regression with single dose of VIP924 in CXCR5+ model OCI-LY1 (day 114)

 

  •   Superior activity versus standard of care

 

  *

P<0.05. **** P=0.0001 vs vehicle. #### P<0.0001 vs rituximab-bendamustine/ lenalidomide or CHOP. Tumor volumes on day 36. RR, response rate.

 

 

Additionally, evaluation in an MCL mouse model showed that VIP924 had superior efficacy and safety compared with Polivy® and Zynlonta® (FDA approved ADCs for B-cell lymphoma). In the study, we observed that animals treated with VIP924 exhibited significant inhibition of tumor growth and experienced a survival benefit compared with Zynlonta- and Polivy-treated animals. Additionally, Zynlonta-treated animals demonstrated reductions in white blood counts, monocytes, and lymphocytes at the end of the treatment, whereas VIP924 treatment showed minimal to no effects on these cell populations.

 

LOGO

LOGO

**** On day 17, tumor volumes of VIP924 treated animals were significantly lower (P<0.00002) compared with control.

 

 

12

Table of Contents

Potential Clinical Path

VIP924 can be evaluated in B-cell malignancies, such as MCL, FL, DLBCL, and CLL in monotherapy and in combination. Our goal is to progress VIP924 to an IND application in late 2025 or early 2026 once additional funding is secured.

Small Molecule Drug Conjugate: VIP236

VIP236 is a first-in-class SMDC created with our VersAptx Platform. It consists of an αvß3 integrin binder, a neutrophil elastase linker cleaved in the TME, and an optimized CPT for high permeability and low efflux. Activated αvß3, an integrin found on tumor cells and in the TME, is overexpressed in advanced and metastatic tumors. αvß3 is a well-established target in solid tumors and, when used as a homing mechanism, allows for targeted delivery of our optimized CPT payload. We believe this approach enhances the efficacy of tumor treatment and the payload’s safety profile.

Preclinical Results

In numerous preclinical studies, we observed significant and superior tumor regression across various cell-  and patient-derived xenograft models with VIP236 as compared with standard of care. In the TNBC MX-1 model below, we show that VIP236 has superior tumor regression compared with common chemotherapies, irinotecan and doxorubicin. In a liver metastasis from colorectal cancer model, we observed that VIP236 caused statistically significant tumor growth inhibition and delayed re-growth.

 

Triple Negative Breast Cancer

 

LOGO

*** P < 0.001 compared with vehicle, # P < 0.05 compared with doxorubicin or cisplatin, ### P < 0.001 compared with doxorubicin or cisplatin or 5-FU.

Liver Metastasis from Colorectal Cancer

 

LOGO

* P < 0.05 compared with vehicle , ** P < 0.01 compared with vehicle, *** P < 0.001 compared with vehicle, **** P < 0.0001 compared with vehicle

 

 

13

Table of Contents

Most notably, preclinical data show enhanced efficacy in patient-and cell line-derived gastric cancer models in NMRI nude mice compared with ENHERTU® (an ADC approved specifically in HER2+gastric and gastroesophageal junction cancer). In these models, ENHERTU had very little effect on tumor growth, while VIP236 slowed and even caused tumor regression independent of HER2 expression.

 

NCIN87 HER2high

 

LOGO

* P<0.05 vs vehicle.

SNU 16 HER2neg

 

LOGO

** P<0.01. *** P<0.001 vs vehicle.

 

 

GXA3040 HER2low

 

LOGO

** P<0.01. *** P<0.001 vs vehicle.

 

 

Clinical Studies

VIP236 is being evaluated in a Phase 1 dose-escalation study treating patients with advanced or metastatic solid tumors (NTC05371054).

 

14

Table of Contents

In January 2023, we dosed the first patient in this study. To date, we have dosed 20 patients with VIP236. Five patients were dosed in three dose cohorts on the initial schedule of 2 days on/5 days off. Fifteen patients have been dosed in four dose cohorts on the once every three-week schedule. Dose escalation continues on the once every three-week schedule. The early safety profile of the once every three-week dosing schedule remains very encouraging, and VIP236 is showing signs of dose-dependent clinical activity (i.e., tumor shrinkage). We expect to release more details regarding the preliminary dose escalation study data during the 2024 AACR Annual Meeting in April 2024.

Potential Clinical Path

Given preclinical and clinical data, VIP236 shows promising clinical potential across several indications, including ovarian and endometrial cancers, gastric cancer, and metastatic disease (specifically in TNBC and lung cancer).

Enitociclib (P-TEFb/CDK9 inhibitor)

Enitociclib is a best-in-class and highly selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer. Enitociclib’s mechanism of action is different from other CDK9 inhibitors, offering a more targeted approach, ultimately leading to cell death and reduction in tumor cell proliferation.

Preclinical Results

Preclinical studies support enitociclib as a best-in-class CDK9 inhibitor. The findings strongly suggest that enitociclib is highly selective and has a favorable safety profile, potentially making it an ideal combination partner in aggressive B-cell lymphomas and pediatric indications. Select preclinical studies are shown below:

In work performed in collaboration with the University of Calgary, enitociclib demonstrated potent cytotoxic activity as a single agent (IC50: 36-78 nM) and in combination with several anti-multiple myeloma (MM) agents in a small molecule inhibitor screening. In a JJN-3 MM xenograft mouse model, enitociclib monotherapy inhibited MYC and MCL1 transcription, inducing pro-caspase-3 and PARP cleavage within an hour of treatment, leading to reduction in tumor volumes by day 20 (96% to 99% tumor reduction). Further, enhanced efficacy was noted when enitociclib was combined with lenalidomide in a mouse model, confirming the earlier findings in the small molecule screening. Taken together, these preclinical results highlight the opportunity to advance enitociclib in optimization studies in MM.

In another University of Calgary collaboration, enitociclib was evaluated as a single agent and in combination in models of pediatric leukemia with KMT2A rearrangement, commonly seen in infant acute lymphoblastic leukemia and AML. Enitociclib alone achieved durable tumor inhibition and complete remission in a rat KMT2A leukemia model. In vitro, the combination of low dose enitociclib and various chemotherapies, prednisolone, and a KMT2A inhibitor showed significant synergistic cytotoxicity. These findings offer initial proof-of-concept for incorporating targeted cytotoxic agents with enitociclib in future clinical trials for KMT2A-rearranged leukemia, particularly in pediatric cases.

Clinical Studies

Bayer Study 18117: Enitociclib Dose-Escalation Study in Relapsed and Refractory Leukemia

In this open-label Phase 1 study conducted by Bayer, enitociclib was assessed for safety, tolerability, and preliminary anti-tumor activity in patients with advanced hematologic malignancies. The study was concluded early, with 21 patients with relapsed/refractory AML treated. Enitociclib demonstrated a consistent safety profile across different dose levels, with gastrointestinal side effects and cytopenia being the most common adverse

 

15

Table of Contents

events. Notably, no dose-limiting toxicities (DLTs) were reported. The study did not include patients with other hematologic malignancies (e.g., CLL or myelodysplastic syndrome).

Study VNC-152-101 (Formerly Bayer Study 17496): Safety, Efficacy, and Expanded Cohorts

Bayer also initiated an open-label Phase 1 dose escalation study, later taken-over by Vincerx and renamed VNC-152-101, designed to evaluate enitociclib as a monotherapy in patients with advanced cancer, including solid tumors and non-Hodgkin lymphoma. In total, the study enrolled 63 patients in the dose escalation and expansion cohorts (Bayer enrolled 37 patients [31 in dose escalation and 6 in the expansion cohort for DH-DLBCL] and Vincerx enrolled 26 patients). Enitociclib showed a favorable safety profile, dose-proportional pharmacokinetics, and on-target pharmacodynamic activity. Early clinical benefits across various indications include two patients with DH-DLBCL who experienced durable complete metabolic remissions, which persisted even after stopping treatment during the COVID pandemic. Additionally, one patient with transformed follicular lymphoma and 13 patients with solid tumors achieved stable disease as their best response to treatment.

 

Monotherapy Activity

2 Complete Remissions (CR) of 7 DH-DLBCL (29% CR rate)

  •   1 on treatment for 3.7 years
  •   1 on treatment for 2.3 years
  •   Both patients continue in full remission ~2 years after stopping treatment

14 Patients had Stable Disease as Best Response

  •   1 transformed follicular, 27 cycles*
  •   5 ovarian cancer, 1 to 10 cycles
  •   2 pancreatic cancer, 3 and 14 cycles
  •   2 esophageal/nasopharyngeal, 2 and 3 cycles
  •   1 salivary gland cancer, 24 cycles
  •   1 breast cancer, 3 cycles
  •   1 clival chordoma, 4 cycles
  •   1 appendix cancer, 4 cycles

 

*

As of January 2024.

LOGO

 

 

Study VNC-152-801: NIH Sponsored Study in R/R Lymphoid Malignancies

In April 2023, we began a study in partnership with the National Institutes of Health (NIH). This Phase 1 dose escalation study aims to establish the maximum tolerated dose and recommended Phase 2 dose and assess the safety and toxicity profile of the combination of enitociclib with venetoclax and prednisone (VVIP) in patients with relapsed/refractory lymphoid malignancies. As of January 2024, a total of 5 patients have been dosed in this study. Of these 5 patients, 2 out of 3 peripheral T-cell lymphoma (PTCL) patients (67%) achieved a partial response (PR) as a best response, with tumor regressions of 91% and 86%. Additionally, 1 DH-DLBCL patient out of 2 lymphoma patients achieved a PR (71% tumor regression) after just one treatment cycle, emphasizing the faster response rate of this combination compared with enitociclib monotherapy. There were no observed DLTs. Enrollment for this study continues.

Potential Clinical Path

We believe enitociclib’s favorable safety profile makes it an ideal combination partner across numerous hematologic malignancies such as DLBCL and PTCL as well as MYC-driven solid tumors such as ovarian cancer. Further research in these areas will proceed once additional funding is secured.

 

16

Table of Contents

Sales and Marketing

Because we are a clinical-stage company, we do not currently have our own marketing, sales, or distribution capabilities. To commercialize any of our product candidates, if approved for commercial sale and marketing, we would have to develop a sales and marketing infrastructure. We may opportunistically seek strategic collaborations or partners to maximize the commercial opportunities for our product candidates inside and outside the United States.

Manufacturing

We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our drug substances or drug products, and there are a limited number of manufacturers that operate under the cGMP requirements of the FDA that might be capable of manufacturing for us. We currently intend to rely on contract manufacturing organizations, for both drug substance and drug product. In addition, we recruit highly qualified personnel with experience to manage the contract manufacturing organizations producing our product candidates and other product candidates that we may develop in the future. Similarly, we do not own or operate a laboratory with expertise in diagnostic assessment of cancer subpopulations and will contract with specific commercial diagnostic labs to develop companion diagnostics to accompany our drug products. We recruit highly qualified personnel with experience to manage these commercial diagnostic companies for our product candidates or those that we may develop in the future.

Our outsourced approach to manufacturing relies on contract manufacturing organizations to first develop cell lines and manufacturing processes that are compliant with cGMP requirements and then produce material for preclinical studies and clinical trials. Our agreements with contract manufacturing organizations may obligate them to develop a production cell line, establish master and working cell banks, develop and qualify upstream and downstream processes, develop drug product processes, validate (and in some cases develop) suitable analytical methods for test and release as well as stability testing, produce drug substance for preclinical testing, produce cGMP-compliant drug substance, or produce cGMP-compliant drug product. We conduct audits of contract manufacturing organizations prior to initiation of activities under these agreements and monitor operations to ensure compliance with these agreements, the mutually agreed process descriptions, and cGMP regulations. A similar approach is applied to commercial diagnostic companies that we would partner with for companion diagnostics.

Competition

The biotechnology industry, especially the oncology sector, is characterized by fast-paced technological evolution, substantial competition, and a strong emphasis on intellectual property. Competitors may come from multiple sources, including specialty, pharmaceutical and biotechnology companies, public and private research organizations, academic research institutions, and governmental agencies. Product candidates that we may develop and potentially get approved will face competitive pressures from incumbent therapies as well as new therapies that may become available in the future.

Many global pharmaceutical companies, as well as medium and small biotechnology companies, are pursuing new cancer treatments, whether small molecules, biologics, bioconjugates, or cell or gene therapies. Any of these treatments could prove to be superior clinically to our products or product candidates and render them obsolete or non-competitive.

Although we believe our bioconjugation product candidates and VersAptx platform are highly differentiated, many companies continue to invest in innovation in the bioconjugate field, including new payload classes, new conjugation approaches, and new targeting moieties. Additionally, many companies have products and/or platforms that target the same indications our programs target. Any of these initiatives could lead to products that have superior properties to our VersAptx platform and bioconjugation product candidates. Some of

 

17

Table of Contents

the companies that may compete with us include, AbbVie Inc., ADC Therapeutics SA, Astellas Pharma Inc., Astra-Zeneca PLC, Bicycle Therapeutics plc, Bristol-Myers Squibb Company, CytomX Therapeutics, Inc., Daiichi Sankyo Company, Limited, Duality Biologics Co. Ltd., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GSK plc, Iksuda Therapeutics Ltd, Innovent Biologics, Inc., ImmunoGen, Inc. (acquired by AbbVie, Inc.), Immunomedics, Inc., Johnson & Johnson Inc, Klus Pharma, Inc, LegoChem Biosciences, Inc., MacroGenics, Inc., Merck & Co., Inc, Mersana Therapeutics Inc., Novartis International AG, ProfoundBio Inc, Pyxis (which acquired Pfizer, Inc.’s ADC technology), Roche Holding AG, Sanofi S.A., Seagen, Inc. (acquired by Pfizer, Inc.), and Takeda Pharmaceutical Company Limited.

Although we also believe enitociclib is a best-in-class and highly selective CDK9 inhibitor that is highly differentiated from other CDK9 programs and therapies targeting the same indications, there are other CDK9 programs in development demonstrating clinical efficacy and several are further along in development than our programs. The companies with clinical-stage programs include Cyclacel Pharmaceuticals Inc., Kronos Bio, Inc., Merck & Co., Inc., Prelude Therapeutics Inc., SELLAS Life Sciences Group, Inc, and Sumitomo Dainippon Pharma Co., Ltd. These or other companies and their current or future partners may develop CDK9 inhibitor programs with attributes to compete in the same indications as enitociclib. In addition, there are many other companies that are pursuing targets around P-TEFb to affect similar transcriptional or disease processes as CDK9 inhibition may affect. Companies that are pursuing the inhibition of CDK7, CDK2, MYC, BRD4, PRMT, and related transcriptional regulators may compete in the same indications as enitociclib.

We expect to compete on efficacy, safety, and tolerability, and if our products are not demonstrably superior in these respects compared with other approved therapies, we may not be able to compete effectively, rendering our technologies, or our product candidates, obsolete or non-competitive.

Many of our potential competitors, either alone or in partnership with other players, have significantly greater financial, technical, and human resource capabilities than us. This in turn might allow them to become more successful than us in achieving treatment approvals and market acceptance, reducing the competitiveness of our product candidates, and accelerating their obsolescence. In addition, merger and acquisition activity in the pharmaceutical and biotechnology space may result in an increased concentration of resources among a smaller number of competitors. Earlier stage companies may also become relevant competitors, especially through collaborations with established companies. The areas of competition also extend to scientific and managerial talent recruitment and retention, clinical trial sites, patient registration for clinical trials, and acquisition or development of technologies that might be complementary or necessary for our drug programs.

Government Regulation

Regulatory authorities, in the United States as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, efficacy, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of small molecule drugs and biologics such as those we are developing.

FDA Drug Approval Process

In the United States, drug products are subject to regulation by the FDA under the FDCA and the regulations promulgated thereunder. Biological products, such as our ADC product candidates, are approved for marketing under provisions of the Public Health Service Act, via a BLA. The application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.

 

18

Table of Contents

The process required by the FDA before drug product candidates may be marketed in the United States generally involves the following:

 

  •  

completion of preclinical laboratory tests and animal studies performed in accordance with FDA’s current Good Laboratory Practices (GLP) requirements;

 

  •  

submission to the FDA of an IND, which must be reviewed by the FDA before clinical trials may begin;

 

  •  

approval by an independent Institutional Review Board or ethics committee for each clinical protocol before clinical trials may begin at each clinical trial site;

 

  •  

performance of adequate and well-controlled human clinical trials in accordance with FDA requirements, to establish the safety and efficacy of the product candidate for its intended purpose;

 

  •  

preparation of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical trials, and satisfactory completion of an FDA Advisory Committee review, if applicable;

 

  •  

satisfactory completion of one or more FDA pre-approval inspection(s) of the manufacturing facility or facilities at which the product candidate is produced, tested, and released to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the product candidate’s continued safety, purity, and potency, and of selected clinical investigation sites to assess compliance with good clinical practice requirements; and

 

  •  

FDA review and approval, or licensure, of the NDA/BLA to permit commercial marketing of the drug product for particular indications for use in the United States.

Preclinical and Clinical Development

Prior to beginning the first clinical trial with an investigational product in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans. The central focus of an IND submission is on an evaluation of safety to support the protocol(s) for clinical studies. The IND also includes results of studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate; chemistry, manufacturing, and controls information; and any available human data or literature to support its use. An IND must become effective before human clinical trials may begin. The submission of an IND may or may not result in FDA authorization to begin a clinical trial. At any point, if the FDA has questions or concerns regarding an ongoing clinical trial, they may impose a clinical hold, for example, until such time as adjustments can be made to that clinical trial to resolve such concerns.

Clinical trials are studies that involve the administration of an investigational drug product to human subjects under the supervision of qualified investigators in accordance with good clinical practices, which include the requirement that all research subjects provide informed consent for their participation. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study and the parameters to be used in monitoring safety and efficacy. A separate submission to an existing IND must be made for each successive clinical trial conducted during drug product development and for any subsequent protocol amendments. For new indications, a separate, new IND may be required. Furthermore, an independent Institutional Review Board for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the Institutional Review Board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board, which provides recommendations for whether or not a clinical trial may move forward based on access to certain data from that clinical trial and may recommend a discontinuation if it determines that there

 

19

Table of Contents

is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical trial results to public registries. For purposes of NDA/BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.

 

  •  

Phase 1—The investigational drug product is introduced into healthy human subjects or patients with the target disease or condition. These studies test the safety, dosage tolerance, absorption, metabolism, distribution, and elimination of the investigational product, the side effects associated with increasing doses, and, if possible, to gain early evidence of efficacy. For certain investigational drug products targeting life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, initial human testing is conducted in patients with the target disease or condition.

 

  •  

Phase 2—The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosage, and dosing schedule, and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

 

  •  

Phase 3—The investigational drug product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy, and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational drug product and to provide an adequate basis for product approval.

Post-approval trials, sometimes referred to as Phase 4 or post-approval commitment studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA/BLA.

During the development of a drug product candidate, sponsors are given opportunities to meet with the FDA. These meetings may be prior to submission of an IND, at the end of Phase 1 or Phase 2, and before an NDA/BLA is submitted. Meetings at other times may also be requested. These meetings can provide an opportunity for the sponsor to share information about data gathered to date, for the FDA to provide advice, and for sponsor and the FDA to reach agreement on the next phase of development.

Additional meetings and correspondence with the FDA can also occur to summarize progress in the clinical trials, to review written IND safety reports, and to develop strategies (for example in accordance with FDA initiatives such as Project Optimus) for dose finding and dose optimization that leverage preclinical and clinical data in dose selection, including randomized evaluations of a range of doses in clinical trials. An emphasis of such strategies is placed on performing these studies as early and as efficiently as possible in the development program.

U.S. Submission, Review and Approval

Assuming successful completion of required testing in accordance with applicable regulatory requirements, the results of drug product development, and preclinical and clinical studies are submitted to the FDA as part of an NDA/BLA requesting approval to market the product. The NDA/BLA must include all relevant data available from pertinent preclinical and clinical studies, together with detailed information relating to the drug product candidate’s chemistry, manufacturing, controls, and proposed labeling. The submission of an NDA/BLA requires payment of substantial fees to the FDA, unless a waiver or exemption applies. Additionally, no user fees are assessed on NDA/BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

The FDA reviews an NDA/BLA to determine, among other things, whether a drug product is safe, pure, and potent and the facility in which it is manufactured, tested, processed, packed, or held meets standards designed to

 

20

Table of Contents

assure its continued safety, purity, and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. This review typically takes twelve months from the date the NDA is submitted and the FDA has approximately two months to make a “filing” decision after submission.

Before approving an NDA/BLA, the FDA will typically inspect the facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the drug product within required specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

After the FDA evaluates an NDA/BLA and conducts inspections of manufacturing facilities where the drug product candidate and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug product with specific prescribing information for specific indications. A CRL would describe all deficiencies that FDA has identified in the NDA/BLA, except that where FDA determines that the data supporting the application are inadequate to support approval, it may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA/BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an NDA/BLA if applicable regulatory criteria are not satisfied, require additional testing or information, and/or require post-marketing testing and surveillance to monitor safety or efficacy of a drug product.

If regulatory approval of a drug product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such drug product may be marketed. For example, the FDA may approve an NDA/BLA with a Risk Evaluation and Mitigation Strategy to ensure the benefits of the drug product outweigh its risks. A Risk Evaluation and Mitigation Strategy is a safety strategy developed to manage a known or potential serious risk associated with a drug product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA may also conditionally approve a drug product based on, for example, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the drug product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the drug product reaches the marketplace. The FDA may require one or more Phase 4 post-marketing studies and surveillance to further assess and monitor the product’s safety and efficacy after commercialization, and may limit further marketing based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.

In addition, the Pediatric Research Equity Act, requires a sponsor to conduct pediatric clinical trials for most drugs. Under this Act, original NDAs/BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. For molecularly targeted oncology drugs, the Research to Accelerate Cures and Equity (RACE) for Children Act (2017) requires an agreement reached with the FDA on which pediatric indications are to be fully assessed with a pediatric study plan. The required assessment must evaluate the safety and efficacy of the product for the selected indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A deferral may be requested and granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or submit a request for approval of a pediatric formulation.

 

21

Table of Contents

Expedited Development and Review Programs

 

  •  

Any drug product candidate submitted to the FDA for approval may be eligible for programs intended to expedite FDA review and approval process, such as priority review, fast track designation, breakthrough therapy designation, and accelerated approval. Priority review designation may be granted for a drug product candidate that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.

 

  •  

If the FDA determines, based on the request of a sponsor, that a product candidate is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors, that drug product candidate may be eligible for fast-track designation.

 

  •  

A breakthrough therapy designation is granted to drugs or biologics that are intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that a drug or biologic may demonstrate substantial improvement over existing therapies.

 

  •  

An accelerated approval determination may be granted for drug product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions.

Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for the FDA review and approval will not be shortened. Furthermore, priority review, fast track designation, breakthrough therapy designation and accelerated approval do not change the standards for approval but may expedite the development or approval process.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition (a disease or condition that affects fewer than 200,000 individuals in the United States) for which there is no reasonable expectation that the cost of developing and making available such a drug or biologic would be recovered from sales in the United States for that drug or biologic). Orphan drug designation may offer a seven-year period of marketing exclusivity, with exceptions. Orphan drug designation does not convey any advantage in, or automatically shorten the duration of, the regulatory review or approval process.

Post-Approval Requirements

Any drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the drug product, such as adding new indications or other labeling claims, are subject to FDA review and approval. There are also continuing user fee requirements, under which the FDA assesses an annual program fee for each drug product identified in an approved NDA/BLA. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting requirements upon us and any of our third-party manufacturers. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP requirements and other aspects of regulatory compliance.

 

22

Table of Contents

The FDA may withdraw approval if compliance with regulatory requirements and standards are not maintained or if problems occur after the drug product reaches the market. Later discovery of previously unknown problems with a drug product, including adverse events of unanticipated severity or frequency, or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a Risk Evaluation and Mitigation Strategy program. Other potential consequences include, for example:

 

  •  

restrictions on the marketing or manufacturing of a drug product, mandated modification of promotional materials or issuance of corrective information, issuance by the FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information, or complete withdrawal or recall of the drug product from the market;

 

  •  

fines, warning letters, or holds on post-approval clinical studies;

 

  •  

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing approvals;

 

  •  

product seizure or detention, or refusal of the FDA to permit the import or export of drug products; or

 

  •  

injunctions, consent decrees, or the imposition of civil or criminal penalties.

The FDA closely regulates and actively enforces the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety, efficacy, purity, and potency that are approved by the FDA and in accordance with the provisions of the approved label. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate such off-label uses, but it does restrict a manufacturer’s communications on the subject of off-label use of its products.

Marketing Exclusivity

The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. During the exclusivity period, the FDA may not approve or even accept for review an ANDA or an NDA submitted under Section 505(b)(2), or 505(b)(2) by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical studies (other than bioavailability studies) that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug product received approval on the basis of the new clinical studies and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.

 

23

Table of Contents

In the United States, pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake such clinical trials.

Biosimilars and Reference Product Exclusivity

The U.S. Affordable Care Act (2010) includes a subtitle called the BPCIA, which creates an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference drug product. To date, a number of biosimilars have been licensed under the BPCIA. The FDA has issued several guidance documents outlining its approach to the review and approval of biosimilars.

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference drug product was first licensed by the FDA. In addition, the approval of a biosimilar may not be made effective by the FDA until 12 years from the date on which the reference drug product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference drug product if the FDA approves a full BLA for that competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials

The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the implementation and impact of the BPCIA is subject to significant uncertainty.

Other U.S. Healthcare Laws and Compliance Requirements

In the United States, our current and future operations are subject to regulation by various federal, state, and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services and other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General). For example, we may have to comply with:

 

  •  

the anti-fraud and abuse provisions of the Social Security Act;

 

  •  

the false claims laws;

 

  •  

the privacy and security provisions of HIPAA and similar state laws;

 

  •  

state and federal anti-kickback and fraud and abuse laws; or

 

  •  

price reporting and physician sunshine laws.

If our operations are found to be in violation of any such laws or any regulations, we may be subject to administrative, civil, and criminal penalties, for example damages, fines, disgorgement, and exclusion from participation in government programs, such as Medicare and Medicaid, any of which could adversely affect our ability to operate our business.

Coverage, Pricing and Reimbursement

In the United States and foreign markets, sales of any drug products for which we receive regulatory approval will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers, and other organizations. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance.

 

24

Table of Contents

We cannot be sure that coverage or reimbursement will be available for any drug product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement would be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any drug product. Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of drug products, in addition to questioning safety and efficacy.

Different pricing and reimbursement schemes exist in other countries. For example, in the EU, governments influence the price of drug products through pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of drug products to consumers. Some jurisdictions operate positive and negative list systems under which drug products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some countries may require the completion of clinical studies that compare the cost effectiveness of a particular product candidate to currently available therapies. Others allow companies to establish their own prices for medicines, but monitor and control company profits.

The marketability of any of our approved drug products may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the influence of health maintenance organizations, and additional legislative changes in the United States, including the U.S. Inflation Reduction Act, is increasing the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more of our approved products, less favorable coverage policies and reimbursement rates may be implemented in the future.

Healthcare Reform

In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, for example, the U.S. Affordable Care Act (2010), which substantially changed the way healthcare is financed by both government and private insurers in the United States. By way of example, certain aspects of the Affordable Care Act seek to lower Medicare and Medicaid spending, potentially including prescription drug spending. We are continuing to monitor any changes to the Affordable Care Act that, in turn, may potentially impact our business in the future.

We are evaluating the impact of the U.S. Inflation Reduction Act (“IRA”) on our business. The IRA was signed into law in December 2022, and among other things, it will regulate out-of-pocket costs for Medicare patients with respect to prescription drugs. The discovery and development of both small molecule and biologic drug compounds may be affected with respect to licensing, production, and marketing of such drugs. The FDA will, in the near-term, propose regulations through its rulemaking process, and while that may take several years, the effect on manufacturer rebates to Medicare, Medicare drug price negotiations, catastrophic drug cost coverage, and other aspects of the commercialization of drug products could be significant. We will continue to monitor the implementation of the IRA.

In addition to the foregoing, individual states in the United States have also become increasingly active in implementing regulations designed to control drug product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing.

Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.

 

25

Table of Contents

FDA Approval and Regulation of Companion Diagnostics

If safe and effective use of a drug product depends on an in vitro companion diagnostic, then the FDA generally will require approval or clearance of that diagnostic at the same time that it approves the drug product. According to FDA guidance, if it determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, it generally will not approve the drug product or new drug product indication if the companion diagnostic device is not approved or cleared for that indication. The review of in vitro companion diagnostics in conjunction with the review of our proposed treatments for cancer will, therefore, likely involve coordination of review by the FDA’s Center for Drug Evaluation and Research and the FDA’s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health.

Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval.

The premarket approval process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device’s safety and efficacy and information about the device and its components regarding, among other things, device design, manufacturing and labeling.

Premarket approval is not guaranteed, and the FDA may ultimately respond to a premarket approval submission with a not approvable determination based on deficiencies in the application and require additional clinical trials or other data that may be expensive and time-consuming to generate, and that can substantially delay approval. A not approvable letter will outline the deficiencies in the application and, where practical, identify what is necessary to make the premarket approval application approvable. The FDA may also determine that additional clinical trials are necessary, in which case approval of the premarket approval application may be delayed for several months or years while such clinical trials are conducted and the data submitted in an amendment to the premarket approval application. If the FDA’s evaluation of the premarket approval application is favorable, it typically issues an approvable letter requiring the applicant’s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, to secure final approval of the premarket approval application. If the FDA concludes that the applicable criteria have been met, it will issue a premarket approval for the approved indications, which can be more limited than those originally sought by the applicant. Premarket approval can include post-approval conditions that the FDA believes necessary to ensure the safety and efficacy of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, approval of the premarket approval application may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing.

Devices, once placed on the market, remain subject to significant regulatory requirements, including for example, the applicable portions of the Quality System Regulation, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping.

The Foreign Corrupt Practices Act

The Foreign Corrupt Practices Act prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the

 

26

Table of Contents

individual or business in obtaining or retaining business. This Act also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

Additional Regulation

In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act, and the Toxic Substances Control Act, affect our business. We believe that our suppliers are in material compliance with applicable environmental health and safety laws and that continued compliance will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect their or our future operations.

Other Regulations

We may also be subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.

Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future drug product candidates, novel discoveries, product development technologies, and know-how; to operate without infringing on the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our strategy is to seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to our proprietary technology, inventions, and improvements that are important to the development of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain our proprietary position.

We have a license to patents and other intellectual property relating to VIP236, VIP943, VIP924, enitociclib, VIP217, and our other current drug product candidates and technologies from Bayer on an exclusive, worldwide basis under the Bayer License Agreement. The in-licensed portfolio as of December 31, 2023 includes 34 issued U.S. patents, 9 pending U.S. patent applications, 293 issued patents in various jurisdictions outside of the United States and approximately 84 pending patent applications in various jurisdictions outside of the United States. The Bayer License Agreement is described more fully below.

With respect to VIP236, we have pending applications in the U.S., Europe, China, Japan, India, Argentina, Brazil, Mexico, and other markets covering the composition of matter of VIP236. Any patent that may issue from our pending patent applications related to VIP236 is expected to expire in October 2039, absent any patent term adjustments or extensions. With respect to VIP943 and VIP924, we have pending applications in the U.S., Europe, China, Japan, India, Argentina, Brazil, and Mexico, along with issued patents and pending applications in other markets covering the composition of matter and uses of VIP943 and VIP924. Any patent that may issue from our pending patent applications related to VIP943 and VIP924 are expected to expire by July 2044, absent any patent term adjustments or extensions. Our in-licensed patent portfolio covering enitociclib consists of issued patents in the U.S., Europe, China, Japan, India, and Mexico, along with issued patents and pending applications in other markets. The issued U.S. patent covering the composition of matter of enitociclib is expected to expire in November 2033, absent any patent term extensions for regulatory delay.

As of December 31, 2023, we own 28 pending patent applications, including five pending U.S. provisional applications, nine Patent Cooperation Treaty (PCT) applications, and 14 applications in various jurisdictions

 

27

Table of Contents

outside of the United States. With respect to our product candidates and processes that we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing, and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies.

We also rely upon trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees, and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

Bayer License Agreement

On October 7, 2020, we entered into the Bayer License Agreement, pursuant to which we have been granted an exclusive, worldwide, royalty-bearing, worldwide license under certain Bayer patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute, for all uses in the cure, mitigation, treatment, or prevention of diseases or disorders in humans or animals, (i) a versatile and adaptable bioconjugation platform, now referred to as the VersAptx Platform, including VIP943 and VIP924, next-generation ADCs, and VIP236, an SMDC, and (ii) a small molecule drug program, including enitociclib, a P-TEFb/CDK9 inhibitor. The VersAptx Platform and these product candidates, currently comprise our entire product pipeline. The Bayer License Agreement became effective upon the closing of the Business Combination.

Under the Bayer License Agreement, we paid Bayer an upfront license fee of $5.0 million upon the closing of the Business Combination. In addition, we are obligated to make significant future payments to Bayer upon the achievement of certain development and commercial sales milestones involving license products as well as ongoing royalties on net commercial sales. The size and timing of these milestone payments vary greatly depending on factors such as the particular licensed product, whether it involves a P-TEFb licensed product or bioconjugation licensed product (and which bioconjugation program – IL3RA, CXCR5, SMDC, or additional programs), the number of distinct disease indications, the number of different countries with respect to which the milestone is achieved and the level of net commercial sales, and it is therefore difficult to estimate the total payments that may become payable to Bayer and when those payments would be due. If we achieve all of the milestones for each of the countries and disease indications, we would be obligated to pay development and commercial sales milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, we could be required to pay aggregate milestone payments in excess of $1.0 billion. If we partner with a third party and receive development milestone payments from such third party that exceed the development milestone payments we are required to pay Bayer for the same milestones, we are required to pay Bayer a small portion of that excess.

Under the Bayer License Agreement, we are also obligated to pay Bayer tiered royalties on worldwide net commercial sales of licensed products at royalty rates ranging from single digit to low double digit percentages based on escalating levels of net commercial sales in a calendar year, subject to standard offsets and reductions. These royalty obligations apply on a product-by-product and country-by-country basis and end upon the latest of (i) the date on which the last valid claim of any licensed patents expire, and (ii) 10 years after the first commercial sale of the licensed product, in each case, with respect to a given licensed product in a given country.

Under the Bayer License Agreement, we have sole control of, and are responsible for, at our expense, the development, manufacture and commercialization of licensed products. We have agreed to use commercially

 

28

Table of Contents

reasonable efforts, consistent with our business judgment and for a similarly situated company, to develop and commercialize at least one P-TEFb licensed product and two ADC licensed products in certain major markets. We have the sole right, but not the obligation, to control the prosecution, defense, and enforcement of the licensed patents, and Bayer has backup rights to prosecution, defense and enforcement with respect to any licensed patents for which we elect not to exercise such rights.

The Bayer License Agreement will expire on a country-by-country and licensed product-by-licensed product basis on the expiration of the last royalty term with respect to a given licensed product in a given country, unless earlier terminated. We may terminate the agreement for convenience upon 90 days’ written notice. Either party may terminate the agreement, either in its entirety or on a licensed technology-by-licensed technology or licensed product-by-licensed product basis depending on the nature of the breach, if the other party materially breaches its material obligations under the agreement and fails to cure such material breach within 180 days of written notice of such material breach, with termination tolled during any period during which a good faith dispute resolution process is being pursued with respect to material breaches other than non-payment. In addition, either party may terminate the agreement immediately upon written notice if the other party files a voluntary bankruptcy petition, is subject to an involuntary bankruptcy petition, or for certain other insolvency events. Bayer may terminate the agreement if we challenge the validity or enforceability of any of the licensed patents.

Human Capital/Employees

We have assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients with cancer. Our management team has broad expertise and successful track records in clinical development and approval of cancer therapies. We are led by Drs. Ahmed M. Hamdy and Raquel E. Izumi, two co-founders and biotechnology entrepreneurs who previously leveraged the discovery know-how of an established pharmaceutical company into break-through cancer treatments. Drs. Hamdy and Izumi were instrumental in the clinical development of IMBRUVICA® and CALQUENCE® for the treatment of blood cancers.

Drs. Hamdy and Izumi, and the rest of our management team, are supported by an external team of experienced cancer drug developers, including John C. Byrd, M.D., the Chair of the Department of Internal Medicine at the University of Cincinnati and Chief Medical Officer of BEAT AML, and Brian J. Druker, M.D., Director at Oregon Health & Science University’s Knight Cancer Institute School of Medicine. Dr. Byrd serves as chair of our Scientific Advisory Committee, and Dr. Druker serves on our board of directors.

As our core ethos, we believe that our people are our company’s greatest asset. We believe that by fostering an open, aware, accepting, and diverse work environment, we will by extension create a responsive, innovative, and successful company. This ethos guides the focus of our human capital objectives and the emphasis we place upon employee retention, inclusive team culture, diversity, equity, inclusion, and belonging. As of December 31, 2023, we had 42 full-time employees globally, 62% of whom hold a Masters’ degree or higher and 33% of whom hold an M.D. or Ph.D. Of our 42 employees, 64% were engaged in research and development and 36% were engaged in general and administrative functions. Of our total number of employees, 19% are based outside of the United States in one of three other countries. The median age of our staff was 44, and 69% of our employees are at or over the age of 40. None of our employees are represented by labor unions or covered by collective bargaining agreements.

As an employer, we believe it is our social responsibility to support employees to the best of our ability while at work as well as in their personal lives. We offer market-competitive compensation to our employees based on peer company benchmarks within the biopharmaceutical industry that take into account an employee’s role, level of responsibility, and geographical location. Additionally, we offer a 401(k) plan with an employer match feature to support an employee’s retirement planning as well as stock option grants and an employee stock purchase plan so that employees can tangibly participate in our success. Our benefits package covers 100% of

 

29

Table of Contents

employee and dependent paid premiums for medical, dental, and vision insurance that start on date of hire, as well as four weeks of paid time off, 17 company holidays, and generous policies supporting sick time and leaves of absence. In addition, we offer a benefit called Summer Hours from Memorial Day through Labor Day, during which we shorten each Friday to half-working days but continue to pay employees their full day’s salary. We also offer learning and development opportunities for our employees, such as culture workshops, training, and education resources and programs, as well as other resources, to help employees at all levels feel a sense of belonging and support to achieve their full potential. We believe that our efforts to create a positive work environment allows our employees to thrive and do their best work, which in turn supports our global mission of creating better treatments for patients.

We consider our relationship with our employees to be very good. Our engagement surveys in 2023 showed a strong overall happiness score, with highest rankings for work relationships, team culture, management, and diversity climate. We have a distributed workforce and have embraced remote work since our inception in 2020, and our remote culture remains strong. In 2023, 52% of our employees worked half-time remote and 40% worked full-time remote, rather than from one of our two global offices located in Palo Alto, California, and Monheim, Germany. Only 7% of our employees were office-based. We believe that our employees and our company benefit from a diverse, inclusive, and safe work environment and that treating our employees well will help reduce headcount turnover and maintain high engagement and morale.

We believe the vast variety of the experiences, backgrounds, and perspectives that our employees bring to their work every day, and our strategy to emphasize diversity and inclusion, make our company stronger. Our employees come from numerous countries, ethnicities, and backgrounds. When surveyed, 38% of our U.S. employees reported they were born outside of the U.S., and 47% of our U.S. employees speak a native language other than English. Women make up 45% of our global workforce and represent 52% of our leadership team (senior director level and higher). Currently, none of our employees identify as non-binary. Of our U.S. employees, 65% reported they have caring responsibilities outside of work, 12% identify as LGBTQ+, 6% identify as having a disability, and 3% identify as a U.S. veteran.

Facilities

Our principal executive offices are located in Palo Alto, California, and our lease agreement for such space expires in December 2025. Vincerx Pharma GmbH, our wholly owned German subsidiary, leases space in Monheim am Rhein, Germany. We do not own any real property. We believe that our office space is adequate to meet our current needs and that additional facilities will be available on commercially reasonable terms to meet future needs.

Legal Proceedings

We are not currently a party to any legal proceedings, and are not aware of any pending or threatened legal proceedings against us, that we believe could have a material adverse effect on our business, operating results, or financial condition. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

Available Information

Our principal executive offices are located at 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306, and our telephone number is (650) 800-6676. Our website address is www.vincerx.com. The information contained on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K.

We make available free of charge on our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. You may obtain a free copy of these reports in the Investor Relations section of our website, www.vincerx.com. All reports that we file are also available at www.sec.gov.

 

30

Table of Contents
ITEM 1A.

Risk Factors.

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

We rely on the Bayer License Agreement to provide rights to the core intellectual property relating to all of our current product candidates, which agreement imposes significant payment and other obligations on us. Any failure by us to perform our obligations under the Bayer License Agreement could give Bayer the right to terminate or seek other remedies under the agreement, and any termination or loss of important rights under the Bayer License Agreement would significantly and adversely affect our ability to develop and commercialize VIP236, VIP943, VIP924, enitociclib, the VersAptx Platform, and other product candidates and technologies that incorporate such intellectual property, raise capital, or continue our operations.

We have licensed our current core patents and other intellectual property relating to VIP236, VIP943, VIP924, enitociclib, the VersAptx Platform, and our other current product candidates from Bayer on an exclusive, worldwide basis under the Bayer License Agreement. The Bayer License Agreement continues in effect on a country-by-country and licensed product-by-licensed product basis until there are no remaining royalty payment obligations in the relevant country and can be terminated earlier by Bayer in the event that we materially breach our material obligations, that bankruptcy or other insolvency proceedings are instituted against us or that we seek to revoke or challenge the validity of any licensed patents. If, for any reason, the Bayer License Agreement is terminated or we otherwise lose important rights, it would have a significant and adverse effect on our business and our ability to develop and commercialize our current product candidates, raise capital, or continue our operations.

The Bayer License Agreement imposes on us obligations relating to development, commercialization, funding, payment, diligence, intellectual property protection and other matters. We paid Bayer an upfront license fee of $5.0 million following the closing of the Business Combination. In addition, we are obligated to make significant future payments to Bayer upon the achievement of certain development and commercial sales milestones involving licensed products. The size and timing of these milestone payments will vary greatly depending on factors such as the particular licensed product, whether it involves a P-TEFb licensed product or a bioconjugation licensed product (and which bioconjugation program), the number of distinct disease indications, the number of different countries with respect to which the milestone is achieved and the level of net commercial sales, and it is therefore difficult to estimate the total payments that could become payable to Bayer and when those payments would be due. If we were to achieve all of the milestones for each of the countries and disease indications, we would be obligated to pay development and commercial milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, we could be required to pay aggregate milestone payments in excess of $1.0 billion. In addition to milestone payments, we are also required to pay Bayer under the Bayer License Agreement ongoing royalties in the single digit to low double-digit percentage range on net commercial sales of licensed products.

To the extent we are able to achieve any of these milestones, many of them would be achieved, and the related milestone payments owed, before we are able to generate sufficient revenues (or any revenues in the case of development milestones). Accordingly, we will need to obtain substantial additional funding, or enter into strategic alliances in order to pay these milestones, and there can be no assurance that we will be able to obtain the necessary funding on acceptable terms or at all or that we will be able to enter into strategic alliances at levels sufficient to pay these milestones or at all. If we are unable to raise the necessary additional funding, enter into the necessary strategic alliances, or otherwise pay these milestones, we would be in breach of the Bayer License Agreement, which if not cured would give Bayer the right to terminate the agreement or seek other remedies, which would have a significant and adverse effect on our business and prospects and our ability to develop and commercialize our current product candidates, raise capital, or continue our operations.

 

31

Table of Contents

We are substantially dependent on the success of VIP236, VIP943, and enitociclib, our lead product candidates. If we are unable to complete development of, obtain approval for, and commercialize these lead product candidates in a timely manner, our business will be harmed.

Our future success is substantially dependent on our ability to timely commence and complete clinical trials, obtain marketing approval for, and successfully commercialize VIP236, VIP943, and enitociclib, our lead product candidates. We are investing significant efforts and financial resources in the research and development of these lead product candidates, which will require additional clinical development, evaluation of clinical, preclinical, and manufacturing activities, marketing approval from government regulators, substantial investment, and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote these or any other product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.

The success of our lead product candidates will depend on several factors, including the following:

 

  •  

the initiation, successful patient enrollment, and timely completion of clinical trials;

 

  •  

establishing and maintaining relationships with contract research organizations and clinical sites for clinical development in the United States and internationally;

 

  •  

the frequency and severity of adverse events in the clinical trials and additional drug-related adverse events;

 

  •  

achieving dose selection, efficacy, safety, and tolerability profiles that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;

 

  •  

establishing and maintaining supply arrangements with third party drug product suppliers, manufacturers, and distributors;

 

  •  

obtaining and maintaining patent protection, trade secret protection, and regulatory exclusivity, both in the United States and internationally;

 

  •  

a continued acceptable safety profile following any marketing approval; and

 

  •  

our ability to compete with other therapies.

We do not have control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights, and the manufacturing, marketing, distribution, and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize these lead product candidates, which would materially harm our business and prospects.

We are at an early stage in development efforts for our product candidates, and we may not be able to successfully develop, manufacture, complete clinical trials, and commercialize our product candidates on a timely basis or at all.

VIP236, VIP943, and VIP924 are the first product candidates from our VersAptx Platform, the potential therapeutic benefits of which are unproven, and we may never develop, successfully conduct, or complete clinical trials, obtain marketing approval, and commercialize these or any other product candidates from our VersAptx Platform. While several bioconjugation and ADC candidates are under development by other companies, there is currently no approved bioconjugation therapy using our proprietary cytotoxin (an optimized CPT payload derived from SN38, a well-known cytotoxic drug and active metabolite of irinotecan) or an ADC using KSPi and CellTrapper. We may uncover a previously unknown risk associated with KSPi or our optimized CPT payload, our CellTrapper technology may not be as impermeable as initial testing suggests, our linker

 

32

Table of Contents

technology may not be as effective as initial testing suggests, or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining, or result in the failure to obtain, regulatory approval or may necessitate additional preclinical and clinical testing. While results from preclinical trials of VIP236, VIP943, and VIP924 have shown proof-of-concept for each, these product candidates may not demonstrate in patients any or all of the pharmacological benefits we believe they may possess. If the KSPi warhead or optimized CPT payload that we use is not safe in certain product candidates, we would be required to abandon or redesign all of our current lead ADC or SMDC product candidates. We have not yet succeeded and may never succeed in demonstrating efficacy and safety of VIP236, VIP943, and VIP924 in pivotal clinical trials or in obtaining marketing approval thereafter.

Enitociclib is a novel P-TEFb/CDK9 inhibitor, and its potential therapeutic benefit is unproven. While several CDK9 inhibitor candidates are under development by other companies, there is currently no approved therapy inhibiting CDK9 for the treatment of cancers, and as a result, the regulatory pathway for enitociclib may present novel issues that could cause delays in development or approval. In addition, enitociclib may not demonstrate in patients any or all of the pharmacological benefits we believe it may possess. Positive results from preclinical studies or early stage clinical trials are not necessarily predictive of the results of planned clinical trials of enitociclib. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for enitociclib in pivotal clinical trials or in obtaining marketing approval thereafter.

If we are unable to successfully develop, conduct, or complete clinical trials, obtain marketing approval, and commercialize our product candidates, our business and prospects would be materially harmed.

Our long-term prospects depend in part upon discovering, developing, manufacturing, and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.

Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for, manufacture, and commercialize product candidates beyond those we currently have in preclinical and clinical development. A product candidate can unexpectedly fail at any stage of manufacturing and preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care, and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.

The success of other product candidates we may develop will depend on many factors, including the following:

 

  •  

generating sufficient data to support the initiation or continuation of clinical trials;

 

  •  

obtaining regulatory permission to initiate clinical trials;

 

  •  

contracting with the necessary parties to conduct clinical trials;

 

  •  

successful enrollment of patients in, and the completion of, clinical trials on a timely basis;

 

  •  

the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and

 

  •  

adverse events in the clinical trials.

Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials.

Positive and promising results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage clinical trials or from clinical trials of the same product candidates for the treatment of

 

33

Table of Contents

other indications. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Late-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen, and statistical design. Moreover, success in clinical trials in a particular indication does not guarantee that a product candidate will be successful for the treatment of other indications. Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage development. There can be no assurance that we will not face similar setbacks in our ongoing or planned late-stage clinical trials and any subsequent or post-marketing confirmatory clinical trials. Therefore, despite positive results observed in early-stage clinical trials, our product candidates may fail to demonstrate sufficient efficacy in our pivotal or post-marketing confirmatory clinical trials.

Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publish preliminary interim or “top-line” data from clinical trials. Positive preliminary data may not be predictive of such trial’s subsequent or overall results. Preliminary data are subject to the risk that one or more of the outcomes may materially change as more data become available. Additionally, preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive preliminary results in any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remains subject to audit and verification procedures that may result in subsequent or final data being materially different from the preliminary data we previously published. As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary data could materially harm our business and prospects.

Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.

Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:

 

  •  

timing of market introduction, number, clinical profile, and potential advantages of competitive drugs;

 

  •  

our ability to provide acceptable evidence of safety and efficacy;

 

  •  

changing standards of medical care;

 

  •  

relative convenience and ease of administration;

 

  •  

restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a Risk Evaluation and Mitigation Strategy, if any, which may not be required of alternative treatments and competitor products;

 

  •  

pricing and cost-effectiveness, which may be subject to regulatory control;

 

  •  

availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third-party payors; and

 

  •  

prevalence and severity of adverse side effects.

 

34

Table of Contents

If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors, and patients, we may not generate or derive sufficient revenue from that product candidate, and our financial results could be negatively impacted.

If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected, and our business may suffer.

We intend to focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we develop could be significantly diminished and have an adverse material impact on our business and prospects.

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

Our competitors are developing a large number of drug candidates and new therapies for the treatment of conditions for which we may attempt to develop product candidates. Several pharmaceutical and biotechnology companies have CDK9 inhibitors, ADCs, immunotherapies, or other products on the market, in clinical trials, or in development that are, or may be, competitive to our product candidates in oncology indications. Our competitors, either alone or together with collaborators, may have significantly greater financial, manufacturing, marketing, drug development, technical and human resources, and commercial expertise than we do and may have begun developing their drug candidates earlier than us. Our competitors may also have more experience:

 

  •  

developing drug candidates;

 

  •  

conducting preclinical and clinical trials;

 

  •  

obtaining regulatory approvals; and

 

  •  

commercializing product candidates.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe adverse effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed, or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive, or not economical. We anticipate that we will face increased competition in the future as new companies enter the markets and as scientific developments progress. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on development programs, therapeutic platforms, and product candidates that we identify for specific indications. As a result, we may forego

 

35

Table of Contents

or delay the pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms, and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.

Clinical trials are expensive, time consuming, subject to enrollment and other delays, and may be required to continue beyond our available funding, and we cannot be certain that we will be able to raise sufficient funds to successfully complete the development, clinical trials, and commercialization of any of our product candidates currently in preclinical and clinical development, should they succeed.

Clinical trials have uncertain outcomes and may be required to continue beyond our available funding. Failure can occur at any stage of the clinical trials, and we may experience numerous unforeseen events that could delay or prevent commercialization of our current or future product candidates, including, but not limited to:

 

  •  

delays in securing clinical investigators and trial sites for our clinical trials;

 

  •  

delays in obtaining Institutional Review Board, and regulatory approvals to commence a clinical trial;

 

  •  

slower than anticipated rates of patient recruitment and enrollment, or not reaching the targeted number of patients, because of factors such as competition for patients from other trials, difficulty identifying patients with our proposed indications, the impact of health pandemics or epidemics, or limited or no availability of coverage, reimbursement, or adequate payment from health maintenance organizations and other third-party payors;

 

  •  

unforeseen safety issues;

 

  •  

uncertain dosing issues that could arise as a result of incompletely explored pharmacokinetic and pharmacodynamic behaviors or initiatives such as the FDA’s Project Optimus;

 

  •  

approval and introduction of new therapies or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications less attractive;

 

  •  

inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols;

 

  •  

inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials;

 

  •  

inability or unwillingness of medical investigators to follow our clinical protocols; and

 

  •  

unavailability of clinical trial supplies.

In addition, we had no involvement with or control over the preclinical or clinical development of our product candidates prior to their in-license from Bayer. We are therefore dependent on Bayer having conducted such development in accordance with the applicable protocols and legal, regulatory, and scientific standards, having accurately reported the results of all preclinical studies and clinical trials and other research they conducted prior to our acquisition of the rights to our product candidates, having correctly collected and interpreted the data from these studies, trials, and other research, and having supplied us with complete information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these product candidates. Problems in any of these areas could result in increased costs and delays

 

36

Table of Contents

in the development of our product candidates, which could adversely affect our ability to generate any future revenue from sales of our product candidates, if approved.

If we suffer significant delays, setbacks, or negative results in, or termination of, our clinical trials, we may be unable to continue development of our product candidates or generate revenue, and our development costs could increase significantly. Adverse or inconclusive results from our clinical trials may substantially delay, or halt entirely, any further development of our product candidates.

Adverse or inconclusive results from our clinical trials may substantially delay, or halt entirely, any further development of our product candidates. Many companies have failed to demonstrate the safety or effectiveness of product candidates in later stage clinical trials notwithstanding favorable results in early-stage clinical trials. Previously unforeseen and unacceptable side effects could interrupt, delay, or halt clinical trials of our product candidates and could result in the FDA denying approval of our product candidates. We will need to demonstrate safety and efficacy for specific indications of use, and monitor safety and compliance with clinical trial protocols and other good clinical practice requirements, throughout the development process. To date, long-term safety and efficacy has not been demonstrated in clinical trials for any of our product candidates.

Certain toxicity and adverse events have been noted in some of the preclinical and clinical trials involving certain of our product candidates. In addition, we have or may pursue clinical trials for more than one indication, and there is a risk that unacceptable toxicity or adverse events observed in a trial for one indication could result in the delay or suspension of all trials involving the same product candidate. Even if we believe that the data collected from clinical trials of our product candidates are promising with respect to safety and efficacy, such data may not be deemed sufficient by regulatory authorities to warrant product approval. Regulatory officials could interpret such data in different ways than we do, which could delay, limit, or prevent regulatory approval. The FDA or we may suspend or terminate clinical trials at any time. Any failure or significant delay in completing clinical trials for our product candidates, or in receiving regulatory approval for the commercialization of our product candidates, may materially harm our business and prospects.

Our preclinical development, clinical trials, manufacturing, supply chains and other operations and business activities, and the operations and business activities of third parties with whom we conduct business, including our contract manufacturers, contract research organizations, shippers, clinical trial sites, and others, have been, and could in the future be, adversely affected by the effects of health pandemics and epidemics.

Our business has been, and could in the future be, adversely affected by health pandemics and epidemics wherever we have clinical trial sites or other business operations. In addition, health pandemics and epidemics could cause significant disruption in the operations of third-party manufacturers, contract research organizations, shippers, clinical trial sites, and other third parties upon whom we rely. We are dependent on a worldwide supply chain for products to be used in our clinical trials and, if approved by the regulatory authorities, for commercialization. Disruptions in operations, whether related to COVID-19 or other health pandemics or epidemics, have impacted, and could in the future impact, personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which has impacted, and could continue to impact, our supply chain. If our relationships with our suppliers or other vendors are delayed, scaled back, or terminated as a result of health pandemics or epidemics we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner.

In addition, our clinical trials have been, and could in the future be, affected by health pandemics or epidemics. Clinical site initiation and patient enrollment have been, and could in the future be, delayed due to staffing shortages, prioritization of hospital resources toward the treatment and management of patients impacted by pandemics or epidemics, concerns among patients about participating in clinical trials during a pandemic or epidemic, or public health measures imposed by governmental authorities in the countries and regions in which the clinical sites are located. Some patients may have difficulty following certain aspects of clinical trial

 

37

Table of Contents

protocols if quarantines or other restrictive measures impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure or experience additional restrictions by their institutions, city, or state governments could adversely impact our clinical trial operations.

Our business entails a significant risk of product liability, and if we are unable to obtain sufficient insurance coverage, such inability could have an adverse effect on our business and prospects.

Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and efficacy of our products, our manufacturing processes and facilities, or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources, and substantial monetary awards to clinical trial participants or patients. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive and difficult to obtain. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims, which could negatively impact our ability to conduct clinical trials and have an adverse effect on our business and financial condition.

Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations, including those under the Inflation Reduction Act of 2022.

In domestic and foreign markets, sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. These third-party payors decide which drugs will be covered and establish reimbursement levels for those drugs. The containment of healthcare costs has become a priority of governments as well as private third-party payors, and the prices of drugs have been a focus in this effort, including the drug pricing provisions under the Inflation Reduction Act of 2022. Governments and private third-party payors have attempted to control costs by subjecting certain drugs to mandatory price negotiations and limiting coverage and the amount of reimbursement for certain medications, which could affect our ability to sell our product candidates profitably. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues. Adverse pricing limitations may hinder our ability to recoup our investment in our current or future product candidates, even if such product candidates obtain marketing approval.

Reimbursement by a third-party payor may depend upon several factors, including the third-party payor’s determination that use of a product is:

 

  •  

a covered benefit under its health plan;

 

  •  

safe, effective, and medically necessary;

 

  •  

appropriate for the specific patient;

 

  •  

cost-effective; and

 

  •  

neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical, and cost-effectiveness data for the use of our products to the payor. Further, there is significant uncertainty related to

 

38

Table of Contents

third-party payor coverage and reimbursement of newly approved drugs. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our products. In addition, in the United States, third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs.

We are making use of biomarkers in certain instances, which are not scientifically validated, and our reliance on biomarker data may cause us to direct our resources inefficiently.

We are making use of biomarkers in certain instances to facilitate our drug development and to optimize our clinical trials. Biomarkers are proteins or other substances whose presence in the blood or tumor cells can serve as an indicator of specific cell processes. We believe that these biomarkers serve a useful purpose in helping us to evaluate whether our product candidates are having their intended effects through their assumed mechanisms and thus identify more promising product candidates at an early stage and direct our resources efficiently. We also believe that biomarkers may eventually allow us to improve patient selection in connection with clinical trials and monitor patient compliance with trial protocols.

For most purposes, however, biomarkers have not been scientifically validated. If our understanding and use of biomarkers is inaccurate or flawed, or if our reliance on them is otherwise misplaced, we will not only fail to realize any benefits from using biomarkers but may also be led to invest time and financial resources inefficiently in attempting to develop less promising product candidates. Moreover, biomarker data are not currently accepted by the FDA or other regulatory agencies in the United States, the European Union, or elsewhere in applications for regulatory approval of product candidates, and there is no guarantee that such data will ever be accepted by the relevant authorities. Our biomarker data should not be interpreted as evidence of efficacy.

Our founders’ success in developing cancer therapies while at other companies does not guarantee that we will be successful in developing or commercializing any of our current or future product candidates.

Dr. Ahmed M. Hamdy and Dr. Raquel E. Izumi were the principal co-founders of Acerta Pharma BV, the company that developed CALQUENCE® and was eventually acquired by AstraZeneca plc. Drs. Hamdy and Izumi’s prior success in licensing a preclinical stage molecule and developing that molecule through clinical trials and to full marketing approval does not guarantee that we will successfully develop or commercialize any of our current or future product candidates.

The failure to attract and retain skilled personnel could impair our drug development and commercialization efforts.

Our business is highly dependent on our ability to attract and retain management, clinical development, scientific, research, technical, and other skilled personnel. There is currently intense competition for executives and employees with these skills and expertise, and this competition is likely to continue. The inability to attract and retain our management, clinical development, scientific, research, technical, and other skilled personnel may delay or prevent the achievement of our drug development and other business objectives and could have a material adverse effect on our business and prospects. We also rely on consultants and advisors to assist us in formulating and implementing our business objectives. Our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, that may affect their ability to contribute to our business and operations.

 

39

Table of Contents

We or the third parties upon whom we depend may be adversely affected by natural disasters, health epidemics, and other natural or man-made accidents or incidents, including the impact of climate change, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, health pandemic or epidemic (such as COVID-19), power shortage, telecommunication failure, wars (such as the wars in Ukraine and Israel), or other natural or man-made accidents or incidents, including the impact of climate change, that result in us being unable to fully use our facilities, or those of third parties upon whom we rely, or conduct our preclinical studies or clinical trials, may have a material adverse effect on our business. In addition, the disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, there can be no assurance that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the facilities of the third parties on whom we rely, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, our business may be harmed.

Our business and operations would be adversely affected in the event that our computer systems or those of our partners, contract research organizations, contractors, consultants, or other third parties we work with were to suffer system failures, cyberattacks, loss of data, or other security incidents, or we fail to comply with applicable data security and privacy laws, regulations, and standards.

Despite the implementation of security measures, our computer systems, as well as those of our partners, contract research organizations, IT service providers, contractors, consultants, law and accounting firms, and other third parties we work with, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, ransomware attacks, denial-of-service attacks, cybercriminals, natural disasters, terrorism, war, and telecommunication and electrical failures. We rely on our partners and third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies, or breaches. The risks of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber-terrorists, have increased significantly and are becoming increasingly difficult to detect. If a failure, accident, or security breach were to occur and cause interruptions in our operations, or the operations of our partners or third-party providers, it could result in a misappropriation of confidential information, including our intellectual property or financial information or clinical trial participant personal data, a material disruption or delay in our drug development programs, or significant monetary losses. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials, or chemistry, manufacturing, and controls data for our product candidates, could result in delays in regulatory approval efforts and significantly increase our costs to recover or reproduce the data.

In addition, we must comply with increasingly complex, rigorous, and sometimes conflicting laws, regulations, and standards enacted to protect business and personal data in the United States, Europe, and elsewhere. These laws impose additional obligations on companies regarding the handling of personal data and provide certain individual privacy rights to persons whose data is stored. Compliance with existing, proposed, and recently enacted laws, regulations, and standards can be costly and time consuming, and any failure to comply with these laws, regulations, and standards could subject us to legal and reputational risks. Misuse of or failure to secure personal information, including any breach, loss, or compromise of clinical trial participant personal data, could also result in violation of data privacy laws, regulations, and standards, proceedings against us by governmental entities or others, imposition of fines by governmental authorities, and damage to our reputation and credibility, and could have a negative impact on our business.

 

40

Table of Contents

Risks Related to Our Financial Position and Need for Additional Capital

We are at an early stage of development as a company, and our limited operating history may make it difficult to evaluate our ability to succeed.

We were incorporated in December 2018, and our operations to date have been largely focused on licensing our product candidates, raising capital, building our management team and infrastructure, and conducting preclinical studies and early clinical trials. We have not yet demonstrated an ability to obtain regulatory approvals, manufacture products on a commercial scale or partner with contract manufacturing organizations to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. Moreover, we will need to eventually transition from a company with a development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications, and delays, and may not be successful in such a transition.

We have incurred net losses since inception and expect to continue to incur significant net losses for the foreseeable future, and there can be no assurance we will be able to raise capital.

We have incurred net losses in each reporting period since our inception, have not generated any revenue from product sales to date, and have financed our operations principally through the sale of our equity securities. Our losses have resulted principally from expenses incurred in connection with licensing our product candidates from Bayer, raising capital, building our management team and business infrastructure, manufacturing, and conducting preclinical studies and early clinical trials. As a result, we expect that it will be several years, if ever, before we have a commercialized product and are able to generate revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our product candidates. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop, and market additional potential products. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, need to raise additional capital, and ability to achieve and maintain profitability.

We require substantial capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and drug development programs or future commercialization efforts and may not be able to continue as a going concern.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and uncertain process that takes years to complete. We expect our expenses to substantially increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for, VIP236, VIP943, VIP924, enitociclib, and our other product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. These expenditures will include payments associated with the Bayer License Agreement and development and commercial milestones, in each case prior to generating any product sales. Additionally, following commencement of any commercial sales of our licensed products, we will be responsible for significant further payments upon the achievement of certain sales milestones and tiered royalty payments on net commercial sales.

Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other

 

41

Table of Contents

unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing, and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations.

As of December 31, 2023, we had approximately $12.8 million in cash and cash equivalents. We intend to use our existing capital resources to advance and expand our preclinical and clinical programs, to fund certain of the milestone payments under the Bayer License Agreement and our public company compliance costs, and for working capital and other general corporate purposes. Based on our current business plans and assumptions, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into July 2024. Our estimate as to how long we expect our existing cash to be able to continue to fund our operating expenses and capital expenditure requirements is based on plans and assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could result in less cash available to us or cause us to consume capital significantly faster than we currently anticipate, and we may need or choose to seek additional funds sooner than planned.

We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other sources, which may dilute our stockholders or restrict our operating activities. Raising additional funds by issuing equity or convertible debt securities may cause our stockholders to experience substantial dilution. Raising additional funds through debt financing may involve covenants that restrict our business activities and options. To the extent that we raise additional funds through collaborations and licensing arrangements, we may have to relinquish valuable rights to our drug discovery and other technologies, development programs, or product candidates, or grant licenses on terms that may not be favorable to us. Additional funding may not be available to us on favorable terms, or at all, particularly in light of the current economic and market conditions. We do not have any committed external source of funds. Market volatility resulting from inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain our listing on The Nasdaq Capital Market, or other factors could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend, or eliminate one or more of our preclinical programs, clinical trials, or future commercialization efforts, or curtail our operations.

In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that our audited consolidated financial statements are issued. In light of our existing cash resources and current and expected operating losses and negative cash flows, we expect to need additional capital prior to the one-year anniversary of the issuance of our audited consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, we have concluded that these circumstances and the uncertainties associated with our ability to obtain additional capital raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that our audited consolidated financial statements are issued.

 

42

Table of Contents

The Bayer License Agreement obligates us to make significant milestone and royalty payments, some of which will be triggered prior to the commercialization of any of our other product candidates, and we may not be able to raise additional capital or enter into strategic alliances at levels sufficient to pay these amounts when due.

We will be responsible for significant future contingent payments and royalties under the Bayer License Agreement upon the achievement of certain development, regulatory, and sales milestone events, some of which may occur prior to commercialization of any of our product candidates. In such event, we would be required to make certain of these payments prior to the time at which we are able to generate sufficient revenue, if any, from commercial sales of any of our product candidates. Accordingly, we will need to obtain substantial additional funding or enter into strategic alliances in order to make these payments, and there can be no assurance that we will have the funds necessary to make such payments, be able to obtain the necessary funding on acceptable terms or at all, or enter into strategic alliances at levels sufficient to pay these amounts or at all. If we are unable to pay these amounts, we would be in breach of the Bayer License Agreement, which if not cured would give Bayer the right to terminate the agreement or seek other remedies, which would have a significant and adverse effect on our business and our ability to develop and commercialize our current product candidates, raise capital, or continue our operations.

We may never achieve or sustain profitability.

We do not know when or whether we will become profitable. To date, we have not commercialized any products or generated any revenues from the sale of products. We do not expect to generate any product revenues in the near term. To become and remain profitable, we must succeed in developing, obtaining regulatory approval for, and commercializing one or more of our product candidates. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing commercialization capabilities for any approved products, and achieving market acceptance for any approved products. We may never succeed in these activities. Even if we succeed in these activities, we may never generate revenue in an amount sufficient to achieve or sustain profitability.

Because of the numerous risks and uncertainties associated with biotechnology product development and commercialization, we are unable to accurately predict whether and when we will achieve profitability. If we are required by the FDA or any comparable regulatory authority in other jurisdictions to perform preclinical studies or clinical trials in addition to those we currently expect to conduct, or if there are any delays or complications in completing preclinical studies of our product candidates or, if preclinical studies are successful, in submitting an IND application, a BLA or an NDA to the FDA, manufacturing clinical trial supplies, and completing clinical trials for our product candidates, our expenses could increase substantially and our ability to achieve profitability could be further delayed. Even if we achieve profitability, we may not be able to sustain profitability in subsequent periods.

Risks Related to Regulatory Approval and Other Legal Compliance Matters

We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.

Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, dose selection and optimization, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising, and promotion, pricing, marketing, and distribution. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to

 

43

Table of Contents

unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through all required testing and obtain the regulatory approvals necessary for us to begin selling them.

We have not conducted, managed, or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority with respect to our product candidates. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity, and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often does change during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, changes in policy, or new initiatives during the period of drug development, clinical trials, and FDA regulatory review. For example, in the U.S., the FDA’s Project Optimus initiative has transformed the dose-finding and dose optimization paradigm across oncology to emphasize selection of a dose or doses that maximizes not only efficacy of a drug but its safety and tolerability as well, which could increase the development time and costs of our clinical trials. In addition, the European Union has transitioned to full implementation of the EU Clinical Trials Regulation in January 2022, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency transitioned the United Kingdom to a fully independent clinical trial regulatory framework, both of which could result in significant uncertainties and delays.

Any delay or failure in seeking or obtaining required approvals for a product candidate would have a material and adverse effect on our ability to generate revenue from such product candidate. Furthermore, any regulatory approval to market a product candidate may be subject to significant limitations on the approved uses or indications for which we may market such product candidate or the labeling or other restrictions of such product candidate. In addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy as part of approving an NDA or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved product candidate. These limitations and restrictions may significantly limit the size of the market for a product candidate and affect reimbursement by third-party payors.

We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing, and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes most if not all of the risks associated with FDA approval as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Any delay or failure in obtaining foreign regulatory approval for a product candidate would have a material and adverse effect on our ability to generate revenue from such product candidate in that foreign jurisdiction.

Our current or future product candidates may cause adverse events, toxicities, or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential, or result in significant negative consequences.

If our product candidates are associated with a high and unacceptable severity and prevalence of side effects or unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay, or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective. Such results could result in a more restrictive label, implementation of a Risk Evaluation and Mitigation Strategy or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences could result in a more restrictive label or the delay or

 

44

Table of Contents

denial of regulatory approval by the FDA or comparable foreign regulatory authorities and may prevent us from achieving or maintaining market acceptance of the affected product candidate, which could harm our business and prospects.

Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not previously observed. Some of our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if such product candidates are used in combination with other therapies, they may exacerbate adverse events associated with the other therapy. Patients treated with our product candidates may also be undergoing surgical, radiation, and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients’ illnesses.

If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to such clinical trials, patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of that product candidate altogether. We, the FDA, or other comparable regulatory authorities or an Institutional Review Board may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business and prospects.

Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates that were not seen during clinical trials may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, implementation of a Risk Evaluation and Mitigation Strategy, significant restrictions on use of the product, or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of such product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. A failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain jurisdictions. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates would be harmed.

 

45

Table of Contents

Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.

Any regulatory approvals we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of those product candidates, may contain significant limitations related to use restrictions, warnings, precautions, or contraindications, and may include burdensome post-approval studies or risk management requirements. For example, the FDA may require a Risk Evaluation and Mitigation Strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans, or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export, and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information, reports, and registration, as well as on-going compliance with cGMP requirements and good clinical practices for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:

 

  •  

delays in or the rejection of product approvals;

 

  •  

restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;

 

  •  

restrictions on the products, manufacturers, or manufacturing processes;

 

  •  

warning or untitled letters;

 

  •  

civil and criminal penalties;

 

  •  

injunctions;

 

  •  

suspension or withdrawal of regulatory approvals;

 

  •  

seizures, detentions, or import bans;

 

  •  

voluntary or mandatory recalls and publicity requirements;

 

  •  

total or partial suspension of production; and

 

  •  

imposition of restrictions on operations, including costly new manufacturing requirements.

The occurrence of any event or penalty described above could inhibit our ability to commercialize our product candidates and generate revenue, require us to expend significant time and resources in response, generate negative publicity, and harm our business and prospects.

There can be no assurance that we will be able to pursue accelerated or other expedited approval of any of our product candidates, and the failure to obtain such accelerated or other expedited approval would result in a longer time period to commercialization of such product candidates, which could increase the cost of development and harm our competitive position in the marketplace.

We may choose to seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant expedited approval to a product candidate designed to treat a

 

46

Table of Contents

serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that such product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit, the FDA may withdraw its approval of the drug.

There can be no assurance that we will decide to pursue, or subsequent to FDA feedback continue to pursue, accelerated approval or any other form of expedited development, review, or approval. Furthermore, even if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application would be accepted or that any expedited development, review, or approval would be granted on a timely basis or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for our product candidates would result in a longer time period to commercialization of such product candidates, could increase the cost of development of such product candidates, and could harm our competitive position in the marketplace.

We may be required to defend lawsuits or pay damages in connection with the alleged or actual violation of healthcare statutes such as fraud and abuse laws, and our corporate compliance programs cannot guarantee that we will always be in compliance with all relevant laws and regulations.

In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws, commonly referred to as “fraud and abuse” laws, have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. Other jurisdictions, such as Europe, have similar laws. These laws include false claims and anti-kickback statutes. Anti-kickback laws make it illegal for a manufacturer to offer or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase of a product. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed products or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.

Our activities relating to the sale and marketing of our products will be subject to scrutiny under these laws and regulations. It may be difficult to determine whether or not our activities comply with these complex legal requirements, and our corporate compliance programs cannot guarantee that we will always be in compliance with all relevant laws and regulations. Violations are punishable by significant criminal and civil fines and other penalties, as well as the possibility of exclusion of the affected product from coverage under governmental healthcare programs, including Medicare and Medicaid. If U.S. or foreign governments were to investigate or make allegations against us or any of our employees, or sanction or convict us or any of our employees, for violations of any of these legal requirements, this could have a material adverse effect on our business and prospects.

Our employees, agents, contractors, or collaborators may engage in misconduct or other improper activities.

We cannot ensure that our corporate compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators, including contract research organizations, electronic data capture companies, data management companies, contract clinical

 

47

Table of Contents

research associates, medical institutions, clinical investigators, contract laboratories, and other third parties, that would violate the laws or regulations of the jurisdictions in which we operate, including healthcare, employment, foreign corrupt practices, environmental, competition, and privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and civil penalties, and could adversely impact our business and prospects.

For example, we are subject to the Foreign Corrupt Practices Act and similar anti-bribery or anti-corruption laws, regulations, and rules of other countries in which we operate. The Foreign Corrupt Practices Act generally prohibits offering, promising, giving, or authorizing others to give, anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The Foreign Corrupt Practices Act also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities, and our dealings with these prescribers and purchasers are therefore subject to regulation under the Foreign Corrupt Practices Act.

There is no certainty that our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. While we have implemented codes of conduct and other policies and controls to mitigate the risk of non-compliance with anti-corruption and anti-bribery laws, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions stemming from a failure to comply with these laws or regulations. Violations of such laws and regulations could result in, among other things, administrative, civil and criminal fines and sanctions against us, our directors, officers, or employees, the closing of our facilities, requirements to obtain export licenses, exclusion from participation in federal healthcare programs including Medicare and Medicaid, implementation of compliance programs, integrity oversight and reporting obligations, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our business and prospects.

Risks Related to Our Dependence on Third Parties

Our manufacturing processes are complex, and we do not currently have our own manufacturing capabilities and will initially rely on third-party manufacturers for the development, clinical trials, and commercialization of any product candidate we may develop or sell.

The processes for manufacturing our product candidates, particularly our bioconjugation candidates, are very complex and take significant time and resources to develop and implement. In addition, our supply chain of raw materials, consumables, intermediates, drug substances, and drug products for use in our clinical trials and, if approved by regulatory authorities, commercialization rely on a worldwide supply chain. We do not currently operate our own manufacturing facilities or have our own manufacturing capabilities for clinical or commercial production of our product candidates under development and intend to initially rely on third-party manufacturers. Third-party manufacturers that have the capabilities, processes, and expertise that we need for our product candidates and that can meet our quality standards may be difficult to identify or retain, and even if retained, such third-party manufacturers may not be able to perform the manufacturing services we require within our planned timeframes. We anticipate relying on a limited number of third-party manufacturers until such time, if any, as we decide to expand our operations to include manufacturing capabilities. Certain of our key third-party manufacturers are located in China, and the United States and China are currently experiencing geopolitical tensions that could result in legislation or government intervention that adversely impacts our ability to manufacture in China, which could necessitate transitioning such manufacturing to other third-party manufacturers and increase costs, delay manufacturing, and lengthen timelines. In addition, the European Union,

 

48

Table of Contents

which is experiencing, and could continue to experience, the impact of the wars in Ukraine and Israel on supply chains, and other economic matters, including inflation. Such third-party manufacturers may implement, and certain of such manufacturers have implemented, price increases that could negatively impact our ability to afford their services.

If the FDA or comparable foreign regulatory authorities approve any of our product candidates for commercial sale, or if we significantly expand our clinical trials, we will need to manufacture them in larger quantities, and we may not be able to successfully increase the manufacturing capacity for any of our product candidates in a timely or economic manner or at all. Until such time, if any, that we directly control the manufacturing of our product candidates, we will have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance, and qualified personnel, and we will be dependent on our third-party manufacturing partners for compliance with current cGMP requirements for the manufacture of our product candidates. If our third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to secure or maintain regulatory approval for our product candidates. In addition, if any third-party manufacturer makes improvements in the manufacturing process for our product candidates, we may not own, or may have to share, the intellectual property rights to such improvements.

Any inability to identify and retain third-party manufacturers on a cost-effective basis, any performance failure on the part of such manufacturers, or any disruption in our supply chain as a result of economic uncertainty, political unrest, the wars in Ukraine and Israel, trade disputes, natural disasters, pandemics or epidemics, climate change, or otherwise, could delay the development, clinical trials, regulatory approval, or commercialization of our product candidates, which would harm our business and prospects.

If we fail to enter into and maintain successful collaborative arrangements or strategic alliances for our product candidates, we may have to reduce or delay our product candidate development or increase our expenditures.

An important element of our strategy for developing, manufacturing, and commercializing our product candidates is entering into collaborative arrangements or strategic alliances with pharmaceutical companies, research institutions, or other industry participants to advance our programs and enable us to maintain our financial and operational capacity. We face significant competition in seeking such collaborations and alliances. We may not be able to negotiate such collaborations or alliances on acceptable terms if at all. In addition, such collaborations or alliances may be unsuccessful. If we fail to create and maintain suitable collaborations or alliances, we may have to limit the size or scope of, or delay, one or more of our research or development programs. In addition, these kinds of collaborative arrangements and strategic alliances may place certain aspects of the development of our product candidates outside of our control, require us to relinquish important rights, limit our commercial opportunities, or otherwise be on terms unfavorable to us.

Dependence on collaborative arrangements or strategic alliances will subject us to several risks, including the risks that:

 

  •  

we may not be able to control the amount and timing of resources that our collaborators may devote to our product candidates;

 

  •  

our collaborators may experience financial difficulties;

 

  •  

we may be required to relinquish important rights such as marketing and distribution rights;

 

  •  

business combinations or significant changes in a collaborator’s business strategy may adversely affect its willingness or ability to complete its obligations under any arrangement;

 

  •  

a collaborator could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

 

  •  

collaborative arrangements are often terminated or allowed to expire, which would delay development and may increase the cost of developing our product candidates.

 

49

Table of Contents

Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.

As product candidates proceed through preclinical and clinical trials towards potential approval and commercialization, various aspects of the development program, such as manufacturing methods and formulation, may be altered along the way to optimize processes and results or due to other factors. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our current or future product candidates to perform differently and affect the costs, results, or timing of planned preclinical or clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification, or FDA approval. This could delay completion of preclinical studies or clinical trials, require the conduct of bridging clinical trials, or repetition of one or more clinical trials, increase clinical trial costs, delay approval of product candidates, or jeopardize our ability to commence sales and generate revenue.

Our applications for regulatory approval could be delayed or denied due to problems with studies conducted before we in-licensed the rights to some of our product candidates.

We currently license all of our product candidates from Bayer pursuant to the Bayer License Agreement. Our present development involving these product candidates relies to a certain extent upon previous development conducted by Bayer or other third parties over whom we had no control and before we in-licensed such product candidates. To receive regulatory approval of a product candidate, we must present all relevant data and information obtained during its development, including research conducted prior to our licensure of such product candidate. Although we are not currently aware of any such problems, any problems that emerge with preclinical or clinical development conducted prior to our in-licensing may affect future results or our ability to document prior development and conduct clinical trials, which could delay, limit, or prevent regulatory approval for our product candidates.

Due to our intention to rely in part on contract research organizations and other third parties to conduct clinical trials, we may be unable to directly control the timing, conduct, and expense of all aspects of our clinical trials.

We intend to rely in part on contract research organizations, electronic data capture companies, data management companies, contract clinical research associates, medical institutions, clinical investigators, contract laboratories, and other third parties to assist us in conducting clinical trials and obtaining regulatory approvals for our product candidates. In addition, we intend to rely in part on third parties to assist with our preclinical development of such product candidates. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, need to be replaced, or the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.

Risks Related to Our Intellectual Property

If we fail to comply with our obligations under any license, collaboration, or other agreement, including the Bayer License Agreement, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.

Pursuant to the Bayer License Agreement, we have been granted a license from Bayer to certain intellectual property rights covering VIP236, VIP943, VIP924, enitociclib, and our other product candidates. If, for any reason, our licenses under the Bayer License Agreement are terminated or we otherwise lose those rights, our business will be significantly and adversely affected. The Bayer License Agreement imposes, and any future collaboration agreements or license agreements we may choose to enter are likely to impose, various

 

50

Table of Contents

development, commercialization, funding, milestone payment, royalty, diligence, sublicensing, patent prosecution and enforcement, or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages, and Bayer and any other licensor, may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology or having to negotiate new or reinstated licenses on less favorable terms, or enable a competitor to gain access to the licensed technology.

Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:

 

  •  

the scope of rights granted under the license agreement and other interpretation-related issues;

 

  •  

the extent to which our product candidates, technology, and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

  •  

the sublicensing of patent and other rights under our third-party relationships;

 

  •  

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

 

  •  

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us, our licensors, and our partners; and

 

  •  

the priority of invention of patented technology.

In addition, the Bayer License Agreement under which we license our core intellectual property and technology is complex, and certain provisions in the agreement may be susceptible to multiple interpretations. The resolution of any disagreement that may arise as a matter of contract interpretation could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under that agreement, either of which could have a material adverse effect on our business and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidate, which could have a material adverse effect on our business and prospects.

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

Our commercial success depends in part on our ability to obtain and maintain intellectual property for VIP236, VIP943, VIP924, enitociclib, and our other product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our product candidates, technologies, and their uses that are important to our business. We also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending applications from third parties.

Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties.

Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our licensors’ proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or

 

51

Table of Contents

limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business and prospects.

Although we have licensed issued patents that cover certain of our product candidates and technologies, we do not have issued patents covering all our product candidates and technologies, and we may need additional issued patents covering such product candidates and technologies. We cannot be certain that the claims in any of our U.S. pending patent applications, corresponding international patent applications, or those of our licensors, will be considered patentable by the USPTO, courts in the U.S., or the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents or our licensor’s issued patents will not be found invalid or unenforceable if challenged.

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:

 

  •  

the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;

 

  •  

patent applications may not result in any patents being issued;

 

  •  

patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage;

 

  •  

our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek, or may have already obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential product candidates;

 

  •  

there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; and

 

  •  

countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates.

The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

In addition, although we enter non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, contract research organizations, third-party manufacturers, consultants, advisors, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection.

Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

 

52

Table of Contents

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.

The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications and those of our licensors may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.

In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents or the patents of our licensors by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business and prospects.

Furthermore, our ability to obtain and maintain valid and enforceable patents also depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period after filing, we may not be certain that we or our licensors are the first to file any patent application related to our drug product candidates or technologies, potentially having a material adverse effect on our business and prospects. This will require us to be to be aware of the possibility of adverse determinations in any such submissions or proceedings, potentially reducing the scope or enforceability of, or invalidate, our patent rights, which would adversely affect our competitive position.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or the patents of our licensors may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review and inter partes review, or other similar proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates, and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, our patents or the patents of our licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications and those of our licensors. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates.

 

53

Table of Contents

The validity, scope, and enforceability of any patents that cover a biologic subject to approval by the FDA via a BLA, such as VIP943 and VIP924, can be challenged by third parties.

For biologics subject to approval by the FDA via a BLA, such as VIP943 and VIP924, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell biosimilar or interchangeable versions of brand name biological products. If a biosimilar applicant successfully challenges our asserted patent claims, it could result in the invalidation of, or render unenforceable, some or all our relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend our intellectual property rights are complex in nature, may be very expensive and time-consuming, may divert our management’s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with VIP943 and VIP924 or any future biological product candidates.

We may be involved in lawsuits to protect or enforce our patents or our licensors’ patents, which could be expensive, time consuming, and unsuccessful. Further, our issued patents or our licensors’ patents could be found invalid or unenforceable if challenged in court.

Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable, or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patents or the patents of our licensors are invalid or unenforceable in whole or in part.

Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation, and prior art could render our patents or our licensors’ patents invalid. Such mechanisms include re-examination, post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents or our licensors’ patents in such a way that they no longer cover our current or future product candidates, technologies, or VersAptx platform. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or the patents and patent applications of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim.

If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates, technologies, or VersAptx platform. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patent and patent applications of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business and prospects. Moreover, the issuance of a patent does not necessarily give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented products and practicing our own patented technologies.

Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings

 

54

Table of Contents

adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.

Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline.

During any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs, or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business and prospects.

Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.

Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using relevant inventions or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party would not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue clinical trials or research programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.

Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

Obtaining and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property, increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents and weaken our ability to obtain new patents or to enforce our existing patents and the patents we might obtain or license in the future.

We may be subject to claims challenging the inventorship or ownership of our licensor’s patents, our patents and other intellectual property.

We may also be subject to claims that former employees or other third parties have an ownership interest in our licensor’s patents, our patents, or other intellectual property. Litigation or other proceedings may be necessary to defend against these and other claims challenging inventorship or ownership. For example, because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. If we fail in defending any such claims, in

 

55

Table of Contents

addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.

Patent terms may not protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from products of third parties. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we do not obtain patent term extension for our product candidates, our business may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our patents or in-licensed patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984. This Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and FDA regulatory review. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during FDA regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only those claims covering such approved drug product, a method for using it, or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, and defending patents in all countries throughout the world can be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our product candidates, and our patents, the patents of our licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing.

The requirements for patentability differ regionally. Some countries limit the enforceability of patents against government agencies or government contractors, while others have compulsory licensing laws under

 

56

Table of Contents

which a patent owner may be compelled to grant licenses to third parties. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business and prospects may be adversely affected.

The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies and product candidates. While we will endeavor protect our technologies and product candidates with intellectual property rights such as patents, the process of obtaining patents is time consuming, expensive, and unpredictable. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor patent enforcement and other intellectual property protection, which could make it difficult for us to stop infringement of our patents or our licensors’ patents or marketing of competing products in violation of our proprietary rights.

Beginning in March 2023, European patent applicants have the option of participating in the Unitary Patent System (“UPS”), subject to the jurisdiction of the Unitary Patent Court (“UPC”), on an issued patent-by-issued patent, or patent application-by-patent application basis. This new system is a significant change in European patent practice, and the UPC is a new court system, with no established legal precedent, resulting in uncertainty for patent holders and applicants. We will consider, case-by-case, with each individual patent or application, the risks and benefits of participating in the UPS. We will continue to monitor the evolution of the UPS and UPC, especially over the course of its seven-years’ transitional period as the new system and the new court gains footing.

Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of not issuing or being invalidated or interpreted narrowly and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution, maintenance, or enforcement of our patent applications or issued patents or those of any current or future licensors. For example, United States and foreign government actions related to Russia’s invasion of Ukraine have limited and prevented the filing, prosecution, and maintenance of patent applications and issued patents in Russia, and actions by the Russian government allow Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. These actions could adversely affect our business.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to the USPTO and various foreign patent offices at many points over the lifetime of our licensor’s patents and applications and those that we own. We rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with many procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the relevant jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business and prospects.

 

57

Table of Contents

If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be adversely affected.

We intend to use registered and unregistered trademarks or trade names to brand and market ourselves and our products and technologies. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential business partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks like ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of resources. If we are unable to enforce and protect our trademarks and tradenames and establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business and prospects could be adversely affected.

If we are unable to protect the confidentiality of our proprietary information, our business and competitive position would be harmed.

We rely on the protection of our proprietary information, including our technologies and know-how, to maintain our competitive position. Although we have taken steps to protect such information, including entering confidentiality agreements with third parties and confidential information and inventions agreements with employees, consultants, and advisors, we cannot provide any assurances that these parties would not breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies in the event of such breaches. Enforcing claims that a party illegally used or disclosed such information is difficult, expensive, and time-consuming, and the outcome is unpredictable. Moreover, third parties may obtain or come upon this or similar information independently, and we would have no right to prevent them from using that information to compete with us. If any of these events occurs or if we otherwise lose such protection, the value of our proprietary information may be greatly reduced, and our competitive position would be harmed.

We may be subject to claims that we or our employees, agents, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of third parties.

We have entered and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, contract research organizations, third-party manufacturers, consultants, advisors, potential partners, and other third parties. In addition, we may engage employees, agents, and consultants to assist us in the development of our product candidates who were previously employed at, or have previously provided or are currently providing services to, other pharmaceutical companies, including our competitors or potential competitors. We may become subject to claims or litigation where a third party asserts that we or our employees, agents, or consultants used or disclosed trade secrets or other information proprietary to such third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a diversion from our business, and we cannot predict whether we would prevail in any such actions. In addition, third parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity, result in the disclosure of our confidential information in discovery, and adversely impact our ability to market or otherwise commercialize our product candidates and technologies. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business and prospects. Even if we are successful in defending against such claims, such litigation could result in substantial costs and be a distraction to our management team and other employees.

 

58

Table of Contents

We may need to license intellectual property from third parties, and such licenses may not be available on commercially reasonable terms or at all.

Third parties may hold intellectual property, including patent rights, that are important or necessary to the development or commercialization of our product candidates. in which case we would be required to obtain a license from such third parties on commercially reasonable terms. Such a license may not be available, or it may not be available on commercially reasonable terms. Our business would be harmed if we are not able to obtain such a license on commercially reasonable terms or at all or if a non-exclusive license is offered and our competitors gain access to the same intellectual property rights. In addition, even if we are able to obtain such a license, we may not have control over, nor the ability to provide input with respect to, the prosecution, maintenance, or enforcement of the patents that we license, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.

Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development, and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale, or import our current or future product candidates, which could impair our competitive position. There is a substantial amount of litigation and administrative proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, inter partes review proceedings, and post-grant review proceedings. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates.

As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. There is also no assurance that prior art that we do not believe is relevant to our business may, ultimately, be found to limit our ability to make, use, sell, offer for sale, or import our current or future products and impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:

 

  •  

result in costly litigation that may cause negative publicity or, if we were found to be infringing willfully, result in treble damages;

 

  •  

require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology;

 

  •  

require us to develop non-infringing technology, which may not be possible on a cost-effective basis;

 

59

Table of Contents
  •  

cause development delays;

 

  •  

prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;

 

  •  

subject us to significant liability to third parties; or

 

  •  

divert the time and attention of our technical personnel and management.

Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent our product candidates from being marketed. For example, we are aware of issued patents that claim a method of treatment based upon a general mode of action. These claims could be alleged to cover enitociclib in certain treatment indications. While we believe that these patents are difficult to enforce and that we would have valid defenses to these claims of patent infringement, we cannot be certain that we would prevail in any dispute and we cannot be certain how an adverse determination would affect our business.

Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the large amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business and prospects.

We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings could distract our technical and management personnel from their normal responsibilities and may cause us to incur significant expenses, which could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. In addition, we may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could compromise our ability to compete in the marketplace. There could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. If we do not prevail in the patent proceedings, such third parties may assert a claim of patent infringement directed at our technologies or product candidates, which could have a material adverse effect on our business and prospects.

We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use third-party proprietary rights. We may be unable to acquire or in-license any compositions of matter, methods of use, processes, or other third-party intellectual property rights that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is competitive, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business and prospects.

 

60

Table of Contents

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

 

  •  

others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;

 

  •  

we or our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions;

 

  •  

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

 

  •  

it is possible that the pending patent applications we own or license will not lead to issued patents;

 

  •  

issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;

 

  •  

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

 

  •  

we may not develop additional proprietary technologies that are patentable;

 

  •  

the patents of others may have an adverse effect on our business; and

 

  •  

we may choose not to file a patent to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, it could significantly harm our business and prospects.

Risks Related to Operating as a Public Company

If we are not able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted, which could negatively impact the liquidity and price of our common stock, our ability to access the capital markets, and the confidence of investors and others.

On September 14, 2023, we received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the closing bid price of our common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. On January 12, 2024, we received written notice from Nasdaq that we had regained compliance with the minimum bid price requirement. However, there can be no assurance that we will be able to continue to maintain compliance with the Nasdaq continued listing requirements, and if we fail to do so and Nasdaq delists our common stock, we could face material adverse consequences, including:

 

  •  

limited availability of market quotations and decreased liquidity for our common stock, resulting in a decline in the trading price of our common stock;

 

  •  

adverse impact on the ability of stockholders to sell our common stock;

 

  •  

limited news and analyst coverage and negative publicity; and

 

  •  

decreased ability to raise capital and potential loss of confidence by investors, suppliers, customers, collaborators, and employees.

 

61

Table of Contents

As a public company, we face increased expenses and administrative burdens, which could have an adverse effect on our business, financial condition, and results of operations.

As a public company, we face increased legal, accounting, administrative, and other costs and expenses. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the Public Company Accounting Oversight Board, the securities exchanges, and the rules and regulations thereunder impose additional reporting and other obligations on public companies. Compliance with public company requirements results in increased costs and makes certain activities more time-consuming, including expenses associated with SEC reporting requirements. In addition, if any issues in complying with those requirements are identified (for example, if the auditors identify a material weakness or significant deficiency in our internal control over financial reporting), we could incur additional costs in rectifying those issues, and the existence of those issues could adversely affect our reputation or investor perceptions of us and also increase our costs of obtaining director and officer liability insurance. Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve on our board of directors or as executive officers. The additional reporting and other obligations imposed by these rules and regulations increase our legal and financial compliance costs and the costs of related legal, accounting, and administrative activities. These increased costs require us to divert a significant amount of money that could otherwise be used to expand our business and achieve our strategic objectives. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs.

We are an “emerging growth company” within the meaning of the Securities Act, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our stock less attractive to investors.

We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, and stockholder approval of any golden parachute payments not previously approved. We will cease to be an emerging growth company on the date that is the earliest of (a) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more, (b) December 31, 2025, the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years, or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in this report and our periodic reports and proxy statements.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and the market price of our common stock may be more volatile.

 

62

Table of Contents

Our failure to timely and effectively implement controls and procedures required by Section 404(a) of the Sarbanes-Oxley Act could have a material adverse effect on our business.

As a public company, we will be required to provide management’s attestation on internal controls in the future under Section 404(a) of the Sarbanes-Oxley Act. Management may not be able to effectively and timely implement controls and procedures that adequately respond to these increased regulatory compliance and reporting requirements. If we are not able to implement the additional requirements of Section 404(a) in a timely manner or with adequate compliance, we may not be able to assess whether our internal controls over financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our common stock.

Our management has limited experience in operating a public company.

Our executive officers have limited experience in the management of a publicly traded company and may not be able to effectively manage a public company that is subject to significant regulatory oversight and reporting obligations under federal securities laws. Their limited experience in dealing with the increasingly complex laws pertaining to public companies could be a significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities, which will result in less time being devoted to our management and growth. We may not have adequate personnel with the appropriate level of knowledge, experience, and training in the accounting policies, practices, or internal controls over financial reporting required of public companies in the United States. The development and implementation of the standards and controls necessary for us to achieve the level of accounting standards required of a public company in the United States may require costs greater than expected. It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company, which will increase our operating costs.

Any material weaknesses in or other inability to maintain effective internal control over financial reporting could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any changes and material weaknesses identified through such evaluation in those internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We have in the past and may in the future determine that there are material weaknesses in our internal control over financial reporting. Any material weaknesses or other inability to maintain effective internal control over financial reporting could adversely impact our ability to report our financial position and results of operations on a timely and accurate basis. If our consolidated financial statements are not accurate, investors may not have a complete understanding of our operations and may lose confidence in our financial reporting and our business, reputation, results of operations, liquidity, financial condition, stock price, and ability to access the capital markets could be adversely affected. In addition, we may be unable to maintain or regain compliance with applicable securities laws, stock market listing requirements, and covenants regarding the timely filing of periodic reports, we may be subject to regulatory investigations and penalties, and we may face claims invoking the federal and state securities laws. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business and prospects.

 

63

Table of Contents

General Risk Factors

Our stock price has been volatile and our stock has been thinly traded, and you may not be able to sell shares of our common stock at or above the price you paid.

The trading price of our common stock has been volatile and is subject to wide fluctuations. Since the completion of the Business Combination, our common stock has been thinly traded. As a result of the low trading volume of our common stock, the trading of relatively small quantities of shares by our stockholders could disproportionately influence the market price of our common stock in either direction. The price for our shares could, for example, decline significantly in the event that a large number of shares of our common stock are sold on the market without commensurate demand, as compared to an issuer with a higher trading volume that could better absorb those sales without an adverse impact on its stock price.

There are numerous factors that can influence our stock price volatility and trading volume, some of which are beyond our control. These factors could include:

 

  •  

our ability to develop or commercialize products;

 

  •  

results of our clinical trials and nonclinical studies;

 

  •  

our capital levels, capital requirements and capital raising activities, including issuances of securities or the incurrence of debt;

 

  •  

our ability to enter into and maintain collaboration arrangements;

 

  •  

actual or anticipated fluctuations in our financial results or the financial results of companies perceived to be similar;

 

  •  

changes in the market’s expectations about our operating results;

 

  •  

success of competitors;

 

  •  

our operating results failing to meet the expectation of securities analysts or investors in a particular period;

 

  •  

changes in financial estimates and recommendations by securities analysts concerning us or the oncology industry in general;

 

  •  

operating and share price performance of other companies that investors deem comparable to us;

 

  •  

changes in laws and regulations affecting our business;

 

  •  

our ability to meet compliance requirements and obtain regulatory approvals;

 

  •  

our ability to obtain and maintain proprietary protection for our current and future product candidates;

 

  •  

commencement of, or involvement in, litigation involving us;

 

  •  

the volume of shares of our common stock available for public sale;

 

  •  

any major change in our board of directors or management;

 

  •  

sales of shares of common stock by our directors, executive officers, or significant stockholders, or the perception that such sales could occur; and

 

  •  

general economic and political conditions such as recessions, interest rates, inflation, fuel prices, international currency fluctuations and acts of war or terrorism.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, particularly those in the

 

64

Table of Contents

biotechnology industry. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory, and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance.

Volatility in our stock price could subject us to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price declines and volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business and prospects.

If securities or industry analysts do not publish research or reports about us, or publish negative reports, our stock price and trading volume could decline.

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us. We do not have any control over these analysts. If our operating results fail to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.

Future sales of shares of our common stock may depress the market price of our common stock.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. As of December 31, 2023, private warrants to purchase 3,295,000 shares of common stock were outstanding. Additionally, up to 6,000,000 Earnout Shares may be issued in connection with the Merger Agreement, provided that certain conditions are met. To the extent such private warrants are exercised or otherwise converted into shares of our common stock or conditions to receive Earnout Shares are met, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the number of shares eligible for resale in the public market. Such shares are eligible for sale in the public market, subject to volume limitations under Rule 144 under the Securities Act with respect to shares held by directors, executive officers, and other affiliates, and certain of such shares are eligible for sale in the public market under our currently effective Registration Statement on Form S-3. Sales, or potential sales, of substantial numbers of shares in the public market could increase the volatility of, or adversely affect, the market price of our common stock.

Our Certificate of Incorporation provides, subject to limited exceptions, that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, or stockholders.

Our Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers, and employees for breach of fiduciary duty, and other similar actions may be brought solely and exclusively in the Court of Chancery in the State of Delaware or, if that court lacks subject matter jurisdiction, another federal or state court situated in the State of Delaware. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation. In addition, our Certificate of Incorporation and our Bylaws provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act and

 

65

Table of Contents

the Exchange Act. In March 2020, the Delaware Supreme Court found that an exclusive forum provision providing for claims under the Securities Act to be brought in federal court is facially valid under Delaware law. We intend to enforce this provision, but we do not know whether courts in other jurisdictions will agree with this decision or enforce it.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees, or stockholders, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business and prospects.

Concentration of ownership among our existing executive officers, directors, and their affiliates may prevent stockholders from influencing significant corporate decisions.

As of December 31, 2023, Dr. Ahmed M. Hamdy, our Chief Executive Officer, and Dr. Raquel E. Izumi, our President and Chief Operations Officer, together beneficially owned, directly or indirectly, approximately 17.7% of our outstanding common stock, and our directors and executive officers as a group beneficially owned approximately 23.3% of our outstanding common stock. As a result, these stockholders will be able to exercise significant influence on all matters requiring stockholder approval, including the election of directors, any amendment of our Certificate of Incorporation, and approval of significant corporate transactions.

We have never paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.

We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. In addition, we may enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.

 

ITEM 1B.

Unresolved Staff Comments.

None.

 

ITEM 1C.

Cybersecurity.

Risk Management and Strategy

We have developed and implemented a cybersecurity policy for assessing, identifying, and managing material risks from cybersecurity threats and have integrated this policy into our overall risk management framework and policies. This policy applies to all of our employees, contractors, and consultants, and any other users who have permanent or temporary access to our data and systems, regardless of their location, device, or network, and all of our employees, contractors, consultants and other users are expected to read, understand, and adhere to this policy and its associated processes and procedures.

Our cybersecurity policy also encompasses the risks associated with our use of third-party service providers. We conduct assessments of our third-party service providers before engagement and maintain ongoing monitoring intended to ensure compliance with our cybersecurity standards.

We are subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees, customers, or

 

66

Table of Contents

patients; violation of privacy laws; and litigation, legal, and reputational risk. We have implemented an approach to identify and assess the threats and vulnerabilities that could affect our data and systems. Our policy is aligned with industry standards and best practices, such as the National Institute of Standards and Technology’s (“NIST”) Cybersecurity Framework Standard (800-53 -Security and Privacy Controls for information Systems and Organizations).

Supporting technologies, processes, and procedures under our cybersecurity policy include the following:

 

  •  

identification, credential/authentication, and access management for all users prior to accessing any data and systems;

 

  •  

encryption of all data at rest and in transit for all devices and cloud services;

 

  •  

firewalls, antivirus software, security traffic inspections, and other endpoint protection and monitoring tools and techniques;

 

  •  

automatic updates and patches of all software and systems regularly and fix of all known or reported bugs or vulnerabilities promptly;

 

  •  

data loss prevention through regular backup of all data and systems and storage of backups in secure and separate locations;

 

  •  

cybersecurity awareness training for all users to educate them on our policy and procedures as well as best practices, potential vulnerabilities, and common threats and promote a culture of cybersecurity risk management;

 

  •  

cybersecurity incident response plans that include procedures for analyzing, reporting, and responding to cybersecurity incidents; and

 

  •  

third-party risk management procedures for service providers, suppliers, and vendors.

We maintain a security team to continuously monitor our data and technology infrastructure, report and respond to cybersecurity incidents, work with users, and report to management and the audit committee. We also maintain a cybersecurity risk insurance policy.

We have not encountered any cybersecurity incidents that have materially affected our business, results of operations, or financial condition.

Governance

Our board of directors considers cybersecurity risk as part of its overall risk oversight function and has delegated that oversight role to the audit committee. The audit committee oversees the implementation of our cybersecurity risk management under the cybersecurity policy.

The audit committee receives regular reports from management on our cybersecurity risks, controls, tools, and incidents. The audit committee reports to the full board of directors regarding its activities, including those related to cybersecurity.

Our Senior Director, IT, Document & Training Compliance, has primary responsibility for developing and implementing our cybersecurity policy and procedures and assessing, monitoring, and managing the prevention, detection, mitigation, and remediation of our cybersecurity risks and incidents. He has served in various roles in information technology and information security for over 20 years, and the IT team holds multiple industry-recognized certifications.

 

67

Table of Contents
ITEM 2.

Properties.

Our principal executive offices are located in Palo Alto, California, and our lease agreement for such space expires in December 2025. Vincerx Pharma GmbH, our wholly owned German subsidiary, leases space in Monheim am Rhein, Germany. We do not own any real property. We believe that our office space is adequate to meet our current needs and that additional facilities will be available on commercially reasonable terms to meet our future needs.

 

ITEM 3.

Legal Proceedings.

We are not currently a party to any legal proceedings, and are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

 

ITEM 4.

Mine Safety Disclosures.

Not applicable.

 

68

Table of Contents

PART II

 

ITEM 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock is listed on the Nasdaq Capital Market under the symbol “VINC.”

As of March 26, 2024, there were 10 holders of record of our common stock and two holders of record of our private warrants. These numbers exclude holders whose stock or warrants are held in “street name” by brokers.

We have not paid any cash dividends on the common stock to date. We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any future outstanding indebtedness we or our subsidiaries may incur. We do not anticipate declaring any cash dividends to holders of the common stock in the foreseeable future.

 

ITEM 6.

[Reserved].

 

ITEM 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and related notes appearing elsewhere in this report. This discussion may contain forward-looking statements based on current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled “Risk Factors” as set forth in this report. Historical results are not necessarily indicative of future results. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “Vincerx”, the “Company”, “we”, “us” and “our” refer to the business and operations of Vincerx prior to and following the closing of the Business Combination.

Overview

We are a clinical-stage biopharmaceutical company focused on leveraging our extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Our current pipeline is entirely derived from the Bayer License Agreement, pursuant to which we have been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute (i) a versatile and adaptable bioconjugation platform, now referred to as the VersAptx Platform, including next-generation ADCs VIP943, in Phase 1 trials, and VIP924, in preclinical studies, and VIP236, an SMDC, on Phase 1 trials, and (ii) a small molecule drug program, including enitociclib, a P-TEFb/CDK9 inhibitor in an NIH-sponsored Phase 1 trial. We intend to use these product candidates to treat various cancers in a patient-specific, targeted approach and believe these product candidates are differentiated from current programs targeting similar cancer biology and, if approved, may improve clinical outcomes of patients with cancer.

License Agreement with Bayer

Following the closing of the Business Combination, we paid Bayer a $5.0 million upfront license fee under the Bayer License Agreement. In addition, we will be responsible for significant development and commercial milestone payments to Bayer as well as ongoing royalties on commercial sales. See “Business—Bayer License Agreement” and the discussion below under “Liquidity and Capital Resources.”

 

69

Table of Contents

Basis of Presentation

We currently conduct our business through one operating segment. As a pre-revenue company with no commercial operations, our activities to date have been limited and were conducted primarily in the United States. Our historical results are reported under U.S. GAAP and in U.S. dollars.

Components of Results of Operations

We are a research and development stage company, and our historical results may not be indicative of our future results for reasons that may be difficult to anticipate. Accordingly, the drivers of our future financial results, as well as the components of such results, may not be comparable to our historical results of operations.

Revenue

To date, we have not recognized any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.

Research and Development Expense

Research and development expenses consist or will consist of preclinical development of our product candidates and discovery efforts (including conducting preclinical studies), manufacturing development efforts, preparing for and conducting clinical trials, and activities related to regulatory filings for our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Costs incurred in obtaining technology licenses through asset acquisitions are charged to research and development expense if the licensed technology has not reached technological feasibility and has no alternative future use. Research and development expenses include or could include:

 

  •  

employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts;

 

  •  

external research and development expenses incurred under agreements with clinical research organizations, investigative sites, and consultants to conduct our preclinical studies;

 

  •  

costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract manufacturing organizations;

 

  •  

laboratory supplies and research materials;

 

  •  

costs related to compliance with regulatory requirements; and

 

  •  

facilities, depreciation, and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance, and equipment.

Research and development activities are central to our business model. We do not currently track our research and development expenses on a program-by-program basis as such costs are deployed across multiple programs under development. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We anticipate that our research and development expenses will increase in the future as we continue to develop our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical and clinical programs. We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical

 

70

Table of Contents

and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, our ongoing assessments as to each product candidate’s commercial potential, and our capital resources. Our clinical development costs are expected to increase significantly as we commence, continue, and expand our clinical trials. Our future expenses may vary significantly each period based on factors such as:

 

  •  

expenses incurred to conduct preclinical studies required to advance our product candidates into clinical trials, including the impact of factors such as inflation, the wars in Ukraine and Israel, supply chain disruptions, and health pandemics and epidemics;

 

  •  

per patient clinical trial costs, including based on the number of doses that patients receive and the cost of drug products for combination therapies;

 

  •  

the number of patients who enroll in each clinical trial;

 

  •  

the number of clinical trials required for approval;

 

  •  

the number of sites included in the clinical trials;

 

  •  

the countries in which the clinical trials are conducted;

 

  •  

the length of time required to enroll eligible patients;

 

  •  

the drop-out or discontinuation rates of patients;

 

  •  

potential additional safety monitoring requested by regulatory agencies;

 

  •  

the duration of patient participation in the clinical trials and follow-up;

 

  •  

the phase of development of the product candidate;

 

  •  

third party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

 

  •  

the cost of insurance, including product liability insurance, in connection with clinical trials;

 

  •  

the availability of capital;

 

  •  

regulators or institutional review boards requiring that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; and

 

  •  

the efficacy and safety profile of our product candidates.

General and Administrative Expenses

General and administrative expenses consist or will consist principally of salaries and related costs for personnel in executive and administrative functions, including stock-based compensation, travel expenses, and recruiting expenses. Other general and administrative expenses include professional fees for legal, accounting, and tax-related services and insurance costs.

We anticipate that our general and administrative expenses will increase in the future as we expand our operations and infrastructure to support the initiation, continuation, and expansion of our preclinical studies and clinical trials for our product candidates. We also anticipate that our general and administrative expenses will increase as a result of payments for accounting, audit, legal, and consulting services, as well as costs associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer liability insurance, investor and public relations activities, and other expenses associated with operating as a public company.

 

71

Table of Contents

Change in Fair Value of Warrant Liabilities

Certain of our private warrants are classified as liabilities pursuant to ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity. The change in fair value of warrant liabilities consists of the change in fair value of these private warrants.

Results of Operations

Comparison of the Years Ended December 31, 2023 and 2022

The following table sets forth our historical operating results for the periods indicated (amounts in thousands):

 

     For the years ended
December 31,		         
     2023      2022      Amount
Change		  

Operating expenses:

         

General and administrative

    $ 13,636      $ 18,885      $ (5,249 ) 

Research and development

      28,973        49,837        (20,864 ) 

Restructuring

      —         2,469        (2,469 ) 
  

 

 

     

 

 

     

 

 

  

Total operating expenses

      42,609        71,191        (28,582 ) 
  

 

 

     

 

 

     

 

 

  

Loss from operations

      (42,609 )       (71,191 )       28,582  
  

 

 

     

 

 

     

 

 

  

Other income (expense)

         

Change in fair value of warrant liabilities

      (47 )       6,303        (6,350 ) 

Interest income

      1,251        664        587  

Other income (expense)

      1,248        1,240        8  
  

 

 

     

 

 

     

 

 

  

Total other income (expense)

      2,452        8,207        (5,755 ) 
  

 

 

     

 

 

     

 

 

  

Net loss

    $ (40,157 )     $ (62,984 )     $ 22,827  
  

 

 

     

 

 

     

 

 

  

Research and Development

Research and development expenses decreased by $20.9 million for the year ended December 31, 2023 compared to the year ended December 31, 2022. This decrease primarily relates to decreases in third party service and supplier expenses, including manufacturing services associated with our ADC program of approximately $9.7 million and clinical services of approximately $2.6 million, as well as decreases in expenses related to headcount, including declines in stock-based compensation of approximately $3.3 million and employee salaries of approximately $3.1 million as a result of our headcount reduction in June 2022.

General and Administrative

General and administrative expenses decreased by approximately $5.2 million for the year ended December 31, 2023 compared to the year ended December 31, 2022 primarily as a result of decreases in stock-based compensation expense of $2.8 million, professional services of $1.4 million, and a decrease in expenses related to headcount of $0.7 million.

Restructuring

On June 4, 2022, our board of directors approved a strategic plan to prioritize and focus our resources on certain of our enitociclib clinical studies and our next generation bioconjugation platform and streamline and realign our resources to support these prioritized studies. This plan included a reduction of full-time employees

 

72

Table of Contents

by 33% and other cost reduction measures. Affected employees were offered separation benefits, including severance and reimbursement of healthcare premium payments.

We incurred approximately $2.5 million of severance and related expenses for the year ended December 31, 2022. This includes approximately $0.5 million of stock-based compensation expense related to the acceleration of stock options to certain affected employees. No further restructuring expenses are expected to be incurred in connection with the restructuring.

Change in Fair Value of Warrant Liabilities

The change in fair value of warrant liabilities for the year ended December 31, 2023 compared to the prior year was primarily due to the decrease in the closing price of our common stock from $10.19 per share as of December 31, 2021 to $1.02 per share as of December 31, 2022, resulting in a $6.3 million gain in 2022. The closing stock price increased from $1.02 at December 31, 2022 to $1.18 at December 31, 2023, resulting in an immaterial change of approximately $50,000 to the fair value of our warrants.

Interest Income

Interest income is primarily comprised of interest income and gains or losses realized on cash, cash equivalents and marketable securities. The increase in interest income from $0.7 million for the year ended December 31, 2022 to $1.3 million for the year ended December 31, 2023 is a result of rising interest rates within our portfolio of cash equivalents and short-term marketable securities.

Other Income (Expense)

Other income (expense) is primarily comprised of estimated grant income of approximately $1.0 million earned in connection with our research activities conducted at our German subsidiary, partially offset by foreign currency transaction gains and losses related to certain transactions with European third-party vendors.

Liquidity and Capital Resources

Net working capital decreased from the year ended December 31, 2022 to the year ended December 31, 2023 by $37.7 million (to $9.1 million from $46.8 million) primarily as a result of cash used in operations of $40.5 million in fiscal 2023. In September 2021, we completed a private placement of 3.5 million shares of common stock, at a price of $14.50 per share. We received net proceeds from this private placement of approximately $47.4 million, after deducting transaction costs of approximately $3.3 million. We also received net proceeds of approximately $40.7 million from the redemption of warrants in 2021.

To date, we have not generated any revenue from any source, including the commercial sale of approved drug products, and we do not expect to generate revenue in the foreseeable future. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be materially adversely affected. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates.

We expect our operating expenses in 2024 to be comparable to 2023, subject to raising additional capital. We intend to prioritize resources towards advancing Phase I studies in these two lead programs and control spending, including discretionary spending, in other areas. We believe we can adjust our operating plan spending levels based on the timing of future clinical trials, which are predicated upon adequate funding to complete the trials. We routinely evaluate the status of our clinical development programs as well as potential strategic options. We will also be responsible for significant payments to Bayer under the Bayer License Agreement. We paid Bayer an upfront license fee of $5.0 million following the closing of the Business Combination. In addition,

 

73

Table of Contents

we are responsible to Bayer for significant future contingent payments under the Bayer License Agreement upon the achievement of certain development and commercial sales milestones as well as ongoing royalties on net commercial sales. As of December 31, 2022, the Company recorded a $1.0 million development milestone payable to Bayer, which was subsequently paid, in connection with our IND filing for VIP236. As of December 31, 2023, we paid another $1.0 million development milestone to Bayer in connection with our IND filing for VIP943. The size and timing of future milestone payments will vary greatly depending on factors such as the particular licensed product, whether it involves a P-TEFb licensed product or a bioconjugation licensed product (and which bioconjugation program), the number of distinct disease indications, the number of different countries with respect to which the milestone is achieved and the level of net commercial sales, and it is therefore difficult to estimate the total payments that could become payable to Bayer and when those payments would be due. If we achieve all of the milestones for each of the countries and disease indications, we would be obligated to pay development and commercial milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, we could be required to pay aggregate milestone payments in excess of $1.0 billion. We will be required to pay certain of these milestone payments prior to the time at which we are able to generate sufficient revenue, if any, from commercial sales of any of our product candidates. In addition to milestone payments, we are also required to pay Bayer under the Bayer License Agreement ongoing royalties in the single digit to low double-digit percentage range on net commercial sales of licensed products.

We therefore anticipate that we will need substantial additional funding in connection with our continuing operations. As of December 31, 2023, we had approximately $12.8 million in cash and cash equivalents. We intend to devote our capital resources to the preclinical and clinical development of our product candidates, our public company compliance costs, certain of the milestone payments under the Bayer License Agreement, and for working capital and other general corporate purposes. Based on our current business plans and assumptions, we believe that our existing capital resources will be sufficient to fund our operating expenses and capital requirements into early third quarter 2024. Our estimate as to how long we expect our existing capital to be able to fund our operating expenses and capital requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could result in less cash available to us or cause us to consume capital significantly faster than we currently anticipate, and we may need or choose to seek additional funds sooner than planned.

The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on our financial condition and the ability to pursue our business strategy, and we may have to reduce our workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail our business operations. In light of our existing cash resources and current and expected operating losses and negative cash flows, we will need additional capital prior to the one-year anniversary of the issuance of our audited consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, we have concluded that these circumstances and the uncertainties associated with our ability to obtain additional capital raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that our consolidated financial statements are issued.

Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical drug products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

 

  •  

the extent to which we develop, in-license, or acquire other product candidates and technologies in our product candidate pipeline;

 

  •  

the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;

 

74

Table of Contents
  •  

the number and development requirements of product candidates that we may pursue;

 

  •  

the costs, timing, and outcome of regulatory review of our product candidates;

 

  •  

the timing and amount of our milestone payments to Bayer under the Bayer License Agreement;

 

  •  

the extent to which we are able to enter into collaboration or other agreements that provide us with additional capital resources;

 

  •  

our headcount growth and associated costs to the extent we expand our research and development capabilities and establish and expand our commercial infrastructure and operations;

 

  •  

the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;

 

  •  

royalty payments to Bayer under the Bayer License Agreement;

 

  •  

the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims;

 

  •  

the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and

 

  •  

the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical development and studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of product candidates that we do not expect to be commercially available in the near term, if at all.

Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders, and the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

Our business operations, and those of third parties with whom we conduct business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including COVID-19, and by economic, business and political events, including inflation and the wars in Ukraine and Israel. The extent to which these factors could continue to impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on our current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on our financial position and results of operations.

 

75

Table of Contents

Contractual Obligations and Commitments

Leases

On December 23, 2020, we entered into a five-year term lease agreement which commenced on January 1, 2021. In April and May 2021, the lease was amended to include additional space. The annual rent payments are approximately $1.2 million.

In connection with our strategic plan and workforce reduction (see Note 5 to the audited consolidated financial statements included elsewhere in this report), we have consolidated our leased office space at our corporate headquarters location. Effective July 2022, we subleased substantially all of our unused office space for a term of 18 months at a base rent of $50,000 per month. Such payments received in the years ended December 31, 2023 and December 31, 2022 were $0.6 million and $0.3 million, respectively. In January 2024, the sublease was extended to include additional space for an additional 24 months at a base rent of approximately $50,000 per month.

Cash Flows

The following table provides a summary of our cash flow data for the periods indicated (amounts in thousands):

 

     For the years ended
December 31,		  
     2023      2022  

Net cash used in operating activities

    $ (40,453 )     $ (59,604 ) 

Net cash provided by (used in) investing activities

    $ 41,500      $ (40,578 ) 

Net cash provided by financing activities

    $ 114      $ 280  

Cash Flows from Operating Activities

Our cash flows used in operating activities to date have been primarily comprised of payroll and professional service fees related to manufacturing, preclinical development and studies, clinical trials, and general and administrative activities. As we continue to expand clinical trials of, and seek marketing approval for, our product candidates, we expect our cash used in operating activities to increase over time before we start to generate any material cash flows from our business.

Net cash used in operating activities was approximately $40.5 million for the year ended December 31, 2023 compared to $59.6 million for the year ended December 31, 2022. Significant components of our cash used in operating activities consist primarily of payments to clinical and manufacturing service providers, payroll costs, and third-party professional services as we engage in preclinical development and studies and prepare for and conduct our clinical trials. Our net loss during the year ended December 31, 2023 was approximately $40.2 million, which included approximately $3.6 million related to stock-based compensation.

Cash Flows from Investing Activities

Cash provided by investing activities was $41.5 million for the year ended December 31, 2023, consisting of sales and maturities of marketable securities of approximately $53.3 million used to fund our operating activities, offset by purchases of approximately $11.8 million. Cash used in investing activities was approximately $40.6 million for the year ended December 31, 2022, which consisted of purchases of marketable securities of $43.0 million, offset by $2.4 million of sales and maturities of marketable securities.

 

76

Table of Contents

Cash Flows from Financing Activities

Net cash provided by financing activities was $0.1 million and $0.3 million for the years ended December 31, 2023 and December 31, 2022, respectively, consisting of proceeds received from the issuance of common stock under our employee stock plans.

Off-Balance Sheet Arrangements

We are not a party to any off-balance sheet arrangements, as defined under SEC rules.

Critical Accounting Estimates

Our consolidated financial statements have been prepared in accordance with GAAP. In the preparation of these consolidated financial statements, the management is required to use judgment in making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods.

We consider an accounting judgment, estimate, or assumption to be critical when (1) the estimate or assumption is complex in nature or requires a high degree of judgment, and (2) the use of different judgments, estimates, and assumptions could have a material impact on the consolidated financial statements. Our significant accounting policies are described in Note 2 to our consolidated financial statements included elsewhere in this report. The critical accounting estimates are described below.

Research and Development

Research and development expenses may consist primarily of salaries, benefits, and other related costs and expenses, including stock-based compensation, in connection with preclinical development of our product candidates and discovery efforts (including conducting preclinical studies), manufacturing development efforts, preparing for and conducting clinical trials, and activities related to regulatory filings for our product candidates. In addition, research and development expenses may include payments to Bayer and other third parties for the development of our product candidates and the estimated fair value for the issuance of equity for the license rights to products in development (prior to marketing approval). Expenses related to clinical trials may be primarily related to activities at contract research organizations that design, gain approval for, and conduct clinical trials on our behalf. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed.

Contingent Milestone Payments

As described above, we will be responsible for significant payments to Bayer under the Bayer License Agreement. We will be responsible to Bayer for significant future contingent payments under the Bayer License Agreement upon the achievement of certain development, regulatory, and commercial sales milestones. The size and timing of these milestone payments will vary greatly depending on numerous factors outlined above.

The transactions provided for under the Bayer License Agreement will be accounted for as an asset acquisition. Contingent consideration in an asset acquisition is generally recognized when it is probable that a liability has been incurred, and the amount can be reasonably estimated. In connection with the successful filings of each of our IND for VIP236 in December 2022 and our IND for VIP943 in August 2023, we have paid $1.0 million development milestone payments to Bayer under the Bayer License Agreement. No further milestone payments are probable, and no further liabilities had been incurred as of the date of this filing.

 

77

Table of Contents

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit carryforwards. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We have recorded a full valuation allowance to reduce our net deferred income tax assets to zero. In the event we were to determine that we would be able to realize some or all of our deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made.

Stock-Based Compensation

We recognize the cost of share-based awards granted to employees, non-employees, and directors based on the estimated grant-date fair value of the awards. Cost is recognized on a straight-line basis over the service period, which is generally the vesting period of the award. We reverse previously recognized costs for unvested options in the period that forfeitures occur. We determine the fair value of stock options using the Black-Scholes option pricing model, which is impacted by the following assumptions:

 

  •  

Expected Term—We use the simplified method when calculating the expected term due to insufficient historical exercise data.

 

  •  

Expected Volatility—Given the limited market trading history of our common stock, volatility is based on a benchmark of comparable companies within the biopharmaceutical industry.

 

  •  

Expected Dividend Yield—We have never paid any cash dividends on common stock and do not anticipate doing so in the foreseeable future.

 

  •  

Risk-Free Interest Rate—The interest rates used are based on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award.

Private Common Stock Warrant Liabilities

As of December 31, 2023, there were 3,295,000 private warrants to purchase common stock outstanding.

Each unit consisted of one share of common stock and one public warrant exercisable for one-half of one share of common stock. Each public warrant entitled the registered holder to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination.

The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by us (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants; provided, however, that such redemption rights may not be exercised during the first 12 months following the closing of the Business Combination unless the

 

78

Table of Contents

last sales price of our common stock has been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the date on which notice of redemption is given), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC, will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.

We evaluated the public and private warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post-Business Combination, these private warrants could be transferred to a non-permitted transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a fixed-for-fixed option on our common stock, these private warrants fail the indexation guidance in ASC 815-40. This conclusion excludes the 500,000 private warrants held by LifeSci Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above.

Since these private warrants meet the definition of a derivative under ASC 815, we recorded these warrants as liabilities on the balance sheet at fair value, with subsequent changes in their respective fair values recognized in the consolidated statement of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. The private warrants were valued as of December 31, 2023 and December 31, 2022. See Note 6 to the audited consolidated financial statements in this report.

Emerging Growth Company Status

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable.

We are an “emerging growth company” as defined in Section 2(a) of the Securities Act and have elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. We expect to remain an emerging growth company through the end of the 2025 fiscal year and expect to continue to take advantage of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used.

Recent Accounting Pronouncements

See Note 2 to the audited consolidated financial statements in this report for more information about recent accounting pronouncements, the timing of their adoption, and our, to the extent it has made one, review of their potential impact on our financial condition and results of operations and cash flows.

 

79

Table of Contents
ITEM 7A.

Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business, including the effects of interest rate changes and fluctuations in foreign currency exchange rates. Information on quantitative and qualitive disclosures about these market risks is set forth below.

Interest Rate Risk

Cash and restricted cash consists solely of cash held in depository accounts and as such are not affected by either an increase or decrease in interest rates. Furthermore, we consider all highly liquid investments as cash equivalents. As of December 31, 2023, we possess cash equivalents. The short-term nature of these investments are not significantly impacted by changes in the interest rates. Any interest-bearing instruments carry a degree of risk; however, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.

Foreign Currency Risk

Our operations are principally denominated by U.S. dollars and we do not expect our future operating results to be significantly affected by foreign currency transaction risk. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements.

 

80

Table of Contents
P2Yhttp://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of
Vincerx Pharma, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Vincerx Pharma, Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the entity has incurred recurring losses from operations and expects to continue to incur operating losses that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, audits of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ WithumSmith+Brown, PC
We have served as the Company’s auditor since 2020
.
East Brunswick, New Jersey
March 29, 2024
PCAOB ID Number 100
 
8
2
Vincerx Pharma, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
 
    
December 31,
2023
    
December 31,
2022
  
ASSETS
     
Current assets:
     
Cash and cash equivalents
    $ 12,782     $ 11,663  
Restricted cash
      72       70  
Short-term marketable securities
      —        40,796  
Prepaid expenses
      51       134  
Grant receivable
      1,044       1,372  
Other current assets
      784       1,929  
  
 
 
    
 
 
  
Total current assets
      14,733       55,964  
Right-of-use
assets, net
      2,201       3,064  
Property, plant and equipment, net
      125       177  
Other assets
      1,158       81  
  
 
 
    
 
 
  
Total assets
   
$
18,217
 
  
$
59,286
 
  
 
 
    
 
 
  
LIABILITIES AND STOCKHOLDERS’ EQUITY
     
Current liabilities
     
Accounts payable
    $ 2,497     $ 4,065  
Accrued expenses
      1,755       3,923  
Lease liability
      1,162       1,024  
Common stock warrant liabilities
      191       144  
  
 
 
    
 
 
  
Total current liabilities
      5,605       9,156  
Lease liability, net of current portion
      1,340       2,412  
Other noncurrent liabilities
      50       50  
  
 
 
    
 
 
  
Total liabilities
      6,995       11,618  
  
 
 
    
 
 
  
Commitments and contingencies
 
(
Note 9
)
     
Stockholders’ equity
     
Preferred stock, $0.0001 par value; 30,000,000 shares authorized, none issued and outstanding as of December 30, 2023 and 2022
      —        —   
Common stock, $0.0001 par value; 120,000,000 shares authorized; 21,407,510 shares and 21,242,884 shares issued and outstanding as of December 31, 2023 and 2022, respectively
      2       2  
Additional
paid-in
capital
      170,324       166,647  
Accumulated other comprehensive income (loss)
      8       (26 ) 
Accumulated deficit
      (159,112 )      (118,955 ) 
  
 
 
    
 
 
  
Total stockholders’ equity
      11,222       47,668  
  
 
 
    
 
 
  
Total liabilities and stockholders’ equity
   
$
18,217
 
  
$
59,286
 
  
 
 
    
 
 
  
The accompanying notes are an integral part of these consolidated financial statements.
 
8
3
Vincerx Pharma, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
 
    
For the years ended
December 31,
  
    
2023
    
2022
  
Operating expenses:
     
General and administrative
    $ 13,636     $ 18,885  
Research and development
      28,973       49,837  
Restructuring
      —        2,469  
  
 
 
    
 
 
  
Total operating expenses
      42,609       71,191  
  
 
 
    
 
 
  
Loss from operations
      (42,609 )      (71,191 ) 
  
 
 
    
 
 
  
Other income (expense)
     
Change in fair value of warrant liabilities
      (47 )      6,303  
Interest income
      1,251       664  
Other income (expense), net
      1,248       1,240  
  
 
 
    
 
 
  
Total other income (expense)
      2,452       8,207  
  
 
 
    
 
 
  
Net loss
   
$
(40,157
) 
  
$
(62,984
) 
Other comprehensive income (loss):
     
Net foreign currency translation gain (loss)
      (40 )      69  
Net unrealized gain (loss) on marketable securities
      74       (74 ) 
  
 
 
    
 
 
  
Comprehensive loss
   
$
(40,123
) 
  
$
(62,989
) 
  
 
 
    
 
 
  
Net loss per common share, basic and diluted
    $ (1.89 )    $ (3.00 ) 
  
 
 
    
 
 
  
Weighted average common shares outstanding, basic and diluted
      21,295       21,029  
  
 
 
    
 
 
  
The accompanying notes are an integral part of these consolidated financial statements.
 
8
4
Vincerx Pharma, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
For the years ended December 31, 2023 and 2022
(In thousands)
 
    
 

Common Stock
     
Additional
Paid-in

Capital
     
Accumulated
Other
Comprehensive
Income (Loss)
    
Accumulated
Deficit
    
Total
Stockholders’
Equity
  
    
Shares
     
Amount
  
Balance as of January 1, 2022
   
 
21,057
 
   
$
2
 
   
$
156,311
 
   
$
(21
) 
  
$
(55,971
) 
  
$
100,321
 
Issuance of common stock from employee stock plans
      186        —         280        —        —        280  
Stock-based compensation
      —         —         10,056        —        —        10,056  
Cumulative translation adjustment
      —         —         —         69       —        69  
Unrealized loss on marketable securities
      —         —         —         (74 )      —        (74 ) 
Net loss
      —         —         —         —        (62,984 )      (62,984 ) 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance as of December 31, 2022
   
 
21,243
 
   
 
2
 
   
 
166,647
 
   
 
(26
) 
  
 
(118,955
) 
  
 
47,668
 
Issuance of common stock from employee stock plans
      165        —         114        —        —        114  
Stock-based compensation
      —         —         3,563        —        —        3,563  
Cumulative translation adjustment
      —         —         —         (40 )      —        (40 ) 
Unrealized gain on marketable securities
      —         —         —         74       —        74  
Net loss
      —         —         —         —        (40,157 )      (40,157 ) 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance as of December 31, 2023
   
 
21,408
 
   
$
2
 
   
$
170,324
 
   
$
8
 
  
$
(159,112
) 
  
$
11,222
 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
The accompanying notes are an integral part of these consolidated financial statements.
 
8
5
Vincerx Pharma, Inc.
Consolidated Statements of Cash Flows
(In thousands)
 
    
For the years ended
December 31,
  
    
2023
    
2022
  
Cash Flows from Operating Activities
     
Net loss
    $ (40,157 )    $ (62,984 ) 
Adjustments to reconcile net loss to net cash used in operating activities:
     
Depreciation and amortization
      52       54  
Stock-based compensation
      3,563       10,056  
Amortization of
right-of-use
assets
      863       885  
Change in fair value of warrant liabilities
      47       (6,303 ) 
Net amortization of discounts on marketable securities
      (630 )      (292 ) 
Changes in operating assets and liabilities:
     
Prepaid and other current assets
      1,228       (3,158 ) 
Grant receivable
      328       200  
Other assets
      (1,077 )      1,372  
Accounts payable
      (1,568 )      1,046  
Accrued expenses
      (2,168 )      208  
Lease liabilities
      (934 )      (738 ) 
Other noncurrent liabilities
      —        50  
  
 
 
    
 
 
  
Net cash used in operating activities
      (40,453 )      (59,604 ) 
  
 
 
    
 
 
  
Cash Flows from Investing Activities:
     
Purchases of marketable securities
      (11,821 )      (42,978 ) 
Sales and maturities of marketable securities
      53,321       2,400  
  
 
 
    
 
 
  
Net cash provided by (used in) investing activities
      41,500       (40,578 ) 
  
 
 
    
 
 
  
Cash Flows from Financing Activities:
     
Proceeds from issuance of common stock from employee stock plans
      114       280  
  
 
 
    
 
 
  
Net cash provided by financing activities
      114       280  
  
 
 
    
 
 
  
Effect of exchange rate changes on cash, cash equivalents and restricted cash
      (40 )      71  
  
 
 
    
 
 
  
Net increase (decrease) in cash, cash equivalents and restricted cash
      1,121       (99,831 ) 
Cash, cash equivalents and restricted cash at beginning of year
      11,733       111,564  
  
 
 
    
 
 
  
Cash, cash equivalents and restricted cash at end of year
   
$
12,854
 
  
$
11,733
 
  
 
 
    
 
 
  
Supplemental disclosure of cash flow information:
     
Cash paid for interest
    $ —    $ —   
Cash paid for taxes
    $ —    $ —   
The accompanying notes are an integral part of these consolidated financial statements.
 
8
6
Vincerx Pharma, Inc.
Notes to Consolidated Financial Statements
December 31, 2023 and 2022
1. Nature of Business
LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”).
The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 4), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and
know-how
to develop, use, manufacture, commercialize, sublicense, and distribute a clinical-stage and
follow-on
small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach.
The Company’s business operations, and those of third parties with whom the Company conducts business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including
COVID-19,
and by economic, business and political events, including inflation and the wars in Ukraine and Israel. The extent to which these factors could continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on the Company’s current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations.
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). They include the accounts of Vincerx and its wholly-owned subsidiaries, VNRX Corp., Vincerx Pharma GmbH and Vincerx Pharma Australia Pty Limited. All intercompany accounts and transactions have been eliminated.
Liquidity and Going Concern
As of December 31, 2023, the Company had approximately $12.8 
million in cash and cash equivalents. The Company has incurred recurring operating losses and negative cash flows from operating activities since its inception and expects to continue to incur operating losses and negative cash flows in the future. Based on current business plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early third quarter 2024, although this estimate is based on plans and assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Accordingly, the Company will need to raise additional capital through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other 
 
8
7
sources, and such additional capital may not be available on favorable terms or at all, particularly in light of the current economic and market conditions. Market volatility resulting from pandemics or other epidemics, inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain the listing on The Nasdaq Capital Market of the Company’s common stock, and other factors could also adversely impact the Company’s ability to raise additional capital. The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on the Company’s financial condition and the ability to pursue its business strategy, and the Company may have to reduce its workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail its business operations.
In accordance with Accounting Standards Update (“ASU”)
2014-15,
Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic
205-40),
the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. In light of the Company’s existing cash resources and current and expected operating losses and negative cash flows, the Company
w
ill
 need additional capital prior to the
one-year
anniversary of the issuance of its consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, the Company has concluded that these circumstances and the uncertainties associated with its ability to obtain additional capital raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business, and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Revision of Previously Reported Consolidated Financial Statements
In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified an error in the computation of stock-based compensation that resulted in an overstatement of stock-based compensation of approximately $2.4 million for the year ended December 31, 2022. This error resulted from the erroneous inclusion of unvested forfeited awards that should have been excluded in the calculation of stock-based compensation. As a result, net loss for the year ended December 31, 2022 and the balances of accumulated deficit and additional paid in capital at December 31, 2022 were also overstated. The error did not impact the Company’s cash flows from operating activities, financing activities and investing activities.
Management assessed the materiality of this presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250,
 
Accounting Changes and Error Corrections
 
(“ASC 250”). Based on this assessment, management concluded that this error did not have a material impact on the prior period stated above. However, the amount of the prior period error in 2022 would have been material to the consolidated financial statements for fiscal year 2023 if the correction of the error was recognized in fiscal year 2023 or left uncorrected. Therefore, the Company has revised the prior
 
8
8
period financial statements impacted for this error. The impact of the revision on the 2022 consolidated financial statements is as follows:
 
 
  
As of December 31, 2022
 
 
  
As Previously

Reported
 
  
Revision
 
  
As Revised
 
Balance Sheet
         
Stockholders’ equity
         
Preferred stock - $ 0.0001 par value
   
$
 		 —      
$
 		 —      
$
 		 —   
Common stock - $ 0.0001 par value
      2        —         2  
Additional
paid-in-capital
      169,030        (2,383 )       166,647  
Accumulated other comprehensive loss
      (26 )          (26 )
Accumulated deficit
      (121,338 )       2,383        (118,955 )
  
 
 
     
 
 
     
 
 
  
Total stockholders’ equity
      47,668        —         47,668  
  
 
 
     
 
 
     
 
 
  
Total liabilities and stockholders’ equity
    $ 59,286      $ —       $ 59,286  
  
 
 
     
 
 
     
 
 
  

 
  
Year Ended December 31, 2022
 
 
  
As Previously
Reported
 
  
Revision
 
  
As Revised
 
 
  
(In thousands, except per share amounts)
 
Statement of Operations and Comprehensive Loss
         
Operating expenses
    $ 73,574      $ (2,383 )     $ 71,191  
  
 
 
     
 
 
     
 
 
  
Loss from operations
      (73,574 )       2,383        (71,191 ) 
  
 
 
     
 
 
     
 
 
  
Other income (expense):
         
Change in fair value of warrant liabilities
      6,303        —         6,303  
Interest income
      664        —         664  
Other income (expense), net
      1,240        —         1,240  
  
 
 
     
 
 
     
 
 
  
Total other income
      8,207        —         8,207  
  
 
 
     
 
 
     
 
 
  
Net loss
    $  (65,367 )     $ 2,383      $  (62,984 ) 
  
 
 
     
 
 
     
 
 
  
Comprehensive loss
    $  (65,372 )     $ 2,383      $  (62,989 ) 
 
  
 
 
 
  
 
 
 
  
 
 
 
Net loss per common share, basic and diluted
    $ (3.11 )    
$
 
(0.11
 )    $ (3.00 ) 
Weighted average common shares outstanding, basic and diluted
      21,029        —        21,029  
The impact of the revision on quarterly unaudited consolidated financial statements is as follows
:
 stock-based compensation expense for the second and third quarters of 2022 were overstated by approximately $2.2 million and $0.3 million, respectively
, and understated by approximately $0.1 million in the fourth quarter of 2022.
Stock-based compensation for the first 
a
n
d
 second quarters of 2023 were understated by approximately $0.3 million 
a
n
d
 $0.4 million
,
 respectively
, and overstated by approximately $0.7 million in the third quarter of 2023
.
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
 
8
9
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of
consolidated
 
financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the
c
onsolidated
financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie
nce
and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Reclassifications
Certain previously reported financial information has been reclassified to conform to the current period presentation. The impact of reclassifications was not significant to the prior year’s overall presentation. These reclassifications had no effect on the reported results of operations.
Concentrations of Credit Risk
The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.
The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products.
The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company.
Cash and Cash Equivalents
Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.
 
9
0
Restricted Cash
Restricted cash represents cash deposits with a financial institution in support of the Company’s corporate credit card program.
Marketable Securities
The Company generally invests its excess cash in money market funds and investment grade short-term to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities or long-term marketable securities on the consolidated balance sheets. Marketable securities with a maturity date greater than 90 days and less than one year at each consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year, if any, are classified as long-term. All of the Company’s marketable securities are considered
available-for-sale
and are reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income on the consolidated statements of operations and comprehensive loss. The cost of securities sold is determined using specific identification.
The Company periodically evaluates whether declines in the fair values of its marketable securities below their amortized cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the marketable security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company’s strategy and intentions for holding the marketable security.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. 
The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. There has been no impairment loss as of December 31, 2023.
Fair Value Measurement
The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance
 
9
1
established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Level 1—Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Private Warrant Liability
As of December 31, 2023 and 2022, there were 3,295,000 private warrants to purchase common stock outstanding. As of December 31, 2020, there were 10,133,767 warrants outstanding, consisting of 6,563,767 public warrants (which included 2,744,586 public warrants constituting part of the units) and 3,570,000 private warrants. Each unit consisted of one share of common stock and one public warrant exercisable for
one-half
of one share of common stock.
Each public warrant entitled the registered holder to purchase
one-half
(1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination.
The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants, provided that such redemption rights could not be exercised during the first 12 months following the closing of the Business Combination unless the sales price of the Company’s common stock had been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.
The Company evaluated the public and private warrants under ASC
815-40,
Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post Business Combination, these private warrants could be transferred to a
non-permitted
transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a
fixed-for-fixed
option on the Company’s common stock, these private warrants fail the indexation guidance in ASC
815-40.
This conclusion excludes the 500,000 private warrants held by LifeSci
 
9
2
Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above.
Since these private warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. 
Leases
The
 Company adopted FASB ASC Topic 842, “Leases” (“ASC 842”), using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 840, “Leases”.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as
right-of-use
assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Operating lease liabilities and their corresponding
right-of-use
assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the
right-of-use
assets may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 9).
In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building) and
non-lease
components (e.g., common area maintenance, consumables). The fixed and
in-substance
fixed contract consideration (including any consideration related to
non-components)
must be allocated based on the respective relative fair values to the lease components and
non-lease
components.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as a single operating segment.
Research and Development Costs
The Company expenses research and development costs as operating expenses as incurred. These expenses include acquired
in-process
research and development expenses for which there is no alternative future use, salaries for research and development personnel, consulting fees, product development,
pre-clinical
studies, clinical trial costs, and other fees and costs related to the development of the technology.
Stock-Based Compensation
The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and
non-employees,
including stock options and restricted shares, based on estimated fair values recognized over the requisite service period.
 
9
3
The fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. No awards have been issued with a market condition or other
non-standard
terms.
The estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risk profiles, volatility, capital intensity and market growth patterns and drivers.
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.
Income Taxes
Income taxes are recorded in accordance with ASC 740, “Income Taxes” (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit (“R&D Credit”) carryforwards. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2023 and 2022, the Company had no liability for income tax associated with uncertain tax positions. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There was no income tax interest or penalties incurred in 2023 or 2022.
German Grant Income
In accordance with ASC 958, the
Company recognizes grant income in the period when the underlying eligible expenses are incurred. The German government grant program provides for tax refunds or direct reimbursements of eligible
research expenses
of up to 1.0 million euros per year over a period of six years. The grant was approved in 2022 and is retroactive to 2021. Grant income for the years ended December 31, 2023 and 2022 has been recorded in other income (expense), net on the consolidated statements of operations and comprehensive loss. The corresponding receivable is included within current assets and other assets, $1.0 million and $1.0 million, respectively, at December 31, 2023 on the consolidated balance sheet depending upon expectations for collection within twelve months of the balance sheet date.
 
9
4
Foreign Currency Translation and Transactions
The consolidated financial statements are presented in U.S. dollars. The functional currency for the Company’s foreign subsidiaries is the local currency. Expenses, gains and losses for this entity are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities are translated using exchange rates in effect at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company’s consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in the functional currency are recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss.
Comprehensive Income or Loss
Comprehensive loss is equal to net loss, net foreign currency translation gain (loss), and net unrealized gain (loss) on marketable securities as presented in the accompanying consolidated statements of operations and comprehensive loss.
Net Loss per Share of Common Stock
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period.
Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported losses for all periods presented, all potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.
Recent Accounting Pronouncements
In November 2023, Financial Accounting Standards Board (“FASB”) issued ASU
No. 2023-07
“Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU
2023-07
requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. The Company expects to adopt this guidance on January 1, 2025 on a retrospective basis and has yet to assess the impact to the consolidated financial statements.
In December 2023, FASB issued ASU
No. 2023-09
“Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU
2023-09
requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. The Company expects to adopt this guidance on January 1, 2025. The Company expects the adoption of this standard to result in increased disclosures in its notes to consolidated financial statements.
3. Business Combination
As discussed in Note 1, on December 23, 2020, the Company consummated the Business Combination, with Legacy Vincera Pharma surviving the merger as a wholly-owned subsidiary of the Company.
Immediately prior to the effective time of the Business Combination, each share of Legacy Vincera Pharma Common Stock was canceled, and the Legacy Holders received (i) 0.570895 shares of common stock, for each share of Legacy Vincera Pharma Common Stock held by them immediately prior to the effective time of the Business Combination and (ii) certain rights to Earnout Shares after the closing of the Business Combination.
 
9
5
The Legacy Holders are entitled to receive Earnout Shares if the daily volume-weighted average price of the Company’s common stock equals or exceeds the following prices for any 20 trading days within any
30 trading-day period
following the closing of the Business Combination: (1) during any such trading period prior to the 42 month anniversary of the closing of the Business Combination, upon achievement of a daily volume-weighted average price of at least $20.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; (2) during any such trading period prior to the six year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $35.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; and (3) during any such trading period prior to the eight year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $45.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share. A total of 90.6% of (rounded to the nearest whole share) of the Earnout Shares then earned and issuable shall be issued to the Legacy Holders on
a pro-rata basis
based on the percentage of the number of shares of Vincera Pharma Common Stock owned by them immediately prior to the closing of the Business Combination, and the remaining Earnout Shares that would otherwise have been issuable shall not be issuable to the Legacy Holders but in lieu thereof the number of authorized shares available for issuance under the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) shall be automatically increased by an equivalent n
u
mber of shares of the Company’s common stock.
4. Bayer License Agreement
On October 7, 2020, Legacy Vincerx Pharma entered into the Bayer License Agreement, which became effective on December 23, 2020 upon the closing of the Business Combination. Pursuant to the Bayer License Agreement, Legacy Vincerx Pharma has an exclusive, worldwide, royalty-bearing license under certain Bayer patents
and know-how to
develop, use, manufacture, commercialize, sublicense and distribute (i) a clinical-stage and
follow-on
small molecule drug platform, including a
P-TEFb
inhibitor compound, and (ii) a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates.
Following the closing of the Business Combination, the Company paid Bayer a $5.0 million upfront license fee on January 5, 2021. During 2022 and 2023, the Company recorded $1.0 million in development milestones payable to Bayer in connection with the Company’s IND filings for VIP236 and VIP943, respectively. Each of these milestone obligations were expensed as incurred.
If the Company achieves all of the development and commercial sales milestones for license products under the Bayer License Agreement for each of the countries and disease indications, the Company would be obligated to pay milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, the Company could be required to pay aggregate milestone payments in excess of $1 billion. In addition to milestone payments, the Company is also required to pay Bayer under the Bayer License Agreement ongoing royalties in the single digit to low double-digit percentage range on net commercial sales of licensed products.
5. Restructuring
On June 4, 2022, the Board of Directors of the Company approved a strategic plan to prioritize and focus its resources on certain of its enitociclib 
clinical studies and its next generation bioconjugation platform and streamline and realign its resources to support these prioritized studies. This plan included a reduction of the Company’s full-time employees by 33% and other cost reduction measures. Affected employees were offered separation benefits, including severance payments, payments to cover premiums for continuation of healthcare coverage for a limited period and in some cases vesting acceleration on certain outstanding stock options.
The Company incurred approximately $2.5 million of severance and related expenses during 2022, which includes approximately $0.5 million of stock-based compensation expense related to the acceleration of stock options to certain affected employees.
 
9
6
The activity in the accrued restructuring balance, included within accrued expenses on the consolidated balance sheet, was as follows for the year ended December 31, 2022 (in thousands):
 
     Restructuring
liabilities at
January 1, 2022		      Charges      Cash payments      Restructuring
liabilities at
December 31, 2022		  
Workforce reduction
    $ —     $ 2,022      $ (2,022 )     $ — 
The Company does not expect to incur additional restructuring charges or cash expenditures associated with this restructuring.
6. Fair Value Measurement
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands):
 
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 4,682      $ —     $ —     $ 4,682  
U.S. government treasuries
      6,233        —         —         6,233  
U.S. government agency securities
      —         999        —         999  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents
    $ 10,915      $    999      $ —     $ 11,914  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 2,266      $ —     $ —     $ 2,266  
Commercial paper
      —         4,496        —         4,496  
Corporate debt securities
      —         3,032        —         3,032  
Short-term marketable securities:
            
Commercial paper
      —         15,587        —         15,587  
U.S. government treasuries
      1,005        —         —         1,005  
U.S. government agency securities
      —         16,069        —         16,069  
Corporate debt securities
      —         8,135        —         8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents and marketable securities
    $  3,271      $ 47,319      $ —     $ 50,590  
  
 
 
     
 
 
     
 
 
     
 
 
  
There were no marketable securities at December 31, 2023. The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly. There were no transfers of assets between Level 1, Level 2, or Level 3 during the years ended December 31, 2023 and 2022.
 
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 191      $ 191  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 191      $    191  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
9
7
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 144      $ 144  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 144      $    144  
  
 
 
     
 
 
     
 
 
     
 
 
  
The estimated fair value of the warrant liability for the private warrants at December 31, 2023 and 2022 was determined using Level 3 inputs. Inherent in a Monte Carlo options pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on its historical volatility for a time period that approximates the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon
yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. There were no changes to the number of private warrants underlying the Level 3 financial instruments during the year ended December 31, 2023. There were no transfers between Level 1, 2, or 3 during the years ended December 31, 2023 and 2022.
The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (in thousands).
 
    
Warrant
Liability
  
Balance – January 1, 2022
   
$
6,447
 
Change
in fair value
      (6,303 ) 
  
 
 
  
Balance – December 31, 2022
   
 
144
 
Change
in fair value
      47  
  
 
 
  
Balance – December 31, 2023
   
$
191
 
  
 
 
  
A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2023 and 2022 is as follows:
 
    
As of
December 31,
2023
    
As of
December 31,
2022
  
Stock price
    $ 1.18     $ 1.02  
Exercise price
    $ 11.50     $ 11.50  
Option term (years)
      2.0       3.0  
Volatility (annual)
      90.9 %      73.7 % 
Risk-free rate
      4.2 %      4.1 % 
Dividend yield (per share)
      0 %      0 % 
 
9
8
7.
Available-For-Sale
Securities
All marketable securities were considered
available-for-sale
at December 31, 2022. There were no marketable securities at December 31, 2023.
 
The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2022 are summarized in the table below (amounts in thousands):
 
    
December 31, 2022
  
    
Amortized
Cost
     
Gross
Unrealized
Gain
     
Gross
Unrealized
Loss
     
Fair Value
  
Assets:
            
Short-term marketable securities:
            
Commercial paper
    $ 15,608      $ —     $ (21 )     $ 15,587  
U.S. government treasuries
      1,007        —         (2 )       1,005  
U.S. government agency securities
      16,105        —         (36 )       16,069  
Corporate debt securities
      8,149        —         (14 )       8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total marketable securities
    $ 40,869      $ —     $ (73 )     $ 40,796  
  
 
 
     
 
 
     
 
 
     
 
 
  
As of December 31, 2022, some of the Company’s marketable securities were in an unrealized loss position. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022.
8. Balance Sheet Details
Other current assets consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
  
Clinical related vendor prepayments
    $ 407      $ 1,560  
Payroll tax refund receivable
      250        —   
Other
      127        369  
  
 
 
     
 
 
  
   $ 784      $ 1,929  
  
 
 
     
 
 
  
Property, plant and equipment, net consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
     
Estimated
Useful Life
  
Furniture and fixtures
    $ 236      $ 236        5 years  
Computers
      20        20       
3-5 years
  
  
 
 
     
 
 
     
Total
      256        256     
Less: accumulated depreciation
      (131 )       (79 )    
  
 
 
     
 
 
     
Total property, plant and equipment, net
    $ 125      $ 177     
  
 
 
     
 
 
     
Depreciation expense was approximately $52,000 and $54,000 for the years ended December 31, 2023 and 2022, respectively.
 
9
9
The following table sets forth the components of accrued expenses at December 31, 2023 and 2022, respectively (in thousands):
 
    
December 31,
2023
     
December 31,
2022
  
Accrued payroll
    $ 332      $ 297  
Accrued bonus
      —         2,042  
Accrued benefits
      918        923  
Accrued manufacturing, clinical trial and related
      505        661  
  
 
 
     
 
 
  
   $ 1,755      $ 3,923  
  
 
 
     
 
 
  
9. Commitments and Contingencies
Litigation
The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
Leases
On December 23, 2020, the Company entered into a five-year term lease agreement which commenced on January 1, 2021. In April and May, 2021, the lease was amended to include additional space. The annual rent expense is approximately $1.2 million.
At December 31, 2023, the Company had operating lease liabilities of approximately $2.5 million and right of use assets of approximately $2.2 million, which were included in the consolidated balance sheets.
In connection with the Company’s strategic plan and workforce reduction (see
N
ote 5), the Company has consolidated its leased office space at its corporate headquarters location. Effective July 2022, the Company subleased substantially all of its unused office space for a term of 18 months at a base rent of $50,000 per month. The Company has not been legally released from its primary obligations under the original lease and subsequent amendments and, therefore, continues to account for the original lease according to Accounting Standard Codification (“ASC”) Topic 842, “Leases.” The Company records both fixed and variable payments received from the sublessee in its consolidated statements of operations and comprehensive loss on a straight-line basis as an offset to rent expense. Such payments received in the years ended December 31, 2023 and 2022 were $0.6 million and $0.3 million, respectively. The Company also received a $50,000 deposit, recorded as a noncurrent liability in the consolidated balance sheet at December 31, 2023.
The following summarizes quantitative information about the Company’s operating leases (dollars in thousands):
 
   
For the years ended
  
   
December 31,

2023
    
December 31,

2022
  
Lease cost
    
Operating lease cost
   $ 1,196     $ 1,196  
Variable lease cost
     —        —   
 
 
 
    
 
 
  
Total operating lease expense
   $ 1,196     $ 1,196  
 
 
 
    
 
 
  
Other information
    
Operating cash flows from operating leases
   $ 1,270     $ 1,048  
Right-of-use
assets obtained in exchange for operating lease liabilities
   $ —    $ —   
Weighted-average remaining lease term—operating leases
     2.0       2.9  
Weighted-average discount rate—operating leases
     8 %      8 % 
 
10
0
As of December 31, 2023, future minimum payments during the next three years are as follows (in thousands):
 
Year ended December 31, 2024
    $ 1,320  
Year ended December 31, 2025
      1,372  
Year ended December 31, 2026
      28  
  
 
 
  
Total
      2,720  
Less present value discount
      (218 ) 
  
 
 
  
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2023
    $ 2,502  
  
 
 
  
10. Stockholders’ Equity
The Company’s Certificate of Incorporation authorizes the issuance of 120,000,000 shares of common stock, $0.0001 par value per share and 30,000,000 shares of undesignated preferred stock, $0.0001 par value per share. As of December 31, 2023 and 2022, there were 21,407,510 shares and 21,242,884 shares of common stock outstanding, respectively, and no shares of preferred stock outstanding.
During the year ended December 31, 2021, 275,000 private warrants were exercised for approximately $3.2 million. No private warrants were exercised during the years ended December 31, 2023 and December 31, 2022.
During the years ended December 31, 2023 and 2022, 161,668 shares and 183,366 shares, respectively, were issued pursuant to the Company’s Employee Stock Purchase Program (“ESPP”) (see Note 11) for approximately $112,000 and $278,000 in proceeds, respectively.
Restricted Shares
Between July and August 2019, Legacy Vincera Pharma issued 471,850 shares (826,510 shares prior to the effects of the Merger) of restricted stock at par value to certain management persons. All amounts owed for the issuance of these restricted shares were settled in cash in July 2020. The grant date fair value of this restricted stock was approximately $6,000.
In May 2020, Legacy Vincera Pharma issued an additional 173,552 shares (304,000 shares prior to the effects of the Merger) of restricted stock at a fair value of $0.07 per share in exchange for services. Pursuant to these restricted share agreements, the term vesting represents the expiration of the Company’s repurchase right for the underlying shares. As of December 31, 2023, there was approximately $1,600 of unrecognized stock-based compensation related to restricted stock that will be amortized in 0.4 years.
A summary of restricted stock activity for the years ended December 31, 2023 and 2022 is presented below:
 
    
Number of Shares
     
Weighted Average
Grant Date Fair
Value per Share
  
Nonvested at January 1, 2022
   
 
182,686
 
   
$
0.045
 
Vested
      (115,684 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2022
   
 
67,002
 
   
$
0.065
 
Vested
      (48,940 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2023
   
 
18,062
 
   
$
0.103
 
  
 
 
     
 
 
  
 
10
1
Warrants
As of December 31, 2023, there were 3,295,000 private warrants to purchase common stock outstanding. After the redemption described above, no public warrants remained outstanding at December 31, 2021.
The private warrants are identical to the previously outstanding public warrants except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants; provided, however, that such redemption rights may not be exercised during the first 12 months following the closing of the Business Combination unless the last sales price of the Company’s common stock has been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the date on which notice of redemption is given), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC, will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.
The previously outstanding public warrants and the private warrants issued to LifeSci Holdings LLC that were amended as described above were determined to be equity classified in accordance with ASC 815, Derivatives and Hedging. The remaining private warrants were determined to be liability classified in accordance with ASC 815, Derivatives and Hedging (see Note 6).
11. Stock-Based Compensation
Equity Incentive Plans
In connection with the Business Combination, the stockholders approved the 2020 Plan, which became effective upon the closing of the Business Combination on December 23, 2020. As of December 31, 2023, the Company had 5,600,152 shares of common stock reserved for issuance under the 2020 Plan.
The 2020 Plan allows for the grant of stock options and rights to acquire restricted stock to employees, directors and consultants of the Company. The terms and conditions of specific awards are set at the discretion of the Company’s board of directors. Options granted under the 2020 Plan expire no later than 10 years from the date of grant. Unvested common shares obtained upon early exercise of options are subject to repurchase by the Company at the original issue price.
 
10
2
Stock option activity under the Plan is as follows (amounts in thousands, except per share amount):
 
    
Stock
Options
     
Weighted
Average
Exercise
Price
     
Weighted
Average
Remaining
Contractual
Life (in years)
     
Aggregate
Intrinsic
Value
  
Outstanding at January 1, 2022
      3,408      $ 18.74        10.0      $ — 
Options granted
      2,509        3.30        —         —   
Options exercised
      (2 )       0.82        —         —   
Options cancelled
      (1,562 )       15.89        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2022
      4,353        10.87        8.6        —   
Options granted
      1,131        1.22        —         —   
Options exercised
      (3 )       0.82        —         —   
Options cancelled
      (262 )       11.74        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2023
      5,219      $ 8.74        8.1      $ 134  
  
 
 
     
 
 
     
 
 
     
 
 
  
Options vested and exercisable at December 31, 2023
      3,628      $ 11.25        7.8      $ 73  
  
 
 
     
 
 
     
 
 
     
 
 
  
Stock-based compensation expense is based on the grant-date fair value. The Company recognizes compensation expense for all stock-based awards on a straight-line basis over the requisite service period of the awards, which is generally the option vesting term of either
two
or three years.
As of December 31, 2023, the Company had stock-based compensation of approximately $0.7 million related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 0.6 years.
The following weighted average assumptions were used as inputs to the Black-Scholes option valuation model in determining the estimated grant-date fair value of the Company’s stock options granted during the years ended December 31, 2023 and 2022:
 
    
For the years ended
December 31,
  
    
 2023 
    
 2022 
  
Exercise price
    $ 0.90     $ 3.30  
Expected term (years)
      5.6       5.8  
Volatility (annual)
      89.5 %      85.1 % 
Risk-free rate
      4.0 %      2.8 % 
Dividend yield (per share)
      0 %      0 % 
Total stock-based compensation expense recognized in the accompanying consolidated statements of operations and comprehensive loss for stock option awards is as follows (amounts in thousands):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Research and development
    $ 1,712      $ 4,988  
General and administrative
      1,851        4,621  
Restructuring
      —         447  
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,563
 
   
$
10,056
 
  
 
 
     
 
 
  
 
10
3
Employee Stock Purchase Plan
The Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) became effective in May 2021 upon stockholder approval and is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. 200,000 of the Company’s authorized but unissued or reacquired shares of common stock have been reserved for issuance under the ESPP, plus an additional number of shares to be reserved annually on the first day of each fiscal year from January 1, 2022 through January 1, 2031, equal to the least of (i) one percent (1%) of the outstanding shares of the Company’s common stock on such date, (ii) 500,000 shares, or (iii) a lesser amount determined by the compensation committee or the Company’s board.
The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP consists of a series of offerings of purchase rights to eligible employees, each with a duration of not more than 12 months and purchase dates every six months. The purchase price cannot, under the terms of the ESPP, be less than 85% of the fair market value per share of the Company’s common stock on either the offering date or on the purchase date, whichever is less. If the fair market value of a share of the Company’s common stock on any purchase date within a particular offering period is less than or equal to the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.
As of December 31, 2023, 241,484 shares of common stock were reserved for future issuance under the ESPP. Shares issued under the ESPP were 161,668 and 183,366 shares for the years ended December 31, 2023 and 2022, respectively. The Company recorded approximately $133,000 and $278,000 of stock-based compensation expense for the years ended December 31, 2023 and 2022, respectively, related to the ESPP.
12. Net Loss per Share Applicable to Common Stockholders
Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.
The following table sets forth the computation of loss per share for the years ended December 31, 2023 and 2022, respectively (amounts in thousands, except per share number):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Numerator:
      
Net loss
    $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
Denominator:
      
Weighted average common shares outstanding, basic and diluted
      21,295        21,029  
  
 
 
     
 
 
  
Net loss per common share, basic and diluted
    $ (1.89 )     $ (3.00 ) 
  
 
 
     
 
 
  
 
10
4
The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive:
 
    
For the years ended
December 31,
  
    
 2023 
     
 2022 
  
Options outstanding
      5,219        4,353  
Warrants
      3,295        3,295  
Restricted stock
      18        67  
  
 
 
     
 
 
  
Total
      8,532        7,715  
  
 
 
     
 
 
  
13. Income Taxes
The Company has no provision for income taxes for the years ended December 31, 2023 and 2022. The Company has no current tax expense from losses and no deferred expense from the valuation allowance.
Income (loss) before provision for income taxes consisted of the following (amounts in thousands):
 
    
For the Year Ended
December 31,
  
    
2023
     
2022
  
United States
    $ (35,281 )    $ (58,708 ) 
International
      (4,876 )      (4,276 ) 
  
 
 
     
 
 
  
   $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:
 
 
  
For the Year Ended
December 31,
 
 
  
 2023 
 
 
 2022 
 
Statutory federal income tax rate
      21.0 %      21.0 % 
State taxes, net of federal tax benefit
      0.1 %      0.7 % 
Change in fair value of warrant liabilities
      — %      2.0 % 
Research and development
      2.0 %      (0.7 %) 
Other
      0.5 %      (0.1 %) 
Change in valuation allowance
      (23.6 %)      (22.9 %) 
  
 
 
    
 
 
  
Income taxes provision (benefit)
      0.0 %      0.0 % 
  
 
 
    
 
 
  
 
10
5
Significant components of the Company’s net deferred tax assets as of December 31, 2023 and 2022, are as follows (amounts in thousands):
 
    
As of December 31,
  
    
2023
     
2022
  
Deferred tax assets:
      
Net operating loss
    $ 15,475      $ 9,639  
Stock-based compensation
      5,235        5,025  
Depreciation and amortization
      —         4,198  
Capitalized research and development
      14,734        7,314  
Research and development credit
      2,231        1,635  
Accruals and reserves
      137        471  
Lease liability
      462        722  
  
 
 
     
 
 
  
Total deferred income tax assets
      38,274        29,004  
Less: Valuation allowances
      (37,748 )      (28,360 )
  
 
 
     
 
 
  
Deferred tax assets, net of valuation allowances
    $ 526      $ 644  
  
 
 
     
 
 
  
Deferred tax liabilities:
      
Right of use asset
      (526 )      (644 ) 
  
 
 
     
 
 
  
Total deferred income tax liabilities
    $ (526 )    $ (644 ) 
  
 
 
     
 
 
  
Net deferred taxes
    $ —     $ — 
  
 
 
     
 
 
  
ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The Company’s valuation allowance increased by $9.4 million and $12.9 million for the years ended December 31, 2023 and 2022, respectively.
Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the U.S. must be amortized over a five-year period and over a fifteen-year period if incurred outside the U.S. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.
At December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $59.2 million and $0.7 million, respectively. The federal net operating loss carryforwards can be carried forward indefinitely, with certain limitations. A portion of the state net operating loss carryforwards will expire beginning in 2039, if not utilized.
As of December 31, 2023, the Company also has Federal and California research and development credits of $2.6 million and $1.1 million, respectively. The federal tax credit carryforwards will expire beginning in 2039, if not utilized. The state tax credit carryforwards do not expire.
 
10
6
The following table summarizes activity related to the Company’s gross unrecognized tax benefits (amounts in thousands):
 
    
Total
  
Balance as of December 31, 2021
    $ 518  
Increase/decrease due to prior year positions
      (164 ) 
Increase/decrease due to current year positions
      625  
  
 
 
  
Balance as of December 31, 2022
      979  
Increase/decrease due to prior year positions
      —  
Increase/decrease due to current year positions
      259  
  
 
 
  
Balance as of December 31, 2023
    $ 1,238  
  
 
 
  
The unrecognized tax benefits, if recognized, would not have an impact on the Company’s effective tax rate due to the valuation allowance. The Company does not expect a significant change to its unrecognized tax benefits over the next twelve months. The Company files income tax returns in the United States, California and Germany jurisdictions and is not currently under examination by federal, state or local taxing authorities for any open tax years. The tax years 2019 through 2023 remain open to examination by the major taxing authorities. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. The Company records interest related to uncertain tax positions as interest, and any penalties are recorded as income tax expense in its consolidated statements of operations and comprehensive loss.
Utilization of net operating losses and tax credit carryforwards may be limited by the “ownership change” rules, as defined in Section 382 of the Internal Revenue Code (any such limitation, a “Section 382 limitation”). Similar rules may apply under state tax laws. The Company has not performed an analysis to determine whether an “ownership change” occurred from inception to December 31, 2023. If a change
in
ownership were to have occurred, additional net operating loss and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.
ASC
740-10,
“Income Taxes”, prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company’s income tax return and also provides guidance on
de-recognition,
classification, interest and penalties, accounting in interim periods, disclosure, and transition.
10
7
ITEM 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
Not applicable.
 
ITEM 9A.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rule
13a-15(e)
under the Securities Exchange Act of 1934, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Based on their evaluation as of the end of the period covered by this Annual Report on Form
10-K,
our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer) have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining a system of internal control over financial reporting (as defined in
Rule 13a-15(f)
under the Exchange Act) to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. All internal control systems, no matter how well designed, have inherent limitations.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, under the oversight of our board of directors, we evaluated the effectiveness of our internal control over financial reporting as of December 31, 2023, the last day of our fiscal year. This evaluation was based on the criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP.
Changes in Internal Control over Financial Reporting
Based on the foregoing assessment, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that there has been no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2023 and that there was no change during such period that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
10
8
ITEM 9B.
Other Information.
 
  (b)
Trading Plans.
During the three months ended December 31, 2023, no director or officer adopted or terminated any contract, instruction, or written plan for the purchase or sale of securities of the Company pursuant to Rule
10b5-1(c)
or any
non-Rule
10b5-1
trading arrangement (as defined in Item 408(c) of Regulation
S-K).
 
ITEM 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
 
1
09

Table of Contents

PART III

 

ITEM 10.

Directors, Executive Officers and Corporate Governance.

The information required by this item with respect to directors is incorporated by reference from the information under the caption “Election of Directors,” contained in our proxy statement to be filed with the Securities and Exchange Commission no later than 120 days from the end of our fiscal year ended December 31, 2023 in connection with the solicitation of proxies for our 2024 Annual Meeting of Stockholders (the “Proxy Statement”). Certain information required by this item concerning executive officers is set forth in the Proxy Statement under the caption “Executive Officers” and is incorporated herein by reference.

There have been no material changes to the procedures by which stockholders may recommend nominees to our board of directors.

Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. To the extent disclosure for delinquent reports is being made, it can be found under the caption “Delinquent Section 16(a) Reports” in the Proxy Statement and is incorporated herein by reference.

Our board of directors has adopted a code of business conduct and ethics applicable to all employees of the Company. The code of business conduct and ethics is posted on our website www.vincerx.com. The code of business conduct and ethics can only be amended by the approval of a majority of our board of directors. Any waiver to the code of business conduct and ethics for an executive officer or director may only be granted by our board of directors or our nominating and corporate governance committee and must be timely disclosed as required by applicable law. We have implemented whistleblower procedures that establish formal protocols for receiving and handling complaints from employees. Any concerns regarding accounting or auditing matters reported under these procedures will be communicated promptly to our audit committee.

To date, there have been no waivers under our code of business conduct and ethics. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics or waivers of such code granted to executive officers and directors on our website at www.vincerx.com within four business days following the date of such amendment or waiver. Stockholders may request a free copy of our code of business conduct and ethics by contacting Vincerx Pharma, Inc., Attention: General Counsel & Chief Legal Officer, 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306. None of the materials on, or accessible through, our website is part of this report or incorporated by reference herein.

Additionally, our board of directors has adopted a code of ethics for senior financial officers applicable to our Chief Executive Officer and Chief Financial Officer as well as other key management employees addressing ethical issues. Any amendments or waivers of the code of ethics for senior financial officers shall be disclosed promptly as required by law. To date, there have been no waivers under our code of ethics for senior financial officers.

 

ITEM 11.

Executive Compensation.

The information required by this item is incorporated by reference from the information under the headings “Election of Directors—Director Compensation,” “Election of Directors—Director Compensation Arrangements,” and “Executive Compensation” contained in the Proxy Statement.

 

ITEM 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item is incorporated by reference to the disclosure appearing under the headings “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” contained in the Proxy Statement.

 

110

Table of Contents
ITEM 13.

Certain Relationships and Related Transactions, and Director Independence.

The information required by this item is incorporated by reference from the information under the headings “Election of Directors—Voting Agreement,” “Election of Directors—Director Independence,” “Election of Directors—Corporate Governance,” and “Election of Directors—Certain Relationships and Related Transactions” contained in the Proxy Statement.

 

ITEM 14.

Principal Accountant Fees and Services.

The information required by this item is incorporated by reference from the information under the caption “Ratification of Appointment of Independent Registered Public Accounting Firm” contained in the Proxy Statement.

 

111

Table of Contents

PART IV

 

ITEM 15.

Exhibit and Financial Statement Schedules.

(a) Documents filed as part of this report

1. Financial Statements:

Reference is made to the Index to Financial Statements of Vincerx Pharma, Inc. included in Item 8 of Part II of this report.

2. Financial Statement Schedules

All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.

3. Exhibits

See Item 15(b) below. Each management contract or compensatory plan or arrangement required to be filed has been identified.

(b) Exhibits

 

Exhibit

No.

   

Description

  2.1+

    Merger Agreement by and among LifeSci Acquisition Corp., LifeSci Acquisition Merger Sub Inc., Vincera Pharma, Inc. and Raquel E. Izumi, as representative of the stockholders of Vincera Pharma, Inc., dated September 25, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on December 30, 2020).

  3.1

    Second Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

  3.2

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 5, 2021).

  4.1

    Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

  4.2

    Form of Warrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

  4.3

    Warrant Agreement by and between LifeSci Acquisition Corp. and Continental Stock Transfer & Trust Company, dated March 5, 2020 (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q filed on November 10, 2020).

  4.4

    Amended and Restated Registration and Stockholder Rights Agreement by and among the Company and certain stockholders of the Company, dated December 23, 2020 (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed on December 30, 2020).

  4.5

    Registration Rights Agreement by and among the Company and the Investors party thereto, dated September 15, 2021 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on September 16, 2021).

  4.6

    Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.7 to the Annual Report on Form 10-K for the year ended December 31, 2021).

  4.7

    Form of Indenture relating to debt securities (incorporated by reference to Exhibit 4.1 to the registration Statement on Form S-3 (File No. 333-262239) filed on January 19, 2022).

 

112

Table of Contents

Exhibit

No.

   

Description

 10.1#

    Form of Indemnification Agreement by and between the Company and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

 10.2#

    Vincerx Pharma, Inc. 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

 10.3#

    Forms of Stock Option Agreement, Notice of Exercise, Stock Option Grant Notice, Restricted Stock Unit Agreement, and Restricted Stock Agreement under the Vincerx Pharma, Inc. 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-252589) filed on January 29, 2021).

 10.4#

    Executive Employment Agreement by and between the Company and Dr. Ahmed M. Hamdy, dated December 23, 2020 (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on December 30, 2020).

 10.5#

    Executive Employment Agreement by and between the Company and Dr. Raquel E. Izumi, dated December 23, 2020 (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed on December 30, 2020).

 10.6#

    Executive Employment Agreement by and between the Company and Alexander A. Seelenberger, dated December 23, 2020 (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed on December 30, 2020).

 10.7#

    Executive Employment Agreement by and between the Company and Tom C. Thomas, dated January 27, 2021 (incorporated by reference to Exhibit 10.8 to the Annual Report on Form 10-K for the year ended December 31, 2020).

 10.8#

    Vincerx Pharma, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 (File No. 333-257042) filed on June 11, 2021).

 10.9*

    License Agreement by and among Vincera Pharma, Inc., Bayer Aktiengesellschaft and Bayer Intellectual Property GmbH, dated October 7, 2020 (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed on December 30, 2020).

 10.10

    Standard Industrial/Commercial Multi-Tenant Lease – Gross Agreement by and between the Vincera Pharma, Inc. and Hohbach Realty Company Limited Partnership, dated November 18, 2020 (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed on December 30, 2020).

 21.1

    Subsidiaries of the Company.

 23.1

    Consent of independent registered public accounting firm.

 24.1

    Power of Attorney (included on the signature page hereof).

 31.1

    Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 31.2

    Principal Financial Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.1†

    Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of Sarbanes-Oxley Act of 2002).

 32.2†

    Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of Sarbanes-Oxley Act of 2002).

 97.1

    Policy Relating to Recovery of Erroneously Awarded Compensation.

 

113

Table of Contents

Exhibit

No.

   

Description

101.INS

    Inline XBRL Instance Document

101.SCH

    Inline XBRL Taxonomy Extension Schema Document

101.CAL

    Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

    Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

    Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

    Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

+

The schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

#

Indicates management contract or compensatory plan or arrangement.

*

Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K.

†

In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the registrant specifically incorporates it by reference.

(c) Financial Statement Schedules

Reference is made to Item 15(a)(2) above.

 

ITEM 16.

Form 10-K Summary.

Not applicable.

 

114

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

VINCERX PHARMA, INC.
/s/ Dr. Ahmed M. Hamdy
Name:   Dr. Ahmed M. Hamdy
Title:   Chief Executive Officer

Date: March 29, 2024

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Dr. Ahmed M. Hamdy, Dr. Raquel E. Izumi and Alexander A. Seelenberger, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the capacities indicated.

 

Signature

   

Title

  

Date

/s/ Dr. Ahmed M. Hamdy

Dr. Ahmed M. Hamdy

   

Chief Executive Officer and Chairman

(Principal Executive Officer)

   March 29, 2024

/s/ Alexander A. Seelenberger

Alexander A. Seelenberger

   

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

   March 29, 2024

/s/ Laura I. Bushnell

Laura I. Bushnell

    Director   March 29, 2024

/s/ Dr. Brian J. Druker

Dr. Brian J. Druker

    Director   March 29, 2024

/s/ Dr. Raquel E. Izumi

Dr. Raquel E. Izumi

    Director   March 29, 2024

/s/ Dr. John H. Lee

Dr. John H. Lee

    Director   March 29, 2024

/s/ Francisco D. Salva

Francisco D. Salva

    Director   March 29, 2024

/s/ Dr. Ruth E. Stevens

Dr. Ruth E. Stevens

    Director   March 29, 2024

 

115

EX-21.1 2 d739497dex211.htm EX-21.1 EX-21.1

Exhibit 21.1

Subsidiaries of Vincerx Pharma, Inc.

 

Subsidiary

   

Jurisdiction

VNRX Corp.

    Delaware

Vincerx Pharma GmbH

    Germany
Vincerx Pharma Australia Pty.    Australia
 EX-23.1 3 d739497dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Registration Nos. 333-252589, 333-260246, and 333-262239) and Form S-8 (Registration Nos. 333-254583, 333-257042, 333-263929, and 333-270908) of Vincerx Pharma, Inc. of our report dated March 29, 2024, which includes an explanatory paragraph regarding the substantial doubt about the Company’s ability to continue as a going concern, relating to the consolidated financial statements of the Company as of and for the years ended December 31, 2023 and 2022, which appear in this Form 10-K.

 

/s/ WithumSmith+Brown, PC
East Brunswick, New Jersey
March 29, 2024
 EX-31.1 4 d739497dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Dr. Ahmed M. Hamdy, certify that:

1. I have reviewed this Annual Report on Form 10-K of Vincerx Pharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 29, 2024

 

/s/ Dr. Ahmed M. Hamdy

Dr. Ahmed M. Hamdy
Chief Executive Officer (Principal Executive Officer)
 EX-31.2 5 d739497dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Alexander A. Seelenberger, certify that:

1. I have reviewed this Annual Report on Form 10-K of Vincerx Pharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 29, 2024

 

/s/ Alexander A. Seelenberger

Alexander A. Seelenberger
Chief Financial Officer (Principal Financial Officer)
 EX-32.1 6 d739497dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Dr. Ahmed M. Hamdy, the Chief Executive Officer (Principal Executive Officer) of Vincerx Pharma, Inc. (the “Company”), hereby certify, that, to my knowledge:

 

1.

The Annual Report on Form 10-K for the year ended December 31, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 29, 2024

 

/s/ Dr. Ahmed M. Hamdy

Dr. Ahmed M. Hamdy
Chief Executive Officer (Principal Executive Officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

EX-32.2 7 d739497dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Alexander A. Seelenberger, the Chief Financial Officer (Principal Financial Officer) of Vincerx Pharma, Inc. (the “Company”), hereby certify, that, to my knowledge:

 

1.

The Annual Report on Form 10-K for the year ended December 31, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 29, 2024

 

/s/ Alexander A. Seelenberger

Alexander A. Seelenberger
Chief Financial Officer (Principal Financial Officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

EX-97.1 8 d739497dex971.htm EX-97.1 EX-97.1

Exhibit 97.1

VINCERX PHARMA, INC.

INCENTIVE-BASED COMPENSATION RECOUPMENT POLICY

 

  1.

Purpose

The Board of Directors (the “Board”) of Vincerx Pharma, Inc., a Delaware corporation (the “Company”), has adopted this Incentive-Based Compensation Recoupment Policy (this “Policy”) to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Listing Rule 5608 of The Nasdaq Stock Market LLC. This Policy provides for the Company’s recoupment of Incentive-Based Compensation paid erroneously to Covered Executives in the event of a Restatement. Capitalized terms not otherwise defined in this Policy will have the meanings set forth in Section 11 of this Policy.

 

  2.

Administration

This Policy will be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board, in which case references herein to the Board will be deemed references to the Compensation Committee of the Board.

The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Subject to any limitation under applicable law, the Board may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). This Policy will be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, any applicable rules or standards adopted by the Securities and Exchange Commission (the “SEC”), and any national securities exchange on which the Company’s securities are listed. Any determinations made by the Board will be final and binding on all affected individuals.

 

  3.

Recoupment of Incentive-Based Compensation

In the event the Company is required to prepare a Restatement, the Board will require that the Covered Executive forfeit, promptly repay to the Company, or offset, on a pre-tax basis, the full amount of the excess of: (a) the amount of any Incentive-Based Compensation received by the Covered Executive that was calculated based on the erroneous data in the original financial statements that were subsequently restated over (b) the amount of such Incentive-Based Compensation to which the Covered Executive would have been entitled to receive based on the restated financial statements (such excess amount, the “Recoverable Incentive-Based Compensation”).

In the case of compensation based on stock price or total shareholder return, the amount subject to recoupment will be based on a reasonable estimate of the effect of the Restatement on the Company’s stock price or total shareholder return upon which the Incentive-Based Compensation was received.

Such recoupment will apply on a “no-fault” basis—that is, regardless of whether any misconduct occurred or a Covered Executive officer’s responsibility for the Restatement. In addition, the Company’s obligation to recoup Recoverable Incentive-Based Compensation is not dependent on if or when restated financial statements are filed with the SEC.

 

  4.

Recoupment Methods

Subject to Section 3, the Board will determine, in its sole discretion, the timing and method or methods for recouping Recoverable Incentive-Based Compensation pursuant to this Policy. The Board will have no obligation to apply the same method of recoupment to each affected Covered Employee in connection with any Restatement.

  5.

Exceptions to Recovery for Impracticability

The Board will recover any Recoverable Incentive-Based Compensation unless such recovery would be impracticable, as determined in good faith by a majority of the independent directors serving on the Board in accordance with Rule 10D-1 of the Exchange Act and applicable securities exchange rules.

Specifically, no recovery will be required pursuant to this Policy if: (a) the direct expense paid to a third-party to assist in enforcing this Policy would exceed the amount of the Recoverable Incentive-Based Compensation and the Company (i) makes a reasonable attempt to recover the Recoverable Incentive-Based Compensation, and (ii) documents such reasonable attempts, which documentation will be provided to the national securities exchange on which the Company’s securities are then listed; (b) pursuing such recovery would violate the home country law of the jurisdiction of incorporation of the Company where that law was adopted prior to November 28, 2022, and the Company provides an opinion of counsel to that effect acceptable to the national securities exchange on which the Company’s securities are then listed; or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.

 

  6.

Notice and Acknowledgment

The Company will provide notice of this Policy to each Covered Executive and will solicit from each Covered Executive signed acknowledgment of, and agreement to, this Policy in substantially the form attached hereto as Exhibit A. In addition, before the Company takes any action to seek recovery of Recoverable Incentive-Based Compensation pursuant to this Policy or any other action provided for hereunder against a Covered Executive, the Company will provide notice of such clawback or other action. Notwithstanding anything to the contrary contained herein, the Company’s failure to provide notice to or receive acknowledgment from a Covered Executive will have no impact on the applicability or enforceability of this Policy against such Covered Executive.

 

  7.

Other Recoupment Rights

Any rights or remedies under this Policy are in addition to, and not in lieu of, any other rights or remedies that the Company may have pursuant to the terms of any other policy of the Company or any provision in any compensatory plan or arrangement, employment agreement, equity award agreement, or similar plan, agreement, or arrangement, and any other legal rights and remedies available to the Company, or any actions that may be imposed by law enforcement agencies, regulators, administrative bodies, or other authorities.

 

  8.

Amendment

The Board may amend this Policy from time to time in its discretion, and will amend this Policy as it deems necessary to reflect the regulations adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by a national securities exchange on which the Company’s securities are then listed.

 

  9.

No Indemnification or Reimbursement

Neither the Company nor any of its affiliates will: (a) indemnify any Covered Executive against the loss of any incorrectly awarded Incentive-Based Compensation, or (b) pay or reimburse any Covered Executive for premiums incurred or paid for any insurance policy to fund such Covered Executive’s potential recovery obligations.

 

  10.

Effective Date

This Policy was adopted by the Company on November 16, 2023 and applies to Incentive-Based Compensation granted, earned, or vested by Covered Executives on or after October 2, 2023 (the “Effective Date”).

 

2

  11.

Definitions

For purposes of this Policy:

(a) “Covered Executive” means current and former executive officers who are, or were at any time, during an applicable Covered Period, executive officers as defined in Rule 10D-1(d) of the Exchange Act. Subsequent changes in a Covered Executive’s employment status, including retirement or termination of employment (including after serving in an interim capacity), do not affect the Company’s rights to recover Incentive-Based Compensation pursuant to this Policy.

(b) “Covered Period” means the three (3) completed fiscal years immediately preceding the Restatement Date. The Covered Period also includes any transition period that results from a change in the Company’s fiscal year of less than nine (9) months within or immediately following such three (3) completed fiscal years.

(c) A “financial reporting measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures, including, but not limited to, stock price and total shareholder return. For the avoidance of doubt, (i) financial reporting measures include non-GAAP financial measures for purposes of Regulation G of the Exchange Act, as well other measures, metrics, and ratios that are not non-GAAP measures, and (ii) financial reporting measures may or may not be included in a filing with the SEC, and may be presented outside the financial statements.

(d) “GAAP” means U.S. Generally Accepted Accounting Principles.

(e) “Incentive-Based Compensation” means any compensation that is granted, earned, or vested on or after the Effective Date based wholly or in part upon the attainment of a financial reporting measure based on or derived from financial information for any fiscal period ending on or after the Effective Date. For the avoidance of doubt, examples of compensation that are not Incentive-Based Compensation include, but are not limited to: (i) salary (except to the extent that a Covered Executive receives a salary increase earned wholly or in part based on the attainment of a financial reporting measure performance goal, such a salary increase is Incentive-Based Compensation), (ii) bonuses paid solely at the discretion of the Board or the Compensation Committee of the Board that are not paid from a “bonus pool” that is determined by satisfying a financial reporting measure performance goal, (iii) bonuses awarded based solely on completion of a specified period of service, (iv) bonuses awarded based solely on subjective standards, strategic measures, or operational measures, or (v) equity awards for which the grant is not contingent upon achieving any financial reporting measure performance goal and vesting is contingent solely upon completion of a specified service period and/or attaining one or more nonfinancial reporting measures.

(f) Incentive-Based Compensation will be deemed to have been “received” during the fiscal period during which the financial reporting measure specified in the compensation award is attained, even if the grant or payment of such Incentive-Based Compensation occurs after the end of such fiscal period.

(g) “Restatement” means an accounting restatement of the Company’s financial statements due to the Company’s material non-compliance with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (often referred to as a “Big R” restatement), or that would result in a material misstatement if the correction of the error was recognized in the current period or left uncorrected in the current period (often referred to as a “little r” restatement).

(h) “Restatement Date” means the earlier of: (i) the date the Board, a Board committee, or officer(s) authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that a Restatement is required, or (ii) the date a court, regulator, or other legally authorized body directs the Company to undertake a Restatement. For purposes of clause (ii), the date of the initial court order or other regulatory agency action would be the measurement date for the Covered Period, but the application of this Policy would occur only after such order is final and non-appealable.

 

3

EXHIBIT A

ACKNOWLEDGMENT OF AND AGREEMENT TO THE

INCENTIVE-BASED COMPENSATION RECOUPMENT POLICY

THIS ACKNOWLEDGEMENT OF AND AGREEMENT TO THE INCENTIVE-BASED COMPENSATION RECOUPMENT POLICY is entered into between Vincerx Pharma, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Executive”) as of the date of the Executive’s signature below. Capitalized terms used herein but not defined will have the meanings assigned to such terms in the Company’s Incentive-Based Compensation Recoupment Policy (the “Policy”).

The Executive acknowledges and agrees that the Company has provided the Executive with a copy of the Policy, attached hereto as Annex A, and that the Executive has had the opportunity to review the Policy. The Executive further acknowledges and agrees that the Executive accepts the provisions of the Policy and will abide by all of the terms of the Policy both during and after the Executive’s employment with the Company, including, without limitation, by forfeiting, promptly repaying to the Company, and/or offsetting, on a pre-tax basis, any Recoverable Incentive-Based Compensation, and hereby agrees to waive the assertion or application of any rights under federal, state, local, or foreign law, or in contract or equity, that would otherwise conflict with or narrow the Company’s authority to interpret, apply, and enforce the Policy to its fullest extent, including but not limited to, the Company’s authority to withhold or divert the Executive’s wages pursuant to the Policy.

The Executive further acknowledges and agrees that all Incentive-Based Compensation granted, earned, or vested on or after October 2, 2023 (the “Effective Date”) will be subject to the provisions of the Policy, and that agreement to the Policy is a condition to the receipt and retention of such compensation. The Executive acknowledges and agrees that the Executive’s acceptance of the Policy is in consideration of Incentive-Based Compensation that is granted, earned, or vested on or after the later of the Effective Date or the date of the Executive’s signature below.

[Signature Page Follows]

AGREED AND ACKNOWLEDGED:
EXECUTIVE
 

 

Signature
 

 

Name
 

 

Date

[Signature Page to Acknowledgment of and Agreement to the

Vincerx Pharma, Inc. Incentive-Based Compensation Recoupment Policy]

EX-101.SCH 9 vinc-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 999001 - Disclosure - Nature of Business link:presentationLink link:definitionLink link:calculationLink 999002 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 999003 - Disclosure - Business Combination link:presentationLink link:definitionLink link:calculationLink 999004 - Disclosure - Bayer License Agreement link:presentationLink link:definitionLink link:calculationLink 999005 - Disclosure - Restructuring link:presentationLink link:definitionLink link:calculationLink 999006 - Disclosure - Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink 999007 - Disclosure - Available-For-Sale Securities link:presentationLink link:definitionLink link:calculationLink 999008 - Disclosure - Balance Sheet Details link:presentationLink link:definitionLink link:calculationLink 999009 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 999010 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 999011 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 999012 - Disclosure - Net Loss per Share Applicable to Common Stockholders link:presentationLink link:definitionLink link:calculationLink 999013 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 999014 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 999015 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 999016 - Disclosure - Restructuring (Tables) link:presentationLink link:definitionLink link:calculationLink 999017 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink link:calculationLink 999018 - Disclosure - Available-For-Sale Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 999019 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:definitionLink link:calculationLink 999020 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 999021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 999022 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 999023 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) link:presentationLink link:definitionLink link:calculationLink 999024 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 999025 - Disclosure - Nature of Business - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999027 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details) link:presentationLink link:definitionLink link:calculationLink 999028 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details) link:presentationLink link:definitionLink link:calculationLink 999029 - Disclosure - Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details) link:presentationLink link:definitionLink link:calculationLink 999030 - Disclosure - Business Combination - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999031 - Disclosure - Bayer License Agreement - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999032 - Disclosure - Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 999033 - Disclosure - Restructuring - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999034 - Disclosure - Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 999035 - Disclosure - Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 999036 - Disclosure - Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details) link:presentationLink link:definitionLink link:calculationLink 999037 - Disclosure - Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details) link:presentationLink link:definitionLink link:calculationLink 999038 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999039 - Disclosure - Available-For-Sale Securities - Summary of Available For Sale Securities (Details) link:presentationLink link:definitionLink link:calculationLink 999040 - Disclosure - Available-For Sale Securities - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999041 - Disclosure - Balance Sheet Details - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999042 - Disclosure - Balance Sheet Details - Summary of Other Current Assets (Details) link:presentationLink link:definitionLink link:calculationLink 999043 - Disclosure - Balance Sheet Details - Summary Of Property Plant And Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 999044 - Disclosure - Balance Sheet Details - Summary Of Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 999045 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999046 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details) link:presentationLink link:definitionLink link:calculationLink 999047 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) link:presentationLink link:definitionLink link:calculationLink 999048 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Activity (Details) link:presentationLink link:definitionLink link:calculationLink 999049 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999050 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999051 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:definitionLink link:calculationLink 999052 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details) link:presentationLink link:definitionLink link:calculationLink 999053 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details) link:presentationLink link:definitionLink link:calculationLink 999054 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details) link:presentationLink link:definitionLink link:calculationLink 999055 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 999056 - Disclosure - Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 999057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:definitionLink link:calculationLink 999058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) link:presentationLink link:definitionLink link:calculationLink 999059 - Disclosure - Income Taxes - Schedule of Income Tax Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 999060 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 999061 - Disclosure - Insider Trading Arrangements - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 vinc-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 vinc-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 vinc-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 vinc-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 g739497g02c90.jpg GRAPHIC begin 644 g739497g02c90.jpg M_]C_X 02D9)1@ ! 0(!>0%Y #_X?(5:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ M-C0U,3DL(#(P,C O,#@O,C4M,3&UL;G,Z&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @ M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q M+C O7!E+T1I;65N7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN&UL.FQA;F<](G@M$$[57-E$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3(M36%R8V@M,C R-" P M.#HP-CHU,"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q,2U-87)C:"TR M,#(T(#(R.C,V.C4P)B-X03M38W)I<'0@5F5R$$[(" @(" @(" @(%1I;65S3F5W4F]M86Y04RU";VQD M350F(WA!.R @(" @(" @("!4:6UE$$[)B-X03M4 M:&4@9F]L;&]W:6YG(&-O;&]R$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&$$[57-E$$[ M3&]C86P@5&EM93H@(" @(" @(" @(" @,3(M36%R8V@M,C R-" P.3HR.3HP M,"8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q,2U-87)C:"TR,#(T(#(S M.C4Y.C P)B-X03M38W)I<'0@5F5R$$[)B-X03M4:&4@9F]L;&]W M:6YG(&-O;&]R$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&$$[ M57-E$$[3&]C86P@5&EM M93H@(" @(" @(" @(" @,3(M36%R8V@M,C R-" Q-#HP,SHQ.28C>$$[15-4 M(%1I;64Z(" @(" @(" @(" @(" Q,BU-87)C:"TR,#(T(# T.C,S.C$Y)B-X M03M38W)I<'0@5F5R$$[(" @ M(" @(" @(%1I;65S3F5W4F]M86Y04RU";VQD350F(WA!.R @(" @(" @("!4 M:6UE$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R M$$[/"]R M9&8Z;&D^"B @(" @(" @(" @(#PO&UP.DUE=&%D871A1&%T93X*(" @(" @ M(" @/'AM<#I-;V1I9GE$871E/C(P,C0M,#,M,3)4,30Z,#,Z,C4K,#4Z,S \ M+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R M-"TP,RTQ,E0Q-#HP,SHR-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @ M(" @(#QX;7 Z0W)E871O7!E/2)297-O=7)C92(^"B @(" @(" @(" @ M(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @ M(" @(" @(" @(" @(" @/'AM<$=);6&UP1TEM9SIH M96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9OF%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%" M24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055% M0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=1 M1$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$ M03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9( M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!0451 M9T%R045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%! M04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%! M028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y- M0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571( M:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E) M2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM M2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U M28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y M5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG M<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B M1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L M2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%# M15%-4D%$.$$Y531Q>&)Z$$[9C%782](<65L,$ME M;4=94$7%245%23&1C=T0X4WE3$$[*WI88FIH5DUV5R]->6)Z$$[04A"<% K>2]&6&9O6#@P4"MP<3!Z+W5$4V8X05IF M:7)V,$PK84@O53%A6B\S0G!0*WDO1EAF;U@X,% K<'$P>B]U1%-F.6PK2W4O M428C>$$[=C5O9CE45G!N+V-':R\W3#A69"MH9GI1+W=#<'$P>B]!3&$$[-V

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g739497g18j79.jpg GRAPHIC begin 644 g739497g18j79.jpg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

&UP M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N M/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" \>&UP1SIM86=E;G1A/C&UP1SIM86=E;G1A/@H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @ M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @ M(" @(#QR9&8Z;&D@&UP1SIS=V%T8VA.86UE/D,]-3 @33TW M,"!9/3@P($L]-S \+WAM<$&UP M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" \>&UP1SIM86=E;G1A/C&UP1SIM86=E;G1A/@H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @ M/'AM<$7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @ M(" @(#QX;7!'.F=R;W5P3F%M93Y'&UP1SIG7!E/2)297-O=7)C92(^"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T] M,"!9/3 @2STQ,# \+WAM<$&UP M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$65L;&]W/C N,# P,# P M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM M<$&UP1SIB;&%C:SX*(" @(" @(" @(" @ M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @ M(#QR9&8Z;&D@&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP M($L].3 \+WAM<$&UP1SIT>7!E M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$65L;&]W/C N,# P,# P/"]X;7!' M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STX,#PO M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \ M>&UP1SIM;V1E/D--64L\+WAM<$&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$65L;&]W M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXW.2XY M.3@W.34\+WAM<$&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$&UP1SIC>6%N M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C8Y+CDY.3&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^ M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@&UP M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-C \+WAM<$&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \ M+WAM<$65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @ M(" @(" @(" @(" @(" @/'AM<$7!E/2)297-O M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C M:$YA;64^0STP($T],"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$&UP1SIM M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL M;W<^,"XP,# P,# \+WAM<$65L;&]W/@H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$&UP1SIM;V1E/@H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\ M+WAM<$&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(#QX;7!'.F)L86-K/C,Y+CDY.30P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @ M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @ M(" @(#QR9&8Z;&D@&UP1SIS=V%T8VA.86UE/D,],"!-/3 @ M63TP($L],S \+WAM<$&UP1SIT M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$65L;&]W/C N,# P,# P/"]X M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STR M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" \>&UP1SIM;V1E/D--64L\+WAM<$&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$65L M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ M.2XY.3DW,#$\+WAM<$&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$&UP1SIC M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/CDN.3DY,3 S M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX M;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU/"]X;7!'.G-W871C:$YA M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9 M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP M1SIT>7!E/E!23T-%4U,\+WAM<$&UP1SIC>6%N/@H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0N.3DX.# S/"]X;7!'.F)L M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @ M(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \ M+WAM<$7!E/2)297-O=7)C92(^ M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"7!E/C$\+WAM<$7!E/@H@(" @(" @(" @(" @(" @(" \>&UP M1SI#;VQO&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP M1SIT>7!E/E!23T-%4U,\+WAM<$&UP1SIC>6%N/@H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P M,# \+WAM<$65L;&]W/C$P,"XP,# P,# \+WAM<$65L;&]W/@H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @ M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@&UP1SIS M=V%T8VA.86UE/D,],"!-/3&UP1SIS=V%T8VA.86UE M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\ M+WAM<$65L;&]W/C$P,"XP,# P,# \+WAM<$65L;&]W/@H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @ M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@&UP1SIS=V%T M8VA.86UE/D,],"!-/3$P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E M/E!23T-%4U,\+WAM<$&UP1SIC>6%N/@H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY M96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @ M(" @(" @(" @(" @/'AM<$&UP1SIM M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2 M3T-%4U,\+WAM<$65L M;&]W/C$P,"XP,# P,# \+WAM<$65L;&]W/@H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX* M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @ M(" @(" @(" @(" @(#QR9&8Z;&D@&UP1SIS=V%T8VA.86UE M/D,],3 P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$&UP1SIC>6%N/@H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL M;W<^,"XP,# P,# \+WAM<$65L;&]W/@H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @ M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @ M(" @(" @(" @(#QR9&8Z;&D@&UP1SIS=V%T8VA.86UE/D,] M-C @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\ M+WAM<$65L;&]W/C N M,# S,#DY/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @ M(" @/'AM<$&UP1SI#;VQO $! (# 0$! 0 " 8'! 4) M P$""O_$ $L0 $$ P$ ,% P<(" (+ 4" P0& $'"!(3% D1%39X%B&V M%R(Q-#BWN!A8='>7L;/6(R0F,E%Q=K5!D24U-T)287)U@:&T_\0 &P$! 0$! M 0$! 0 $"!08'! /_Q !#$0 " 0#!00%"08& P$ 0(# M!!$%(3$&05%A<1*QP? 3@9&AT0<5%B(R5I;4X11"4E.2\4-BVTO[8"Q7@RB+,B!0#/9;:> 6&O7A@1K< M:=W&_C>8#2]<_;*0$G\8H'GRM4]4!=$&56#;.4=1=YR1ETM\NY73C;O/.>=$A%848XC\2'K3#Z"P)E0WY$Q M*I(IV:U(2U,1%C"-:<_BUX&^,$& , 8 P!@# & , 8 P!@# & , 8 P!@# & M 8 -OC1'J=RYCH:XT]4*!S6^.&-RDK:G-=&L76*^R-1"TPE<=P2OEC\IR4J2 MZF8DTTTEB/N"MR4+;*_-KV6^)G^"# , %WMHET^ZIU)YSF$KCK%JYN](+*OF=UE(, QDGS7XC*I>YBWU M,1'GUQF-KW':TG;32/EITI#?P)<7I65]J+E;>]^9I_9ATW[EN?%*_M^!DV:, MC & 3S6O[5_:?T\^8?[R?76"[EU?="4-@@P">JM_:G[=_J,\U_QOZBP"A< 8 M P!@# & >:7VEG63?,J-SB%7NF=GXI+NMD-!B_5O._FHGZ?[,(J\$7')DZO4 MJF.J-Y8IT>U%60#QGH1NK&A(F* ;"L0V+'8*\8$C4*5\TGEHXNRO;E[+KP>0 M?9Q=9+]FY!:"5FO75>ND^7=+/

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g739497g28l72.jpg GRAPHIC begin 644 g739497g28l72.jpg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end GRAPHIC 17 g739497g44r00.jpg GRAPHIC begin 644 g739497g44r00.jpg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

GA6;U%9U-SAU849E6#%T9EA.:D9* M9#)J1C=E67)2;%EU2DLW57(X86AH6'9V:7%9-'$W1EA9<35%Z86,F(WA!.SAD>%EV0W-184\T:&8Q M235#>DMZ3W%T46U.:55*04Y+:D%Q1&PX%8R2W5X5C)+=7A6 M,DMP9#5C+S0T3F@O>&A4.5=9*VLO=6\K-6I$-E%M3UI$2FE0:U O:G(K9'8K M,BMF*S9B630F(WA!.W%Y-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ M-T9867$W1EA9<3@Q,'I83F%U+WI4,4=X:78S:'-G.4)A;&QL9TM7-DES9T4F M(WA!.UI13W-J;%0X6$U!941D4U504W-#56@X=TI/9&4X&9M>G%.-3E1;F3-Q9G5X5E!S5F1I$DT-VDQ:FM22E-&8T)L<4]3,4Y$ M;49G>C0T445:4T9G3F-:041M;E@K23E"+W=#5RM(+V=X;'8U=D8O3T1,:FHF M(WA!.S-S37-:+T]7:U@O;5BMN4$PF(WA!.V5K-C$V M4#%F.4M79'9E+U8K6% P+W)%4WDX3V1&-6-E5DLP1F-M;$US5F1I&-#9#"MG%8R2W5X5C)+=7A6,DMU>%8R2W!*1"]!3'=A,R]X;750 M.$%K,'59*VXU>2]R2#E$1U!60R]L;"]W0U,F(WA!.S(X<"\YDE:36QX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU M>%9)9DU&=$,R=F573&MG*W,F(WA!.VPO3D=P-4Y4:3)N,U)0=S$T+W-J96U+ M<#EID@P+T\F(WA!.U@Y62]O67@V;U@XE@F M(WA!.W Q+W%/:'I7;&EW13=344]53&U)4WA25'!*3D%:1D1&4E!%:E)L<6)C MC!P='DYF)+:T-24$5286]88C%/6$MQ9715055'1E5B*VIF3E@O5C=H+S91:"\Q5G=+ M-SE'*V%V*W(S1"\P:$0O<7(F(WA!.VEQ,E-X.'I225AK,3)"149+CE'*V%V.$$F(WA!.W$Y=R\Y25$O-G$T1F0K:F9.6"]6-V@O-E%H+S%6>%9" M-FY$-7=T;VLK6I+,'8Q6D]1=49)26@T*W18;#8F(WA!.V17*U%W<6HO04Y'*V%V M.$%Q.7D]I33%8R2W5X5C)+=7A6,DMU>%8R2W5X M5FIV;41Y:S(F(WA!.W)A+V\K<6DV.49D35II.%)1E)O.'5S-DAC-F1$26M5 M:WAJ2WE32UA51T]26DXQ0E@K6'AX5D)E5E!+5&%$9#9R3S$F(WA!.S$Y62]3 M33=3;T%H57%R4WEZ9D=3>F,U2WIK33(Q44)T:7))$)D9D4S<6-42S!LB]&6%EQ:'15=%AU.4YU%!':3-#97)#5UI30C9I M5DA*83E26$8F(WA!.U=.951F27 X=EA:=6UM:4QT85)7:VE7>5-2<$E9-D@Q M6%8S:T%91V]8:'A&1'5/;$-R3'-#=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F M(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS4B]-:GDS4MZ9C-K:4XY1F5O1TMS8G0F(WA!.TY"+T]A M,S%',G1B;EAH4&)+07DS2TI%55I963-6:&--,%-UC=Q1V]A2&4S=#-"9'I7;6YY,C(F(WA!.W!-2E=H5C=L-4]58VEH M14&UP.E1H=6UB;F%I;',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^ M061O8F4@4$1&(&QI8G)A$$[4V-R:7!T(%9E$$[(" @(" @(" @ M(%1I;65S3F5W4F]M86Y04RU";VQD350F(WA!.R @(" @(" @("!4:6UE$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R$$[/"]R9&8Z;&D^ M"B @(" @(" @(" @(#PO&UP+FEI9#IC-F%D M83@V,BTW-F-C+6(V-&$M.3@X-RTR9# T,&)E,SDV9F(\+WAM<$U-.DEN&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM M<"YD:60Z.38V,S@Y9C(M93AD,"TY,30W+3EE,C,M.&0V,#)D8C8S,#DT/"]X M;7!-33I/7!E/2)297-O=7)C92(^"B @(" @(" @ M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^&UP+FEI9#HY M-C7!E M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^ M&UP+FEI9#IB.3EC,V,S82TQ-S@R+3DS-#(M8F(T-BTT M,S(X-SAA93%D834\+W-T179T.FEN&UP34TZ1&5R:79E9$9R;VT@&UP+F1I9#HU8V8V M-F8Y,"UA,F(X+6,U-&4M.#&UP+F1I9#HY-C8S.#EF,BUE.&0P+3DQ-#&UP5%!G.DY086=E&UP5%!G.DAA&UP5%!G.DAA M&UP5%!G.DAAF4@&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @ M(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \7!E/2)297-O=7)C92(^"B @ M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\ M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @ M(" @(" @/'-T1FYT.G9E3Y4:6UE7!E/D]P96X@5'EP93PO&UP5%!G.D9O;G1S/@H@(" @(" @ M(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@ M(" @(" @(" @(" @(" \&UP5%!G.E-W M871C:$=R;W5P&UP1SIG&UP1SIG M&UP1SIG&UP M5%!G.E-W871C:$=R;W5P $ M @, P$! !P@%!@D" P0!"O_$ $D0 $$ P$ 0!"0(("PD! M 4" P0& $'" D1$A,4%187&2%8EYC8>-88(C$W.;:WUR,X4E97-V>93^E.SZ/JK'HM0LMYCLR4]!JJYP^P5VE$1% MT!OA>F$X%OK%+)G[/5Y31X./5H5:\?'CKT.92_57Q+*>%)@H/DK\4 M5%;15ZBKHC1BH2"XNR];HO-*T KME!5GJ3-,Z" M(#6EF#<7=&M"V7'?9K);TN+Z[JZZB=NQWSWX)!])!QJ54KB/A4W@%ZHUVY70 M^E5$T5,V?L*@74.4RZXUV _:XINETZ$.M[]D'2MBYE=F$AYP#$V\II *W;P; M5NO-6MT>T^:U^B_?M, \X_'>>Z_8[47]%%.:W-BF\XZ 5573M#. MV^P_I$M#)"MUMFC0&RX^=NPPDN!EO?=VZ6R[-_%:D7V9GW4SY1\Z&0<'KUY] M"V[UY;376:O-L71N4Q)?.]P^XAP%;L14/&L97CW)R&PG)W?QHH;H4&E$VK%% MB-J(S77!/&#)"^T;I ME!8)>MXUI]"!NNNVVK49N?SL1^*G,<87V9)0B3J37.U.GJ66($7VCCXN23M: M]XMZ>5E;7-[[6SOKP+=^4B7?(W"N(6"\5GK=L]*/TBI"/4-9ZQ9K#1*D+Z29 M3"E=4LM/_*E;-44K"K%O''H-!$\?U&IHJP,ET8NUW;3=DM-U^SC M=W-,%VWV,#\HW,R(8NY7L\'WM9P(Q5WY[//V)SRH4^(Q^;C9V#4HS-Y;QJI^F:AR"J6DY9G.FV%M-AMO(CI3N,&61J8>O308DH MF,AF."^H^%D[YZ)<,W9WX;\MY#-=]K_$J@<];N73/+U2"*@B#A>WN)Y7URKI MJ4)CRSRGK<4U('V.^2A"ETZ3XGDTF^& M^?RK?*MH>?6@5V]'AXI-%G6\2IU!+]%A""-?GCA,@%LZ:<=]K;6^W5UFXEO5 M?Q.K,S=8(KSK'H\)RC5LY5C4;AW3B%@"F-A_AUGK7"?2;N3PZSS%*[Y[4KPT M%"KPLU$E^:XOV]%"31".5%M#K?QYW"SRM"^W<>KMOH;XD5IH+ M#4F.R4WA'K?H J/7#0&T5L=%1<^H5+AG-+J%WOND5V2)D'.&@.9=3-#B,7<0GHUUUJ)>1[=G&\OH?5>I6 MD1J&0KY& 0Y.:'FH19D20>FA:'C^5W).W:VEWZ&"Y7Z<^(B0G4R78O-Q0-9. MJV'@YV]AK'S'LS])YZ$G>0N%6[KU=KI>1=78-&*-^B2]PXM7T3HT\7O MG3B5#YIV,/\ >CV&'W@1UKF71OSOD(8H8SE,H3R?9-LY$."NAD+;%LM$L\@" M"DO;!)*]VGD[=EFGV_%9W)&ZQ6_9@/NW52W/[SU OYYZC#ZE#9U#%$2UZ\O= M4I?FJS+IMZY15IR!FNN\JZ1;9#+:^=DY9 0/[17JJ[7)?Y'MI:"%!6MIG[U? M1O<^GAD1?4K;[J$&H93NO-.FE^:TOC/I5Y@%P&S=C<7V;T'6BW,G.62QSMBA M;[YSNI7>@HZ)&H=5Z/++5$'T5=I_.2T'AR./E)(9/H=UK;1WOT977#H2LRP7 M=>V^U.>F?.E:XGR%-GKMHH% D]8.7GG5YZ=8Z?8"_9>#<\/1BYZAV^B@_P K M5OFE[ZGTXZE8E>RC_-);D;0T;*=2@16SO\-SZ]]N\A#D'I/XAA6XU9VZ>HE$S:7S^[ MTFOQ>@CCT^PNS"(K2SL[VTW7S?1GE9_3D=%/*-^['T_A].O'=Z@,H?1K!#9G MF*B-K5YI[E>7(APWI ,M7.AL-GX!D$3<(@YTAB67 &-C6SM<,D0I2&_L1Y-[ MRQN"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 53]?^KZKX[YF,ZA<:Z5 ML8SY'ENMUT!7!-YL9":]1R!;U.+_ ">2 M(F#,9N-SSJ *Q$(1,+75W,5P6;5\O.MQM#>]UN>7M19'M'N%_P ]=*"\LF<4 MU+@M,"Q4V(3.&^ M;1#A:+'@RVA(,P_.BN$IL2&$(A:[LFM%[4N%]&[<>A9VSI3XO7+T4DW>JWR' MH9\4(+<^K_VI)6J@9>C]_P"-".UQAQ*-,(/RAZ(59L8+[4YB.2B%6GYI""YN M.V)0<#9SM=;_ &.W"_5QZ\BW_E/U%KT\OMTV'5&:L#YATFI4NO;?.:(GSXBV M<"XSV^(;/"6X$>-7Y'V>M-B68L0B8CR-BI"VY>_M; M6VP08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# ,>3$B MC47\"9&#RT+[S$G\(3A1I\7\1%=2_&?_ \IIUK[T=]"'F'?H^MEU"7&U)6G M6] 8C5(I>OQ'RJ-8U^+:W'E_( *U^*8VJ&O;,C_V3_AFMJ'P%;;<^I&U08:O MI^<9G: /9JG5%/T?35JYK[449!;^0,9K[<(+(\Y-G?DW8?\;+<< MCJ5)E_DC>Q7XE[:WOR;O<'Z_PN]M8!Z)-+ITU[GR)$UU>U?4Y+?>DKWMYU:U ?BZ5374+;U M&T[J#$CQ-.ZAQ&($33FF&V]+U%@QHT*-I7STQ$CL1VOI9:;0D#[L 8 P!@# M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%!.]<#[3T"3U/\ ,$\W6OSG MMCI8%,4<7&0XJ=Y2Z%Q\ 86TPI;L-VB=AL5'Z-\MH1+8;IC9\ U/LHX-!?%3 M2W?KSOV99'VTOBGJFI@KXS3^P<\IMO-E*YJ,?Z-SNR]OK9R6+.]$(W*_2:4BO07HX*V].W0[/OLUKT&I^4K3["]%> M9> ][,=RXO62O9N/\]Z:2KHCS?8)8L'-NM7&V"2)'2IWH):"VDK5%C./I0K>O0'STE6T:3O>OVZUO>]8!$_B#J7HKT]Y \V^B+7?^:@; M+VCCE%Z.<"@^2EU!Q9.T@XI27!&JF=2>E[A1W9"FV-R'7'MMIU]:U*^>\VTJ MIP:&5+AG87639J@A4R9!BL,J".-+SHH93PZ8Y:;S4/.1VTVGJ:Z=3XJYTUR< M1I9MX!Z+Y<1/.Z/C0VQQ2TU^,0:*29\,/H,ZPDFZG99H]/AUUV%'=?7JPR8X9O;A"0PP MX!K"?3?G3\UAMVD=TY*.JI>+J7!-F.@5<+#<;U6 ]U=;>V6)PW(DR)4; "LL M^!+;8G#@A@:2G1X\2;'=<"VO1J;J[U3F+$&RE'NB4=H;3)3$*W3W+4#1#K$R M2]N-&B'Y*IVF1$F3*UN+'8GK8=>E)7&:2I]"F] 8:7W?B,"4Q!G=AY=#FRB< M$-%B2K]58\F46)R24(<-C,.E4.OS9TT,9A1(S25NR)@@K%:2I\;-;8 Q@'T? MP&S0H<\)V?F4UBG&)90+6^B6BH4ZNHG#5ND/R_=;&U M6!$D>/VH,>L2+<.KH$!*K*'C M-OEP*V+GC;P06)H5@&3R,Q$5\->RK+XRIK>=C$"I%K<%(YJ4[&:>"QGAW>>' MF&A+PGL?+2C)Z2]"!O#[_59C1B9'&1S;\06Y'*N(GR6PLJ*74Q%VZ[^2Y,R1*A6>6'0\^F1,%C)4I;##D.?'ABV?LOV$Z8(, P-ILX.E5FPW&S MSTBZW5 A2QGR:V)4I(X*%A/D2OFG>M_+>M;U_\]:W@ ML6KZW[R]&"# & , PMD3M==/HUM.MK"E4ZVM:&TZVJ"_K6U+6I*$)^>_\9:U M)0G7SVI6M:WO .!WPYO3WKCF'@[R-SL+\,_N/4!-*X%S:MC^BTCT;X=:BX_FL MNC_AL^S/_P 2GIK^8KP?_4S@QV5^7#W1_P#R5*]$^QO7Y_M7@6MROA[WWC+Y M_P!;NP!Y/L_<_.I"M6F6UYQ]!$%56 2XATOKMDK9MV)"DFV#1:E3J_N$$GBW MWHY(D,5O?8#B,NCF5]'4U'R3#\;H'AF(U<%&Z^HIZ555-7PS*6F5710QSG4T M4B6]N4>6/HOA/K M1,^H1^DGV=^ZMR3^:B;_ $_X\E\A?2_&O5"7]I!Y1Y8^B^$^M$SZA'Z2?9W[ MJW)/YJ)O]/\ CR7R%]+\:]4)?VD'E'ECZ+X3ZT3/J$?I)]G?NK4>6/HOA/K1,^H1^DGV=^ZMR3^:B;_3_ (\E\A?2_&O5 M"7]I!Y1Y8^B^$^M$SZA'Z2?9W[JW)/YJ)O\ 3_CR7R%]+\:]4)?VD'E'ECZ+ MX3ZT3/J$?I)]G?NK4>6/HOA/K1,^H1^DG MV=^ZMR3^:B;_ $_X\E\A?2_&O5"7]I!Y1Y8^B^$^M$SZA'Z2?9W[JW)/YJ)O M]/\ CR7R%]+\:]4)?VD'E'ECZ+X3ZT3/J$P1JQ>Y+=,I8@=RGF''1R.E\T*W M6Y#^T1NFSU\U"WD$6Z35H-4,\8K\5V7=:3#.5..68,0"=?=+I-BGT$8,;>?" MJPWD;+II\RDY4XO4U4$F9%3T\WDM+II<^=#"W+E3*A8_/^'714@Q;KCSZO'CY)\& M*@@P[TLD0A/27G1@<8/&P7%+VN-#AQV&E)0TG6A;OB^\DT3P#D-9XT8X!2:. M#H')35=MM7=IU&@QJT+@BKP@IJS)%1Q[2&1\DF\:)S'9+#6G/QLMV5K?WE?5 M@AH+/C[B;=J3=%B"KQ]9-!,@]^5/PD TZBTT*[[T9##8T$,0EO6WEO.B\NP. MP/SKG1J8 K4X_(I\)->V+?QP\?KUS-$UXEJ++(B -L+@82)*4<>J.-&E%3RO M.*!R&W\?$UPJ0)VLDVY=R-?M[D&P=,@01\DM7:W3:\NMLNU@89:"_5X=]--> MPDT5Y6Y/7Z<8HU<9M%>!DK_$Z4-V&M)6&0J5F@6M5WA?FG/2XI\:)C61\A(0 M'D;G0%"BDNJNLN5)L>"A!?Q[#!3O&?$9\N?-7 L;4@B4,%'G4V.8^^E1TYU* MTD(6I(PA"P"!MA>#. MI?@OCY5BF2&I59F\[!B?9+!=8+9FQ2XZ:U>K,.@"R=[ MK.P* JQ-V8A#8[5?M25/&ZCIXIJI3 :3IU)(6[\>[JZ"8#/.AEDK,"LV,O83 MC4&TTJY;*S9D-DK+/T"X +S6Y#^APZ"*CQH]@K(=^2.&"Q\"6RP\R[&W^-F* M?$\=YHXSS?RT*%( 0PN>,@S[5SVV:5&(N+D0'N4V\9>.>@ACDE$A,*JU:P"F M7AE>;;W!;C22$125,SY*5A=\?#U[R#V?"U,$7:F'ZM:R(:KU@'$!$JW-$13Y M<["A^OC-OZ?&5 MOMN_B:KFI3I8TA* M)C+(.(5\'5P,\+*A !GX8+\<_'CZ+'Q7;T1T>K>C.:$)K/4#-L"4VCZ M"=CL5\LJ:&MQFWD)W7*L)G\FYF9'.LRV1M(O(5.CI<>[68MS8+N3=!PME?AK MFM^Y+5_ZY97+T8(, HU\,?\ T=/AK^REPC_9O7<%BU?6_>7EP08 P!@'QD(F MB$"= 4O[:9L.3$4Y]"'?HU)96SM?VW-;;<^G2_J^A>MH7\OI5K:=[P#EER'X M6U/Y/R^AZ( VV"%&KD_;^XJ&+AQH3 M&]_;CLH;UI.N-J\%Y73JF?-IN65/24\R;'')IO\ 9FDG\Q+;O#+YZ9B"CF[* MRVXDG%JTM#R3)==%'%%!70P0MMPP?)88ME;EM.:G%;BU=ZLD;]7O4O\ [S2O MX5I_OOGG\@\M?3JG]4Z+ZQ,.9Q#]T8?T.'_]BF_HKR\$X?Z=^%W9Q<^ORGR? MN>4 6V)IFJW(2S(\D>I9ZEN3-6(O]YG2AR$[C?AV_J6I#OWD_:^VYML'PWE# M15$R;BW*.5C%/%)F5!61B.1EJW&[;GV)]WC+I*E?>M^]?$RO3^O%*[YOZWV MBK@YP0Y2>6=+NH$+TJN%!*TF*77#A0:U8J]N<(+?DN;.%L[<98)#I,T<^ER) M-C*>:>23ON:ZU8GC)_3F5MD12/O53\V%!. M\W#EU@.U]FV&EMC"M;XBZ)MDP-?#$<5R]!Y=>3PK;$2?^6"?/F:+)L$^N07'#1\! M*%38$9@H78"-BI7[??\ K)-L/5[3#O'G,,/B"X<7J,\DB^TR<-9(W6L!'.:7 M*TBS?W]W, 1$0Q]N!!:R9E-T*X0_O$94:8Z!UILM'$X^/&_@0&9^(#5:T>L@ MP_2%P15>+VX.X<:N85]'U5>U>@*GLG/A.PXJX(E3WFCI!HHN.^2)CP9"B*&" M; :L)4)61;9:Z_JR]J]O!7\X?M)V5?N#;DC @SGW<*!990^*[.8G2QU[&+XD M7&)E] B3?S2ABY8WJ!&A0X$J"ELUUZ,!I\>Q0))=A#H6UO>_5U_J_660\Z]T M">C.9#NI5R"Q!!ER!"(-0P<'GMOQX*FD:DO/CT-IAON+6M*Q\EIN2SI"7=_< MCR([S@CRR)TP!@# & , YATR0JE^L^EO]*,]ON'0['TA^=R,-5O)]PCT8)SL MD'T'V'/=LK_'M<4GQGQR GUWJS]51T4-% Q !V[B(1DCS""+NOEP>:O?H5[O MNLNO,Z>8(8&TB29ZLV$($LY:DF# 0H,%7(##KY Y5",^$_%A6,/ M@:QU>:4 M"276R4")8Z^E+WK:E:;0A&M[WI*4I^6M"Q:OK?O+T8(, 8 P!@# & 8K3S6H]@Y9ZVB]$KI/K#1I^GN(3Y_[U3IL68R!!V":X^N+;G' M6$J'+9TIG:E+0K2/GJ,4Q>1AE1@U--E39D>-XHL*IXI>QLRIWR"NQ'G)VU%" M^:YK#YD%X%'%SD<'F[.TU\XZB"3%*@C43^43.8A<-O-BV(YMXKM>;LRFLKN[ M66\T[R-UWWN$]G6[RU[4M/!;FE7F&%W^HF.(#CT.+$V]U;?.G!I=RPU:KRUO MJU&F2M(98DQ]-JC*T]IW[B$[97WOW?!'V:AM=7UMG;AT'7+*8C & , 8 P!@ M# & , 8 P!@# ,+8:Z%M8E\%88#9,1+>@/RQ[SC[<>7L:0BDXS,M+#K6Y,-4 MN&Q^,@/[<@DHNGAY&/*@29,9X#-8!@[)6PMN#2Z_8(>YPN:N(ZZRB5,@R&I( MZ;&)C9\$@.D1"(TF,)PX9(63'2XI :1B19T&3'E1V7D &*V"C@%U= R,X >A M2QTH;*TN:S.BD$O:)))+F+?>).D]R9+I25/=DRBDN(4VXG M2N:UU6DK0K6E(7KY_)2%:TI*OGK>M;UO!8M7UOWEZ,$& , 8 P!@# *L>E@' M>2IWS<:X MZV=EY).^=EUES<'T& , 8 P!@# & , 8 P"O/5J[Z)L9<,CFULHE/KP.X5>R M+=E*-K.6@.(0AXW3+"C0@@/8"6"4M^/)D"5L%&X+494>7&D[=WG+8D^6JK9W MDB#DL\/^]\P\2F8M#6WYJ#G>>5+*BD+[]SG-[$3^];&U:/:/'-=?SD7,0T;E M9;/.Q3U,^:K[2@A<.45[6;NK7S;1NQY/0'>3VQLG5:G=+\]5K0Q#I@LS-"U. MT$7X4]D-7Y)\U'5+$#RZ5Q()@H[#D*'H?ER8T67]EIAW=8;Y3='*\L*@6(7F M<\L-BJ(J-+G(N:YIU4,,]OFMCG-N%)3-I0WALST2>=V(>?YM3+O:YK:E*'6G.<\E)&Z_87>2=;MUBGGZK3V!I'MYEMXA2K%4 M2*15UYY7!%@Z%83(Q?*YES.MT3F//Z;'A#!T2<_*->\^N7#?[.#]F=L\S)QJ M-[2@WVS6(6:&M-'AL>MH-E'*&Z0FKJ?5^VD>;F;0&@C- M5QSEM@I CIZ*D- M!W8D3?@[JLF)L'/5L,NG=^OVZ&G3:U\2"-6WY,*WN%+MOGDH4->DRN+1!0^] M3>>\'?67(AH]2B!S,!KK$'L<:+M28LL=1Y:Y<9R1/T(!F@R\=N_+=:V3SULK MEDBM [ CT3 Z7!EORZ6AROKDCFC<:.\BJ*IUDJQGGBA+\EN"[^&O1T-UV0=2 MM2IS-<4"9</@1\CH$H#6!-7YC9I:Q4DCZCU1XX8* JB+@1(PX2_*#, M=,N9/VTO=ZF6-DHQ'(Z6+YO#KXK3LSS/97Z]Z8+V7@_:9,2QR9(^OV"J]2A6 M>#4:G?%TDH;Y@50N+41NRE7AV%LT.NDV4B*-DD3-!&,@1S=5NQ\2U:TIM(+F-=N\>.XNYY/5=7:[9:Y=?:=5\$& 4:^&/_HZ?#7]E+A'^S>N MX+%J^M^\O+@@P!@# & , 8 P#EU))C1GQE)3I(A"'M.?#*&MMN3I;$1#B_\ M"G+J^A"Y#C:5+^G6U?2G>]_+6]_+Y:S&Z46;MYOTF7_)_&^@Z2_G95?^YE;AF!0^>S_\ "_%:7_BXNN*[RM--IZIV?6B0_P [*K_S MFK__ (R._P#Z<77%=Z(?1%L5?G/MQ81T/,E._5]J-%)PI#[GT(4XO[;+3ZW% M_2VA2U?2G?TH2I6_DE.]Z77%=X,QE P!@# & , PYBP@*\D:H^<#@TF3 ^O! MU&"<(8DJ?+.*:%@QNYK[&IQ@DZA;8\9%^[-F.)4B.PXI.]: ]-ILH>F5FPW" MPO2XX&K!"EB-R((LJLCW+O$B1)A1P!H7$DS&A;/7QU]73H;Y3NO M=VAM;^]-)5MS?TX(8.%U2@3[E9 M*#'L<9-HJ8RMF#<*3'FPHC(^VQ#4\"]#,S(S 4LY+@UXS,>BB2$V6/BPE22+ M$1AZ.X\!N\*=")169PZ9%GPI*/N1YD*0U*BR&_GM/ULR&%N,NH^K6]?4VM2? MGK>OG\];P#ZL 8 P!@'*2Z]ALM,^*-0>4@+K<8P+K5,KJKE1X37'2]5F)JM, MZZ7&F)L8Q:I'9JVK;D1AF<5J=1B5^<_$ QB4MR,DG-0,DO-;X=?%=%O:M_0= M6\&)@;2 9M=9L-7D$SP1BQA"@-XQ5C,VN684T5A/P7"->L QQDB#-PD/[DBR M\!UJ8.G-L2XSB'F4*T!37X8:--_#E\+MZ4M>F_)_!D:6XK:W%:3S6NI^I:U? MXRUJ^7S4K?[5*WO>_P!N\%BU?6_>7HP08 P!@# & , 8!QH]?LMU">2(MLK!2T'+96AL>KN=C.!]0(Q.M64'J3._*SI&1N#(8>VF.M< MC[NODA">-QC&)6 8[+K\;QBBPSDY/PF&CD05D^7*4S&U63)T44$,4&VW\A5K MJ/9M"UL75SQSI[I:A39T^7*HXI*EPJ.)*]3MN)M7AO\ \++YV=M,KFJ_JZ/@ M>_\ 13R+^*G5O]X.?']DCD!Z5X'^F2R>5Z#]NR/Y\/P'ZNCX'F_\O*.1?Q4Z MM_O!Q^R1R ]*\#_3)8\KT'[=D?SX?@2K5_@S?"9/ !A:H^6://KJD1*9*G0***!Q01K*)**&*&_%-;CV2Y\,Z"&;+F*9!'=PQPV:BLVFT[9Y MIHSWZD_X7G[IM9__ 'OKO^\'/79<%W(SVXN/L7P*N]&\$>2/('M_X7-N\W\= M'\ML5P]+]DJ5F(BK1>BVS%<3XN])'$BI<6RV@W"VPDL*'SDK;C-OI?BM;T[I M/U)4LN"[C)-N&.^=E#;3\I'?#*?,8 P!@# & 5AZCY!XKV.TKM]^8Z(2+?E8 M&>B,#NQ]8KP(0=K<&- "F@-: 7(: EH#41MYHD'&PIGXYR214\J=+DR'>FP M_E;BV&44F>7BN0QK%T$#3PU'[+SB"V+)U MF6233>S5611989V?9*G8''F*#2%CZESG3B%:#5\"!&EDGHPY"%>$]M\[[[W\ M6]INEB\J569NK$:H+/LY<>@C M7/R]/$RYH<#8#[==4'*$G"R0ONXF=YQYTH_+[Q8.BU\M=Y=IM5$IU#/J+VJ; M)KLN-2WS$B <@4>(B#1ZT9EJ,.,OQJG70-9&0HLYQ5J@ #,FYH5V//,4KFA#CPB]&$#0 M3]L=YN4G5F M>B$J!5GV'M36:S&(MHEZ%;;[;^^]N\KA:_ART^+2XH'G5KMBB$876ZRZFP&* M774S:V'K_FNJ2=Z/5[D)9^$9>$>7J,ZX\L 1@S7+%T.!J&-:L(&;31=K?9>+ M].F9(=X\4C+ %,$0UZLXJ]D.&VSC#T.!)KX;G1@9;(72%3VY8*13K1*"MM&> MC.R@)@;N8;JD&L5X0-1)FG;"6L$I^1-:% 4%23SY5QPN;T"";.E533"@XQ4[<%@0E/ & , 8!R/YL M7X]8_<9TN[[_ *!;^E [Y>^=TGR8Y=S-4N]&A"BO33G4!+G+2G9)Y/H%T/%U M!E:NI?GJZ>&X=R^NHYU3@:2&^A-C)IV^;EOBMD]+*]K+WN^9?;T9:+W4^?QY MW.9@UBSR+*(8:'/SX4"Q64;$;FFC%7Y\HM5KB#G=!.C1,F'6@YP*@::>4^*V M;J\N9$LP@8KQXNB":;Z"]"M!+P9(>>.A=D("R]>B1J9S:1RBFV, ;+&NCQ+= M5-$>T])Y-3C8;G(JLT*2Z;:L\DT>?OSVU[:6XWM2-[VE6VW%HWO6]H6I/R5L(M7 MUOWEZ,$& , 8 P!@# & >K;+.W?O[9:V]]O[7WMMHV[]KZOK^W]S>OK^W]>] MJ^CY_3]7^-\OG^W //Z$?\E/_=U_Z8 ^A'_)3_W=?^F 0;YJ_P R=)_ZMA_U MK.YQ'W./Q,P7JQ#_ !2N-?A7X!(_E?[:83IG;FP.9WMK_C=_"4_M<]F_\C/J M+!G#\R9U0_UD=,<& P!@# & , 8 P!@# & , 8 P!@# & , 8!2"Q\9M1KVK M3>M!^T5L35:W57H]FX_K=L9LIN7!!@# & , 8 P!@# & , @OS5_F3I/_ %;#_K6=SB/NY)8H\^79^;03KPJKO M=RYW"IM6O<(J"IUY#>SU6[EQ"PGJYJW3+)SCS_ N)6GE -?NVQ*H9!RLC+/9 MW^VSTZ+=[.[^#$P-JK .[5FPTZS0MDJY:@I.NGAZ9:U)@RXTMC:_N1WVG4H6D"FOPPVT-?#E\+M-Z^E#?D_@S:$_/>_DA' M-:ZE.OFK>U;^6M:U\][WO?\ EWO>\%BU?6_>7HP08 P!@# & , 8 P!@# (+ M\U?YDZ3_ -6P_P"M9W.(^YQ^)F"]6(?XI7&OPK\ D?RO]M,)TSMS8',[VU_Q MN_A*?VN>S?\ D9]18,X?F3.J'^LCIC@P& , 8 P!@# & , 8 P!@# & , 8 MP!@# .(HT)(;^)Y4Y(/G_K%ENI2%U6P'K.)+NT2+03 M-(A.SG E:U+.R")Z(@1.%6+3 >&((C-OS;=6]:*R65[]+R[.';K!@8"U2K+! MK-AFTP*(LENB!2DFKUX_89-2!'+ Q"><#B#-IA5ZVS*X+(STQXD\Y%JUCD"H MSKLUD&5<83"? IM\,/;F_AR^%]NH2V[OR?P;;B$+VXA#F^:UW:T(DKVVWM6M:5M"=[^G0L6KZW[R]&"# & , 8 P!@# & , 8!SL\7>Q?/E]\T M\WM3%_$5E!)5S:V"ML\6,L(]P7T"U"'D$8,0@2CL*=>@.2(^FYKWUPWH[J_M MN+4TW^8X#RCY,.\IL#IL5PN*IEUDCYU+AS;M=6B>JIZBEH9,%)455/#.DN-1P\XLG''%,2\Y0OYL2O=+/O+1_P"$ MMP'_ *7:+_X[$_\ ]9N/V2.07I;@?Z=*^)]_*>'_ +5%AVHW/T[/JECQE\F'FE M-R(C*?R5]3SJV]+8=]N'WE_ MH+W-4_9O)/,OJD3Y/FUWL?$>Z]4K]@\_,=?8-"2/%K%QL(^.,:Z,3=@KA%V^ ML(>:_!0W7TK&+^M]A.])>ZD]=E9M-Y-+-6U3?%\#J5@Q& , 8 P!@# & , 8 M P!@# & , 8 P!@'$VRQJQ?OBY\JN#G!#@VQ4(58*Z(Z;9^:6L)9"C5?I/6: MX?L5D2I4I];;$>.PTA;KS[RT M---I4M:DI3O>@*1_#&WI7PZ/#*D[UM._*/!]ZWK>MZWK?-J[O6];U^S>MZ_; MK>OV;U@L6KZW[R\V"# & , 8 P!@# & , 8!Z&XL9I&FVH[#:$_/Z4-M-H1K MY[VK?R2E.M:^:M[WOY:_;O>][_;O>8[,/Y,//\ORUK.(Y1 MPPKE5]SJR2_WUCNB2_Z2QS@>"I257AMDE]_J-/\ PZ@J'V+_ $LWAC^QY[U_ MU_\ &6=R;)?,B_.A]T9TSP8C & , 8 P!@# & , 8 P!@# & , 8 P#DU$A5 M7KWQ,B5YIM1A=,B\&$5ZCW.]T_I'+8K7([Y+K72HTZ%T6H%I)+JY:2F+*:KE M>:H[M9JK9,A:XME$G2=?,3((RTAX7=[9YK+L[\].B_67!B8HZ""6@*7K5F#" MK%7+ -G!CP Z.B%PIL.3C.0R0DN*(,R()(:0AO/19T&8P]%EQG7&'VG&EJ3L M"EOPQ$(;^'/X8;;2E"$>4.#(0A"=)0A">;5U*4I2G6M)2G6M:2G6M:UK6M:U MK6"Q:OK?O+SX(, 8 P!@# & , 8 P!@# & 05TS_ #L>"J_"\,_?ZC^YU!4'L7^EF\,?V//>O^O_ (RSN#8KYD7Y MT/NC.F>#$8 P!@# & , 8 P!@# & , 8 P!@# & 5(KOB3A-5[7)] AGNU-= M(F6>PVV6B;Z9]'%N3;[!,"A6N?-C:^3G*-@X\ M VVV22+=]'E);VY^C6N_7M"5*4I*-J^>TZ4I2M)^6MJWO]N"Q:OK?O+T8(, 8 P!@# & M , 8 P!@# & 05TS_.QYP_[:WW_9#>,X?E)^-7W.OX:QW_*..'@JOPO#/W^H M_N=05![%_I9O#']CSWK_ *_^,L[@V*^9%^=#[HSIG@Q& , 8 P!@# & , 8 MP!@# & , 8 P!@# & 4UB>Z_/HH$;M?6;W4N&U* _5G0UJZG;P-4KU@$WPAT M0?2'6BIJ2-B0K">_17=IZJFZX\2@#!\>4ZZXJ0^S#%L]V?5V?$H[\._XA_@V MD^#?&]/N'LCS/5[75_-'%P-DK9[M//Q1L$;%4 %")B2PR:>9ECR(^6R[%F0Y M33;\=]IQIUM"T*3H6*&*[R>KW,N1^LW^'5^_+Y1_CSS7^\6"6?!]S'ZS?X=7 M[\OE'^//-?[Q8%GP?T_5K7U:UO>OG\MX&S%P?>:_P!XL"SX/N8_6;_#J_?E\H_QYYK_ 'BP+/@^YC]9O\.K]^7R MC_'GFO\ >+ L^#[F>"_B=_#F1M&E^Z/)R-NK^VUI?>^:)VXY]*E_0C6['K:U M_0A:_I3\U?2A2OE\D[WH+/@^YGG^LW^'5^_+Y1_CSS7^\6!9\'W,?K-_AU?O MR^4?X\\U_O%@6?!]S'ZS?X=7[\OE'^//-?[Q8%GP?N:I2E*=;VI2E;L>M)2G6M[WO>]:UK6][W\L"SX/N9^I^)Q\.A24J M3[F\H*2K6E)4GO7-=I4G>OGI2=ZL>];UO6];UO6_EO7[=8&S%P??'8P'ZA\]6ROGND]4B72YA.V\_D .6#(7G[IA00>N4EDM(8@#+)8H8ND MBGIDH>T]8; +BM//R'FHKVAQ3!H\0Q?DUB4,^&5#@-=B%9,E.!Q15*K<&K\+ MAEP1*)*6Y<58ISB<,:BAEN!).)1+X3::*;-IIVUL_)IDR-PN%MQ\Y)F2;)[K M;>TV[Y*V^Y#'5/?GAXG\33QQT4=ZY\YSJ#4_*_M.LVBYQ.PT216*]8K?=O)\ MRJ@S1QHVH<-*V.)6+')"0)M[U^W6!LQ<'W,\_P!9O\.K]^7RC_'GFO\ >+ L M^#[F/UF_PZOWY?*/\>>:_P!XL"SX/N8_6;_#J_?E\H_QYYK_ 'BP+/@^YDK< M?]A>4O0=EGTWA?H_B78+:+!R+,2K/-NF5"Y'8%$-%DWWB%/DR&2D$8+CDXCT>>D4,W(W CBO5WWY]Y8[!!@# *MR-SX%T'EW9.;0JW*K\2! M;;KUJG>EN,"0SSI*9M3D,+48G4#IYDCNO--*8K\H64*R$21#HJO9Z6::?8T_ M?;_0M33;8$OM0JEZK,E&QY@F+>Z9: MFYQ)V21?3^&:0,@3HL:1#@F)+)24/6L6[!U,D1@^@^'SO=:W;^=,C:J$M5<% MV84:26F#QD= MV0Y]+:7ITZ+%:^K:WGD(3O> 4@\O=1Y&NW7>OTNO]%KQSM'0[3U:VL7E8%]L M5U*?S'C%NL--@N YS2:L\W_%3^+_T5R]F# M$8 P!@# & , 8 P!@# & , 8!B3X$-:@1NL6,;$,UZQB"0$Z'GM)?@E0QB&\ M/*#9K"O\5Z).@R'XLEI7^*XRZM&_V;P#Y:O50-,$(!5N!H:,20-EE,_B)#UY@6+D3-?CGX;DS M>W]@;)@# & 5?'S_ "WWVWW@:)LE4O%Y:CP:WZH<- F(DB%9'S=1/D%R&'1;0N?9[/%BR8T:/##H @3!B#!0J% M%&C!L".U$@CQ\%AN+"@PHK"4,1HD2,TTQ&CLH0TRRVAMM*4)UK0A#ISTEPJL MEKJ$L/3JP&(\XFQAM];(RGHK%0)3*\(M\0;8)[K"8 PA*J1\+:8\&3)1*>K9 M2$=;94+?1+V%GPZ>SB3?@&MV*K +*H!)/07)JZE8(MM!*:E$8RX1X?#(08TW M38Z0PJ=]$,G.9W EHEPI&G_F[$=<0SM ?2:YR=?.R%$K]IY889M%*O(H1<0E MR;LI:YN7067"C$A+,]<#Q(P:LR9U>BAV8)4D4G/K$Q1\=M_\+'CMH D? & 8 M.RUT7;J\:JYM,]0>P#)@?,D; 24U<9BK M58]VFP#2G4>H&*X3**:(,.1WJH5N,RL(KS[!)YB346!#54DLQ1#4@*XV!!I' MA>WCQWDM8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & R'_1Y #.'4Z#'B ?J[UY3?6W8P)2$JPN2+([+*T&M4&JE$D@F MZT 04,:@$3\]J7!&6UT;DNZ'97LUUN^!M--^'ZA26)Q#I)X$=JWI3CG9A)(. M0E6)N5-XC007-SDQB&6C!HH5WOD$,Y9.DU0VST.N ;25G6())+76.*O \-I^ MQKL>[LW6L;1T?X?C5]M?K.QL]9>!L>MI]>DVR'^9THI(K4*N376V3DB:IP2DHV%3^#<$OIT?&_T])6B=\,RQP.Z4&4]W:6: MK9WI/2NUV4D_7Y(JVURR-'?&Q>LB.=1XQJ<*%;DC_-4^&8MS\IB<*E7 Q('U M\L@Y)0(%VLM-UEU9WO:U]?=GEG(M=^%7!K@L8);]!W8S% !.8":Y&L(PT3@A M8G+/2YST1"J;L/\ 2!'U;>9WV&88Y9UNL=#>N5KOM3""R+_0QQQTQ**AM7U2 M>OM275NNLLGGP.@WG/CD3SQP+C'!AYQ^S#^-@5V&3 ME#8\B7'A29D8>T_(CL2'&&WEKTSM+?TI2(W=MZ7;=NLF?!!@# & , 8 P!@# 3 & , 8 P!@# & , 8 P!@'__V0$! end GRAPHIC 18 g739497g48u85.jpg GRAPHIC begin 644 g739497g48u85.jpg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end GRAPHIC 19 g739497g58u95.jpg GRAPHIC begin 644 g739497g58u95.jpg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end GRAPHIC 20 g739497g60m33.jpg GRAPHIC begin 644 g739497g60m33.jpg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end GRAPHIC 21 g739497g61b65.jpg GRAPHIC begin 644 g739497g61b65.jpg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end GRAPHIC 22 g739497g67a65.jpg GRAPHIC begin 644 g739497g67a65.jpg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end GRAPHIC 23 g739497g74b32.jpg GRAPHIC begin 644 g739497g74b32.jpg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end GRAPHIC 26 g739497g82i65.jpg GRAPHIC begin 644 g739497g82i65.jpg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end GRAPHIC 27 g739497g93f68.jpg GRAPHIC begin 644 g739497g93f68.jpg M_]C_X 02D9)1@ ! 0(!>0%Y #_X=_):'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ M-C0U,3DL(#(P,C O,#@O,C4M,3&UL;G,Z&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @ M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q M+C O7!E+T1I;65N7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN&UL.FQA;F<](G@M$$[ M26QL=7-T$$[)B-X03OB@*(@.3<@8FQA M8VL@=&5X="!C:&%R86-T97)S(&-H86YG960@=&\@;W9E$$[ M)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P$$[(" @(" @(" @($--64LF(WA!.R8C M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9SDS9C8X+F%I M)B-X03M5$$[26QL=7-T M$$[ M(" @(" @(" @(%1I;65S3F5W4F]M86Y04RU";VQD350F(WA!.R @(" @(" @ M("!4:6UE$$[(" @(" @(" @(%1I;65S+4ET86QI M8R8C>$$[(" @(" @(" @(%1I;65S+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO M=VEN9R!C;VQO$$[ M(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TF(WA!.SPO&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A M=&]R(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E871O&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6&UP1TEM9SIF M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @ M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%! M14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%) M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1" M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF M2'@X9B\X04%%46=!;4%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%( M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)! M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-" M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/ M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2 M;%IM9&]A5W!R8D71R<2MV M+V%!07=$05%!0T5135)!1#A!.54T<6=.9FUS24Y'=DIT4G94<#DF(WA!.VA( M1U=UBMP.'$Q+W8O M05!J,2MX>BM$:"MZ:7(R3U17-S8F(WA!.S,Q%8R2W5X5C)+=7A6,DMU>%8R2W4F(WA!.WA6 M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6-2\U8VHX=E=F;F%F5'10 M,$8Y3VM34V%1,U1/-%8S34U65SE-3WEN-$-&5V\F(WA!.RM&96Q+:UE696=9 M1F1ID%'6&]!0G534V-64450 M;4QY+U!+:TU'<#)K%)X>55K5E9L2VYW27@F(WA!.U96 M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9.=$\X>F5:2B]Z M9W4Y16PQ3TXY2V=6,VHP-E!I4W-99U=J4V8V2T3$Q M-68F(WA!.WI&,5130EDS05-,5#=6:F9K1#!/4W9+,T1K1'-32CEQ-R]#,C%. M>45O+WI0-65F5UDY4$U6>4Q7-3!Y.6EV-V%2;WI+:&5*6%1I-D(F(WA!.V]Y M5DMY2&]W,W=O6790.$%L=#5O961*279/3C-B4DID4EA!=%E9-4DT4D9'>FLR M-F]T=T%S6D1Q9U9D9W%J66YF0E-B53=0.'$Y9'0F(WA!.W)3,71H-75V1$AB M:4M*;S%%=VEA0T=+1TU20T4S1%)I=F]V6&)F,4158DM1,'1O:38O2W-V86%: M.5,Q:6%W,5!49$QH,'A,*T)#=DHF(WA!.W)9;TDU:6=K5679:8G%,>F9C:'!23#A):FU5.' W<&)I56QX9&,O,V=4 M9S56;$HV,7)J4S(F(WA!.WE0>5HU13%,>35Q5C-03')S,2]96$)N84145U)O M-&]7=4HO6%EQ4%9D935(,F$W:S$S<&ER34U+2%EQ-T9867$W1EA9<3=&6%EQ M-T8F(WA!.UA9<3=&6%EQ-T9867$X;C!U*W,R+U!R55E!651-25-N.7A:C5B M-'%M971+<2MB+TLV<4%Q<4PT040F(WA!.UE!0T)C2W-K=TLW1EA9<3=&6%EQ M:$PS55)A,T9N05E*2E1E>6U&2&HT8U5923!L6#5-<'!W4FHX25!4-5EQ:%!, M5EIR3V)55#$Q3V0F(WA!.S=P1#)-5S!6=5%/,TM#2TUN,WA353)X43=&6%EQ M-T9867%S:FYJ:V%254HU4DYX96]);V%6-VIF63ES5E=8>7EV6EA#=S$Y6F\S M168F(WA!.T4X5S5&5%-J5D9$6'981E=!-DY:9FU86BMK,'%3>6Q6:D5I5%A+ M5&EN2S$Y4VAE53%,2VMX,RMZ=G@V:6]:8DDQ-W8X>DQQ0S!3-# F(WA!.S9+ M,TQ.1SDQ.5AD1DML3&M-5D0O049M=D)O4CA105!H,TY&1WDU9%,O32M21$A. M<$9S;V0T1DUK8F]P5TXP8C9W4B]P1&9%:E5#;C@F(WA!.T0R5C)7>$PK67

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end GRAPHIC 28 g739497g93n77.jpg GRAPHIC begin 644 g739497g93n77.jpg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g739497g98w03.jpg GRAPHIC begin 644 g739497g98w03.jpg M_]C_X 02D9)1@ ! 0$ E "4 #_X874:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ M-C0U,3DL(#(P,C O,#@O,C4M,3&UL;G,Z>&UP1TEM9STB:'1T M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @ M(" @(" @("!X;6QN7!E+U)E7!E+U)E&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O&EF+S$N,"\B"B @(" @(" @(" @('AM;&YS M.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&7!E+T1I;65N7!E+T9O;G0C M(@H@(" @(" @(" @("!X;6QN&UP.DUE=&%D M871A1&%T93XR,#(T+3 S+3(X5#$R.C(R.C4P*S U.C,P/"]X;7 Z365T861A M=&%$871E/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @ M(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \&UP M1TEM9SIH96EG:'0^,C0P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @ M(" @(" @/'AM<$=);6&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI2 M9T%"06=%05-!0DE!040O-U%!#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF M)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF M2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G03A!14%!=T52)B-X03M!04E2 M05%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A# M06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE# M46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R M16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ M2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1. M5DM"DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K M=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U M4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P7=S-TD&5I5E=23FUB875&5W8X)B-X03M99FTS M2%EE=&-E6#=E2V53-E-"5CE+-FQ72DIB5G)H5VM7,TTXCAW-V@Y1F$V=$Q/,T]Q86ID)B-X03M7:SEJ2F)814YZ1&)7 M-WEC8FEK5=6.$9I;FQ%<&Q51E$S2&E9;%AI M=RM(;4-Z53-X)B-X03M6;"\U9BM9+T]/=$%5H5U@T<3=&6%EQ-T9867$W1EA9<3=& M)B-X03M867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=& M54IP*W%7="\Y6BMR;&HY56YE,6TU0VXW>4]N2VYI3CA64UAZ)B-X03LS+VIJ M.4A19C12.5 V,WIL.69N-EA,+V5A6#!+970X2$0V>C9F<69T8TLX9#A696-A M%9K97)6,C9J0W%E*UDO3&9M>GI2*U@K:%=U;WA.96%Z238S,3!# M;&LY<6MV<'4P8V0Q1D]S465%)B-X03MC=VIE:T]9*S!+-'%I=D]Q9FUK9DTP MFM3;%8V.7$Q=W%Q02\X-4)81VY15W0Y66E5>7-&,40T=$Y!84-73S!% M)B-X03LP9G=U4'-L-V])5CA&FER8VTK M0D9Q-V(X5DY$:7%&+S58;C5$+T%.*WHY968R1B\S;2]W0U=R-V8Y,2]W+RM4 M:'!8;T]"6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W M1EA9<3=&5T8V5C5*85$QU>E!S-FQD.%9:3&ER M45+56AN1E S62M.3G)8+VQK*W@O M8R\X4#A!-5=.<7,O369Y:C59)B-X03MI;C!V>D)&<&1S;750%8V3&ER%),3S%T M1S!R4D\U:D)605=B-&=R-S!',C)+;VU!>FU*5$]I<$U2.&%)>&119EII<44O M)B-X03LX0TU66#1Q-T9867$W1EA9<3=&6%EQ:$1R1VM#,64W3CEB:3!J8WA0 M8V5Q;G!R24'A65"]X0F]0+T%&8W)8*R\K)B-X03MQ+S,X M9BLY2"LK9G1F,VXK5#%X5DE0>DTO=T-/4G!(+T%',SE%+S=Q54=+%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X5C)+ M=7A6,DMP9#5L+S52>E9F*UE/-"]W0U1467%M3TMU>%8R2W5X5C)+=7A62G17 M.#-A4'!6.3E2=55V<&)N,&QN)B-X03M+,F5N,S$V<7AY339Q5V4Q9VU24U1' M,GA.9'-64FUK87I9-G1A=&,R9G)"16-X=6QZ8GHR',S>&)Y9&9B8D%R,%A&6%EQ-T98)B-X03M9<3=& M6%EQ-T9867$W1EA9<3=&6%EQ-T9867%H9%0Q0TQ4%I/86AU3$-J)B-X03M#;W)1:GAX5F1I&UA6C1I1#="67!A-'$W M5$PQ-WDP.6%335)30U-72U-.5S5Q1VAL84IQ35%L45-L4G--5E)72W9)+WIB M)B-X03MU<%EV3DYN2'!L,W)8-E9E,&I-.6Q:6%173VYF5GA,3'AK;75+<4DU M83AX.$MU84%F0C!W:%AP4&QD63$X$@X>E K3U)P2"]B9C!4+T%,<55' M2W-U>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MU>%8R2W5X5C)+<&0U M;"\U4GI69BM93S0O=T-45%EQ;4]+=7A6,DMO2%AB<3=T3DAV3'4P84Y:-V%& M-6LY5D=K42MM<&%H5E=J3SE0)B-X03M(1E50$-& M6&I!:$1Z5$]E2U)1>$9M2F52:49695=+<$)O2&QQ+TU';RM:=DUQ22]M4%4W M9&LK#).)B-X03MO=%AIC,O-4YJ1E5Y>%8R2W!D;T@K.$UV+TU: M)B-X03ME+SA!55I,:7%9-'$X;2].5S4Q97@X>'1E5TXW63)K8C)D;&)Y3&,R M;6\S33AZ4UA5-%&]4=%%(0W(P4'EJ)B-X03M#,%!L M5%)96&%.,VIS3%I'94%-26U+=W%#67&-4,G)V5$%R>2LW,5@X>FPX<%-2 M5TYH515;WA"1T5N)B-X03MA1U5X4S(W3CAC86M! M1#1Q3'E)2W!#4"M6.#=61CDQ,S-L+S0V9CA!,E-F.&MC5EHO=T1M4$XU=$TK M;'AY,FQG=6=F<"]2948P;'I-)B-X03MB=R\V9D%25T%W0TEF2'0O93E.+V)! ME9F.$%M1'50)B-X03LK5%19<6U/2W5X5C)+<$0U-S%7>3!R>61R1C=E>E)1 M45(R:W=,>D])=U,P6D%64V$Q6FIS<6IC;F)&566U.1E=:-G!*2$AP M='DP:FA&.4IX>5EG0W!59V1C5E)%8VMC:4(T,D1O,C9S<$)")B-X03LK4D=+ M<&9F+T%02%HP=CA!-3FIV2E=I835M M1G5*85=W9%$X675735I98WE4>&HK2G%9<7EN4TDW4U!38DM/>E=23%))26QT M,&Y74DI21T5!45-,349L5F=V)B-X03LR9S0U5C8W-'%I.%9D:7)%9GI-+S0U M1VMF.70O4E X075P45EQ>3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9 M<3=&6%EQ=U0X)B-X03LX=%HQ3%(O>70Q-B\P-E=/1V195FA:<%9,5FIU6%3A8<$Q65'8X04QU1E=:85I,8WIA8F%3,U)1,TUK36)Z1TY3:6,R549U M)B-X03M+;&Y)1F5G-4@U-'%I8U933EET2W-V35=Q86A+:T9S23=+,VQN=3)# M2GA5>5A":V1N3DMB24]22C=9<7A3.3 V9CAW56LQ1%5K94QY)B-X03M28DE: M9$TP>5%&1S%'5D)Y5S9U5D\O,6132WA2;C=8,FU&2T1&5V%36"MM851$0G!T M2]W M1$U:92\Y4FMU2W!J:7)&=GI'.#-W*U9T170W*U&98+T%,378K."\O04-Z9F$O=B]!4$LV)B-X03MF-4=. M2WDO.'@O371P2E!P96EI,'8Q=44Q+U)A,U0R5GET;6%8.$0W6%I144AB8C=F M6&)R9U8V3&ERG Q)B-X03MP3#AI.$-%9S!*-EEQ;FU+=DMB2TQ6 M9D\S-6HV%9-3DTP;7@P,C-%3G)'13)(<5-D6&-J.7 R-FLT1E)E2W5X5DQB+R]!23=/ M)B-X03ML+SA!4&8X035.:D95>7A6,DMP9&](*SA-=CA!>D=8=B]56DQI<5DT M<7=0.#4R'A6<'9*2&MT:D57,$145TU%)B-X03MR6$5"3G!!945Z:TTX M<69".$QS5D),1&,P>%9&+W=#2#E"+S9T='(O04@O,7(K-&HO=T(V4#DO9EHO M=E X'E.22\W)B-X03MB*VEF.3%+1$976%EQ-T9867$W1EA9 M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9725AF*VTO;71P.%)*-&%.;SEX8VQ2 M,#E3+W5%:&I*)B-X03LO=T)H87E$1E8S-50X52],+U-B9&5L:THW241F8C9N M8U-7.4XY.793<&EQ=#4K,74K3AW;6\Q=%12;D$K34AR='91-'%Y3'EL85179FQ44F)/ M94EW5#(Q:&)1>7=-23%:2&IH)B-X03M65U%R1"LV0E5I;$4K2'%9)3'(X M,V9+5G):4C-C+S%I3T]3-G4W4FQA3E%Y9E5*0D9C>7-#,SDS1WI$<%9T.6AI M<40O-5AN-40O)B-X03M!3BMZ.65F,D8O,VTO=T-7%8R2W5X5C)+=7A6,DMU>%9I2&Q(+T%%=GIJ-7DQ M5&EE0UA6'AGGIM-D$X04%*.%919FQ/94Q7.5@Q2'HY94]&,#!).6@U9$Q5 M-')94E!7839',R]!0CE3<%5F-4-P-#1Q;D]J)B-X03MA8F-83W)483=D.#%J M:U=M;C(P:D9M:E$Y5TE0,E-W,T%(4W!'1E=1-$9D:7)S5F1I<5#)D M3"]!3V4O+TIS67%J9G)6DAY.7%-,G!A M)B-X03M"<&UO>F]Q5#-T<$)C4V]G8TMR>7AQ-T)227%0449T=5-G*TEX5FES M=C5/*U9:-U)B5S=L=7)P5G4W>3A,>4Y%1U V46M%='I#9453)B-X03M$,'!( M44A98W1T;7A61&HX:79)47!31V-5+V1J-# R=&8K5U0W2#EZ+W=!4"]L63)Q M22]-;E)D2&IH,')5-#=#,U15;3$W4E$Q-G-3)B-X03M#8S$Q1T)45U%$;G5U M,UAP:7)/%9J9C55,6TX;G!Q5AO0T]7)B-X03M,GAH5FU!<5DR4$MG96C%X5DE0>DTO M-#5':V8Y="]24"LV;$)I#AR85!:5W)"-V$Q%)*<7-X6D-N<#A6;VM!5E%533-' M%9-'%R=E)10E52:W918FYJ47)X M;W=6%90+THP56MF;#)Y4#%U,79,5U-+3CE097AT:EHR M)B-X03MY,G!J6#!%:6AA4V1L54E",6,O44YS5EDY*UIV:T15+TYK,FQY5TYX M1F).64-C1U(R6E=R33A*;W=#>4Q,159I65-1#)K:4QQ,$UK=VAN%8R2W5X5C)+=7A6,DMU>%8R2W5X5D)A M>F983FI94&17.$-81&]6DPU=3 O M>3E:45-8<790<4XR9E-S9$MT0C8Q>&-Z57(V8TLO1%5$=3=5541D<5EQ:VQJ M-4EU9&5U:S%N)B-X03MZ-4A$93-#-S)(;"]A87=S469&5TA'-&XO;6M954A2 M04]P5EIB9$HY6# V4F)9*V=)26HV45%,44)&,D9'0D9.'AF=55R4VY54C$K;D95,GA6,DMU>%8R2W5X5C)+ M<&)F+T%02%HP=CA!-3%9-8U9E8R]N=%!B>"M58E-/-FMJ:G1B:2]J:FXY85,R9VI)14TP:6AP M8G$S=EDP*TY&4#DP4U1T=%=U2W-T.&QY=$XU)B-X03M/,$M6<%!68514FERG=X>4MZ>&MB14]O2DMN-31Q=VHX>5!.*W!F5C4O3&9K M*WDO5&YM<"M$)B-X03MY,G%-<7A7DMX5TY#,T=I27I";39J<&EQ M8V559DHO=T-J6$]T87A.*VLO3E8W1T)F86LT,FI5+T5B93%19V5J07 V2T)6 M)B-X03MU%9+4$Y/;W19-DY/,&%#4V%91T=+3W!$175#2W%!1W%6 M-C X3592=6LR<'1D3'1,6FPT4$1#:4]O3F%-1DA,9G9V:7%+)B-X03MX5C)+ M=7A6,DMQ5C)85S)L6D=+37%L9W=O9'=+.7=C;$1M1T=1;FA.2VEG:%%#4WA( M-U)P52]D5$EL:T5U=CA!+VIS-E@O>C,O=T-4)B-X03M9>%-M5TMU>%9,=$$O M=T(T6F8X06U-=F8K;WE81E5X>%8U="MC97)A9TQ3>C!V4W),5F)I+U-63'AP M9$]'<'=X:4EP3D9X838P-D=D)B-X03MU6$QF,'I4&-J1E0Q83E&-EE&96PT<3=&6%EQ-T98)B-X03M9<3=& M6%EQ-T95;G1.46Q85F154S9V67IA5UAP+T%1<65N-FDX+VIE=F@T-'%L=#,K M84AK84-:31$<6]B1E=F84YO)B-X03ME:&573DM&<' Q=C9&DQQ=#AP5UIL-#)D M=35*345*2&5U+W%0*S)F;WA63CA69&ERB]E4V8O:D3DO-FI*8U942$97069N56M%=FQI>71P5FML)B-X03LKFEK<#1)0E=19&TR*TPS>%9')B-X03M9<3=&5TDO;5HO>'E. M22\W8BMI9CDQ2T1&5UA9<3=&6%EQ-T9867$W1EA9<6LO;79Z4%HK6&1+3C=. M1SEZ8U-UDXO4Q-2V0U+W9*4"]W05DR+S1I)B-X03MC;$1M1T=4-E0W;%A) M&96=V]U2&4U345:.4DQZ=#5K,5,V='1"F]4)B-X03MZ86DT M="]Q87E'.70S6D)39' O=$AH=D8Q.70X0W948U9D:7)S5F1IC X44EE:S$T-%@O:VQ(>F(W>4U$ M2D-79FQE6G(V)B-X03ME-3%E-DXX:VI+.&1T5GA!D5!1#949T%*-4UP4T%&;$MB*SEV8C8Q94Q3;S)0)B-X03M,63-4 M9TQ'4C-#.'A6<2M.37E-8TEW3GHK5&A:6A!0U=90W!#9U5&5&Q%-G,Q>6-V)B-X03M&>&-)-'9Q-G!D.5EM M=F182\X04U: M92\Y4FMU2W!J:7)Z+S@V>$DO)B-X03ML97IT-#!:;G5,*TY!,%5::VU7:T4P M;%EQ6%=N:%DTO-#5':V8Y="]24"LV M;$)IE)W3"LY M)B-X03MC2GDU4T=L1C568G=&5#!'14)5:51Z,7)F;49&5'E6<&8Q:3-C0W5V M-FIZ9S Y83DT5F]*')514U">FQO0V$P2CAF9DTS)B-X03M0;W%X9V=B=49G,7 X43A8,"]J-2]" M-E!B,U9T8W@K<$))7!R42M".$TQ:V]'3WAD<$1*1U%U2G1E4E*-W8P M;V952G17=F)6-#=#,V%%3G0V,'A#35(S05$Q3S0X85I02$=%)B-X03M48VIF M=6%S,'-U4TI%0EAM9'9S5G)04V%X>%,V:7AU&AL:FUI=$Q#,6=J;6A9=D4V>'=Q;V%.:G5624915#)X5E(X-6598B]13DAB M56)05$1Q:&E:)B-X03M"3&)R2W-,1EAD57!(5EA,>7-Z9TEL4&E/,TE9<7=. M4"MC:$Y):W1N:V@P=5(U9E-L=DE)>DM!2',T8D\T=F953&-0:&M:3$YL0U5) M)B-X03MQ4CA62VY&57DX.65C=DMU<%=E:%=&<'$Q<$IQ8S)T849-=6UE=D8Y M8D-.9E$Y.)B-X03MC4W!$ M174W4U--1E5F36UG=V=%-T)"3E!+6G8K8VAT1VXQ3%5T2#!,4W Y83%E>FM- M5G9(85-2=F)3055R3DIC+W=",TA%0V%6<5-4)B-X03MS06-Y4'EX4$DK+WEA M2F%G05=F:#5P0G)F-65F;4XK64U-9#$U:VQ18TIO-6)E>5)N4WIG54U/46IJ M<6AD=49F,VIL>64S16):9$-/)B-X03M#2#%(:5 R3U!/965F,$1H2&YZ96]W M*U9V36,P2W!Q4&UE-S1H4BLWD5:5V,K34@P=TAX4QC M,FIM9GDY<6-T;DE05=N:#EL1&MI6D(OF=-44-10V])3UDR M5%-4:6549D17)B-X03MW22]95F4K.'HV3F%11UHW<4E!14%H;4LY9F]*=U$P M,#5'<5=E='AX1C)&1S9M=CE94MM=E5G M)B-X03M:2T%J:E!Q,U!C,35:5'I2<4=W-WHK:$(V6#5O:4]P5&%63DAC>5@Y M<$-G;6I(0U%&=U-#4GA9=#A62S%91$HU9$XV94E6=VMS34]Q)B-X03MO.$HT M:DE$,S=P=C9E<3-8.31W3E2*WAY87E4 M-2MG9F(K<%(P*S P5T162FQT;4Q8-G!78FUZ)B-X03MS,T9J,4IB>$EW-4UK M>D58.4LT=%!J:$UK9E5M5GAC,CEV15IB:59)66PK,4I)=U92.'EA1$M216Y9 M3U%30GI84GE2>7AR2DD-3:G%T4U9!5&)L,RLW26YH:TU9:UDQ=GIA6359;5II1'5N*UEZ96AB>E5R M)B-X03ME,%I6;%-D:7=Q4%)T-35H.4II4G=0<'A643AV:"\P8WI-:G@K<&,S M8VER26I2='AK=7!(56Q80W-+<7=/-'A636-662]Q,VM,>7!R)B-X03M'=&Y6 M.5DP,C(Q3V8V$=Q>'E027))6EDR:U9Q>7-$4BM*.$LW-'%N M5FQ:,G1J6G=75G!%6563D4X>5#A3=%-B95-)='-4,7A63'@K M5U!K35=J,FDV4$5L=3=->%)7)B-X03MK5V=A2C1'4E-'0E=->%-U;G!Q94A& M:4MB-'%X=C@V=%6=Z;#!$1CE!,%0O;DER5711,5)D4C%3,CAT M)B-X03LR8VMW6D@O-#9,.$151DQ8:W=61D9+.&U7=2]T;'-S,% U;S(O1S=5 M36,K.#'AQ=C)+.&%5039C:BMR<&Q5D=-+U-U6%DY)B-X03MD:VEB-71/5%(T-6EU4VAR4&M45C5.1FMS3DLQ-C5# M;$%I45@V=S-%9$9&04$O<&5Q;3-C135,2'$T.&9&2TDK1FHY3$=E;6QW.$U: M)B-X03M%92MV,4LR;2]L:#56=%9%;#%B;3EV;E)28S-5C$R43AJ45I1,&M"=5):4G8K0E!,<3=W2F,R-T1O)B-X03LX3C5D M>&M%9#EP859Y2#5U9E=J.$(K<&UD4$AZ*UHO5V5E$5%9) M:U-L.#(Y6#AQ95I:=$YU8E=W.'I846%:1U%,9'A7>G%1=V]W3'AX238Q2&-D M36-E;WAI44UO1#18*W1:-$IK)B-X03M%0UHK3F9Q4DUE:&5B1FI54#5M9&Y! M05IH6C(T<64U-EI!-6-F.'HW4S)$2% K9#EG42MQ*U=V3C$S<#%Z8E)E6E=$ M>E)S9S57&Q)9U!99S5%-F]J-D%) M)B-X03LK-VXX,4=N0BMO;5@T-W538U=E:39067I'87ES64QA5FM%4F5'3DEZ M=U4Q0R]#0G182TI:6E-&16MTF-5:6I:,DY+ M04-P>%9)=GI*9$@P6%)N4F=Y3G(R:4UR2V%G)B-X03MG-FQ!45%2:7),.%9D M:7)S5F1I%4Q9E5H5RM&=W8K;C9I85=E,TMZ+S-R,W)V M)B-X03LK.2LP2RLR2W50-4XV9#A63E@Q259V:&-,+W K;VUL;G1Y5IS1SEF:')'<$HV;"]$8U%F-F1Q M2CE+>50P=E=S.3=V-"]6-%-F=E0X4S@Y=G-J)B-X03M&54AQ+W=#55IG:%IT M3W9.4W4U2CE8%9'4V9K>EE.-B]$5TY35#%,)B-X03LK1S1G+W="3S%%*VQ:2C98F)3,E K;F%I+W=" M5W0T=E,K%8Q>BM43FA*.64Y1%=. M4V'1U;E!B-TEX5D,V-RM566DP+U9:9$IV3E-U8GEE93-B)B-X03M3-V(Y M2C,V9E9O45EK=4DK8VPQ>&LU8UI:3U0W:FQ19$)I<4QU+WEB,#94-B]W1%8Y M6#%+,RMS3D-B1"]!12]56"MR26Y(,6PK2S6(P-E@Y22]69%@Q2S$K7-N)B-X03LK;#%A-R]E+V)J+V1..%!W9C52>%9B9"]K>EE39EAF M<3)S86QB*W190S-S=CE/,4=4-G9E:C%+,VYX6&8W>79/4#DP,W35**S9B-%)X+W=!;S1Q:'12+THK,VIS8G53>C%$ M57 W;&1-94B]! M165+-6@P:7AI=7$O5V\W94I**U(U2#%&44)Q3-/;GHR.7). M5GEQ+W5,:5)8-C%(,FQQ4FER3F1/:'593E!T66)Q6#$W;4M+3DHU=C4U1E5" M;3,O;4\K2V]J)B-X03M&6%EQ-T9702ME9DQV;695=DY6;F,V36IW>$12=%9S M;3%%4V]Q43-6,&E#,5EP>D5H-'-R1W%O85EQ:F9Y69&26IV#8Q*S9%>3)#=S(S<4Q*4U7%N3THT9U)Y04(R)B-X03MX5E8O M2U1Y=C5L,$14-S)05W8S46U7=U=',CE26DM3,C)N=U&E0U6D5J>&Y6-TPQ23%6 M<$4K3=:>$I,8S9N87A*3$5* M-&55,%E-:V)!)B-X03ML6&I&9FI$0E13;EA&56TX=F9M9C50,74P5S13.%=X M2G0T3'1O8C5O-$A71S9:,6=9,5ER.&9P1F=/5F%%5G!81E5Y=E!/9FQ7,'-. M)B-X03M3=C5.571N=#E)47EA;#9-<5-T0T%71DA20WI!;&M:44M62D9-5E@O M04],=DMN2U)0,#%98V]A97%V,6U'<6-Q535$;'17=F9&5D\Y)B-X03LX-BM5 M-TIO,'5.5W11,&QY3$]G;5)U33=";31042]"=$=X4$MN5$964S,X,RM5-VQU M3G9R9&A-,T8S<$AD475E36$X,V)::G-Q9D5X)B-X03LW1&9&5D\W.#=E5#=3 M3U-39E=R1F94:&4T2T,T:5IZ1D=J4TTV;W)&;4%33FTR2%%(1E93*S@R95A, M1%-9.5=V=%)G=&)'5T$S555S)B-X03MS:7)Z:591-5I!5%9T;4=W.&-69$@U M=#AR=D(V,S976@S:5-:84U.;55P24M-3G5O-TA& M57EX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<4XU95=L;&%Y M)B-X03LS9#502&)7:T-M4V4T;619-#!29'EZ=7A#<4(T;D961S$Q;E(W=6%/ M0S!V6IK5FI5;7)%1&9B1E9B)B-X03M&5VY"6E-!>%5K14)H M4V\Y>%5%67$X+W0O=T%K+TLP3VQ1868Y8W8U0F$R.$YN8EA,4$(V<5%EQ:#,O M2F)Y6TX M:V%6,6I:63%!5EAC;$%W3E!F1E5,9"]L4#5D=DE,=4\X;G5,)B-X03ML6PR6E!59TI74E!R44A'GE&*U9M;U(V;F-4 M*V)M;%)B96$R,4-C6#%H4T-/9$EB851M=VEP2'9A;U!I,D16<#%W<7IJ>2]: M)B-X03ME5W1',57E/4T959VUH0D]+4I.8GI)%9#5U=S85)F6$XQ83)6.6(S5GI9=4DW,D-'5DI(9V,Q;W-Q<5-58C14 MD%G M16YB1E5X>%8R2W5X5DPY8G-D5G9B4DET33%.=$MN5U%-,7=K354U6D%#0VY' M)B-X03M51E)5:T=V6&)&5TE74&MJ.'AO9%IV-S)B>C%.2F)846I%34@Q1S%0 M1#!X5&]6-&ET5#EK1#,U9&-66G1(6FPY3E=Z=FXK=6QO4D1D)B-X03M3=7%R M-C%6-'5Z279W:FYVDQ50VYS)B-X03M3<55Z*U50>E=T5SAW M;7EG=D=U3E1T-W='84LY9U-/835.;G P3G)-16%D06HK6)&6%EQ M-T9867$W1EA9<3=&5DFU!:79):%9A=CA!=U=3:5%/671H3TUJ M)B-X03MY3DI6<'5K-C=!,'AU3E)*1&MC3W-V4W1F-W=F1#$W6FM:375-,55F M,$]&9S K84XX52\P+V5M.#!%53EV2F)Z<4I96E5-8W%-3FU6)B-X03MH4F=2 M-VI-5C)$>7(O05!M;7@X;3-D9S!4-G1Q15=O86)B85E),VE6:'!';&%H2&-W M8VUM:U)E66HY4W9X5DIO34MR8D1Y6#5H=% P)B-X03MJ3-9,U=I,T]K5T4X3G1,)B-X03MD4U=$>#AP3E!M=%EM85-*<%HO#!U>G5R83EJ965A1U=71S-T=$IF5&9Q56YP=3%:2&1H2S-#7G=#5S5%8WEX M$9R2WE7>4I$ M9#)J3S%I2E),2VLS<%)44T=6)B-X03MZ1VI';G=G2&MA0E=*-G(U92].>#=E M4G)!86]G*W)87=Q5T%29T$MQ5&%4-4$X-2]P-GEV3F%S8FDX=48Q M)B-X03MM>'4W+U5&=30O4FMH:3!B-G!C4T-0-G='-&TW+UHT06Q.=5!(-&-6 M93 T1F1I'=Q6&9I2&%.4U%Q M:S=T:7%7,FYN7-Y,7%!4G11-'$S<&YN-WER9GA8-R]P0T,P9E1*<')E+V=U<&]9-4E4 M0D\Q=7IY3'I01D=K:DE6:G-C)B-X03M65F)Z>C$U37,W>4=Y=61C31K M14U6=C8X6FM,7-"-$5(=FEQ5%=V-6HK6')L=$M% M46Y-97$R.6QD3$M654Q!=7 X:%I,4#A65F%::UI60VAT>'9154]+<'!0-70X M)B-X03MQ,CEZ2F)4-GI9=S--3$-/5T-3-6A6,&1I1D-S<&%O2DI!;V-683%B M>E!P3VY71CED*V],=#E094]'93!T5VIE9C$U;59964],36]7)B-X03M34G!& M0VAY3V]X5D0V1C4U.'(V,7!&=G%L=&9W>%$S0W=%=WIY>$I,13DP;V5#2U9/ M4C134TMW2W(S-UEQ<6%V-7%T9% Q1F1.:71B)B-X03MN5612*W)T95-7=&]) M>397-G1W.5)V5F5*9FEB-%9517-D-D1B1E5R=G9Z33!A,W0W5S=TC9N,6%:2G928WA3*VUW8FA)=C)K86Y2 M:#1:2U533UE12D$X;&UP,W!S3D]U8C!7.'0Q.5=I95@V=&)H5$Q*=TA,:D=( M)B-X03M:1DQ';3%71U)3>%-B.#%.1UA4;TY29S K.75R4V4Q,#8W16M(,54X M4G%S+S%A,FIB;$]V-WHQ4'15,DAJ:7$R1#@Q9$UN=7!B3TQ2)B-X03LY56MV M;&$X:G1R5DEO2&$T9E1P+W$Y,$EM5UIO,3E.-F8S:DI5155Q9'-64C%R*UEU M:%A,85A):U9Y=6YA=F%T95=U<5-2:$Q926M()B-X03LQ;&QK3$U*1G!%2VQU M2$%(-&582V=X5DTW8GI*<#AU9W9R'=.0E!)<4Q' ME),2C8P>4Q)='5Y:&HK*T%95FIR6$97 M.6,X,S)':39H6C)L,V(S3%(S57-%1%AS84MB948W<5)O;T)+)B-X03MZ37)F M1S9L9F=6=4\S3&E#2W%Q>#@S*U5X2$1)9&)S0DAC17)B=6)Q1VMH1$)#15!, M-'9I641B=6-644=J9FU$-6,Q5T153'1*,'1D)B-X03M/,#8T83!E+W5:-U99 M;FM6;5)U4$=:-44S5'!-<45G9V=%67%G3E(O3FYY=%HV>2MJ>&E7.74P;FIT M1BMR3F)L6'5:;VA-6XU9%=2,RMO46MV M4W%L459&4$%D)B-X03MS5F$X>39"*VPO2VUP95@W959B2DY15A42&Q+9E=39E5-8W%S5'DT+T%0:$),35951F-F:U)C M>EAL;F1(6&M$5TTR;U1W>&DP;%)(3W!826YK4UEX6&-B=6ER)B-X03M62TMY M.6I886A65&U(.'!F4W5434Y45#1,*S%V8EEF5G9I4T\R,#,Y1FU&;3E8-'55 M4'AC:%-J9&E.3-F84MU)B-X03MO%=K96I2>39G2FLP-C(P M<3-V47-"5#9Y,FAU.&QL271:)B-X03M(.4EH-4MY1#1U5DYU3TMP8G(O-4XS M=7)8*W,S43%U2T)D6$=O<55.:WIM3F129W,W8R]&.5E8:UDQ6)P,VQE>G5K,75Y=#=T M)B-X03MP1F-74(T:#EJ;#A014MZ M8EAF3&9M93%A3%@O04,R='%.9EA423E,=6)&=V9184Y8.5)7)B-X03MG8W-L M1VA:,S1".6U";U-/=4MT84HK6%9P8G U8C5):TYP-61H5F)'1U="1'%!4&]3 M47E2>C-A5%-X=$%E35$5*;$1C4S%+,'(T,'EZ)B-X03M(;&Q$-E140V5+32]Q1G!40BM82&MI M17E&9$AT,CE6>34U6XK2711,&U)9G=H:V%Q<4M& M55564E)13V=!)B-X03MZ1F-H9W)F;%AB5R]L>2\P6%-R,%=O=F15:#%15%12 M3F-#3DE,<4\V:G1K6#%9>G=6;W5)*TQ913=9<71T9GEY=DQ/=S%B-G!Q8T-A M)B-X03LS<6PS9%1(5DAT6EA%9')E,TIU6G)626ID1&E'6G%&;S-1.40Y;U9X M5F1R;C599C1GF,S)B-X03M255=,9&)R5C=F5FU&9G)06C=54F$9R M5G!P&A939R1EHV4UE:66)M,4YQ,'-X85I41S P37=M:E=/ M4DDR65)L;S-#:SAQ13!O1EEX<6XU2S-E;U(S2F9826MU8C8Q)B-X03MV3%5II9D%"5E!,,SAV3#(Y,5%A-5!Q M5G5U='!,039Y4E=B3&%-:T5.>D%&;'1M;F-Y)B-X03M-,&0V-$PK<#)8"UD969A=6QT(CYG.3AW,#,\+W)D M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I M=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR M9&8Z06QT/@H@(" @(" @(" @(" @(" \$$[ M57-E$$[3&]C86P@5&EM M93H@(" @(" @(" @(" @,C@M36%R8V@M,C R-" Q,3HU,3HP,"8C>$$[15-4 M(%1I;64Z(" @(" @(" @(" @(" R."U-87)C:"TR,#(T(# R.C(Q.C P)B-X M03M38W)I<'0@5F5R$$[5&AE M(&9O;&QO=VEN9R!F;VYT$$[(" @(" @(" @(%1I;65S M+5)O;6%N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P$$[ M(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @ M(" @(" @(" @(" @9SDX=S S+F%I)B-X03M5$$[26QL=7-T$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I$$[(" @(" @(" @(%1I;65S+4)O;&0F M(WA!.R @(" @(" @("!4:6UE$$[)B-X03M4:&4@9F]L;&]W M:6YG(&-O;&]R$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&$$[ M57-E$$[3&]C86P@5&EM M93H@(" @(" @(" @(" @,C@M36%R8V@M,C R-" Q,CHR,CHS."8C>$$[15-4 M(%1I;64Z(" @(" @(" @(" @(" R."U-87)C:"TR,#(T(# R.C4R.C,X)B-X M03M38W)I<'0@5F5R$$[)B-X03M4:&4@9F]L;&]W M:6YG(&9O;G1S(&%R92!P$$[5&AE(&9O;&QO=VEN9R!C;VQO$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @ M(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C-E.60V-C5C+3EF-3 M M-# T.2UB,V(R+3@T-35F-3DW,3%B83PO>&UP34TZ1&]C=6UE;G1)1#X*(" @ M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D%!,4(Q M1$,S1#9$1D5%,3$Y13&UP34TZ1&5R:79E9$9R;VT@&UP+F1I9#HS.6$U8C9C8RTW9F4T+60V-&,M83@T92TW8S(P930S M864X-34\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO M&UP+F1I9#I!03%",41#,T0V1$9%13$Q.44W M-45%0D5#,$0T13(X1CPO&UP34TZ1&5R:79E9$9R;VT^ M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z M0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C@Q M-#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L M641I;65N&UP5%!G.DY086=E&UP5%!G.DAA&UP5%!G.DAA&UP5%!G.DAAF4@&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @ M(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \7!E/2)297-O=7)C92(^"B @ M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE3Y4:6UE3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O M;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @ M(" \&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @ M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \&UP5%!G.E-W871C:$=R;W5P&UP1SIG&UP1SIG&UP1SIG&UP5%!G.E-W871C:$=R;W5P $ @(# 0$! !P@&"0$$!0,* M O_$ $H0 $$ @( !0$#" 0+!0D 4" P0& 0< " D1$A,4%187,2$B-W%T M>+&W&",UMB0R.4%8=G>5L[78)2ZYT:WQ:.#GV7)1J@W^JL M;&%4W'4HI*@4*):-EP5QKCN^O["[3XUY52\Z1-U/9]25&M[)^NR)1%\X^_O[ M"6;EH-8!7AN^-6:E&VV1IO>MZ!9H= MK"5YVT;W8;$7.J5BQT>$1*&YRAX[94$W1L5URJW:*F9.BV5T@#>).E^ SOIQ M]NO0>Y8>UW9*D]3/$)WU8!^D39CJG4.P5@TO8:N&/2-;;;;U=K^Q;9JEBFQH M.U[$1= /5TC2-?7,7 M0!%R!_4=X5:X/ M8OQ($=A8-X7IBREM63<0M>/!8.H=M,5*S49KL!M0-#VZ"J4^Z?*USL%.OF:F M5*IM$TNBP5R./*)@@@MC#.BB6;;7/AQSL/"U[\/'(KNC.[WB=3:B3L+'2E)2 M;$&7A<0,[JW;].L:YL/4;&Q*41(UJU'8\7(E\WDK2#0JL6RTVV3>PPVBB KB M+BU=JR5W6Y?%WZ<]/#GH=1E=;A]2F;I8=C ;^+#7,&J4.3$E2@]D&1"@N6\_!D(7EC#KA84B\(G")PB<(G")PB<(G M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBP&_[-IFL6*G)NA1P6S=[] M4M95M30\@0S.N=X(_2JT+6D=%E*AMSIV?:60F88'P\?UDR4PW^?PGWY+/N$6 MG#9O:KQ+ QNV#*3U;KJ8$*^W,$',3M9[+O3,.LB+;VP$TDAENL[ KZ;A]MZ3 MK#KO?GSP5T:(J+R!+5@!F;GD/#OM;/RX<>OUMWIW==V> KM\ MJPZ"/W3V O\ -L-.V8,M+-_U)0,:;TGL -8J0,-74(2:TBR: ;^U;'=^S)Y M[;Y_7K6"+(IBPC)I"!;V(T.9%LKYVL>X&^95B*9]_P#"[?=FK[/EW"V:>C:X M(#*#6)0'=-1@TNXU(7KMR*!!5&TV>9J3=;>RW%62P"-H:NC50K7)0LW0K,RY M(-12.2F5ASXZ9ZY\QRMXJG%<[:>(A9A]0%D>FX,;4#!U*;Z#-=;-S0G)];/; MNZ4")7H$3KJB#6RZM5[Y[0W,_@A#NL%FR: FN*8'G MSR4>UOM9XK=%U,%&U_JU'+SZIIEN7"#VK1G86Q68Q>0_7FW;#;KT^RD=N8F2 M5%MK5<)J>-\IJ1,'NW4?E^<0F"/01)9O/CEF-+\K99<[= I'VGV2\1"X;->@ M4/1=SJM=U9O J5I1F3JG=E:KFQJM%IGB.TR."V['#/VUVSZ[38=9]0+KDA1V MGR)M.U@9L4)'$B<&HUDK9MAGKKIEFW3/7,ZVTY+;%J#8UO.Z,!;,W/49FLK6 MD =.WBI2Q[K4BL("SBWOLMQ6IYB7.C)%P&ID":I44@:ANQR4BO5N9-X0KEJ$0SH.0MM)%E?")PB<(G"*KUC[I=7*E M9,_N2LPX='N5]H%K<:8- M$' UJU;K9&X-D0)$8:*F2G8M&UDXBYVDU%9?!A0^?7W>WNA3 MNGU9#9M2)^Z:DEZF$\ACD:-DH0F?4V['?*?+B!88\=*E6E8JT:MV4!.*J[)E ML"4H-PB&EP':Z53%)8\NOWWW%N=Q;4*R(@L+/BAAT&1@F AH?"+!RXR4S.&E M!9*,U,'D1\V,MR/,@SHCS,F)*8<<9D,.MNM+4A:59*+T.$3A$X1.$3A$X1.$ M3A$X1.$3A$X1.$3A$X1.$5&._&JKKN'7VE*G1IM\"$8W:[KW8RUMULT)]]$9]^+&>>82O#3KL=AQ:%+9;RDE MQR'K]5V?Z&U__P!/[O)_O[K/_P!,/"7'(>OU3^AM?_\ 3^[R?[^ZS_\ 3#PE MQR'K]4_H;7__ $_N\G^_NL__ $P\)<OU6';$Z7[)E:_O4:#WK[PFYTFG69B&&<-=;GFR\IX+.;CC%LQ>LT>2ZB>\ MI$53<>0P^XEW*67FG,I6DEQ_"/7ZJQ_46N'J=U0ZPU&TB9P&SU;KSI:N6,$3 M87%)!3P/6]:&%Q)",YC#D:<.(19$.6PO&%LR&7&U8PI.>%%8;A$X1.$3A%IC MWEX3A#>]?W77[)N<./:VCVCVGVAJA$502D$YJR[WG059TG1;!7[# O4(\]:] M1$JO&O<&1$)!*SL!HD6H]NK2!+\IOZ ?):#K6RX6.>HO<@]#[@$+## M'@I@)EB8ML'>IC!^G6;81_5\@M5$S8\'[V-K]O=HWE-[8A6$8FTO>KMZ> % M#LU_$+%%$FI>9CU@FCA55WSR' > %N/\(OJL9\3KHQI#4?AR[.V56Y>W(NV M>K74:H:[U;L +OS>M+^%!U "$UJJEB%%I6R &M29A45EQ\C+)5"8X1>?RF$3A$ MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%7FR_\ U7Z6_=Y[/?S) MZB\(K#<(G")PB<(G")PB\TB9#A\-*+%1HM+^5X8R1G186'LMX3ES#69+K6', MMX6C*\(]64X6GU>7JQYD7]#RPLNVMX42'DV6E^TZZ/F1IK;;GIPOVUN1G'4H M7Z5)5Z%9PKTJQGR\LXSPBT"[6J7B(C$;Y?TM7-@6(0OO3V'VJ$I]_GV@K"VC M0PG3:NYZVZ\EOE[<"-Q^O=Y[/5/-2MX(390@T6S(%NV6'#U41L"ITY]3Y9#Y M\N:V-W*_*U^7Q9Y<[7_UL5"UJZ]^*3,L-BG$EW=^IN7C8)#=-=K]M>EM;$B% MM\]^#VFDZT;:(Q),L72-?WKJ@U*5 9%J%U8+3*T0QF1K$B)J]5NST'#B V_' MB01QX\[J5_% HO?T;X6^RU6W=^BDU.N=+*,)[#U&P:H],;"J.ZMU 3\QZEZDN>Y96K=EU6 MC753%3EQ1UX=J>C; 2;KJ"[[:V+70,DB@218VXC9:L-V]\R#)82RIIXDK9VRM4T_':)\U)7"*NESW\:H4@E(L77S=3% M0%V"$$D[!C$]!2JTJ&1/Q:]!LS0QK>F;XH')?FQ9R6%4Q%D:@.^;]?:G(<@H M)]^ERK%\(G"+4WXK#N:M3=9;5(.^'XS5J0]=Q=A5WRUZWL6.XJU)J#HF-I@+ M+V-K*!*N$N9751RXK)]PL8@+A, 8$\BP@?-+3%$X1:T?&0_R7?=[_ &$V;_CP>%IGZV_S M-]PMEJ?PQ^K'\.%E<\(G")PB<(G")PB<(G")PB<(G")PB<(G"*O6M/TZ=EO_ M %'4W\O(_"IT;W?,JPO"B<(G"*$/O)O/](#[I/L/4_L9]W^;Y]N_O",?:?V\ M$< _IGW??=M]*]?UK/M_+^\;T_2_\/\ C_+_ .RN$5:^Z/9?8%3+TKJAU9;% M'.Y?8$<1>IKA.+@K5] :L@R6QEU[/[7AISEMJH4=4C$"D@)RFW=G;*>#TT4S M-818'!Q: &IT'F3P&H\>0\%G76_JYK[JF+UWJF@D+<30BO[%NE_M]@M!R59M MP[7+6&E2[;MS9ZVI[4"TWNVE3YF<4)$(;R&6)$ - ;C!0 & -O ]XX=_'P6" M;N!Z'+AE:V6G$JY/(JJ]:$_M7L)^\+:O[F:_X5.C>[YE6%X45>NU/Z"KC^WT M?^8-5X5&O@[V*L+PHG"+5OXB5VK>LKEU\V*3ZU;+[)6>J"=Q2:$(U-J/>-_M MM;L$R;J.'(G_ &VT93]B'M5#)0AVNR$A@H+#,A(V"R2)::+W%P!Q MN0+^=K^:LYTHLJ;CUUK-F0*V4#9,7;=LN*)W#2+KKG9T&'G>.QVX3-SI^PV8 MEP&&/B-LKV X]7J<&+O0U!Q0F.VT\:N]MG2/I-)J0PT>)Y7F"W M"E+?=PJ!>_(:FQR'/_3BIHZ6]5SVBQ%VVMNVQC=E=ONPQ$=<.Q6T(##[89N= M!C.,574.LH\W*YH/2^GQ4ARLT,.ZI$DDKZM<3;?V@LQ)+9"0ZTY>![Q[.6>([C[M6;PG[PMJ_N9K_A4Z M-[OF587A15Z[4_H*N/[?1_Y@U7A4:^#O8JPO"B<(J-=YNLEA[)T: &#;H$Z' M!10]IK6T+^JN2R%T':;MLVHD-I1M:W-%WJ@[5=KL50IY&DR]@DQEH2#J=MLD MB' C2D)<>*@VX7XCE<7M?+/7HIVZZ:YBZHU)7:.,:JL.O"Y5@DU$31YI@C3P M5++V$F7J .O3CTF83F0A==FCHKDMR3\*9.1+EA808&^-!C"$W-UFK6K]:,0+ M0+8UW161EW)*,W0[B4XPE*=$67"4XQC&,8P] QC&,8_ M)C&,?DQC'Y,8_#A:9^MO\S?<+9(YU_1KXG7U=?G^OK%@L4LZ%G#9Y&Q44FZ-4( M:A95/E(,"HT>=EN0Q%4&1$7&*88(2F8BBT19K3SO;70'ZDW]N)VI\+*K]VN( MV4'UHWS9:=;#E'M=0U)?[G7+/74!72@PU4*N4L8Q2&;"'/")$5^8,9C$(\L7 M(Q(@O2&6U,.K0^V1>#V#[&:XZ::8AW3:!VV7&;B4'HM!JXV#$LFXMY[--><. MJ:]H=7"0Q*+5L&WSD9;8AC!X\;"81..%G ]?&$R,.$V^]2J!?[TZE4%ZP]&K MJ>[C"_$.[@+AQ>U%DU];6:EI*LS1YW4_6>AF_LZ"#TL$2H/T5+M&#].9)XDBVO3/('2P6SJ[;GK55 M+8J(:&3O^Q7VL.Q:!36F2!EEMSRPU-L4QUUD141'J6WEPI8YT!K+2LKB-3%X MPTH&DYG(*CZLZIV<>VV!W3LFU1PF15>+"(.JJ<4L#]> M'?-<85!=-E9,^-!LI%+;LM9E;%>&0'YXZNN1T26Q33RM%P#2T"]R#O$"_AR' M+O*@!OM"?VKV$_>%M7]S-?\*G1O=\RK"\**O7:G]!5Q M_;Z/_,&J\*C7P=[%6%X43A%6KN!C2:^N.T(W8BS%:?J,F&C5^SV('-MT,U ? MM16!5J\D2BBI=LQ(I-LAD0/'!!\0B@W-E,"Y@PA"E2(CI47N+9]%V^II+3A3 MKWK=[0)FPV#4L*"9!50S:VKZS8)RJW9S=>L#I%G9T>)=6G$V<6::9;*Q8\9$ M9ME(-EL!@6G!#>YOKQ^PH:N_B!:TI.O-];-QJ[>=LKO6C=)73&X6:C6*9.+5 MM\!6*);K!L"-!*; #I.4<.'V-6UN0@C\_9)1Y1)NOZ\,)&2W$/DEM,QF+C7N MMIK?PZJ/CWBQ=3P)DS7%2KV4/Q+%9:Q5!(L"$5)V;/I&P-^ZUO+U"=GV@?"D M0:A9>M&VLE9-EE5CY8L.,) 6S,<\*^25W7'A_2]CGX$'QYY*$_%F[)Z#N7A9 M]EUA-P:Z40VWU;CWK75<(6\")M]KJU['BCE3*":B3GQ;'):-C)#:\8072MM:H[S&7.XU\[@K]*?"^:HE MXFF[ F@.B'9O8!^OV*SQ)&JK10H(:K+KWUJ;9-H#7]=T^+%C6$\!20S/MMF" M#?IP59>RRU34-@J\:F^B$X5:+D#2_$Z :D^ 4+](]+W??)RI^(WVXAQ)>[[] M479O733S)"$>H'3S2EUCMRX%?I4-)[@V^XW&,D4R6:" AUR MI!WQ9$J2 -UNG$Y@N[^@X#AKF58'X&Q-X;CLY2K;$LE4T4!$R*2^5KL:N0RU MIM \A%S9AU.L*QCIV#7VI3*(LRSQGW9&2XPJ/!RVHZTR(OTR:W, N-C8WR&= MKC0G.]LLK'/,+Y?J.1-AEESRO8\M,_+)6CI5 IVNA.0M, 0@<)QU4F8MA+CT M\I-7G.7"!DI*6^3,D7SC&,8P22;G[\-%H 6"S'D53A% M7K0G]J]A/WA;5_Q5A>%$X M14@\1Z-'E=,=R)E?99N.QC7Q!R;=[O:]=5(/D5M*D$VK ?N-'VEI2V"!M>?A MM&Y& FTZ=+()@?3,D)+,UT9.*MU'EH#KEH0;]UET_#8#W&O=/-= ;]5YM,M8 M:U;L'%JT1E7";-%O1=Y[(;PU)EW_ 'AV-N+SCB<8>S@[N*VR(_N8B1E"A[$, M- ([4^!RRU%]+#V^J\ZR^'_7# S9XRN=B^R.M\;<[(O=HKA+I$W1BI3^P/LM M4JL-$Q$7'1-O@M5$ BBU6P@8,B'*-C[<%'6--@<(082XSYJWTR&0MQYDGCQO MG:V7BL +^$CU,*DB)M+>Q1IS)RQ6"GF(5E#OS]:3;G?=_;'NZ*2LO6"C.8]P ML79C;&#"++5U4ZVU/PO^R,X5 MHW5;MATYU:AT36ET+4.L&[[3ZM0!XL'3Q@:\E1O^\MU35-(B:AT_LK9TC+_ )>U[5#IIFT+2O"LXPK"\"_1 MZ/Q7E6$8QG*L8X09D#FM+_3[5DKK1O#P?!;.8>=/B%AT^( 6U M)'UNOT!\+"TV;P2GO!VTM=(1C!+K)XQF'M*^T9B9%S-J#R6J/U#O"IR8< MREID2E:Z!_B.8X=3].?ST6#_ MR/'H/K]Y:J:JY70M1 B*Q71[ L&"@1A@L M?'QG#4:'%;PVTC&594MQS.,>MY]U2WI#RG'WW''G%K5DF^96@+9!>UPB<(G" M*O6A/[5["?O"VK^YFO\ A4Z-[OF587A15Z[4_H*N/[?1_P"8-5X5&O@[V*L+ MPHG"*BOB5.D$=+-PQA DD:*F)&LZV-AA8.V2AIN=:=N4.MQB(8;HX_5=G$"X MATJDH-@5VS 6)TR&S$L)2+67C*LE6Y$_<=%_'AJ#C8OIGJR/9X%@@V MA9O;TJRKMH7; "V%SDG=6PWB%DM _>5ZV7M7-@LSRLGBL^VW8T^5ED'"8K P M#+%!QY#J?Z'V 'HKA2[Y1X"9*YUSJD)$*PM5&8J78A$9,2UOP6";%8DJ>F(P MQ87ALJ*0:"NY02<@R6):(V8[S;BBB^,[8NOAC1]\E>J,IP14!\8_.,^%UW=SC.,XSH MBRYQG&?/&<9>@YQG& M5!H-N:]:/SD-,:])W"?(5C\U,>&\IW*&L..(+3/U7Y GR!(MIG<+Y=U66JAV MO\*#8C;;<<= [3;6TI)0TA+;;_P!*B)2C&$MQ\V*@5[*48QA'NL1V M\8\\HQP@T=W \>#A]=5.W>/LF2ZQZ%*VBE!6+AN_8-@K^F>MVO'E^G[P-_;+ ME+!Z\!/XPI&4@1:N%IRA3J97'R= MH>02V1=Y+5GV.:_(O,JPR8[:4B(2_4OVJ_5HOM@:_":5B/'@1/>0C#\N2MS+ MCQ5A>%$X14P[MV*@A]6R(?8+5FB;_P!3)K@N M3V",]@]DU:FT6K#QUQJ+])6]6KO4C5.O,B7<Y]N++]L_LBBI MI174L?;_ .U/U3 E.(WUWZIYX]WW.$-[G>O?C>]_&^>BU [R\,/L)M<5V0'5 MPO1Z7&VMV*[I7JJ"5G9*1#-2[5]%8G5>KW4RP*$?X)=-=WR')M!4)#;DI=IM MB,RPEBGV3S 2I;7J;^@'R6@X"V5[6]';Q'BH]+>$'V;184'XNX05F13+7LLK M&A'#Q>.]O./LS>/?;9T*#TZV!2/"XV9*G]Q>R;;&B^EM&US9-65HAJ9G2^U M2NM*R$KI>R6V%9=06#:#C]UE1E3C?TO9H=Q6&XN(GP7L27)!&D;P^$9N%CG< M7/#.V7"X/6Z_0TG\,?JQ_#A87/")PB<(G")PB<(G")PB<(G")PB<(G"+4CVF MV?K3?/=[P[NM=)V'1KL0UWV*W#V$W'6JC;0%C.T>1UPT5;P5:$W82'(3)M8F MHVAN6C2D#CT>#*7*&8<::]V&KT%H AKC;4 ]Y]DEK)RVV'W\P0MGW0'U ?E93';=:C'7UVKG:/MGL;NS;I_P#[J_1O[::%ZONO,O*@W[?1/#8# MLKO(/#4AIXJ[7G$Q>MFL%LHFXEDF=M+%^ATTSE5 )-AK]^G72V>B&S6ZYG,\ M@. [SKY<5L+UA4#YX\_N?9<%<*X&(+D"F5*0I+K6KZ5*4EY G"<>;:K@>PAF M;YAY+ &(IL<.RF12;#=!RU)_B/O896DX1. M$3A$X141G#MRE=6=PA_7PD%#[BE;PL3=()6&4W$#Q9V*]K%4YS:Z6Y)3;@A:R^&_(^Y^_JL.*U3Q&W(75)(VYZR1/$V";)[ M0.*-16VBPW,2[YAL5?&=;K2-@+%S0\/+4EG8,T7:V:B,O4Z?5\Z=#A23#]C'^]MRDN!_K:$T\:J=EB MO,3&WL1Y%416Y,A(B?C=$R4C80$J+<-;&_7(^7AK?AHMI/"RG"*B'B7?44], MMH.ASY"LEXUCTI,%E1'WLX-8(0M[ZSEQ!P%>B==[7W"R?,OLH#@7]>4,W9&2 M\^$[$<#MH>.#2TW,CQY&_*L,WIOJN5:YML(GWC&W%3YEYD[TEV MI_\ [ZMBIBY+/]E:)K/=RUIA8CMQ<7JC@9+<%$5H*U,K: Q*84=D3X:6Y9?I MR\M>]7CX43A%K1\9#_)=]WO]A-F_X\'A:9^MO\S?<+9:G\,?JQ_#A97/")PB M<(G")PB<(G")PB<(G")PB<(G"+3#HRNE;9XVG=RU3(ZEU[1/773P,$^[G*FF M['V? :QFV)<5"L>A,A(?JE7F7W6\Y=2Q)2TYZ&WTX<+9_0.I-_#0_P#<>'/D MI=\8O3^U]^=!]J:ETOKH48JJ[5IUX27AVF(1BDJT=K M;]89M 8D+%V@@[+"X&QJ^ZN?@H+H!.0O?HLM<&D%V@^[>/\ 595TMT3 #Z:T M!6,"6!.F] T2K5K4=80-R*:N=I#BVXYO==A%.$C+BWRIAPH1J>")8Q.ERB)* M[SY\HF8BS.:N&C='ZB/B/(?PC_R/',9A8N7NWB;B^5^)YGY:>''8OS"TG")P MB<(G")PBKUH3^U>PG[PMJ_N9K_A4Z-[OF587A15Z[4_H*N/[?1_Y@U7A4:^# MO8K =LG>X,+LIIT5JBOTF?UQFCHV=N%S0UMVRPIKMD2T3^AOXMD',MR-6VV7 MHV)46KL ER)I2'C;Q%YBD 296ZW]/+Y_UXZU'>X):_[XC]DZ]20M$@6H.SI5 MZK#6H<^6"55P,DDX5<1;3V$(7*E8RZ.1FRH'VENWQX]])A6P(0,0VX7]/OV[ ME@OB,Q1-WT$4T@4C[,A*VI+KLV);:/UFWWVAKP->M=D:ZO$L1>:1U\?%6M$& MVCX,L4/:GVFKBB3;15+\^:U#>$$"#7^H'E=>AX=@@51NN #4@B#;\Q];%[>U M(/V+K5NCJH(.3+M?;?L!355U=OF>9O;4(3#LD&*4+XL%B!D"[DI8TJRZF8#" MD.OEQ!Z:A0QXL.RNSVM-044KU:F6!JW+,;3EV(8&$RE?: ""Z_[5,#Q@BS0F MIL@9LZ+;(U>L&F:;)$DP6W-DA 6M;,TT /SW.%6@7^+3+C;CZC@;&X!N,PM= M-B[*>)QFY6.-,$;+ Z_>V1;X6W23U3;@&M35&!V*[1@-(_9ET8,=CP'KQJ:K MZ&7:GPN9;$P23#VIU$!=UDD3!:LRVMC86[[-O?IO$\\N@N)!\2S:/?@IX4M[ M8O?6K5LH+;NCVNS?8S8QK>Y"B[ H>TCU1 3=LB!.BHNE#HPKBM695S>XZY%?HI3^&/U8_APOFN>$3A$X1.$ M3A$X1.$3A$X1.$3A%'=#VSKO9TJU0J)9X=BET@LV"M;$6//86#,NM+?0-FXF MQ(N$S,QTXD*9;RXI$=V.^O"6I49;I%5SM+W2A:9LP'0>E:1*[$=QMB"W">O] M"5LFT.C5ZO>]B&]MG>MPRU+@:ATR%EK2W+LYIETO9YR<5VA@[&<6\Q#+0;?, MFS1J=? #B>GB/MDNL""$@@ "P%[CR1;,YN]'IXEN$4EDV'&ZC6RB MDRI,*"N*J0A"ULOK2G.VY?%?1I/7^$>IYW*^3C?X<\R!?@+YJV,:/'AQV(D5 MEJ-%BLM1XT=AM+3+$=A"6F666D8PAMIIM*4-MHQA*$)PE.,8QC',+:^W")PB M<(G")PB<(J]:$_M7L)^\+:O[F:_X5.C>[YE6%X45>NU/Z"KC^WT?^8-5X5&O M@[V*L+PHG"*HG?&\7?774[;MLUK:#%/V!#@U@=3C->K%LN)URPV*[UFN"P0< M!1M/[]MTDC:Y19NKQI0#3U[(BG#&"K(N/\+)2 5: 2 =..8'N0/4+U.ENS-C M[CZZ4W9FV1Z@MZMIW9DXI75TK9] 558D;:5S&A*EBO;GHFK]G+9K .$.!Q#] MNUU2Y]MAP8]I9 18)B(MTA%C;V(/J"1GWY:*T_"B<(M:/C(?Y+ON]_L)LW_' M@\+3/UM_F;[A;+4_AC]6/X<+*YX1.$3A$X1.$3A$X1.$3A$X1<*5A*5*SYYP MG&59PE*EJSC&///I0C"E*S^3\B4XRI6?R8QG.<8X1:**IW6V!V+VOV8ZW>') MD19KJ_O0O*VQVUM=?GDM"]9*\JA:YK4IR%"EMCT;EWL\1!FXE0U0,D- AQ$> MLSL8R.!#Y0LB6RVP:7999#BY]#E&,OU&W@"3\QT/@OF,WGH/D KC\^:^B<(G M")PB<(O$?-Y8/00/TLDZN?!FD&R32A>!S+ ]V(S*P_ATDT1PXVZ0@HPED<\E M>9*5(4I#4A3/*92[])+5_F(&B&6*$P.$_;.?,V1T>[NP.ALYL,INZ9MNS(< M71A_7R8AV>(TV'?DZI[JFGGJ6U3#2?E8XZ9\$PG[PMJ_N9K_A4Z-[OF587A15Z[4_H*N/[?1_Y@U7A M4:^#O8JPO"B<(J!>*&+'F.CFY8)5#SH]1'44F3':&T,PB6W!W=K>;\&:*V?N MGKQ0" N?X5>06.B^H MH]=CCH8R%8-VPDP18+7]:A0I+&^]G8FQFPFK-O[[H$)29675.JK6W+I#FN+4 M0=FPI*D%;"#* $WMP%_ M4#+F<]%K_*>-53&[>FDU[4SYXC<;O>:;I\OBVJCU^V)U;N;?FG;T*_0FG\,?JQ_#A87/")PB<(G")PB<( MG"**[[MZN:ZLVMZH;$W*>2VK97JC5'ZY4R]@%X.Q@I:RR(IHD.9=B@VV:X / MG5R22V(^!H0D[AS*V4MN$M]W"E3A%2SN1M@5H_[A]BW3L)*Z]ZFC[5/"MLGY M,C6L"KE:I%TMM>_0X1\I?Z9:)<%Y=FU^!&C6ZK-"F"J2\\-%^<3("G'0$A_CG_;(T3MUV[ +_ P 8?1'.]8M$V-K M/KP:E-QMY7\ MI0V-K<,8S,DEH6;GJ[S:.O4^@XW6Q/1_73176JIL470>J:3 MJ6ILQ!D1P+20D4-'(9$1EQ(9$TXPGY)X\J.O+<^R&GY]@+>3:RI.:XTVM!9) M)-SF5-'"BK]<=R&*K(/A6JZ,,VZ3944[6E7%EY4@I;C4@$)L.)I1IX9#9!U\ M(-,L3;06^5+C"HT61GWENOP6Y&@W0WRMM MN$A"Y"ER%N*X*H%M[YE6%X45>NU/Z"KC^WT?^8-5X5&O@[V*L+PHG"+71XG.N3=R MZUV6R#=C;*JL&B1F2!*ETV/295.O3Q*TT]@66VJU9>K';NPXJ6LY45=V=ET? M4Y8N,8AD"S\=Q$!B:,+33GH#?+/_ % ^[+.?#CC$HG3+3$8M-+$YB(MR<^K% MT81]6C3-AVR="(!?^X7K XY4I$.2QFG/OZ%UP](JR1,A0TMAU-E-E':FUK=, MN'0GW5@-Q:$T_P!@ D"N[BH8>]"!:K+D=&)KG1G(C=SHUHUG;XK,T7,@3DP+ M3KZZVRG6(=\G, S7SQ <1C2&'O2D@)&8^[&_N%&\_I+U3(N69U_2-/:>MI&* M6*OCT$Q,B,1C66SW%4NMOBB,-ZFO3[3=K@?-YJ"P6+ 4LYV4=P1<*3,O$WCS MZ?+QRR[K#@JQ>+D""U?PG^XM9K8H>"KU=ZZ%00$()B,P!88*(:%CQ8H;!C(; MCPQX^#'8B0XC#:&8\=EMEI"4(2G!5GZV_P P]PMH2?PQ^K'\.%E<\(G")PB< M(G")PB<(M-GN/<;1G7;HK1=3[=N&ABV-P]CSFQYUE$T;0S6PJ!?=0: MZ'76P5V:MXF=M C:!O8T?75?@.7=NJT)PT^ED)9($Y@M "Q+KB_Z;6SL<\N7 M"^E^9%E+?]%7OWM3^LWUXC)+78B=^>1H7230=!T_'CI_'$"/M3=LKL5L=UK& M? 6'NL5(^"UT;M-SU_LO:0G=&]MFZY MLH:W"+]O_L!M?=14M MM---IRI:U92A"$YRK.$XSGA85+M:]D!MC([";H5 W9LGX]P?%C947$$E56DP MH,1MR)%N!RXYJT!G!)E&3IIE*L*PKW$^E><_ .)=W?".ZYN?3ZJ_$>3?4_1?#4'7V#K&UWB^F++, MO=UNT[WW; 4&Q!RQ,-]MA\F.$08:UQ!L0D4;^2^S#2RC,2&(A+PY]/P\[7/W M@!:P T[KY^I0-L2=2>*L1S"TG")PB<(O&PWP19>SS MC+G+&)?_ (S ?ZL6[_FM)YSX_P"ZZS_G\-_R^*KJ)O[^PW_I&-_YW9]9/S@+ MMU7K0G]J]A/WA;5_=J)3:)33+-JM^HJW#V,"I=8OY\&<.;@H8RN1*]6[I5;M M5OM#9#\D;5P5@-U4U#IA M6+K\ <'ER[C,#6^B7.NV1JH,G]<.0"HVH^DY>G M[J[4]B)9^NZNJ MXV^4*S7A9: &IT&O7D!U-O#,\%.W6'06L.FFM >JH-JEV2[W>QE;ELC:%S>; MJG\<)%AV,Q1(V +C*4A>8XZ' M'A,94U'8B-JRS&;:;]3<2+&C(SZ?-$>.RRGR;:0E.;DZFZU8#067?X1.$3A$ MX1.$3A%BZ/\ QI(_U7A_\VG%=2W^_9?^DP?YRH646P-J:=[FL(^(=I6PAI!(-I,[L(7A* MO:O"(=O,(V;=+*[$Y<*Q-@9'&'PL?5.H:R)DDH?^[=^7PJJ>YKFW;>'(B4$3 M-SS*]VJ]:$_M7L)^\+:O[F:_X5.C>[YE6%X45>NU/Z"KC^WT?^8-5X5&O@[V M*L+PHG"*@WB@,T]_HIOQ%^50T5!(RER#6=D3=:P*SEJ'LJF2XJ&7MR%@>J7+ M6N>Q$3086PR<>HD;WFN0#:)4&2[#?*MO<6O?I>]N.F>E[VX+SO"L52U]#-$K MUW]C/L6I&QE!]^M_GGYK,.^?35?=_1QO3K6Z;UI-\B/-PXYZIAJG:!,EPX/P*D M?:BKVD6\Z6BL#G9\:(JN6.EGF&R9!AJPH@SIT.40&QTO]_>MU1XOX+50F7/- M]A;SL.+'6+Q>;QK"0:J+!)H--VIN7?>Y-C-7ED?9 ;5VR1G[^.@ZZZ,13L ( MX 62E-&WYUS-TVKHZ-]>V+I&I6>QS!5#(LA"LJ MS7/"*/\Q+(ZM@INRL]I=^ZD=OS@0B62T0N9&1Q@DR .\1M'M12X-C&S6&S M8B*.3&J\4[8#0S5+IXW Q,+)H_@@<^NDHZ6[R0V.HDF(W8W.;:Z'UQUP]*9) M7;%BVR787AQJ?M,_,ML5E>/RXS$K#WQJ8/QA62FZ% @CHK$$?"B0(45.$18<*,S%BQD8\_)#$=A#;3*< M>K/DEM"<8\\_D_+GF5I=OA$X1.$3A%Y<0V*G3IHV)-:?G#5>F=&1A?N15>>, M82[ZD83C.?4G*<85GU)SA2?-.<9YR)*6HBBBGDB;6D&>;;$FPL0A)T#[@ $W!&9N#<7&:]3G'7+6(7^-&ET M>W-2H[$EI-<-/I;D--O-I>CCI+\=["'$J3AUAYM#S+F,>MIU"'$92M.,X['" M)'QXIA[HWOC=^" ^.1K7L=;>8]K7-(< 5E,>/'B,-18C#,6-';2 MTQ'CM(989:1C"4-M,MI2VVVA.,82A"4I3C&,8QC'. ][Y'NDD>Z21[BY[WN+ MGO<3M06IZY$Y+[Y%QGYJY+$",W&C2$*G29< MEAF%E#R7U)6UE.?7TVS%?/@4-?/)28?0NJY)75-=,Z$,B+60AW9!CYGE[V$1 M,C8YTMVE@(==?F];MY@])M=4X/208CC.+,PZ&G90X33LJ3).))*ET9J'31TT M+8HI6FHEGECCIR'B1P* =QYYJE*F^_89+6?_M&[LMI M&8N<^7I=C5B)%5Z5*0DR[Y>K/"_.8)A>6'TO[7JV_P"\,3BW*-COXJ7"PX]I M_P +ZZ207%S2MT'9_LW:O:#XL:K_ .S6'._W/@$_:XG*P_X*_'W,;V-]'PX1 M!"ZQ(;B#AFLN ZWH-87$?!U"OP9L++JHY7 V-(-)<>2XA]]PW*0^6D2'T.NH M?DR)KK[R'%I<<4E6<9Z^KQO%ZYLC*K$JR6*7=#ZK7?KZZ^UO4]7AI@.H1S+<0D9G6$G+L M5MMMY/%31)$=N81*VB\G+'92.MB.6@J.ME+V#O2.1F-QEPHA+6U5F'A+TA!19D) MIIN"IC8E?&3H;<9N&(976V SSI':GY6^67EER5Y>%$X1:T?&0_R7?=[_ &$V M;_CP>%IGZV_S-]PMEJ?PQ^K'\.%E<\(G")PBTK^)%XJ^GM(5/;&@=(CJ7V8[ M2,50I"+:KFQ@MFT_K[,EAQMR)V+-D[15:X-;)Q$3(L75L$_/V=9'5LMPZ_^R"A-/"NCND6DNO-[K'52K30SBHT,[>JAJH(^$[%7"S.0<7 MY:-NWNQUZ64.SX#3D3YR/\ $G9N>>HI:%N,5U93U$U-/24."8G6 MU$2FPJ,.+' 2=@VHEJ9F@D.[)LE--+8L8^)[@\5 ZVZ?[\[-J58 ML9^IA=:Y"SRF1.>P5AMJSPJ:F8MMP\"U?'I#2AE#!TN9"G7F8N'1!2' M"?"27VI:T,<[= MD:YS7,;XS!:3\7,=H(F.J:396@#WM>V>.OAQB"G;@;$/TLY).SX<#5]B0!ER5,MYC-O8G[9)V6 MPM+4B0+FI,6:.E(DG/R'0(D/243/CAOXK[/X928G00;&RFEK8&P0EV*TC9HV MW(>6MAP6&CIR&ELK.RHWDS1,$YG8&EFZ[\%ZJOJ**MJ-I635D,IDJ9IZ'$*A M\Q!9+'>HJ<;GKY+2Q@._VR$-8YSJ?L'@A\F_>7W%ZZ_F;-U=(VS1H?\ \:W: MHDF-A1(\5/FXM^36Y,;&XZPVQ'0K+C6!FXH,7RSAPXRS_7XZK]F[!;5YX=BK M<"Q*3)M+B<<&&.?(38#MFO\ V%6%SB+.9/@$CRGIS&(YM@L2; M#GL)DP9<:;&7_B2(C[4EA?X9_-=96MM7Y,XS^16?QQS\KDCDB<62QOB>-62, M&>"IC;+3S13Q.S;)#(R6-PYM>PN:? KJ#C8LL[.8'3$2G1K MR(T]M"'4JBOK1[B&G?<0CR6IOR+&J+ M&9<8)!980_+D%I46&S"2I.%*1+DK?S$;4WG/H7E,A;65XSAMQ:FC?52N<61LIXY)'RD&P,<89VC@[4 L#K'-H-POT2>MIJ.E=65TT5!3LC$ MDTM9-#!' " 2)I72=BTM)W7$2.9O [KG"Q, WR_6F^50R'TM5RUB=(1E0EVR M?'AA*LN%)5B//;$R+)(&NG7G8JWV6Y YA<%G*L2$3G5(0TYZ_"<(H,)Q"FJ- MIZZ"B;"\2C#X72U5>)6 OB-0RBCG;2-;(&.X%US:;8(&RMO6LX0ER(;#A&E Y#%9K,1];:5/P2"JY(S.L&6G?R+/9R@I88V2O$.*53'UU=(QKO@EA%:P14>\W,-92B9 MH-C*7"Y[##]E\8QFBI)MML9Q"JGE@C=58#A\L>$X3#*YH,E/4G"Y/S&)[C\G M.EKW4DA%VTP80!(P6@46N26)H"FU8-.C,9C,3QH$7#(-L*;]I;>)[$5$O*7& M_-#OJ>SEW&<^YE7GGSZ6JQC%JUCXJO$Z^IBD=OOAGJYY87.#MX'LGR&/X79M MLT!I W;6"]10;-;.X7+'48;@6#T-1#&8HZFEPVC@J61ENXYHJ(X6SV"=Z]RLNYUR[M.$75G2TP(4R4S#AQTK?ERG M<(RB/&80MU]U2&FTJ6K&,[C89)&1AS&&1[6!TCVQQM+G!H<][B&L8+W<]Q#6 MM!)-@L2/$;'R%KW!C'/+8VE[W!H)W6,:"Y[S:S6M!+C8 7*Q^E7$1?JR)MP% MHJV%.1&" M9@00!S)4"4RW(B3,#RD>--;CRX[K;T=QUE'N-KPK&/QQCDU]#- MAM7-15)A,].]TZ-X#F/[.5K7AKVD.:2T7!65J;'4I[E MT,@"1^>H&2=FE<5BGF*_-)M1GI9M9:N#"@UPJ.)Y6SM>WJ /NRGWIE49E%ZY MT:L$>O0;JQ.&DK^E_1P&\1-EP*FA[8]M?AD)51R6S.NS^OPVF]\;>*VJQ#8$*1UY/U"O[ M U8MI+LQ>V ;]ZV_IFM.V:J(CY32%S+&04.M\X27>!D1< HRH@UU [[^60.O MJ,KA:I;AU,\2@OL&WV"8Y99]%G;2N]AVS4HUU&S%[>JQ[LAVFN>FAU<949CQ MY;6I]67C1T4E%E*&,0!0874QSA212G!PQ]E:NWE;*VFAW6@GS!(_JLW\2S67 M?NN^%)>X=R[ Z8=K%+Z/Z[KG8BI6'3-INVTKWLVO5$ .VL<";JB;H @1^++8 MV7I8^9,UB>5'7B3+?62^:A$&1_4+9BPSRN+$GKF%^B93C;32G75H::; M;RXXXXI*&VT(3ZEK6M6<)2A*<94I2LXPG&,YSG&,D=U;&TAMO<<*B&-8@QQH];BC@8A M2B#A6-#D1 %:>KQLS:C]ERN4]$>#P:FIYB4,)H=4EN,EUWUSMC,19@]+C#Z_ M!(C5%I&%U6),H<5@B?/6T[)YX:Z.FIFQ/?03EH95R2EKH3V0,S ?+MVMH7XM M4X4R@QF84P=?$J;#WUN&S2,AHYWPP2T3ZBH?(QE;"'EU*R(.$H[2T3R*XE?& MG/;9>=$]#NA/:CM')=5EB#?K36/N&U$]G/\ ^R@V2]-+.6(S])" ^NQ(6(!#:6$0QNMJQU7C,F%L)Y24$&*,(^)H>" ?G- MM.YYDKYV',-)I,"AQ9T5SD68E4858Y/>RQ(HO+Z+^,%W0[A# M][]AKP&ZEZL.TR95#=1ZT[!6U4V'T6&"")S M'D24=!%4!KFM:^=P[==08<>K*S\S2X3)A^,3,,0VAQ;#\%=0X?2MC=&YU'AU M%C5;BTE5,P@,@KJUU+OM,D[86DTAW,=9_"HZA]9@L$=6M; 2LN)A2U/S!^?C MNRWL?X7-D*G2BATK*GJRM9)T^?+HGNKR^\QAWRSCYU7X@;0/I8\.PN:/ ,*@ M=O0X?A#12L!%OWDTK;2SSNW09)W%KYC\4N\VB&OP4^'Q=G100MN>RB,4I@%A$]H"V#52HUBC H-8IP(96Z\,0IN '$1 M&H4"*E:LK7[3#24IQE:\Y6M6?-:U9RI2LYSG//(UM;5XC4R5E=4S5=5+N]I/ M.\R2OW6AC=YSLSNM:&CD ,@O<8=AM!A-)'08;2045'"7F*GIV".)AD>Z20A MH_Q/D>Y[RNU!ZEVC9 (H-L=,+X)8/ MT:6/JQVSP\_%RJOVPXP*D%R09*H3"X:HDX<9#N9D+!F!BIDS+_N=E?Q$VFV/ MIZZEPJIBDIJZ'LOR^(,DK*>DD&_:IHJ=TS8(I[2.#]^.6"8!HJ()0Q@;XO:; M8+9S:R>CJ,4II&3TDI>Z:C='32UD9#0::LF$3I98/@;N[KXYHOB[&6/??O1K M+\.RN!7U$-3=A.P^L2"?R1V56X1?0[:>G>FQ[;_\ M-L=APB&IV8Q?=HZ(1O$;Z5K*6:3=[:&!AJ&/J&!S!NS=M2;S P&$6 9YS!OP MSV_P.3$9<.VQBI'U%2"'=I/4NKHH3)V%15NK*.K9%,6R$/C$51G=IF<>7Y';(C'GG*L]%BV-&W=2'+/=O\ "N^_*?C%1"QQ/#L3 M T>QN$S%P&@[&7#-G[DZYU3="-[0FKFG]\[P)[5WB&[0=>NP(2A [*AN-'U? MILP6@DY+TB9E<>X3M=NG)EC!,#F(LR-BF$K+7R2I"RLZ=(3.;?)>PQS!MGX< M&V>GV.VBV9FQ.:D_]W&<>B9-3L#66?018MV$-)5NEJ,9VACVWPW:=V%OJ^UJ:/ \#%-1UM0Y[@(\0?@L4E95X>V$"9M/3 MU];2RR/?/4RU+IGRU&$[T[0%>RN;YI/I#IRR2ML:YF0U1;14"MJU--@4AMR+ M&L,:U"SXW3A<,]BV1_9L^FTE93; M5.GP;8' IJ3&,&?N,K<',F"2C"G!L=725L-3380Z*,S"G9^4E=.]M1 3&S<# MI'7'IC/:8(,K5K MERB9TPM_U.RK.5?RN>_X?$*K9.HDJXL%VR;@%%/-,3!#LC6T;I8WR.K+[NDKIG$R.[>_>WF^-;:ANUE3T]WY4["&%MOB M#(\CI#8%<@S5RXT:.\:35;]:S*0F%O8^H.PZG,D,Q/<4I0Q.%D8?%V#D"4V=URO5ACHD38$>2^Z[*U\#+1/;]QU7I=0,&X M6GTJ^GPU*S&;Z[$-@I65U9#0;1;%5,<=3/%$R/:C#J9Q9'(YC0&8E40OO9HN M#++8W D>!OGG4.VL3J.DEK<"VNIWR4\,DCY-G*ZH:'/C:]Q+L/@E;:Y/Q"*( M$6/9L)W1&\?Q+-&YWU.UO/NI037(M.C'/IYCKWNL1M;^)>!''I,-DK98J9E&R?LYMGL;BK!.=./]/'JWY9SG8!Y/EYXSZM2[E1G'E^/GA6O ML9_)_GS^'X_^6>>?_P#3K:__ .MIO#&L"/MB2[W^W>R^OY^H'?A&,CWP]5\L M/B*:8<[#TBB4>W;JOB2U'LA)S6U TZ\178K-'E05UZ!$C6.DC+W[J@<>XES$ MF*6@5V$T'$2912#&;,M2/2TOX8XZ-F<0Q&OHL!P[L<0I8ABN)8XV(4M(YD@J M9'OI:^7#MW\P^A@@8^&2JD=/,QD,CC YOGJG\1<%_M#0T%%5XW7]M0U$IPW# M\',AJ*IKHS3QL;4T,5?O&!M9-,YLL=-&V&)SY8VB9KII,7SNEL\04BZMTO2] M QYPZ6W*2W9;TZTPXG"9P*&/!DC?BV+/HYY(WM!832XHE!W;J_0E*HG8"WUVZ[#KC4P0"Y<.S#A%'V.R.'XWA> 45!M!64]=B-,'QF:E%HFT[ M7D4L.\8:&Z^Y:G#ZX67,8-IF*Q,25OT&EKY\ MF50U."$2HP$5 MA+.5EUZ*]B&]$LP1\@%<^M#S@N [,9,J"$)@V&UCE4E2:5[W@/._$^$F.3LG MM;(6AY:XLD%W,#F?$QP&]O6) "X5=0BO9!&71 15,50!-!^8B>^(/[(/C[2) MUFRNCE)9(QY[/<#FAY(\3?XW%@+S=Q )*^<>&4K:>FIY(H)&T\,432VGBB'[E@8TLW M6F2-K;?!&V4M8+-N0 IBTIX3/AW]=MH.[BT]U:UQ4;TL2L,Q/^+/.P!\5W(= M3DD8&LDXN+'F%.A(CZ3\6*V<:22($!Q LS+*UK M"VQ!AAB,TW'C,M1V&DX0TRPVAIIM&/P2VVWA*$)Q_F2E.,?_ ,YQB222222; MDDW)/,DYDKE@!H#6@-: !H !D . "^O(JG")PB<(G")PB<(G")PB<(G M")PBQT94*D$-'K(&J]=$6*TKB.6<^,"#(!JQN#VE,0%GBD6,U.+KA,+4S$40 M?D*C-*4VSE",YQGE35M;404U+/5U4U+1AXI*::HED@I1*[>D%-"][HX!(X!S MQ$UH>X7=5C1),6 D,,CG;H) L M"LBYQ5R4X1.$6/IJ=5197+HFLU]-Q=%)!.VQ(8=BRN!$/XE(#N'<1L%%BDR< M8D)'JE9B)?QAW#.'/SNU\UD' M.,N0O%=K==?/1+4^ "O6B /?$P;(Z*@N'H8N2Y[TD;$,+840CCY#W]:_#9D( MCNN?GN-J5^7G(;553:9]&VIJ&TDDK9I*5LT@II)F#=9*^ .[)TK6_"V1S2YH MR! 7P--3.J&5;J>!U5'&Z%E28HS4,B<=YT3)BWM&QN=FY@<&DYD77M#=^P-%ZXUL6UY%9:G7[L'IS4U@M4F P1C4&IWNQ MJA&;4Y%F(<&YD.JCQ*J*>*-NP(QJS#9#L>6XVU$?*@7\B?(+4#XA/=_9NRO" M"M#]UZ?=DE6+?_1'76S;OLJCU.@+T/KJR[)J(*P'A!LE9ML"=BBXX">Z[F3$ M11C,V!"FC65NSIF)F&"VT /&8R=UN;'NU/#JK2V_QKJ%0&=RO7'HEXAP!KKR M'J)[=*YNL^ON<:]#WN(_.J,\W[/9MW.63L2+(?A_"Q+7Z&E>\AK/EC)9W2;9 MC.]M>&O!?:X^-/1]?KW0W@UW:.ZTS=:=?//7FO[9'MLJN6@Y[ M/9QWS'%H]$MSL;X/S)'I!3/<8;S[.'2!M[6(S-AKF\3=TS;F;#/CY=1GHN)_C/TT9/-#)_0OQ$8L^NZ4:[&FXSFM.O?N# MM(OO%H[6QG_3V=4GZ$MX$7;QA"ESO5!>\X>,>C*R;O4:VXZ^7KHD7QGZ=-GC M1D3H7XB+\\QI1SL8,C(UGU[]R9I%IX?'*#V\X4I,[U2F_*' MG'JRDF[U&MN.O+1(=8&NQ "U6G M2JX6L^OOEL.OTB+ G6LH#]_LXSG$<)$*0'Y?SL0W/1*;]EMW/JPDA:1>Y&6N MN7HN:MXUU"NK6H7JKT2\0XTUOPA>!6GEQ-:=?/*^D-;0SA"\Q0ON]G&\XPIY7MI63=M?,9:Z\?! 'C74*T1M8RP'1+Q#BD;<]_V!JW M5[T?6G7STW/8.J_M[]X56%>YV<;S@C5?NOO_ -1^5B-'S]F"'QGW_./[Y7<( MOF,@"H]O MUW#]79Q.?K@%_65\;FY>PU!]59(>S,=QF/E\H6VOF,@#QT-K<.H7#7C74)YB M'*:Z)>(F1OH.2*B">LD>?9S&?M!#) RT-W*L8'^[!>] M$U2?0I1"VVI&@/'0BXXBYG^-=0AD:WS) M_1+Q#HL:A;IJ/7:X/.:TZ^>@#NN^O42/3]=S?3V<5GZX>>V;0VX>6<.P<*LP M_P!Z8UC$C+!-PY9C,$C/@+WX<+'+7)<'_&NH56B[1FV#HEXAPN+I6^4#6&TW MI.M.OGHI=^VDFAJU_6"WM]G%YR0M*=GT'([XF),?_P!IQ_R'V/\ "/8)NDVS M&8)&N@O?AT.O)5"G;*BAIM%C& M?9[..YRY98MA"OP/AXE)]!!CWU,J]>$$W=,QGIKG;PZ%<7+QKJ%KYO=#USZ) M>(=7VNN]?JMJW6N=K/KYZ=>5Z[Q"$ZJ%3GL=G'?.,;B"R#\3X/S',(BN>\VU MGTX40-O:Q&9L-=?+KESX+LV_QHJ707MRQ[AT-\1 "]U[UT$VWNAN;K3KWZM? M:XLD>X2@=M-^SV==QD82CT"Y.L8@YER?2 F^Y'1G+&'B;I-LQ\1L-NB_ MJQ>,_3:E.OHVQ]"_$1$SM7Z6B=BK_&DZTZ]Y%D&\82I4[U17/.'C'IRHFZ>8UMQU\O M71"%C^A7B(RB%FTJ_V+ Q6]:=>_<)Z2C/!8[^Q8_J[.I3]";?L0 M5M6'%(G>HBQY0\X]S*";IYC6W'7R]=%Q5_&?IMTEZR@U;H7XB)J7N73LOL#K M!B)K3KWZ[EIJ"BF.2[^*]WLZUCZ*PC8=*4O$K,:;Y6&#Y1,^3_LD+2+W(R-C MKKGEIT.G)?&G>-/1]@*TNBF]#_$/L"^Q%"L6T-*)A:TZ^>>PZ!4X]3E6.T _ M?[.->0X3'O51=D_.^'(])V'[3#F?>PT0MM>Y&1L==<^G0KXU#QKJ%?FM,OT_ MHEXAQYKL,+MAK2RX6M.OGEL(71839&VS0?O=G&LX:!0G6Y$SYV(B_0O'LI=5 MYXP3=M?,9:Z\?!YN^US4*XNM.OGE>S>KXMEG7\ M<&]WLXWG#]7B4ZS/D?F8BH] >5\=;ZO:PX3=M?,9:Z\?!2)HSQ<-:;SNFDJM M&ZL]RM: ^P&T]C:5UYLW:-$TZ)US*V9JB#LZ7>*L0(5C>MNL4::'DZ>V '6J M/69C#A4&XTES$5Q,SA"TB^8R .1X&UCZA;8.%E.$3A$X1.$72(C1Q>%(&EH$ M(F.EHPW*@$8K$V%)1A25X1(BR6W6'D86A*\)<;5C"DI5C'GC&<$55>[R-%&. MNUGU?V&BGRFN-[&:=H3-7J,KX%JMUAVK9QE7KE:KTWYPMJ!,E$)3947N"-1G?E;._@I?U7=]6[]U73-R:_P*M&O-V4:I7H$8D! MVVE6:J6$-%,5QPS!GQDR\/,#YS:'!A5KY0N1[\)YEA]IUM)312+("!IF2698 M@9*R9B,P"^9$"(_DK!CXD)CPB7NM*^=$83+E89CRO=9:Q)D80A.'G/41L]0;%N/68PQ6[*1F$#1X55=C:/-T\]*+KC22DP8&L#>"HLT*,2B M$'4\<_$BX]#<=#WJY\<(&B9'9B"!D7(>&Z/$9CP(K.12A&'$JPG&,$1@&$BX'XC!Q4? A=2[E>'%XR18/L(R&UG22-OB:XL%W:H-T] M[0=%C!&EZ=Z^X/L8W$P-/A=Q+4']^R3IAP%=Y^OMU)V/ MD0Q#:KXBN%Y84272Y"6'05(.=R,LO ?"#W96Y\>JV8X!A,82G <5A*"JSB,8 M'Q,80;<6XXX83CV?))5QQUUQ9#'E+6MQQ2GLJ6K.2RF083.%8R'%9PLJV<7C M(^)G"S;2FUM&%8RSY**MK9:6V0SYRT*:;4E[&4)S@B+!A'$R$K#BUIEDHYF6 ME8^(I,DO$S%5%*R,99SAXE&S!A9CSG,*E,YAQMB-J FC V27+S1Z(TJZAE*UX;2G"LXR65S("AI>2.98D M9*R8AM#B^9$"*]DH/8Q(2S!(Y<:5F=#9Q,EX:C2?=9;Q*D80C&'W?41RN+C,J1G#6/><]1$ M4%#J6MQ0D8I;@S 5Q:H$7*W ^,K5@2M66LY4,QEQ><0%9S%QE:\^UYJSYD6K M/:')LDX<2C5KZP6*9#N/O[\EH!Q%N9N!S.0^86T(5#K@",QX$1C(J#(Q'3(AC?::3\&(^F)%2]'B^TR[B-'PM"L, MM^DBXC@PD3 W$4.+C8#(D-",1Q\1G IN6G")38W#;*?@HDHQA$A$7VDO)QA+ MF%8QY<(C ,)&P/Q&#BX^!+LMX5A@?$:P->GI>1.>'X;93\-V8F3(3+VN0 MF0]A[*\.N841:N=L]J.F!O:@N#:*K<2]BZ:=C1L6B%*7+IR03_8_85*V)1)U M3&B 6PXQ-^Q,TZU[5G'!NR:[6!66PIVQ0GR,N*%DSRT ;:BQ&?<"#GX@:9\. M:V3:XV#4=M:\H>U: 7:L%$V73:Q?Z6=9:?89-5.XA(-AKI5MB2VS)800$$8< MM+,AEJ0UAW#;S3;B5(P6=%FG")PB<(G")PBA+?.AZCV!J]8KEKE%!DBC[.US MN"F'0RXF" &^:OL\*T5N>EDA%FP)L&2[$?#&X$F,K,T$5)QXDD<07$)PBH-K M]01YKVM':&F44G888Q,GO2).&6O=]M)0FY)YYJ4^$3A$X10'V,Z_@^R%+K%(L5GLM5@5 M;;NFMS0YU52#R0E671FS*QMFG#YF3X+'GS12)4&(1'N2/ ME-E0;>1'F"#[J.M#=)--]=MH7K:U$^T#AVZ0+@'BP2TV'(%5,+L'>NT.R%V& M5]J- B2O9/;6VW8R"LDY<_ \&*JH(8B(@7.E%R$DZ\/H![ *X/"B<(G"*)MX MZP([FU;;=9#-EW74;MN@MBY5YU[#HL^V#ABY++A2".C;(IU^ISC)R B0%)X* MU0GYBY\Q,3XLQ3$Q@@[K]#?Y$'U57]4^'AJ+5VZ*YOURUW^\[* I67D&+4NE MP(YW8OWT6O*#X5G6:'LX1 MM_+5AQ=LWNI[.OCHQ%:KX+9%\H6RJ[N&EG3%;!5Z ( ?9_95:AV9,*GQP,8U M)F%UV9)N:4ESUEK>/I8:Y Z\?>_1;+.%E.$3A$X1:DCW@P]2S!C:)B.>WM#< MVK$(@RD8MN.W;"17J=8^M]_ZLVZH5.;M&9=C(L6?UGL@X^W(?*32(.PB:;@- M*BU&J#JAPM;QRTRMH+:&XTM]D\.TVTWC*LYPA&,9SG/Y>%E=[A$X1.$6O/8/ANZ;VC:36P[O9 M+26VA(OT>\U;9$.NZEJUGJ#(ZQGCP*J*=I6MJS$O8.O0K18*D'(;.C7.VQ*R M3F>FRYL9$U8RI6_#ARSMWZ\=3:PN!EDKEZEUC4=)ZKUKIJ@0GAU%U-0:?K6F M0),A4R3#JM&KX^L5^-*F+2ER7)9%#(CMQ7"$W))XF_FI!X M43A$X1.$3A$X1.$3A$X1.$3A$X1:+=K]ZM_:][4=DZ15K:&NPK4_;SHQJ2J: M4D@JGF::U1OW6%;LV^B39<6.@6V,1UD,*67:C%K)%WP%6 TTBW;8DL'B4]&+ M=A8'FUQ)Z@NMYV:/&ZD;3'BS_?FW1)U'T#]6!7/>-6T"_8Q&T7S@9_7B*+.I6_P#7.@)M)MUT=@-*-;-+ZHA5DTB[1Z9* MK9P68"[7"V^ND==JV!6+%7'1;\&U(FSBL*NE+9\\KY M#N$XM;L3]F@X4&%FX;4A9:+;7'*]CU#MT^%LSRRZJW^@/$SMG8NW=9*S3NO% M;%L=DM?6[;D F9['5$DY7];4&-U3G7&8D51Z9<);EW$,]ERHW.N+HO75D38] M1V*"22*"V$!9%E"VU\]"!IQ.]UT^'47U7#?B([+3V5O/7 9J36=MLZNXMLZW MZ^BR=Q$:+.@56G=-=>=I'[=%")7"/6CNU. ML6I2Q,O5:\/,$JS:J'9.Q)%B]46\8J$P-)UO.BL%9[5D@3H!"W7.]N(&6A/D M0"01>XY+&Z'XQ-R*/:JK1[26M"]LV0>JPR?*#;S( 152D[0[>[2ZO4H'/&R- M560@Y+K$NG5XO<9K\J'(D"B<\N/"LRF8@"45W-3?(=,]+Z7\._D%WJAXUT.] MZUE;*KG6M]H8*I?5^PG(UDWM1J_+@F^S[/7*16X< ,Z"EW2Q4H3]_)D2K8X& MG3A4JT:IM%>*#*X_-BR(Q-W.P-S\7 \+_2_0$*<^L/B/G.P^P=ACIVOZ53:K M3.IX_?,,*WLF.2LY2V#.P?:31MX$QCQP+4:_(I0^5UWCSHMHFQ@"0S5H%2K( MRP@M\8$4( M8W)-M,K6!'7CI91%"\7QY=Q$?:/652U]5YVL://E52_7RP5._ MPMNW/MLWUA*TR0X;UU"CSHE#D1Y)4G*K08\/.ORF'0!PA7GH!Z43=-KZ_3=W MK^7CSLH=#T 97:IK3I)L&P&]B[MEIDUK/6Q0F+%:6SAV5=;0HBJDWXC?0EW8DC5:.X_6;-UCA M8QM0W[\=9^RXU(ESHF1K,_%GS#Q MMSMES5KZM;ZK>Z] ME%LU1.'RT1B$2 M5!DKBO/_ !Y<:1'V*)M!@+"G:G MSUZLKU2O!2WO)D+&J%N&7JXX)DC9\I)(!=*M:H'RJW-E%(14BWUSSO\ 9\BN MP*[?Z/+;5?U6W< \64NN5(N%L4TN-BACYZRW[;NM)U"BMO24$1]TJ5PTW9*_ M9PIJ&.DCK#*@5I2,V#+XUHEC:_WP/K?)=&U]PM35+2;^XGC 8\ZUIF1NJ)3: MK:ZT>GG@<+7N=H2QE7L,8@FK6$BJF-R;&,Q *+2:KD9RRC4O@O.VAO; M/@>JGP'L2BV6R'Z@ M80M9ZNPQ*/ X4YEXB.B2"IH"W-KUX::;;QGT(2G!%UG1 1*5.O#! M24-.RIJG'843"6GI+[0ZF%\5$8FE.G&]*SXJA\32"YP<6L>6YP,73C M:7G0RZT70RU'AR'!BA<]+++;KLJ+%>7%R[AMIMYQ^1'87G"$NN.O-HPM:U9Z MJ>EJ:4M;4T\].YX):)X9(2X V):)&M+@#D2+@%>AI,0H*]KW4-;25K8R&R.I M*F&I;&YP):UYA>\-) ) <02 2% =^[!535VR;#K2RB,H<@"RBW8?-+>U_6UN_P"]FC)> MX]9'C4/7H5D^&!"J$2FUNQ EVQTA5?B1MA!(HX^89S39\@:8^ :4.D4TA<"$ M6XC(VM]_?-=N@]Z=/7XKJJL1IPL%;MHP"9>*+/76D,"(0>%LFPZI!D!-FAG) MHV]8VE:ZE9,:7BTE!J7L 0*DF'&0$!J0ZP0BU^^VA'W;BLEWIVP"]>3+GW@: MVO\ ]@_LY>2T;88/-4)P)QNB:^([+G5R/7562-9F\%P0@@%!V&8-B@)%Y;AU M.=-'OF LPB0"_P!,_/D!WE9R"[#:^D#-D3;F6%ZYD:AV@%T[L)-H,CXP@1?+ M2%UW9*:,A'G5QH1)NX@]M:YE5_.$1IDF9:88=^#'+-OPVR6.747'=G?RL?)? MT.[.=?3 PH8%;>HQ$>$B!IQ1V&;CR'8<:P/V2()6Y$:RJ8I4F;3+E 6RW'6_ M$(TZVCYC<>;63;$$ECR*P,YW#U<(V32Z1%<78*Q=!X2="VS7RH0OKUE=AUYM M+: N(T1@3Y,@J_(IVLD%TY$L3&W85XI$N.I^.92X@ECY?6WN?=3@'VOK8_<) MVOP]WKSU;=L>P*OLFK6'3A*CXJ<^&JZ3:U.C6T!=0MUL B:$=J9L^M M!P6&US=C%TJ4QMDW3P )RT$VU5:0R:R5MRS[K_>=\EWK%VNT4'&7M\%?@6Q+ M#0:78+S/HNMR$6Z7(J,KH.J6"5&!A03LQXE-='7Z@R$(9SEJ/%NU7(SG8HPO M%F+*636_:'5%_I% N+UIJX!S8PT64!!D7"M6I6&+&:-@:BPZ;J1 N R0MQ.O M%A5<'H(9EF;&+-544W.L(,J/BD4-TCN^UM; AO5&G+A<)I_7=(W(&A3"D"J* MF:FV4V213+0J4>AL0HY-XF"/!CE9>D8FCI@]J8(D6('+27:*VZV[^8U&5_I[ M*^'"B<(G"+'[34JI>0K(@>!!CDRI3\Z4F")%1XL")B3-DR9C^(\=O#TJ0_(<]3KKB MU%%72T]/-/VF3V7(+390A/M6 KX?9) (780L>3K-99J0VXT^ 5'E0H2UO"1= M40:ER19,997*/4$6,26B",17BM]-,ONQZ?4K%D=(J/DU#L&E)?7W;]QW53Y;H"MZE$@QJRUKNQ2':V@, 2P4"QH/Q6QQ]96P%"7^ M?J+>@T6.5SH!1JKJ:]Z.#;DWHQK+8^G &G[2 =GZIDNRL5_3-:T!'V%%)OZE M7-@7B9JVFU0'/C1'&M?NS@4>P,T2.P+(-&G:U2:Y;3@MVTV(I*%M7NQ6^2 'K8# MA)4 >RIETIK]\E8'A$X1.$3A$X1.$3A%_*TI6E2%I2M"TY2M"\84E258SA25 M)SC.%)5C.<9QG&<9QG.,X\N4$@@@D$$$$&Q!&8((S!!T*A <"UP!:0000""" M+$$'(@C(@Y$+ 3.J=X!'FJ[8W9;$IJ2>MP+#I9:%YDIG-@$(C>71O)+8#$R3XHHS:5KQ\-@+.<# MF4$6,%I<0-'0!R'5)4ZF#$CQ$NJ3C.$J<3';;PM2<9SA.58SG&,YQCRQG/.L MEJ)YR#/-+,6@AIED?(6@YD OCI*,.;24M-2M>07BG@B@#R 0"X M1-:'$ D FY )LHJVEHG7VX;#I^T7.%/>,:0V,QLZDR1I!T:K)V.#,!4#C2X^ M,/%:TX\3AGY0!UU$"98JS5BT#%OV$4FS M>T0WMI)JI'&MYU-=V&*ZML=0XP%P?+UP^5.!V@HRGQ@NB)]/J,5B'%9;177 M2^E9][Q'=(,/')T$O>BD*>6F..2651H **()X#U^JCG'2'3[1::5AR;+ ^T1 MVE66^08;P%F#>C>N^R=N[9TZ>6:2 PH6\)W3L"]&58K"P;4\5;2PN>W(<9#S MA1+GW]1;V]EDNU>KPWK1+L";'["[E;+4DZ'T!=GQELQ?M]E@4U"P[$0QJ]N36G"$(A()DCY7>Y@>5^0Y\ MA]\)!,]!Z/=*=KX7:KU>Z]OFRM<[OVU MLJWF:W-!W0S>WP<*#/#%I342PV<.0'$8,"!J'7CM#(G0X 60V:+B6B[#;=>D M.6%Z0IZ/"EMD)%M/OS/WWE>Y ZDML'15J,[]W?;K37=BE-FU<]88FBHLP!8+ M!1[GKBPQ_;J.D:I$LHHI3;E@*S&O$>TO5^)4:5%JTD' "OPR!+]!I;CTZ]%B MFONA6N]0$Q)?4NQMKT236X$D15HL9_7!\6 "/ZPZX:@:",1K1K@S+FCX='ZO MT$?'=)D)9C,DQ<)[Q9V7/!NUTA-]<_GF2?,E9,WTGU,P=GFXQ2Y1\'S^M[?; MQ3QFN9<%%H.\-B6BTD&:P\"$F(TF$#(C'A V'$;) M<^_D1N^RRK1_5ZHZ&DU>16;A?[ FI:!U=UT'Q[;)ITAB13=1$+20JIJ=FO4N MN2'+:[BW$X1:9&?B@YD1J%EBOQ)C3TN00F_B259;A1.$3A%X=D.8K@>48R(. M',151T_3*V.66,2/D2&H_G%@(<:4\EGW??D9PO'M1VW7<^>$>6:!<\!WJ$VY MGNU569#T;SEP'5/\ L+7$N1W&7]AP>4).UXI;7 MF.'C;W/OXRALGO/9*..LT:'U]L[MJJM,L5W+-6>UB*O6(X$5;D4T.59D/0I= MYD1K+,)5PL,A3=?A2R QM#Q*&->BOMX(!>V>IM]_?!3EJGLR(VC?7]?,U4D& M)QV=XYLW1%G:1E#4:1E@L:CQSH&0IA#CHJ0ZT0C#YD=+<@I M]^:@R1V-VN1OCVMF9]: N%^U&Y-/P+LBO+5#KU/UUUHE[FK\9^&2*S8DVR$K M&S&28ER74,3ZB-MN!<,$0R-(ABMM>@!\[>G]%V7N]R &F>O.S++J:RRB^YNJ MJNTEA @B06&FE@:^QH15ZKZ<6*? DD#HY_>XQ(* O$=DBL)-BDB0C+J9:"6U MSR!M?GK;SLLJ!]TAQPU6*['U3=%%BMYO%%L*(\L6] !OZ[W?>-$W$^))OJB1 M;/7ZF=HLNX6]YO(HE6]>&Z_8I@M;OL*+3(NH!$VI19$<@S92Q MLA)D013D5'"$>F7CW:\[*2K_ -O+'"ZQ7;=]0U\Z'*#MA:VUM5IEJ<2:I4R- MM#8>LZ#'V^W)#2Q4PYK>C1]D.6:UM*?K4[RI%M!.S1*H2B[9 ,[=_'E?+O-L MM=1JL8V-N/L(!LW:O36O9LF\W#2W7W4^^]?VB#3Z@0M!XMLB5OL!]U%A%3SU M'H;LZ)8M+B[.V3BK!DIVO+9,KK ^/:806ZERM@;<+DCNM;QX\?-01L_OIL'4 MNT1"CQ1DOJ25*Z^]A)I0;1G86(_2K<5;G:ROEL?)WM$N9<7*ZR9L0^/"@M MSHQ27'43D5Z/&'89@R9(?+V 3+S.&DD78292\-KDKPG3&[[V,WFLWW-;OO.Z MQN\0-Y[K&S6WNXV-@";%?-[MQCW[KG[C7.W6"[W;H)W6--KN=:S1<7) R5-= MG]^7M,59VOV4@_9-(*H,&(F9LU^TRED+(ORT?[O=$P9 M.3(^-G9C>!7Y_BFWQPVKPFE&RVTTW[3JC3;[J$1&*VX+Q,WY?S$GQ[W9%\ [ M-CW]I\)"N!KG8RMBQ2VXMM.$J]7GCQ&*87^S'Q,_:.%XCVK7.W\+JS5LBW2!NRN,4>XYU[M% MC< FXLO88=B/[1;*[\AB5!V3FMW<1I13.DW@3O1 22;[6VLXW%B0,[JL'8?> M.S-,[DJ58;FPE4KL!KRR:YTB^L+'=4#[=0)L>93ZU82.4K5- ; IL\Q9![;K M34>NP]1[ F%),YDR&C"NK79@7\-=-.E_O,* +AV;WR%W$=UN,LDDG @>("*Z MKP,!:-5BMHET25X7\3N2J9&AS7!(J3:G=N2L#'9LB4.$,Z\;<%*CQ#*%VU,Y M=^?D5;9>%_\ NMY*?=;V+N,9.:SC;)(ZUKIBR:%DE-TT6L55!.#IS<&!U&]IC1>P#].I; &9* MJ>E=Z6R:,L0&QOOEM@4RCU"YU)UN;%4/AL4$ */2"5MF19D5 M=]9DH![C/E]_Z7X3/"[,&J6%[ +N8(E=[*?;A^R2VO3Z@?-6]H M6_?MYMFX:NC:]M@UJF(L#!:W2\1L!HAFMDP8UP03BN_'(CEVJ.=9LFNIF6), M:XU&"3.(R-5"7"R2WR]?IH>JAT7O#;-"V.5I-W? ;7C[$N,6I:,E5\1'UVB7 M>Z[K+:&S=R4AXC-,'81&J4X5KT>+J5F4VX8EW0V>IUE5ABFGK0,);PL+GKGD M?&^GCQ6(4WO9*[ ,F*SU\UP19MUGUE8K1I\_M$H/KM8*V)C3O7'<8*+:APA% MDL &([5^T-%D.X6.DNY*U^TA)B!R$#2W$ MMAULUJ>E[@^IP:S7IE5O.\NSVS^IM)@0Q-9(6$.>K@KD;JZCP4P%P[6$O<14/$4&UB*J+>*U7+E& M4QZ,L6NOA+$UE)<5 F,%;GF5]V>O.@8Z$MQ]&Z>8;0N.XAMG6=+:0A<2#9QD M1:4(")2E<4;=KF/CJQC&68-NL\1O*6#Y5N62YYGS^^0\ES Z]Z#%!%UH9H_4 M ZN.5&=K]P! UI3(81RADYJB1*DK%1PKKFI=54^Q$[?4M9:^JUM-(F-&+17*97 EB+-D71SY!LF;I*> MB>\'$/3$2I+J93HL+]J*C7[!\:LG9(68;KL?ZL/E^R",S*W79940WZ1Y"2!"ORX[SH MN"M@BU =@*K2(_B:Z0U8C76KUT2UZL VXR%D:PU_+=59CFXMKF+,:&F95;>. M@)]S)R'IE[> DQF;VZYG%PP;1A*<%H?I\_0MMY7RY*_7;?66M&.OO8?8+>N: M#]NZ_HO91D'*V3V%U,FB5HO0 M*7L\9?:J#MHUB[NA+;;JBI)!ELR T^N2,DA,"?E^O%%QG"8)[,J.[ET, M1$%,P)PO)(8Z^VXN 0R,)DAV9D534G, A.B>Y\>7(;<(L$SI?3JK$JWJU/K M15M7PX]9S2H]\4;R*^I*N;%-SFI,VC,G)QJLYR!1.2*SF) MPK<\SI;PO>W=?/OS7C%>NG7P]:S][.:)TV8O%KAY'VBYE-8TF?;+) S"AC

)D<.'P/CD)LAKX<"%&]'LQ6$-DN=+FW*ZRUW6>N'I0*<]K^DNS: MOY_9F8Y502Y5=\RL4[G -]4#+HG&3<*$9\H"V,?5H<4C_P#.1V7D%%[1>KUF MP.LOGJZ"-OQQY@0P\7$#R3K JQ,,Q; ,95P[J76IX Q3D.LACM'K1H8VY=:=D%<5HA$QLJ/A5K!%282QYPW MYF@Q":*(_)@27HZRESKS_P!?=:\>@C\F4T#H@X],DFM*ZE+R2$J1.GR">N*?.?FS94>IQ)4R M6]*#.NR)OJ0LG7X+0 MP"155 *IP0:S)=F,CQ$O,#,@;!:EOO2FHD)QEAN2\Z^EO#KBU9(OG5M6ZRHS M\*32==42G21M6&48=(JU1K]??@4D)+ESPU/A.B1\1R+5A$XA/FC*^PIL3 ES ,9DO+61?__9 end XML 31 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Mar. 26, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Registrant Name Vincerx Pharma, Inc.    
Entity Central Index Key 0001796129    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 23.0
Entity Common Stock, Shares Outstanding   21,413,389  
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity File Number 001-39244    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-3197402    
Entity Address, Address Line One 260 Sheridan Avenue, Suite 400    
Entity Address, City or Town Palo Alto    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94306    
City Area Code 650    
Local Phone Number 800-6676    
Document Annual Report true    
Document Transition Report false    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol VINC    
Security Exchange Name NASDAQ    
ICFR Auditor Attestation Flag false    
Auditor Name WithumSmith+Brown, PC    
Auditor Firm ID 100    
Auditor Location East Brunswick, New Jersey    
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120 days of December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form
10-K.
    
Document Financial Statement Error Correction [Flag] true    
Document Financial Statement Restatement Recovery Analysis [Flag] false    

XML 32 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 12,782 $ 11,663
Restricted cash 72 70
Short-term marketable securities 0 40,796
Prepaid expenses 51 134
Grant receivable 1,044 1,372
Other current assets 784 1,929
Total current assets 14,733 55,964
Right-of-use assets, net 2,201 3,064
Property, plant and equipment, net 125 177
Other assets 1,158 81
Total assets 18,217 59,286
Current liabilities    
Accounts payable 2,497 4,065
Accrued expenses 1,755 3,923
Lease liability 1,162 1,024
Common stock warrant liabilities 191 144
Total current liabilities 5,605 9,156
Lease liability, net of current portion 1,340 2,412
Other noncurrent liabilities 50 50
Total liabilities 6,995 11,618
Commitments and contingencies (Note 9)
Stockholders' equity    
Preferred stock, $0.0001 par value; 30,000,000 shares authorized, none issued and outstanding as of December 30, 2023 and 2022 0 0
Common stock, $0.0001 par value; 120,000,000 shares authorized; 21,407,510 shares and 21,242,884 shares issued and outstanding as of December 31, 2023 and 2022, respectively 2 2
Additional paid-in capital 170,324 166,647
Accumulated other comprehensive income (loss) 8 (26)
Accumulated deficit (159,112) (118,955)
Total stockholders' equity 11,222 47,668
Total liabilities and stockholders' equity $ 18,217 $ 59,286
XML 33 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock shares authorized 30,000,000 30,000,000
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Common stock par value $ 0.0001 $ 0.0001
Common stock shares authorized 120,000,000 120,000,000
Common stock shares issued 21,407,510 21,242,884
Common stock shares outstanding 21,407,510 21,242,884
XML 34 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
General and administrative $ 13,636 $ 18,885
Research and development 28,973 49,837
Restructuring 0 2,469
Total operating expenses 42,609 71,191
Loss from operations (42,609) (71,191)
Other income (expense)    
Change in fair value of warrant liabilities (47) 6,303
Interest income 1,251 664
Other income (expense), net 1,248 1,240
Total other income (expense) 2,452 8,207
Net loss (40,157) (62,984)
Other comprehensive income (loss):    
Net foreign currency translation gain (loss) (40) 69
Net unrealized gain (loss) on marketable securities 74 (74)
Comprehensive loss $ (40,123) $ (62,989)
Net loss per common share, basic $ (1.89) $ (3)
Net loss per common share, diluted $ (1.89) $ (3)
Weighted average common shares outstanding, basic 21,295 21,029
Weighted average common shares outstanding, diluted 21,295 21,029
XML 35 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2021 $ 100,321 $ 2 $ 156,311 $ (21) $ (55,971)
Beginning Balance, Shares at Dec. 31, 2021   21,057      
Issuance of common stock from employee stock plans 280   280    
Issuance of common stock from employee stock plans, Shares   186      
Stock-based compensation 10,056   10,056    
Cumulative translation adjustment 69     69  
Unrealized gain (loss) on marketable securities (74)     (74)  
Net loss (62,984)       (62,984)
Ending Balance at Dec. 31, 2022 47,668 $ 2 166,647 (26) (118,955)
Ending Balance, Shares at Dec. 31, 2022   21,243      
Issuance of common stock from employee stock plans 114   114    
Issuance of common stock from employee stock plans, Shares   165      
Stock-based compensation 3,563   3,563    
Cumulative translation adjustment (40)     (40)  
Unrealized gain (loss) on marketable securities 74     74  
Net loss (40,157)       (40,157)
Ending Balance at Dec. 31, 2023 $ 11,222 $ 2 $ 170,324 $ 8 $ (159,112)
Ending Balance, Shares at Dec. 31, 2023   21,408      
XML 36 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash Flows from Operating Activities    
Net loss $ (40,157) $ (62,984)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 52 54
Stock-based compensation 3,563 10,056
Amortization of right-of-use assets 863 885
Change in fair value of warrant liability 47 (6,303)
Net amortization of discounts on marketable securities (630) (292)
Changes in operating assets and liabilities:    
Prepaid and other current assets 1,228 (3,158)
Grant receivable 328 200
Other assets (1,077) 1,372
Accounts payable (1,568) 1,046
Accrued expenses (2,168) 208
Lease liabilities (934) (738)
Other noncurrent liabilities 0 50
Net cash used in operating activities (40,453) (59,604)
Cash Flows from Investing Activities:    
Purchases of marketable securities (11,821) (42,978)
Sales and maturities of marketable securities 53,321 2,400
Net cash provided by (used in) investing activities 41,500 (40,578)
Cash Flows from Financing Activities:    
Proceeds from issuance of common stock from employee stock plans 114 280
Net cash provided by financing activities 114 280
Effect of exchange rate changes on cash, cash equivalents and restricted cash (40) 71
Net increase (decrease) in cash, cash equivalents and restricted cash 1,121 (99,831)
Cash, cash equivalents and restricted cash at beginning of year 11,733 111,564
Cash, cash equivalents and restricted cash at end of year 12,854 11,733
Supplemental disclosure of cash flow information:    
Cash paid for interest 0 0
Cash paid for taxes $ 0 $ 0
XML 37 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure    
Net Income (Loss) $ (40,157) $ (62,984)
XML 38 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 39 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business
1. Nature of Business
LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”).
The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 4), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and
know-how
to develop, use, manufacture, commercialize, sublicense, and distribute a clinical-stage and
follow-on
small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach.
The Company’s business operations, and those of third parties with whom the Company conducts business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including
COVID-19,
and by economic, business and political events, including inflation and the wars in Ukraine and Israel. The extent to which these factors could continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on the Company’s current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations.
XML 40 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). They include the accounts of Vincerx and its wholly-owned subsidiaries, VNRX Corp., Vincerx Pharma GmbH and Vincerx Pharma Australia Pty Limited. All intercompany accounts and transactions have been eliminated.
Liquidity and Going Concern
As of December 31, 2023, the Company had approximately $12.8 
million in cash and cash equivalents. The Company has incurred recurring operating losses and negative cash flows from operating activities since its inception and expects to continue to incur operating losses and negative cash flows in the future. Based on current business plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early third quarter 2024, although this estimate is based on plans and assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Accordingly, the Company will need to raise additional capital through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other 
sources, and such additional capital may not be available on favorable terms or at all, particularly in light of the current economic and market conditions. Market volatility resulting from pandemics or other epidemics, inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain the listing on The Nasdaq Capital Market of the Company’s common stock, and other factors could also adversely impact the Company’s ability to raise additional capital. The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on the Company’s financial condition and the ability to pursue its business strategy, and the Company may have to reduce its workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail its business operations.
In accordance with Accounting Standards Update (“ASU”)
2014-15,
Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic
205-40),
the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. In light of the Company’s existing cash resources and current and expected operating losses and negative cash flows, the Company
w
ill
 need additional capital prior to the
one-year
anniversary of the issuance of its consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, the Company has concluded that these circumstances and the uncertainties associated with its ability to obtain additional capital raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business, and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Revision of Previously Reported Consolidated Financial Statements
In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified an error in the computation of stock-based compensation that resulted in an overstatement of stock-based compensation of approximately $2.4 million for the year ended December 31, 2022. This error resulted from the erroneous inclusion of unvested forfeited awards that should have been excluded in the calculation of stock-based compensation. As a result, net loss for the year ended December 31, 2022 and the balances of accumulated deficit and additional paid in capital at December 31, 2022 were also overstated. The error did not impact the Company’s cash flows from operating activities, financing activities and investing activities.
Management assessed the materiality of this presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250,
 
Accounting Changes and Error Corrections
 
(“ASC 250”). Based on this assessment, management concluded that this error did not have a material impact on the prior period stated above. However, the amount of the prior period error in 2022 would have been material to the consolidated financial statements for fiscal year 2023 if the correction of the error was recognized in fiscal year 2023 or left uncorrected. Therefore, the Company has revised the prior
period financial statements impacted for this error. The impact of the revision on the 2022 consolidated financial statements is as follows:
 
 
  
As of December 31, 2022
 
 
  
As Previously

Reported
 
  
Revision
 
  
As Revised
 
Balance Sheet
         
Stockholders’ equity
         
Preferred stock - $ 0.0001 par value
   
$
 		 —      
$
 		 —      
$
 		 —   
Common stock - $ 0.0001 par value
      2        —         2  
Additional
paid-in-capital
      169,030        (2,383 )       166,647  
Accumulated other comprehensive loss
      (26 )          (26 )
Accumulated deficit
      (121,338 )       2,383        (118,955 )
  
 
 
     
 
 
     
 
 
  
Total stockholders’ equity
      47,668        —         47,668  
  
 
 
     
 
 
     
 
 
  
Total liabilities and stockholders’ equity
    $ 59,286      $ —       $ 59,286  
  
 
 
     
 
 
     
 
 
  

 
  
Year Ended December 31, 2022
 
 
  
As Previously
Reported
 
  
Revision
 
  
As Revised
 
 
  
(In thousands, except per share amounts)
 
Statement of Operations and Comprehensive Loss
         
Operating expenses
    $ 73,574      $ (2,383 )     $ 71,191  
  
 
 
     
 
 
     
 
 
  
Loss from operations
      (73,574 )       2,383        (71,191 ) 
  
 
 
     
 
 
     
 
 
  
Other income (expense):
         
Change in fair value of warrant liabilities
      6,303        —         6,303  
Interest income
      664        —         664  
Other income (expense), net
      1,240        —         1,240  
  
 
 
     
 
 
     
 
 
  
Total other income
      8,207        —         8,207  
  
 
 
     
 
 
     
 
 
  
Net loss
    $  (65,367 )     $ 2,383      $  (62,984 ) 
  
 
 
     
 
 
     
 
 
  
Comprehensive loss
    $  (65,372 )     $ 2,383      $  (62,989 ) 
 
  
 
 
 
  
 
 
 
  
 
 
 
Net loss per common share, basic and diluted
    $ (3.11 )    
$
 
(0.11
 )    $ (3.00 ) 
Weighted average common shares outstanding, basic and diluted
      21,029        —        21,029  
The impact of the revision on quarterly unaudited consolidated financial statements is as follows
:
 stock-based compensation expense for the second and third quarters of 2022 were overstated by approximately $2.2 million and $0.3 million, respectively
, and understated by approximately $0.1 million in the fourth quarter of 2022.
Stock-based compensation for the first 
a
n
d
 second quarters of 2023 were understated by approximately $0.3 million 
a
n
d
 $0.4 million
,
 respectively
, and overstated by approximately $0.7 million in the third quarter of 2023
.
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
 
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of
consolidated
 
financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the
c
onsolidated
financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie
nce
and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Reclassifications
Certain previously reported financial information has been reclassified to conform to the current period presentation. The impact of reclassifications was not significant to the prior year’s overall presentation. These reclassifications had no effect on the reported results of operations.
Concentrations of Credit Risk
The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.
The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products.
The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company.
Cash and Cash Equivalents
Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.
 
Restricted Cash
Restricted cash represents cash deposits with a financial institution in support of the Company’s corporate credit card program.
Marketable Securities
The Company generally invests its excess cash in money market funds and investment grade short-term to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities or long-term marketable securities on the consolidated balance sheets. Marketable securities with a maturity date greater than 90 days and less than one year at each consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year, if any, are classified as long-term. All of the Company’s marketable securities are considered
available-for-sale
and are reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income on the consolidated statements of operations and comprehensive loss. The cost of securities sold is determined using specific identification.
The Company periodically evaluates whether declines in the fair values of its marketable securities below their amortized cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the marketable security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company’s strategy and intentions for holding the marketable security.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. 
The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. There has been no impairment loss as of December 31, 2023.
Fair Value Measurement
The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance
established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Level 1—Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Private Warrant Liability
As of December 31, 2023 and 2022, there were 3,295,000 private warrants to purchase common stock outstanding. As of December 31, 2020, there were 10,133,767 warrants outstanding, consisting of 6,563,767 public warrants (which included 2,744,586 public warrants constituting part of the units) and 3,570,000 private warrants. Each unit consisted of one share of common stock and one public warrant exercisable for
one-half
of one share of common stock.
Each public warrant entitled the registered holder to purchase
one-half
(1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination.
The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants, provided that such redemption rights could not be exercised during the first 12 months following the closing of the Business Combination unless the sales price of the Company’s common stock had been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.
The Company evaluated the public and private warrants under ASC
815-40,
Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post Business Combination, these private warrants could be transferred to a
non-permitted
transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a
fixed-for-fixed
option on the Company’s common stock, these private warrants fail the indexation guidance in ASC
815-40.
This conclusion excludes the 500,000 private warrants held by LifeSci
Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above.
Since these private warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. 
Leases
The
 Company adopted FASB ASC Topic 842, “Leases” (“ASC 842”), using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 840, “Leases”.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as
right-of-use
assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Operating lease liabilities and their corresponding
right-of-use
assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the
right-of-use
assets may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 9).
In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building) and
non-lease
components (e.g., common area maintenance, consumables). The fixed and
in-substance
fixed contract consideration (including any consideration related to
non-components)
must be allocated based on the respective relative fair values to the lease components and
non-lease
components.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as a single operating segment.
Research and Development Costs
The Company expenses research and development costs as operating expenses as incurred. These expenses include acquired
in-process
research and development expenses for which there is no alternative future use, salaries for research and development personnel, consulting fees, product development,
pre-clinical
studies, clinical trial costs, and other fees and costs related to the development of the technology.
Stock-Based Compensation
The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and
non-employees,
including stock options and restricted shares, based on estimated fair values recognized over the requisite service period.
 
The fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. No awards have been issued with a market condition or other
non-standard
terms.
The estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risk profiles, volatility, capital intensity and market growth patterns and drivers.
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.
Income Taxes
Income taxes are recorded in accordance with ASC 740, “Income Taxes” (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit (“R&D Credit”) carryforwards. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2023 and 2022, the Company had no liability for income tax associated with uncertain tax positions. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There was no income tax interest or penalties incurred in 2023 or 2022.
German Grant Income
In accordance with ASC 958, the
Company recognizes grant income in the period when the underlying eligible expenses are incurred. The German government grant program provides for tax refunds or direct reimbursements of eligible
research expenses
of up to 1.0 million euros per year over a period of six years. The grant was approved in 2022 and is retroactive to 2021. Grant income for the years ended December 31, 2023 and 2022 has been recorded in other income (expense), net on the consolidated statements of operations and comprehensive loss. The corresponding receivable is included within current assets and other assets, $1.0 million and $1.0 million, respectively, at December 31, 2023 on the consolidated balance sheet depending upon expectations for collection within twelve months of the balance sheet date.
 
Foreign Currency Translation and Transactions
The consolidated financial statements are presented in U.S. dollars. The functional currency for the Company’s foreign subsidiaries is the local currency. Expenses, gains and losses for this entity are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities are translated using exchange rates in effect at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company’s consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in the functional currency are recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss.
Comprehensive Income or Loss
Comprehensive loss is equal to net loss, net foreign currency translation gain (loss), and net unrealized gain (loss) on marketable securities as presented in the accompanying consolidated statements of operations and comprehensive loss.
Net Loss per Share of Common Stock
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period.
Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported losses for all periods presented, all potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.
Recent Accounting Pronouncements
In November 2023, Financial Accounting Standards Board (“FASB”) issued ASU
No. 2023-07
“Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU
2023-07
requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. The Company expects to adopt this guidance on January 1, 2025 on a retrospective basis and has yet to assess the impact to the consolidated financial statements.
In December 2023, FASB issued ASU
No. 2023-09
“Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU
2023-09
requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. The Company expects to adopt this guidance on January 1, 2025. The Company expects the adoption of this standard to result in increased disclosures in its notes to consolidated financial statements.
XML 41 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Business Combination
 12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
Business Combination
3. Business Combination
As discussed in Note 1, on December 23, 2020, the Company consummated the Business Combination, with Legacy Vincera Pharma surviving the merger as a wholly-owned subsidiary of the Company.
Immediately prior to the effective time of the Business Combination, each share of Legacy Vincera Pharma Common Stock was canceled, and the Legacy Holders received (i) 0.570895 shares of common stock, for each share of Legacy Vincera Pharma Common Stock held by them immediately prior to the effective time of the Business Combination and (ii) certain rights to Earnout Shares after the closing of the Business Combination.
 
The Legacy Holders are entitled to receive Earnout Shares if the daily volume-weighted average price of the Company’s common stock equals or exceeds the following prices for any 20 trading days within any
30 trading-day period
following the closing of the Business Combination: (1) during any such trading period prior to the 42 month anniversary of the closing of the Business Combination, upon achievement of a daily volume-weighted average price of at least $20.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; (2) during any such trading period prior to the six year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $35.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; and (3) during any such trading period prior to the eight year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $45.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share. A total of 90.6% of (rounded to the nearest whole share) of the Earnout Shares then earned and issuable shall be issued to the Legacy Holders on
a pro-rata basis
based on the percentage of the number of shares of Vincera Pharma Common Stock owned by them immediately prior to the closing of the Business Combination, and the remaining Earnout Shares that would otherwise have been issuable shall not be issuable to the Legacy Holders but in lieu thereof the number of authorized shares available for issuance under the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) shall be automatically increased by an equivalent n
u
mber of shares of the Company’s common stock.
XML 42 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Bayer License Agreement
 12 Months Ended
Dec. 31, 2023
Bayer License Agreement [Abstract]  
Bayer License Agreement
4. Bayer License Agreement
On October 7, 2020, Legacy Vincerx Pharma entered into the Bayer License Agreement, which became effective on December 23, 2020 upon the closing of the Business Combination. Pursuant to the Bayer License Agreement, Legacy Vincerx Pharma has an exclusive, worldwide, royalty-bearing license under certain Bayer patents
and know-how to
develop, use, manufacture, commercialize, sublicense and distribute (i) a clinical-stage and
follow-on
small molecule drug platform, including a
P-TEFb
inhibitor compound, and (ii) a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates.
Following the closing of the Business Combination, the Company paid Bayer a $5.0 million upfront license fee on January 5, 2021. During 2022 and 2023, the Company recorded $1.0 million in development milestones payable to Bayer in connection with the Company’s IND filings for VIP236 and VIP943, respectively. Each of these milestone obligations were expensed as incurred.
If the Company achieves all of the development and commercial sales milestones for license products under the Bayer License Agreement for each of the countries and disease indications, the Company would be obligated to pay milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, the Company could be required to pay aggregate milestone payments in excess of $1 billion. In addition to milestone payments, the Company is also required to pay Bayer under the Bayer License Agreement ongoing royalties in the single digit to low double-digit percentage range on net commercial sales of licensed products.
XML 43 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Restructuring
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring
5. Restructuring
On June 4, 2022, the Board of Directors of the Company approved a strategic plan to prioritize and focus its resources on certain of its enitociclib 
clinical studies and its next generation bioconjugation platform and streamline and realign its resources to support these prioritized studies. This plan included a reduction of the Company’s full-time employees by 33% and other cost reduction measures. Affected employees were offered separation benefits, including severance payments, payments to cover premiums for continuation of healthcare coverage for a limited period and in some cases vesting acceleration on certain outstanding stock options.
The Company incurred approximately $2.5 million of severance and related expenses during 2022, which includes approximately $0.5 million of stock-based compensation expense related to the acceleration of stock options to certain affected employees.
 
The activity in the accrued restructuring balance, included within accrued expenses on the consolidated balance sheet, was as follows for the year ended December 31, 2022 (in thousands):
 
     Restructuring
liabilities at
January 1, 2022		      Charges      Cash payments      Restructuring
liabilities at
December 31, 2022		  
Workforce reduction
    $ —     $ 2,022      $ (2,022 )     $ — 
The Company does not expect to incur additional restructuring charges or cash expenditures associated with this restructuring.
XML 44 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurement
6. Fair Value Measurement
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands):
 
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 4,682      $ —     $ —     $ 4,682  
U.S. government treasuries
      6,233        —         —         6,233  
U.S. government agency securities
      —         999        —         999  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents
    $ 10,915      $    999      $ —     $ 11,914  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 2,266      $ —     $ —     $ 2,266  
Commercial paper
      —         4,496        —         4,496  
Corporate debt securities
      —         3,032        —         3,032  
Short-term marketable securities:
            
Commercial paper
      —         15,587        —         15,587  
U.S. government treasuries
      1,005        —         —         1,005  
U.S. government agency securities
      —         16,069        —         16,069  
Corporate debt securities
      —         8,135        —         8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents and marketable securities
    $  3,271      $ 47,319      $ —     $ 50,590  
  
 
 
     
 
 
     
 
 
     
 
 
  
There were no marketable securities at December 31, 2023. The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly. There were no transfers of assets between Level 1, Level 2, or Level 3 during the years ended December 31, 2023 and 2022.
 
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 191      $ 191  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 191      $    191  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 144      $ 144  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 144      $    144  
  
 
 
     
 
 
     
 
 
     
 
 
  
The estimated fair value of the warrant liability for the private warrants at December 31, 2023 and 2022 was determined using Level 3 inputs. Inherent in a Monte Carlo options pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on its historical volatility for a time period that approximates the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon
yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. There were no changes to the number of private warrants underlying the Level 3 financial instruments during the year ended December 31, 2023. There were no transfers between Level 1, 2, or 3 during the years ended December 31, 2023 and 2022.
The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (in thousands).
 
    
Warrant
Liability
  
Balance – January 1, 2022
   
$
6,447
 
Change
in fair value
      (6,303 ) 
  
 
 
  
Balance – December 31, 2022
   
 
144
 
Change
in fair value
      47  
  
 
 
  
Balance – December 31, 2023
   
$
191
 
  
 
 
  
A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2023 and 2022 is as follows:
 
    
As of
December 31,
2023
    
As of
December 31,
2022
  
Stock price
    $ 1.18     $ 1.02  
Exercise price
    $ 11.50     $ 11.50  
Option term (years)
      2.0       3.0  
Volatility (annual)
      90.9 %      73.7 % 
Risk-free rate
      4.2 %      4.1 % 
Dividend yield (per share)
      0 %      0 % 
XML 45 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Available-For-Sale Securities
 12 Months Ended
Dec. 31, 2023
Debt Securities, Available-for-Sale [Abstract]  
Available-For-Sale Securities
7.
Available-For-Sale
Securities
All marketable securities were considered
available-for-sale
at December 31, 2022. There were no marketable securities at December 31, 2023.
 
The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2022 are summarized in the table below (amounts in thousands):
 
    
December 31, 2022
  
    
Amortized
Cost
     
Gross
Unrealized
Gain
     
Gross
Unrealized
Loss
     
Fair Value
  
Assets:
            
Short-term marketable securities:
            
Commercial paper
    $ 15,608      $ —     $ (21 )     $ 15,587  
U.S. government treasuries
      1,007        —         (2 )       1,005  
U.S. government agency securities
      16,105        —         (36 )       16,069  
Corporate debt securities
      8,149        —         (14 )       8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total marketable securities
    $ 40,869      $ —     $ (73 )     $ 40,796  
  
 
 
     
 
 
     
 
 
     
 
 
  
As of December 31, 2022, some of the Company’s marketable securities were in an unrealized loss position. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022.
XML 46 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details
8. Balance Sheet Details
Other current assets consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
  
Clinical related vendor prepayments
    $ 407      $ 1,560  
Payroll tax refund receivable
      250        —   
Other
      127        369  
  
 
 
     
 
 
  
   $ 784      $ 1,929  
  
 
 
     
 
 
  
Property, plant and equipment, net consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
     
Estimated
Useful Life
  
Furniture and fixtures
    $ 236      $ 236        5 years  
Computers
      20        20       
3-5 years
  
  
 
 
     
 
 
     
Total
      256        256     
Less: accumulated depreciation
      (131 )       (79 )    
  
 
 
     
 
 
     
Total property, plant and equipment, net
    $ 125      $ 177     
  
 
 
     
 
 
     
Depreciation expense was approximately $52,000 and $54,000 for the years ended December 31, 2023 and 2022, respectively.
 
The following table sets forth the components of accrued expenses at December 31, 2023 and 2022, respectively (in thousands):
 
    
December 31,
2023
     
December 31,
2022
  
Accrued payroll
    $ 332      $ 297  
Accrued bonus
      —         2,042  
Accrued benefits
      918        923  
Accrued manufacturing, clinical trial and related
      505        661  
  
 
 
     
 
 
  
   $ 1,755      $ 3,923  
  
 
 
     
 
 
  
XML 47 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
9. Commitments and Contingencies
Litigation
The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
Leases
On December 23, 2020, the Company entered into a five-year term lease agreement which commenced on January 1, 2021. In April and May, 2021, the lease was amended to include additional space. The annual rent expense is approximately $1.2 million.
At December 31, 2023, the Company had operating lease liabilities of approximately $2.5 million and right of use assets of approximately $2.2 million, which were included in the consolidated balance sheets.
In connection with the Company’s strategic plan and workforce reduction (see
N
ote 5), the Company has consolidated its leased office space at its corporate headquarters location. Effective July 2022, the Company subleased substantially all of its unused office space for a term of 18 months at a base rent of $50,000 per month. The Company has not been legally released from its primary obligations under the original lease and subsequent amendments and, therefore, continues to account for the original lease according to Accounting Standard Codification (“ASC”) Topic 842, “Leases.” The Company records both fixed and variable payments received from the sublessee in its consolidated statements of operations and comprehensive loss on a straight-line basis as an offset to rent expense. Such payments received in the years ended December 31, 2023 and 2022 were $0.6 million and $0.3 million, respectively. The Company also received a $50,000 deposit, recorded as a noncurrent liability in the consolidated balance sheet at December 31, 2023.
The following summarizes quantitative information about the Company’s operating leases (dollars in thousands):
 
   
For the years ended
  
   
December 31,

2023
    
December 31,

2022
  
Lease cost
    
Operating lease cost
   $ 1,196     $ 1,196  
Variable lease cost
     —        —   
 
 
 
    
 
 
  
Total operating lease expense
   $ 1,196     $ 1,196  
 
 
 
    
 
 
  
Other information
    
Operating cash flows from operating leases
   $ 1,270     $ 1,048  
Right-of-use
assets obtained in exchange for operating lease liabilities
   $ —    $ —   
Weighted-average remaining lease term—operating leases
     2.0       2.9  
Weighted-average discount rate—operating leases
     8 %      8 % 
 
As of December 31, 2023, future minimum payments during the next three years are as follows (in thousands):
 
Year ended December 31, 2024
    $ 1,320  
Year ended December 31, 2025
      1,372  
Year ended December 31, 2026
      28  
  
 
 
  
Total
      2,720  
Less present value discount
      (218 ) 
  
 
 
  
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2023
    $ 2,502  
  
 
 
  
XML 48 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Stockholders' Equity
10. Stockholders’ Equity
The Company’s Certificate of Incorporation authorizes the issuance of 120,000,000 shares of common stock, $0.0001 par value per share and 30,000,000 shares of undesignated preferred stock, $0.0001 par value per share. As of December 31, 2023 and 2022, there were 21,407,510 shares and 21,242,884 shares of common stock outstanding, respectively, and no shares of preferred stock outstanding.
During the year ended December 31, 2021, 275,000 private warrants were exercised for approximately $3.2 million. No private warrants were exercised during the years ended December 31, 2023 and December 31, 2022.
During the years ended December 31, 2023 and 2022, 161,668 shares and 183,366 shares, respectively, were issued pursuant to the Company’s Employee Stock Purchase Program (“ESPP”) (see Note 11) for approximately $112,000 and $278,000 in proceeds, respectively.
Restricted Shares
Between July and August 2019, Legacy Vincera Pharma issued 471,850 shares (826,510 shares prior to the effects of the Merger) of restricted stock at par value to certain management persons. All amounts owed for the issuance of these restricted shares were settled in cash in July 2020. The grant date fair value of this restricted stock was approximately $6,000.
In May 2020, Legacy Vincera Pharma issued an additional 173,552 shares (304,000 shares prior to the effects of the Merger) of restricted stock at a fair value of $0.07 per share in exchange for services. Pursuant to these restricted share agreements, the term vesting represents the expiration of the Company’s repurchase right for the underlying shares. As of December 31, 2023, there was approximately $1,600 of unrecognized stock-based compensation related to restricted stock that will be amortized in 0.4 years.
A summary of restricted stock activity for the years ended December 31, 2023 and 2022 is presented below:
 
    
Number of Shares
     
Weighted Average
Grant Date Fair
Value per Share
  
Nonvested at January 1, 2022
   
 
182,686
 
   
$
0.045
 
Vested
      (115,684 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2022
   
 
67,002
 
   
$
0.065
 
Vested
      (48,940 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2023
   
 
18,062
 
   
$
0.103
 
  
 
 
     
 
 
  
Warrants
As of December 31, 2023, there were 3,295,000 private warrants to purchase common stock outstanding. After the redemption described above, no public warrants remained outstanding at December 31, 2021.
The private warrants are identical to the previously outstanding public warrants except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants; provided, however, that such redemption rights may not be exercised during the first 12 months following the closing of the Business Combination unless the last sales price of the Company’s common stock has been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the date on which notice of redemption is given), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC, will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.
The previously outstanding public warrants and the private warrants issued to LifeSci Holdings LLC that were amended as described above were determined to be equity classified in accordance with ASC 815, Derivatives and Hedging. The remaining private warrants were determined to be liability classified in accordance with ASC 815, Derivatives and Hedging (see Note 6).
XML 49 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2023
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation
11. Stock-Based Compensation
Equity Incentive Plans
In connection with the Business Combination, the stockholders approved the 2020 Plan, which became effective upon the closing of the Business Combination on December 23, 2020. As of December 31, 2023, the Company had 5,600,152 shares of common stock reserved for issuance under the 2020 Plan.
The 2020 Plan allows for the grant of stock options and rights to acquire restricted stock to employees, directors and consultants of the Company. The terms and conditions of specific awards are set at the discretion of the Company’s board of directors. Options granted under the 2020 Plan expire no later than 10 years from the date of grant. Unvested common shares obtained upon early exercise of options are subject to repurchase by the Company at the original issue price.
 
Stock option activity under the Plan is as follows (amounts in thousands, except per share amount):
 
    
Stock
Options
     
Weighted
Average
Exercise
Price
     
Weighted
Average
Remaining
Contractual
Life (in years)
     
Aggregate
Intrinsic
Value
  
Outstanding at January 1, 2022
      3,408      $ 18.74        10.0      $ — 
Options granted
      2,509        3.30        —         —   
Options exercised
      (2 )       0.82        —         —   
Options cancelled
      (1,562 )       15.89        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2022
      4,353        10.87        8.6        —   
Options granted
      1,131        1.22        —         —   
Options exercised
      (3 )       0.82        —         —   
Options cancelled
      (262 )       11.74        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2023
      5,219      $ 8.74        8.1      $ 134  
  
 
 
     
 
 
     
 
 
     
 
 
  
Options vested and exercisable at December 31, 2023
      3,628      $ 11.25        7.8      $ 73  
  
 
 
     
 
 
     
 
 
     
 
 
  
Stock-based compensation expense is based on the grant-date fair value. The Company recognizes compensation expense for all stock-based awards on a straight-line basis over the requisite service period of the awards, which is generally the option vesting term of either
two
or three years.
As of December 31, 2023, the Company had stock-based compensation of approximately $0.7 million related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 0.6 years.
The following weighted average assumptions were used as inputs to the Black-Scholes option valuation model in determining the estimated grant-date fair value of the Company’s stock options granted during the years ended December 31, 2023 and 2022:
 
    
For the years ended
December 31,
  
    
 2023 
    
 2022 
  
Exercise price
    $ 0.90     $ 3.30  
Expected term (years)
      5.6       5.8  
Volatility (annual)
      89.5 %      85.1 % 
Risk-free rate
      4.0 %      2.8 % 
Dividend yield (per share)
      0 %      0 % 
Total stock-based compensation expense recognized in the accompanying consolidated statements of operations and comprehensive loss for stock option awards is as follows (amounts in thousands):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Research and development
    $ 1,712      $ 4,988  
General and administrative
      1,851        4,621  
Restructuring
      —         447  
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,563
 
   
$
10,056
 
  
 
 
     
 
 
  
 
Employee Stock Purchase Plan
The Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) became effective in May 2021 upon stockholder approval and is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. 200,000 of the Company’s authorized but unissued or reacquired shares of common stock have been reserved for issuance under the ESPP, plus an additional number of shares to be reserved annually on the first day of each fiscal year from January 1, 2022 through January 1, 2031, equal to the least of (i) one percent (1%) of the outstanding shares of the Company’s common stock on such date, (ii) 500,000 shares, or (iii) a lesser amount determined by the compensation committee or the Company’s board.
The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP consists of a series of offerings of purchase rights to eligible employees, each with a duration of not more than 12 months and purchase dates every six months. The purchase price cannot, under the terms of the ESPP, be less than 85% of the fair market value per share of the Company’s common stock on either the offering date or on the purchase date, whichever is less. If the fair market value of a share of the Company’s common stock on any purchase date within a particular offering period is less than or equal to the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.
As of December 31, 2023, 241,484 shares of common stock were reserved for future issuance under the ESPP. Shares issued under the ESPP were 161,668 and 183,366 shares for the years ended December 31, 2023 and 2022, respectively. The Company recorded approximately $133,000 and $278,000 of stock-based compensation expense for the years ended December 31, 2023 and 2022, respectively, related to the ESPP.
XML 50 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss per Share Applicable to Common Stockholders
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Net Loss per Share Applicable to Common Stockholders
12. Net Loss per Share Applicable to Common Stockholders
Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.
The following table sets forth the computation of loss per share for the years ended December 31, 2023 and 2022, respectively (amounts in thousands, except per share number):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Numerator:
      
Net loss
    $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
Denominator:
      
Weighted average common shares outstanding, basic and diluted
      21,295        21,029  
  
 
 
     
 
 
  
Net loss per common share, basic and diluted
    $ (1.89 )     $ (3.00 ) 
  
 
 
     
 
 
  
 
The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive:
 
    
For the years ended
December 31,
  
    
 2023 
     
 2022 
  
Options outstanding
      5,219        4,353  
Warrants
      3,295        3,295  
Restricted stock
      18        67  
  
 
 
     
 
 
  
Total
      8,532        7,715  
  
 
 
     
 
 
  
XML 51 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
13. Income Taxes
The Company has no provision for income taxes for the years ended December 31, 2023 and 2022. The Company has no current tax expense from losses and no deferred expense from the valuation allowance.
Income (loss) before provision for income taxes consisted of the following (amounts in thousands):
 
    
For the Year Ended
December 31,
  
    
2023
     
2022
  
United States
    $ (35,281 )    $ (58,708 ) 
International
      (4,876 )      (4,276 ) 
  
 
 
     
 
 
  
   $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:
 
 
  
For the Year Ended
December 31,
 
 
  
 2023 
 
 
 2022 
 
Statutory federal income tax rate
      21.0 %      21.0 % 
State taxes, net of federal tax benefit
      0.1 %      0.7 % 
Change in fair value of warrant liabilities
      — %      2.0 % 
Research and development
      2.0 %      (0.7 %) 
Other
      0.5 %      (0.1 %) 
Change in valuation allowance
      (23.6 %)      (22.9 %) 
  
 
 
    
 
 
  
Income taxes provision (benefit)
      0.0 %      0.0 % 
  
 
 
    
 
 
  
 
Significant components of the Company’s net deferred tax assets as of December 31, 2023 and 2022, are as follows (amounts in thousands):
 
    
As of December 31,
  
    
2023
     
2022
  
Deferred tax assets:
      
Net operating loss
    $ 15,475      $ 9,639  
Stock-based compensation
      5,235        5,025  
Depreciation and amortization
      —         4,198  
Capitalized research and development
      14,734        7,314  
Research and development credit
      2,231        1,635  
Accruals and reserves
      137        471  
Lease liability
      462        722  
  
 
 
     
 
 
  
Total deferred income tax assets
      38,274        29,004  
Less: Valuation allowances
      (37,748 )      (28,360 )
  
 
 
     
 
 
  
Deferred tax assets, net of valuation allowances
    $ 526      $ 644  
  
 
 
     
 
 
  
Deferred tax liabilities:
      
Right of use asset
      (526 )      (644 ) 
  
 
 
     
 
 
  
Total deferred income tax liabilities
    $ (526 )    $ (644 ) 
  
 
 
     
 
 
  
Net deferred taxes
    $ —     $ — 
  
 
 
     
 
 
  
ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The Company’s valuation allowance increased by $9.4 million and $12.9 million for the years ended December 31, 2023 and 2022, respectively.
Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the U.S. must be amortized over a five-year period and over a fifteen-year period if incurred outside the U.S. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.
At December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $59.2 million and $0.7 million, respectively. The federal net operating loss carryforwards can be carried forward indefinitely, with certain limitations. A portion of the state net operating loss carryforwards will expire beginning in 2039, if not utilized.
As of December 31, 2023, the Company also has Federal and California research and development credits of $2.6 million and $1.1 million, respectively. The federal tax credit carryforwards will expire beginning in 2039, if not utilized. The state tax credit carryforwards do not expire.
 
The following table summarizes activity related to the Company’s gross unrecognized tax benefits (amounts in thousands):
 
    
Total
  
Balance as of December 31, 2021
    $ 518  
Increase/decrease due to prior year positions
      (164 ) 
Increase/decrease due to current year positions
      625  
  
 
 
  
Balance as of December 31, 2022
      979  
Increase/decrease due to prior year positions
      —  
Increase/decrease due to current year positions
      259  
  
 
 
  
Balance as of December 31, 2023
    $ 1,238  
  
 
 
  
The unrecognized tax benefits, if recognized, would not have an impact on the Company’s effective tax rate due to the valuation allowance. The Company does not expect a significant change to its unrecognized tax benefits over the next twelve months. The Company files income tax returns in the United States, California and Germany jurisdictions and is not currently under examination by federal, state or local taxing authorities for any open tax years. The tax years 2019 through 2023 remain open to examination by the major taxing authorities. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. The Company records interest related to uncertain tax positions as interest, and any penalties are recorded as income tax expense in its consolidated statements of operations and comprehensive loss.
Utilization of net operating losses and tax credit carryforwards may be limited by the “ownership change” rules, as defined in Section 382 of the Internal Revenue Code (any such limitation, a “Section 382 limitation”). Similar rules may apply under state tax laws. The Company has not performed an analysis to determine whether an “ownership change” occurred from inception to December 31, 2023. If a change
in
ownership were to have occurred, additional net operating loss and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.
ASC
740-10,
“Income Taxes”, prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company’s income tax return and also provides guidance on
de-recognition,
classification, interest and penalties, accounting in interim periods, disclosure, and transition.
XML 52 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). They include the accounts of Vincerx and its wholly-owned subsidiaries, VNRX Corp., Vincerx Pharma GmbH and Vincerx Pharma Australia Pty Limited. All intercompany accounts and transactions have been eliminated.
Liquidity and Going Concern
Liquidity and Going Concern
As of December 31, 2023, the Company had approximately $12.8 
million in cash and cash equivalents. The Company has incurred recurring operating losses and negative cash flows from operating activities since its inception and expects to continue to incur operating losses and negative cash flows in the future. Based on current business plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early third quarter 2024, although this estimate is based on plans and assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Accordingly, the Company will need to raise additional capital through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other 
sources, and such additional capital may not be available on favorable terms or at all, particularly in light of the current economic and market conditions. Market volatility resulting from pandemics or other epidemics, inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain the listing on The Nasdaq Capital Market of the Company’s common stock, and other factors could also adversely impact the Company’s ability to raise additional capital. The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on the Company’s financial condition and the ability to pursue its business strategy, and the Company may have to reduce its workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail its business operations.
In accordance with Accounting Standards Update (“ASU”)
2014-15,
Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic
205-40),
the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. In light of the Company’s existing cash resources and current and expected operating losses and negative cash flows, the Company
w
ill
 need additional capital prior to the
one-year
anniversary of the issuance of its consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, the Company has concluded that these circumstances and the uncertainties associated with its ability to obtain additional capital raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business, and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Revision of Previously Reported Consolidated Financial Statements
Revision of Previously Reported Consolidated Financial Statements
In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified an error in the computation of stock-based compensation that resulted in an overstatement of stock-based compensation of approximately $2.4 million for the year ended December 31, 2022. This error resulted from the erroneous inclusion of unvested forfeited awards that should have been excluded in the calculation of stock-based compensation. As a result, net loss for the year ended December 31, 2022 and the balances of accumulated deficit and additional paid in capital at December 31, 2022 were also overstated. The error did not impact the Company’s cash flows from operating activities, financing activities and investing activities.
Management assessed the materiality of this presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250,
 
Accounting Changes and Error Corrections
 
(“ASC 250”). Based on this assessment, management concluded that this error did not have a material impact on the prior period stated above. However, the amount of the prior period error in 2022 would have been material to the consolidated financial statements for fiscal year 2023 if the correction of the error was recognized in fiscal year 2023 or left uncorrected. Therefore, the Company has revised the prior
period financial statements impacted for this error. The impact of the revision on the 2022 consolidated financial statements is as follows:
 
 
  
As of December 31, 2022
 
 
  
As Previously

Reported
 
  
Revision
 
  
As Revised
 
Balance Sheet
         
Stockholders’ equity
         
Preferred stock - $ 0.0001 par value
   
$
 		 —      
$
 		 —      
$
 		 —   
Common stock - $ 0.0001 par value
      2        —         2  
Additional
paid-in-capital
      169,030        (2,383 )       166,647  
Accumulated other comprehensive loss
      (26 )          (26 )
Accumulated deficit
      (121,338 )       2,383        (118,955 )
  
 
 
     
 
 
     
 
 
  
Total stockholders’ equity
      47,668        —         47,668  
  
 
 
     
 
 
     
 
 
  
Total liabilities and stockholders’ equity
    $ 59,286      $ —       $ 59,286  
  
 
 
     
 
 
     
 
 
  

 
  
Year Ended December 31, 2022
 
 
  
As Previously
Reported
 
  
Revision
 
  
As Revised
 
 
  
(In thousands, except per share amounts)
 
Statement of Operations and Comprehensive Loss
         
Operating expenses
    $ 73,574      $ (2,383 )     $ 71,191  
  
 
 
     
 
 
     
 
 
  
Loss from operations
      (73,574 )       2,383        (71,191 ) 
  
 
 
     
 
 
     
 
 
  
Other income (expense):
         
Change in fair value of warrant liabilities
      6,303        —         6,303  
Interest income
      664        —         664  
Other income (expense), net
      1,240        —         1,240  
  
 
 
     
 
 
     
 
 
  
Total other income
      8,207        —         8,207  
  
 
 
     
 
 
     
 
 
  
Net loss
    $  (65,367 )     $ 2,383      $  (62,984 ) 
  
 
 
     
 
 
     
 
 
  
Comprehensive loss
    $  (65,372 )     $ 2,383      $  (62,989 ) 
 
  
 
 
 
  
 
 
 
  
 
 
 
Net loss per common share, basic and diluted
    $ (3.11 )    
$
 
(0.11
 )    $ (3.00 ) 
Weighted average common shares outstanding, basic and diluted
      21,029        —        21,029  
The impact of the revision on quarterly unaudited consolidated financial statements is as follows
:
 stock-based compensation expense for the second and third quarters of 2022 were overstated by approximately $2.2 million and $0.3 million, respectively
, and understated by approximately $0.1 million in the fourth quarter of 2022.
Stock-based compensation for the first 
a
n
d
 second quarters of 2023 were understated by approximately $0.3 million 
a
n
d
 $0.4 million
,
 respectively
, and overstated by approximately $0.7 million in the third quarter of 2023
.
Emerging Growth Company
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
 
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of
consolidated
 
financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the
c
onsolidated
financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie
nce
and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Reclassifications
Reclassifications
Certain previously reported financial information has been reclassified to conform to the current period presentation. The impact of reclassifications was not significant to the prior year’s overall presentation. These reclassifications had no effect on the reported results of operations.
Concentration of Credit Risk
Concentrations of Credit Risk
The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.
The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products.
The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company.
Cash and Cash Equivalents
Cash and Cash Equivalents
Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.
Restricted Cash
Restricted Cash
Restricted cash represents cash deposits with a financial institution in support of the Company’s corporate credit card program.
Marketable Securities
Marketable Securities
The Company generally invests its excess cash in money market funds and investment grade short-term to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities or long-term marketable securities on the consolidated balance sheets. Marketable securities with a maturity date greater than 90 days and less than one year at each consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year, if any, are classified as long-term. All of the Company’s marketable securities are considered
available-for-sale
and are reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income on the consolidated statements of operations and comprehensive loss. The cost of securities sold is determined using specific identification.
The Company periodically evaluates whether declines in the fair values of its marketable securities below their amortized cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the marketable security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company’s strategy and intentions for holding the marketable security.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. 
The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. There has been no impairment loss as of December 31, 2023.
Fair Value Measurement
Fair Value Measurement
The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance
established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Level 1—Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Private Warrant Liability
Private Warrant Liability
As of December 31, 2023 and 2022, there were 3,295,000 private warrants to purchase common stock outstanding. As of December 31, 2020, there were 10,133,767 warrants outstanding, consisting of 6,563,767 public warrants (which included 2,744,586 public warrants constituting part of the units) and 3,570,000 private warrants. Each unit consisted of one share of common stock and one public warrant exercisable for
one-half
of one share of common stock.
Each public warrant entitled the registered holder to purchase
one-half
(1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination.
The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants, provided that such redemption rights could not be exercised during the first 12 months following the closing of the Business Combination unless the sales price of the Company’s common stock had been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination.
The Company evaluated the public and private warrants under ASC
815-40,
Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post Business Combination, these private warrants could be transferred to a
non-permitted
transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a
fixed-for-fixed
option on the Company’s common stock, these private warrants fail the indexation guidance in ASC
815-40.
This conclusion excludes the 500,000 private warrants held by LifeSci
Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above.
Since these private warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. 
Leases
Leases
The
 Company adopted FASB ASC Topic 842, “Leases” (“ASC 842”), using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 840, “Leases”.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as
right-of-use
assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Operating lease liabilities and their corresponding
right-of-use
assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the
right-of-use
assets may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 9).
In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building) and
non-lease
components (e.g., common area maintenance, consumables). The fixed and
in-substance
fixed contract consideration (including any consideration related to
non-components)
must be allocated based on the respective relative fair values to the lease components and
non-lease
components.
Segments
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as a single operating segment.
Research and Development Costs
Research and Development Costs
The Company expenses research and development costs as operating expenses as incurred. These expenses include acquired
in-process
research and development expenses for which there is no alternative future use, salaries for research and development personnel, consulting fees, product development,
pre-clinical
studies, clinical trial costs, and other fees and costs related to the development of the technology.
Stock-Based Compensation
Stock-Based Compensation
The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and
non-employees,
including stock options and restricted shares, based on estimated fair values recognized over the requisite service period.
 
The fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. No awards have been issued with a market condition or other
non-standard
terms.
The estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risk profiles, volatility, capital intensity and market growth patterns and drivers.
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.
Income Taxes
Income Taxes
Income taxes are recorded in accordance with ASC 740, “Income Taxes” (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit (“R&D Credit”) carryforwards. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2023 and 2022, the Company had no liability for income tax associated with uncertain tax positions. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There was no income tax interest or penalties incurred in 2023 or 2022.
German Grant Income
German Grant Income
In accordance with ASC 958, the
Company recognizes grant income in the period when the underlying eligible expenses are incurred. The German government grant program provides for tax refunds or direct reimbursements of eligible
research expenses
of up to 1.0 million euros per year over a period of six years. The grant was approved in 2022 and is retroactive to 2021. Grant income for the years ended December 31, 2023 and 2022 has been recorded in other income (expense), net on the consolidated statements of operations and comprehensive loss. The corresponding receivable is included within current assets and other assets, $1.0 million and $1.0 million, respectively, at December 31, 2023 on the consolidated balance sheet depending upon expectations for collection within twelve months of the balance sheet date.
Foreign Currency Translation and Transactions
Foreign Currency Translation and Transactions
The consolidated financial statements are presented in U.S. dollars. The functional currency for the Company’s foreign subsidiaries is the local currency. Expenses, gains and losses for this entity are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities are translated using exchange rates in effect at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company’s consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in the functional currency are recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss.
Comprehensive Income or Loss
Comprehensive Income or Loss
Comprehensive loss is equal to net loss, net foreign currency translation gain (loss), and net unrealized gain (loss) on marketable securities as presented in the accompanying consolidated statements of operations and comprehensive loss.
Net Loss per Share of Common Stock
Net Loss per Share of Common Stock
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period.
Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported losses for all periods presented, all potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In November 2023, Financial Accounting Standards Board (“FASB”) issued ASU
No. 2023-07
“Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU
2023-07
requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. The Company expects to adopt this guidance on January 1, 2025 on a retrospective basis and has yet to assess the impact to the consolidated financial statements.
In December 2023, FASB issued ASU
No. 2023-09
“Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU
2023-09
requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. The Company expects to adopt this guidance on January 1, 2025. The Company expects the adoption of this standard to result in increased disclosures in its notes to consolidated financial statements.
XML 53 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Statement of Financial Position [Abstract]  
Summary of Impact of Restatement on The Balance Sheet of The Company
 
  
As of December 31, 2022
 
 
  
As Previously

Reported
 
  
Revision
 
  
As Revised
 
Balance Sheet
         
Stockholders’ equity
         
Preferred stock - $ 0.0001 par value
   
$
 		 —      
$
 		 —      
$
 		 —   
Common stock - $ 0.0001 par value
      2        —         2  
Additional
paid-in-capital
      169,030        (2,383 )       166,647  
Accumulated other comprehensive loss
      (26 )          (26 )
Accumulated deficit
      (121,338 )       2,383        (118,955 )
  
 
 
     
 
 
     
 
 
  
Total stockholders’ equity
      47,668        —         47,668  
  
 
 
     
 
 
     
 
 
  
Total liabilities and stockholders’ equity
    $ 59,286      $ —       $ 59,286  
  
 
 
     
 
 
     
 
 
  
Summary of Tabular Form of Impact of Restatement on The Income Statement
 
  
Year Ended December 31, 2022
 
 
  
As Previously
Reported
 
  
Revision
 
  
As Revised
 
 
  
(In thousands, except per share amounts)
 
Statement of Operations and Comprehensive Loss
         
Operating expenses
    $ 73,574      $ (2,383 )     $ 71,191  
  
 
 
     
 
 
     
 
 
  
Loss from operations
      (73,574 )       2,383        (71,191 ) 
  
 
 
     
 
 
     
 
 
  
Other income (expense):
         
Change in fair value of warrant liabilities
      6,303        —         6,303  
Interest income
      664        —         664  
Other income (expense), net
      1,240        —         1,240  
  
 
 
     
 
 
     
 
 
  
Total other income
      8,207        —         8,207  
  
 
 
     
 
 
     
 
 
  
Net loss
    $  (65,367 )     $ 2,383      $  (62,984 ) 
  
 
 
     
 
 
     
 
 
  
Comprehensive loss
    $  (65,372 )     $ 2,383      $  (62,989 ) 
 
  
 
 
 
  
 
 
 
  
 
 
 
Net loss per common share, basic and diluted
    $ (3.11 )    
$
 
(0.11
 )    $ (3.00 ) 
Weighted average common shares outstanding, basic and diluted
      21,029        —        21,029  
XML 54 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Restructuring (Tables)
 12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Accrued Restructuring and Accrued Expenses
The activity in the accrued restructuring balance, included within accrued expenses on the consolidated balance sheet, was as follows for the year ended December 31, 2022 (in thousands):
 
     Restructuring
liabilities at
January 1, 2022		      Charges      Cash payments      Restructuring
liabilities at
December 31, 2022		  
Workforce reduction
    $ —     $ 2,022      $ (2,022 )     $ — 
XML 55 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Summary of Fair Value Assets Measured on Recurring Basis
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands):
 
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 4,682      $ —     $ —     $ 4,682  
U.S. government treasuries
      6,233        —         —         6,233  
U.S. government agency securities
      —         999        —         999  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents
    $ 10,915      $    999      $ —     $ 11,914  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Assets:
            
Cash Equivalents:
            
Money market funds
    $ 2,266      $ —     $ —     $ 2,266  
Commercial paper
      —         4,496        —         4,496  
Corporate debt securities
      —         3,032        —         3,032  
Short-term marketable securities:
            
Commercial paper
      —         15,587        —         15,587  
U.S. government treasuries
      1,005        —         —         1,005  
U.S. government agency securities
      —         16,069        —         16,069  
Corporate debt securities
      —         8,135        —         8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total cash equivalents and marketable securities
    $  3,271      $ 47,319      $ —     $ 50,590  
  
 
 
     
 
 
     
 
 
     
 
 
  
Summary of Liabilities Measured at Fair Value on Recurring Basis
    
Fair Value Measured as of December 31, 2023
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 191      $ 191  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 191      $    191  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Fair Value Measured as of December 31, 2022
  
    
Level 1
     
Level 2
     
Level 3
     
Total
  
Liabilities:
            
Common stock warrant liabilities
    $ —     $ —     $ 144      $ 144  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total fair value
    $    —     $    —     $ 144      $    144  
  
 
 
     
 
 
     
 
 
     
 
 
  
Summary of Changes in Level 3 Warrant liabilities measured at fair value
The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (in thousands).
 
    
Warrant
Liability
  
Balance – January 1, 2022
   
$
6,447
 
Change
in fair value
      (6,303 ) 
  
 
 
  
Balance – December 31, 2022
   
 
144
 
Change
in fair value
      47  
  
 
 
  
Balance – December 31, 2023
   
$
191
 
  
 
 
  
Private Warrant [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Summary of Fair Value of the Company's warrant liabilities
A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2023 and 2022 is as follows:
 
    
As of
December 31,
2023
    
As of
December 31,
2022
  
Stock price
    $ 1.18     $ 1.02  
Exercise price
    $ 11.50     $ 11.50  
Option term (years)
      2.0       3.0  
Volatility (annual)
      90.9 %      73.7 % 
Risk-free rate
      4.2 %      4.1 % 
Dividend yield (per share)
      0 %      0 % 
XML 56 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Available-For-Sale Securities (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Securities, Available-for-Sale [Abstract]  
Summary of Available For Sale Securities
All marketable securities were considered
available-for-sale
at December 31, 2022. There were no marketable securities at December 31, 2023.
 
The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2022 are summarized in the table below (amounts in thousands):
 
    
December 31, 2022
  
    
Amortized
Cost
     
Gross
Unrealized
Gain
     
Gross
Unrealized
Loss
     
Fair Value
  
Assets:
            
Short-term marketable securities:
            
Commercial paper
    $ 15,608      $ —     $ (21 )     $ 15,587  
U.S. government treasuries
      1,007        —         (2 )       1,005  
U.S. government agency securities
      16,105        —         (36 )       16,069  
Corporate debt securities
      8,149        —         (14 )       8,135  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total marketable securities
    $ 40,869      $ —     $ (73 )     $ 40,796  
  
 
 
     
 
 
     
 
 
     
 
 
  
XML 57 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Summary of Other Current Assets
Other current assets consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
  
Clinical related vendor prepayments
    $ 407      $ 1,560  
Payroll tax refund receivable
      250        —   
Other
      127        369  
  
 
 
     
 
 
  
   $ 784      $ 1,929  
  
 
 
     
 
 
  
Summary Of Property Plant And Equipment
Property, plant and equipment, net consist of the following at December 31, 2023 and 2022 (in thousands): 
 
    
December 31,
2023
     
December 31,
2022
     
Estimated
Useful Life
  
Furniture and fixtures
    $ 236      $ 236        5 years  
Computers
      20        20       
3-5 years
  
  
 
 
     
 
 
     
Total
      256        256     
Less: accumulated depreciation
      (131 )       (79 )    
  
 
 
     
 
 
     
Total property, plant and equipment, net
    $ 125      $ 177     
  
 
 
     
 
 
     
Summary Of Accrued Expenses
The following table sets forth the components of accrued expenses at December 31, 2023 and 2022, respectively (in thousands):
 
    
December 31,
2023
     
December 31,
2022
  
Accrued payroll
    $ 332      $ 297  
Accrued bonus
      —         2,042  
Accrued benefits
      918        923  
Accrued manufacturing, clinical trial and related
      505        661  
  
 
 
     
 
 
  
   $ 1,755      $ 3,923  
  
 
 
     
 
 
  
XML 58 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Contractual Obligation, Fiscal Year Maturity [Abstract]  
Summary of Quantitative Information About the Company's Operating Leases
The following summarizes quantitative information about the Company’s operating leases (dollars in thousands):
 
   
For the years ended
  
   
December 31,

2023
    
December 31,

2022
  
Lease cost
    
Operating lease cost
   $ 1,196     $ 1,196  
Variable lease cost
     —        —   
 
 
 
    
 
 
  
Total operating lease expense
   $ 1,196     $ 1,196  
 
 
 
    
 
 
  
Other information
    
Operating cash flows from operating leases
   $ 1,270     $ 1,048  
Right-of-use
assets obtained in exchange for operating lease liabilities
   $ —    $ —   
Weighted-average remaining lease term—operating leases
     2.0       2.9  
Weighted-average discount rate—operating leases
     8 %      8 % 
Summary of Future Minimum Lease Payments
As of December 31, 2023, future minimum payments during the next three years are as follows (in thousands):
 
Year ended December 31, 2024
    $ 1,320  
Year ended December 31, 2025
      1,372  
Year ended December 31, 2026
      28  
  
 
 
  
Total
      2,720  
Less present value discount
      (218 ) 
  
 
 
  
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2023
    $ 2,502  
  
 
 
  
XML 59 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Summary of Restricted Stock Activity
A summary of restricted stock activity for the years ended December 31, 2023 and 2022 is presented below:
 
    
Number of Shares
     
Weighted Average
Grant Date Fair
Value per Share
  
Nonvested at January 1, 2022
   
 
182,686
 
   
$
0.045
 
Vested
      (115,684 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2022
   
 
67,002
 
   
$
0.065
 
Vested
      (48,940 )       —   
  
 
 
     
 
 
  
Nonvested at December 31, 2023
   
 
18,062
 
   
$
0.103
 
  
 
 
     
 
 
  
XML 60 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-based Payment Arrangement [Abstract]  
Summary of Stock Option Activity
Stock option activity under the Plan is as follows (amounts in thousands, except per share amount):
 
    
Stock
Options
     
Weighted
Average
Exercise
Price
     
Weighted
Average
Remaining
Contractual
Life (in years)
     
Aggregate
Intrinsic
Value
  
Outstanding at January 1, 2022
      3,408      $ 18.74        10.0      $ — 
Options granted
      2,509        3.30        —         —   
Options exercised
      (2 )       0.82        —         —   
Options cancelled
      (1,562 )       15.89        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2022
      4,353        10.87        8.6        —   
Options granted
      1,131        1.22        —         —   
Options exercised
      (3 )       0.82        —         —   
Options cancelled
      (262 )       11.74        —         —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Outstanding at December 31, 2023
      5,219      $ 8.74        8.1      $ 134  
  
 
 
     
 
 
     
 
 
     
 
 
  
Options vested and exercisable at December 31, 2023
      3,628      $ 11.25        7.8      $ 73  
  
 
 
     
 
 
     
 
 
     
 
 
  
Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model
The following weighted average assumptions were used as inputs to the Black-Scholes option valuation model in determining the estimated grant-date fair value of the Company’s stock options granted during the years ended December 31, 2023 and 2022:
 
    
For the years ended
December 31,
  
    
 2023 
    
 2022 
  
Exercise price
    $ 0.90     $ 3.30  
Expected term (years)
      5.6       5.8  
Volatility (annual)
      89.5 %      85.1 % 
Risk-free rate
      4.0 %      2.8 % 
Dividend yield (per share)
      0 %      0 % 
Summary of Stock Based Compensation Expense
Total stock-based compensation expense recognized in the accompanying consolidated statements of operations and comprehensive loss for stock option awards is as follows (amounts in thousands):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Research and development
    $ 1,712      $ 4,988  
General and administrative
      1,851        4,621  
Restructuring
      —         447  
  
 
 
     
 
 
  
Total stock-based compensation expense
   
$
3,563
 
   
$
10,056
 
  
 
 
     
 
 
  
XML 61 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss per Share Applicable to Common Stockholders (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Summary of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of loss per share for the years ended December 31, 2023 and 2022, respectively (amounts in thousands, except per share number):
 
    
For the years ended
December 31,
  
    
2023
     
2022
  
Numerator:
      
Net loss
    $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
Denominator:
      
Weighted average common shares outstanding, basic and diluted
      21,295        21,029  
  
 
 
     
 
 
  
Net loss per common share, basic and diluted
    $ (1.89 )     $ (3.00 ) 
  
 
 
     
 
 
  
 Summary of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock 
The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive:
 
    
For the years ended
December 31,
  
    
 2023 
     
 2022 
  
Options outstanding
      5,219        4,353  
Warrants
      3,295        3,295  
Restricted stock
      18        67  
  
 
 
     
 
 
  
Total
      8,532        7,715  
  
 
 
     
 
 
  
XML 62 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Income (Loss) before Provision for Income Taxes
Income (loss) before provision for income taxes consisted of the following (amounts in thousands):
 
    
For the Year Ended
December 31,
  
    
2023
     
2022
  
United States
    $ (35,281 )    $ (58,708 ) 
International
      (4,876 )      (4,276 ) 
  
 
 
     
 
 
  
   $ (40,157 )     $ (62,984 ) 
  
 
 
     
 
 
  
Schedule of Effective Income Tax Rate Reconciliation
The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:
 
 
  
For the Year Ended
December 31,
 
 
  
 2023 
 
 
 2022 
 
Statutory federal income tax rate
      21.0 %      21.0 % 
State taxes, net of federal tax benefit
      0.1 %      0.7 % 
Change in fair value of warrant liabilities
      — %      2.0 % 
Research and development
      2.0 %      (0.7 %) 
Other
      0.5 %      (0.1 %) 
Change in valuation allowance
      (23.6 %)      (22.9 %) 
  
 
 
    
 
 
  
Income taxes provision (benefit)
      0.0 %      0.0 % 
  
 
 
    
 
 
  
Schedule of Net Deferred Tax Assets
Significant components of the Company’s net deferred tax assets as of December 31, 2023 and 2022, are as follows (amounts in thousands):
 
    
As of December 31,
  
    
2023
     
2022
  
Deferred tax assets:
      
Net operating loss
    $ 15,475      $ 9,639  
Stock-based compensation
      5,235        5,025  
Depreciation and amortization
      —         4,198  
Capitalized research and development
      14,734        7,314  
Research and development credit
      2,231        1,635  
Accruals and reserves
      137        471  
Lease liability
      462        722  
  
 
 
     
 
 
  
Total deferred income tax assets
      38,274        29,004  
Less: Valuation allowances
      (37,748 )      (28,360 )
  
 
 
     
 
 
  
Deferred tax assets, net of valuation allowances
    $ 526      $ 644  
  
 
 
     
 
 
  
Deferred tax liabilities:
      
Right of use asset
      (526 )      (644 ) 
  
 
 
     
 
 
  
Total deferred income tax liabilities
    $ (526 )    $ (644 ) 
  
 
 
     
 
 
  
Net deferred taxes
    $ —     $ — 
  
 
 
     
 
 
  
Schedule of Income Tax Contingencies
The following table summarizes activity related to the Company’s gross unrecognized tax benefits (amounts in thousands):
 
    
Total
  
Balance as of December 31, 2021
    $ 518  
Increase/decrease due to prior year positions
      (164 ) 
Increase/decrease due to current year positions
      625  
  
 
 
  
Balance as of December 31, 2022
      979  
Increase/decrease due to prior year positions
      —  
Increase/decrease due to current year positions
      259  
  
 
 
  
Balance as of December 31, 2023
    $ 1,238  
  
 
 
  
XML 63 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business - Additional Information (Details)
 12 Months Ended
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Incorporation date Dec. 19, 2018
XML 64 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
shares
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
shares
Jan. 31, 2023
$ / shares
shares
Dec. 31, 2021
shares
Dec. 31, 2020
shares
Summary Of Significant Accounting Policies [Line Items]                        
No of Warrants outstanding       3,295,000     3,295,000   3,295,000     10,133,767
Cash equivalents | $             $ 12,800          
Federal depository insurance coverage amount | $             250,000          
German grant income | €               € 1.0        
Share-based Payment Arrangement, Expense | $             $ 3,563   $ 10,056      
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]             Research and Development Expense (Excluding Acquired in Process Cost) Research and Development Expense (Excluding Acquired in Process Cost)        
Current asset [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
German grant income | $             $ 1,000          
Other Assets [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
German grant income | $             1,000          
Revision of Prior Period, Adjustment [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
Share-based Payment Arrangement, Expense | $ $ 700 $ 400 $ 300 $ 100 $ 300 $ 2,200            
Share Based Payments [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
Share-based Payment Arrangement, Expense | $             $ 2,400          
Public Warrant [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
No of Warrants outstanding       0         0   6,563,767  
No of Warrants outstanding                     2,744,586  
Shares Issued, Price Per Share | $ / shares                   $ 11.5    
Class of warrant or right redemption threshold trading days             20 days 20 days        
Private Warrants [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
No of Warrants outstanding             3,295,000       3,570,000  
Shares Issued, Price Per Share | $ / shares                   $ 11.5    
Class of warrants exercised                     275,000  
Warrant expiration term                   5 years    
Class of warrant or right redemption threshold trading days             20 days 20 days        
Class of warrant or right redemption threshold consecutive trading days             30 days 30 days        
Class of Warrant Or Right Excludes The Warrants Post Business Combination To Remove Cashless Exercise Provision Shares                   500,000    
Private Warrants [Member] | Common Stock [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
Share redemption trigger price | $ / shares             $ 20     $ 20    
Private Warrants [Member] | Rosedale Park LLC [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
Class of warrants exercised             500,000     500,000    
Warrents expiration date             Mar. 05, 2025 Mar. 05, 2025        
Private Warrants [Member] | LifeSci Holdings LLC [Member]                        
Summary Of Significant Accounting Policies [Line Items]                        
Class of warrants exercised             500,000     500,000    
XML 65 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stockholders' equity      
Preferred stock - $ 0.0001 par value $ 0 $ 0  
Common stock - $ 0.0001 par value 2 2  
Additional paid-in-capital 170,324 166,647  
Accumulated other comprehensive loss 8 (26)  
Accumulated deficit (159,112) (118,955)  
Total stockholders' equity 11,222 47,668 $ 100,321
Total liabilities and stockholders' equity $ 18,217 59,286  
Previously Reported [Member]      
Stockholders' equity      
Preferred stock - $ 0.0001 par value   0  
Common stock - $ 0.0001 par value   2  
Additional paid-in-capital   169,030  
Accumulated other comprehensive loss   (26)  
Accumulated deficit   (121,338)  
Total stockholders' equity   47,668  
Total liabilities and stockholders' equity   59,286  
Revision of Prior Period, Adjustment [Member]      
Stockholders' equity      
Preferred stock - $ 0.0001 par value   0  
Common stock - $ 0.0001 par value   0  
Additional paid-in-capital   (2,383)  
Accumulated deficit   2,383  
Total stockholders' equity   0  
Total liabilities and stockholders' equity   $ 0  
XML 66 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Impact Of Restatement On The Balance Sheet Of The Company [Abstract]    
Preferred stock par value $ 0.0001 $ 0.0001
Common stock par value $ 0.0001 $ 0.0001
XML 67 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Line Items]    
Operating expenses $ 42,609 $ 71,191
Loss from operations (42,609) (71,191)
Other income (expense):    
Change in fair value of warrant liabilities (47) 6,303
Interest income 1,251 664
Other income (expense), net 1,248 1,240
Total other income (expense) 2,452 8,207
Net loss (40,157) (62,984)
Comprehensive loss $ (40,123) $ (62,989)
Net loss per common share, basic $ (1.89) $ (3)
Net loss per common share, diluted $ (1.89) $ (3)
Weighted average common shares outstanding, basic 21,295 21,029
Weighted average common shares outstanding, diluted 21,295 21,029
Scenario Previously Reported [Member]    
Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Line Items]    
Operating expenses   $ 73,574
Loss from operations   (73,574)
Other income (expense):    
Change in fair value of warrant liabilities   6,303
Interest income   664
Other income (expense), net   1,240
Total other income (expense)   8,207
Net loss   (65,367)
Comprehensive loss   $ (65,372)
Net loss per common share, basic   $ (3.11)
Net loss per common share, diluted   $ (3.11)
Weighted average common shares outstanding, basic   21,029
Weighted average common shares outstanding, diluted   21,029
Restatement Adjustment [Member]    
Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Line Items]    
Operating expenses   $ (2,383)
Loss from operations   2,383
Other income (expense):    
Change in fair value of warrant liabilities   0
Interest income   0
Other income (expense), net   0
Total other income (expense)   0
Net loss   2,383
Comprehensive loss   $ 2,383
Net loss per common share, basic   $ (0.11)
Net loss per common share, diluted   $ (0.11)
Weighted average common shares outstanding, basic   0
Weighted average common shares outstanding, diluted   0
XML 68 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Business Combination - Additional Information (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
Business Acquisition [Line Items]  
Business combination share issue ratio 0.570895
Vincera Pharma [Member]  
Business Acquisition [Line Items]  
Number of consecutive trading days 20 days
Number of trading days 30 days
Percentage of the earnout shares to be issued to the shareholders of the acquiree company 90.60%
Vincera Pharma [Member] | Volume Weighted Average Price One [Member]  
Business Acquisition [Line Items]  
Daily volume weighted average price per share | $ / shares $ 20
Base amount for determining daily volume weighted average price per share | $ $ 20.0
Vincera Pharma [Member] | Volume Weighted Average Price Two [Member]  
Business Acquisition [Line Items]  
Daily volume weighted average price per share | $ / shares $ 35
Base amount for determining daily volume weighted average price per share | $ $ 20.0
Vincera Pharma [Member] | Volume Weighted Average Price Three [Member]  
Business Acquisition [Line Items]  
Daily volume weighted average price per share | $ / shares $ 45
Base amount for determining daily volume weighted average price per share | $ $ 20.0
XML 69 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Bayer License Agreement - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 05, 2021
Dec. 31, 2023
Dec. 31, 2022
Bayer License Agreement [Line Items]      
Date of licence agreement with Bayer   Oct. 07, 2020  
Licence fee payable to Bayer   $ 1.0 $ 1.0
Licence fee paid to Bayer $ 5.0    
Aggregate milestone payments Payable to Bayer   1,000.0  
Maximum [Member]      
Bayer License Agreement [Line Items]      
Milestone payments payables per licenced product to Bayer   318.0  
Minimum [Member]      
Bayer License Agreement [Line Items]      
Milestone payments payables per licenced product to Bayer   $ 110.0  
XML 70 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Charges $ 0 $ 2,469
Workforce Reduction [Member]    
Restructuring Cost and Reserve [Line Items]    
Beginning balance $ 0 0
Charges   2,022
Cash payments   (2,022)
Ending balance   $ 0
XML 71 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Restructuring - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Percentage of employees reduction 33.00%    
Restructuring costs expected to be incurred through the year   $ 2,500  
Share-based Payment Arrangement, Expense   3,563 $ 10,056
Employee Stock Option [Member]      
Share-based Payment Arrangement, Expense   $ 500  
XML 72 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   $ 50,590
Cash Equivalents [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities $ 11,914  
Cash Equivalents [Member] | Money market funds [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 4,682 2,266
Cash Equivalents [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   4,496
Cash Equivalents [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 6,233  
Cash Equivalents [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 999  
Cash Equivalents [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   3,032
Short-term marketable securities [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   15,587
Short-term marketable securities [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   1,005
Short-term marketable securities [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   16,069
Short-term marketable securities [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   8,135
Level 1 [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   3,271
Level 1 [Member] | Cash Equivalents [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 10,915  
Level 1 [Member] | Cash Equivalents [Member] | Money market funds [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 4,682 2,266
Level 1 [Member] | Cash Equivalents [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 1 [Member] | Cash Equivalents [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 6,233  
Level 1 [Member] | Cash Equivalents [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0  
Level 1 [Member] | Cash Equivalents [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 1 [Member] | Short-term marketable securities [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 1 [Member] | Short-term marketable securities [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   1,005
Level 1 [Member] | Short-term marketable securities [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 1 [Member] | Short-term marketable securities [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 2 [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   47,319
Level 2 [Member] | Cash Equivalents [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 999  
Level 2 [Member] | Cash Equivalents [Member] | Money market funds [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0 0
Level 2 [Member] | Cash Equivalents [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   4,496
Level 2 [Member] | Cash Equivalents [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0  
Level 2 [Member] | Cash Equivalents [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 999  
Level 2 [Member] | Cash Equivalents [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   3,032
Level 2 [Member] | Short-term marketable securities [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   15,587
Level 2 [Member] | Short-term marketable securities [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 2 [Member] | Short-term marketable securities [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   16,069
Level 2 [Member] | Short-term marketable securities [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   8,135
Level 3 [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Cash Equivalents [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0  
Level 3 [Member] | Cash Equivalents [Member] | Money market funds [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0 0
Level 3 [Member] | Cash Equivalents [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Cash Equivalents [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities 0  
Level 3 [Member] | Cash Equivalents [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities $ 0  
Level 3 [Member] | Cash Equivalents [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Short-term marketable securities [Member] | Commercial paper [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Short-term marketable securities [Member] | U.S. government treasuries [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Short-term marketable securities [Member] | U.S. government agency securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   0
Level 3 [Member] | Short-term marketable securities [Member] | Corporate debt securities [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total cash equivalents and marketable securities   $ 0
XML 73 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring [Member] - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Liabilities:    
Liabilities fair value disclosure $ 191 $ 144
Level 1 [Member]    
Liabilities:    
Liabilities fair value disclosure 0 0
Level 2 [Member]    
Liabilities:    
Liabilities fair value disclosure 0 0
Level 3 [Member]    
Liabilities:    
Liabilities fair value disclosure 191 144
Common Stock Warrant Liabilities Restates [Member]    
Liabilities:    
Liabilities fair value disclosure 191 144
Common Stock Warrant Liabilities Restates [Member] | Level 1 [Member]    
Liabilities:    
Liabilities fair value disclosure 0 0
Common Stock Warrant Liabilities Restates [Member] | Level 2 [Member]    
Liabilities:    
Liabilities fair value disclosure 0 0
Common Stock Warrant Liabilities Restates [Member] | Level 3 [Member]    
Liabilities:    
Liabilities fair value disclosure $ 191 $ 144
XML 74 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Marketable Securities, Unrealized Gain (Loss) Marketable Securities, Unrealized Gain (Loss)
Level 3 [Member] | Warrant [Member]    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning balance $ 144 $ 6,447
Change in fair value 47 (6,303)
Ending balance $ 191 $ 144
XML 75 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details)
 12 Months Ended
Dec. 31, 2023
$ / shares
Dec. 31, 2022
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Exercise price $ 0.9 $ 3.3
Option term (years) 5 years 7 months 6 days 5 years 9 months 18 days
Volatility (annual) 89.50% 85.10%
Risk-free rate 4.00% 2.80%
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Dividend yield (per share) 0 0
Measurement Input, Share Price [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Stock price $ 1.18 $ 1.02
Measurement Input, Exercise Price [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Exercise price $ 11.5 $ 11.5
Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Option term (years) 2 years 3 years
Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Volatility (annual) 90.90% 73.70%
Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Risk-free rate 4.20% 4.10%
XML 76 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and marketable securities   $ 50,590
Marketable Securities [Member] | Debt Securities [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and marketable securities $ 0  
XML 77 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Available-For-Sale Securities - Summary of Available For Sale Securities (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Debt Securities, Available-for-Sale [Line Items]  
Amortized Cost $ 40,869
Gross Unrealized Gain 0
Gross Unrealized Loss (73)
Fair Value 40,796
Short-term marketable securities [Member] | Commercial paper [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Amortized Cost 15,608
Gross Unrealized Gain 0
Gross Unrealized Loss (21)
Fair Value 15,587
Short-term marketable securities [Member] | U.S. government treasuries [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Amortized Cost 1,007
Gross Unrealized Gain 0
Gross Unrealized Loss (2)
Fair Value 1,005
Short-term marketable securities [Member] | U.S. government agency securities [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Amortized Cost 16,105
Gross Unrealized Gain 0
Gross Unrealized Loss (36)
Fair Value 16,069
Short-term marketable securities [Member] | Corporate debt securities [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Amortized Cost 8,149
Gross Unrealized Gain 0
Gross Unrealized Loss (14)
Fair Value $ 8,135
XML 78 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Available-For Sale Securities - Additional Information (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Available-for-Sale Securities [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Marketable securities $ 0
XML 79 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Details [Abstract]    
Depreciation Expense $ 52,000 $ 54,000
XML 80 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details - Summary of Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Jan. 31, 2023
Dec. 31, 2022
Disclosure Of Balance Sheet Details [Line Items]      
Other current assets $ 784   $ 1,929
Other Current Assets [Member]      
Disclosure Of Balance Sheet Details [Line Items]      
Clinical related vendor prepayments 407   1,560
Payroll tax refund receivable 250 $ 0  
Other $ 127   $ 369
XML 81 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details - Summary Of Property Plant And Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 256 $ 256
Less: accumulated depreciation (131) (79)
Total property, plant and equipment, net 125 177
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 236 236
Property plant and equipment, useful life 5 years  
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 20 $ 20
Computer Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, useful life 5 years  
Computer Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, useful life 3 years  
XML 82 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheet Details - Summary Of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued payroll $ 332 $ 297
Accrued bonus 0 2,042
Accrued benefits 918 923
Accrued manufacturing, clinical trial and related 505 661
Total Accrued Liabilities $ 1,755 $ 3,923
XML 83 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Dec. 23, 2020
Jul. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]        
Duration of lease agreement 5 years      
Date of lease Commencement Jan. 01, 2021      
Annual lease rent $ 1,200   $ 1,196 $ 1,196
Operating lease liabilities     2,502  
Operating Right of Use Assets     2,201 3,064
Lessee Operating Sub Lease Term Of Contract   18 months    
Lessee, operating sub lease, rent amount   $ 50,000    
Sublease Income     600 $ 300
Other Noncurrent Liabilities [Member]        
Loss Contingencies [Line Items]        
Lease Deposit Liability     $ 50,000  
XML 84 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 23, 2020
Dec. 31, 2023
Dec. 31, 2022
Lease cost      
Operating lease cost   $ 1,196 $ 1,196
Variable lease cost   0 0
Total operating lease expense $ 1,200 1,196 1,196
Operating cash flows from operating leases   1,270 1,048
Right-of-use assets obtained in exchange for operating lease liabilities   $ 0 $ 0
Weighted-average remaining lease term—operating leases   2 years 2 years 10 months 24 days
Weighted-average discount rate—operating leases   8.00% 8.00%
XML 85 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Contractual Obligation, Fiscal Year Maturity [Abstract]  
Year ended December 31, 2024 $ 1,320
Year ended December 31, 2025 1,372
Year ended December 31, 2026 28
Total 2,720
Less present value discount (218)
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2022 $ 2,502
XML 86 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders' Equity - Schedule of Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Beginning balance, Shares 67,002 182,686
Vested, Shares (48,940) (115,684)
Ending balance, Shares 18,062 67,002
Beginning balance, Weighted Average $ 0.065 $ 0.045
Vested, Weighted Average 0 0
Ending balance, Weighted Average $ 0.103 $ 0.065
XML 87 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 2 Months Ended 12 Months Ended
May 31, 2020
Jul. 31, 2019
Aug. 31, 2019
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2023
Dec. 31, 2020
Class Of Stock [Line Items]                
Preferred stock shares authorized       30,000,000 30,000,000      
Preferred stock par value       $ 0.0001 $ 0.0001      
Preferred stock shares outstanding       0 0      
Common stock shares authorized       120,000,000 120,000,000      
Common stock par value       $ 0.0001 $ 0.0001      
Unrecognized stock based compensation       $ 700,000        
Amotization period of unrecognized stock based compensation       7 months 6 days        
No of Warrents outstanding       3,295,000 3,295,000     10,133,767
Common stock shares outstanding       21,407,510 21,242,884      
Employee Stock Purchase Plan [Member]                
Class Of Stock [Line Items]                
Stock issued during period shares employee stock purchase plans       161,668 183,366      
Stock issued during period value employee stock purchase plans       $ 112,000 $ 278,000      
Private Placement [Member]                
Class Of Stock [Line Items]                
Shares issued price per warrant       $ 11.5        
Public Warrant [Member]                
Class Of Stock [Line Items]                
No of Warrents outstanding         0 6,563,767    
Shares issued price per warrant             $ 11.5  
Class of warrant or right redemption threshold trading days       20 days        
Private Warrants [Member]                
Class Of Stock [Line Items]                
No of Warrents outstanding       3,295,000   3,570,000    
Common stock conversion       each private warrant is exercisable for one share of common stock at an exercise price of $11.50        
Shares issued price per warrant             $ 11.5  
Class of warrents exercised           275,000    
Class of warrant or right redemption threshold trading days       20 days        
Class of warrant or right redemption threshold consecutive trading days       30 days        
Warrant expiration term       5 years        
Proceeds from Issuance of Common Stock           $ 3,200,000    
ClassOfWarrantOrRightExercisedDuringThePeriod       0 0      
Private Warrants [Member] | Rosedale Park LLC [Member]                
Class Of Stock [Line Items]                
Class of warrents exercised       500,000     500,000  
Warrants expiration date       Mar. 05, 2025        
Private Warrants [Member] | LifeSci Holdings LLC [Member]                
Class Of Stock [Line Items]                
Class of warrents exercised       500,000     500,000  
Restricted Stock [Member]                
Class Of Stock [Line Items]                
Unrecognized stock based compensation       $ 1,600        
Amotization period of unrecognized stock based compensation       4 months 24 days        
Stock Issued During Period, Shares, Reverse Stock Splits   (826,510)            
Issuance of restricted stock, Shares     471,850          
Fair value of restricted stock     $ 6,000          
Stock issued for services 173,552              
Stock issued per share $ 0.07              
Restricted Stock [Member] | Vincera Pharma [Member]                
Class Of Stock [Line Items]                
Stock Issued During Period, Shares, Reverse Stock Splits (304,000)              
Common Stock [Member] | Private Warrants [Member]                
Class Of Stock [Line Items]                
Share redemption trigger price       $ 20     $ 20  
XML 88 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
 12 Months Ended
May 31, 2020
Dec. 31, 2023
Dec. 31, 2022
Jan. 31, 2023
May 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized stock based compensation   $ 700,000      
Amotization period of unrecognized stock based compensation   7 months 6 days      
Share-based Payment Arrangement, Expense   $ 3,563,000 $ 10,056,000    
Employee Stock Option [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Expense   $ 500,000      
Employee Stock Option [Member] | Maximum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period   3 years      
Employee Stock Option [Member] | Minimum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period   2 years      
Twenty Thousand Twenty Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares of common stock reserved for issuance       5,600,152  
Employee Stock Purchase Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares of common stock reserved for issuance   241,484     200,000
Employee stock purchase plan annual increase shares percentage   1.00%      
Employee stock purchase plan annual increase shares, shares         500,000
Share based compensation arrangement by share based payment award, discount from market price 15.00%        
Purchase price of common stock expressed as a percentage of its fair value 85.00%        
Stock issued during period shares employee stock purchase plans   161,668 183,366    
Share-based Payment Arrangement, Expense   $ 133,000 $ 278,000    
XML 89 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Outstanding, Stock Options 4,353 3,408    
Options granted, Stock Options 1,131,000 2,509,000    
Options exercised, Stock Options (3,000) (2,000)    
Options cancelled, Stock Options (262,000) (1,562,000)    
Outstanding, Stock Options 5,219 4,353 3,408  
Options vested and exercisable, Stock Options       3,628,000
Outstanding, Weighted Average Exercise Price $ 10.87 $ 18.74    
Options granted, Weighted Average Exercise Price 1.22 3.3    
Options exercised, Weighted Average Exercise Price 0.82 0.82    
Options cancelled, Weighted Average Exercise Price 11.74 15.89    
Outstanding, Weighted Average Exercise Price $ 8.74 $ 10.87 $ 18.74  
Options vested and exercisable, Weighted Average Exercise Price (in years)       $ 11.25
Outstanding, Outstanding, Weighted Average Remaining Contractual Life (in years) 8 years 1 month 6 days 8 years 7 months 6 days 10 years  
Outstanding, Outstanding, Weighted Average Remaining Contractual Life (in years) 8 years 1 month 6 days 8 years 7 months 6 days 10 years  
Options vested and exercisable, Weighted Average Remaining Contractual Life (in years) 7 years 9 months 18 days      
Outstanding, Aggregate Intrinsic Value $ 134      
Options vested and exercisable, Aggregate Intrinsic Value       $ 73
XML 90 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Payment Arrangement [Abstract]    
Exercise price $ 0.9 $ 3.3
Expected term (years) 5 years 7 months 6 days 5 years 9 months 18 days
Volatility (annual) 89.50% 85.10%
Risk-free rate 4.00% 2.80%
Dividend yield (per share) 0.00% 0.00%
XML 91 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 3,563 $ 10,056
Research and Development [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense 1,712 4,988
General and Administrative [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense 1,851 4,621
Restructuring [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 0 $ 447
XML 92 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Net loss $ (40,157) $ (62,984)
Denominator:    
Weighted Average Number of Shares Outstanding, Diluted 21,295 21,029
Earnings Per Share, Basic $ (1.89) $ (3)
Earnings Per Share, Diluted $ (1.89) $ (3)
XML 93 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 8,532 7,715
Option Outstanding [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,219 4,353
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,295 3,295
Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 18 67
XML 94 R64.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]    
United States $ (35,281) $ (58,708)
International (4,876) (4,276)
Total $ (40,157) $ (62,984)
XML 95 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Statutory federal income tax rate 21.00% 21.00%
State taxes, net of federal tax benefit 0.10% 0.70%
Change in fair value of warrant liabilities 0.00% 2.00%
Research and development 2.00% (0.70%)
Other 0.50% (0.10%)
Change in valuation allowance (23.60%) (22.90%)
Income taxes provision (benefit) 0.00% 0.00%
XML 96 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2023
Jan. 31, 2023
Dec. 31, 2022
Deferred tax assets:      
Net operating loss $ 15,475,000   $ 9,639,000
Stock-based compensation 5,235,000   5,025,000
Depreciation and amortization 0   4,198,000
Capitalized research and development 14,734,000   7,314,000
Research and development credit 2,231,000   1,635,000
Accruals and reserves 137,000   471,000
Lease liability 462,000   722,000
Total deferred income tax assets 38,274,000   29,004,000
Less: Valuation allowances (37,748,000)   (28,360,000)
Deferred tax assets, net of valuation allowances 526,000   644,000
Deferred tax liabilities:      
Right of use asset (526,000)   (644,000)
Total deferred income tax liabilities (526,000)   (644,000)
Net deferred taxes $ 0 $ 0 $ 0
XML 97 R67.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes - Schedule of Income Tax Contingencies (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Uncertainties [Abstract]    
Unrecognized Tax Benefits $ 979 $ 518
Unrecognized Tax Benefits, Increase Decrease Resulting From Prior Period Tax Positions 0 (164)
Unrecognized Tax Benefits, Increase Decrease Resulting From Current Period Tax Positions 259 625
Unrecognized Tax Benefits $ 1,238 $ 979
XML 98 R68.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jan. 31, 2023
Operating Loss Carryforwards [Line Items]        
Provision for income tax   $ 0 $ 0  
Current tax expense   0    
Deferred tax assets valuation allowance $ 0 0 0 $ 0
Increase in valuation allowance   $ 9,400,000 $ 12,900,000  
Tax credit carry forward expiration year   2039 days    
Minimum [Member]        
Operating Loss Carryforwards [Line Items]        
Open Tax Year 2019      
Maximum [Member]        
Operating Loss Carryforwards [Line Items]        
Open Tax Year 2023      
U.S. Federal [Member]        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward   $ 59,200,000    
State [Member]        
Operating Loss Carryforwards [Line Items]        
Operating loss carry forward expiration year   2039 days    
Net operating loss carryforward   $ 700,000    
Research [Member] | U.S. Federal [Member]        
Operating Loss Carryforwards [Line Items]        
Tax carry forward   2,600,000    
Research [Member] | State [Member]        
Operating Loss Carryforwards [Line Items]        
Tax carry forward   $ 1,100,000    
XML 99 R69.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements - Additional Information (Details)
 3 Months Ended
Dec. 31, 2023
Insider Trading Arrangements [Abstract]  
Rule 10b5-1 Arrangement Adopted [Flag] false
Non-Rule 10b5-1 Arrangement Adopted [Flag] false
Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 215 331 1 false 63 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://vincerx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Balance Sheets Sheet http://vincerx.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Cash Flows Sheet http://vincerx.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 999001 - Disclosure - Nature of Business Sheet http://vincerx.com/role/NatureOfBusiness Nature of Business Notes 9 false false R10.htm 999002 - Disclosure - Summary of Significant Accounting Policies Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 999003 - Disclosure - Business Combination Sheet http://vincerx.com/role/BusinessCombination Business Combination Notes 11 false false R12.htm 999004 - Disclosure - Bayer License Agreement Sheet http://vincerx.com/role/BayerLicenseAgreement Bayer License Agreement Notes 12 false false R13.htm 999005 - Disclosure - Restructuring Sheet http://vincerx.com/role/Restructuring Restructuring Notes 13 false false R14.htm 999006 - Disclosure - Fair Value Measurement Sheet http://vincerx.com/role/FairValueMeasurement Fair Value Measurement Notes 14 false false R15.htm 999007 - Disclosure - Available-For-Sale Securities Sheet http://vincerx.com/role/AvailableForSaleSecurities Available-For-Sale Securities Notes 15 false false R16.htm 999008 - Disclosure - Balance Sheet Details Sheet http://vincerx.com/role/BalanceSheetDetails Balance Sheet Details Notes 16 false false R17.htm 999009 - Disclosure - Commitments and Contingencies Sheet http://vincerx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 999010 - Disclosure - Stockholders' Equity Sheet http://vincerx.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 999011 - Disclosure - Stock-Based Compensation Sheet http://vincerx.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 999012 - Disclosure - Net Loss per Share Applicable to Common Stockholders Sheet http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholders Net Loss per Share Applicable to Common Stockholders Notes 20 false false R21.htm 999013 - Disclosure - Income Taxes Sheet http://vincerx.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 999014 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://vincerx.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 999015 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://vincerx.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 999016 - Disclosure - Restructuring (Tables) Sheet http://vincerx.com/role/RestructuringTables Restructuring (Tables) Tables http://vincerx.com/role/Restructuring 24 false false R25.htm 999017 - Disclosure - Fair Value Measurement (Tables) Sheet http://vincerx.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://vincerx.com/role/FairValueMeasurement 25 false false R26.htm 999018 - Disclosure - Available-For-Sale Securities (Tables) Sheet http://vincerx.com/role/AvailableForSaleSecuritiesTables Available-For-Sale Securities (Tables) Tables http://vincerx.com/role/AvailableForSaleSecurities 26 false false R27.htm 999019 - Disclosure - Balance Sheet Details (Tables) Sheet http://vincerx.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://vincerx.com/role/BalanceSheetDetails 27 false false R28.htm 999020 - Disclosure - Commitments and Contingencies (Tables) Sheet http://vincerx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://vincerx.com/role/CommitmentsAndContingencies 28 false false R29.htm 999021 - Disclosure - Stockholders' Equity (Tables) Sheet http://vincerx.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://vincerx.com/role/StockholdersEquity 29 false false R30.htm 999022 - Disclosure - Stock-Based Compensation (Tables) Sheet http://vincerx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://vincerx.com/role/StockBasedCompensation 30 false false R31.htm 999023 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) Sheet http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersTables Net Loss per Share Applicable to Common Stockholders (Tables) Tables http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholders 31 false false R32.htm 999024 - Disclosure - Income Taxes (Tables) Sheet http://vincerx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://vincerx.com/role/IncomeTaxes 32 false false R33.htm 999025 - Disclosure - Nature of Business - Additional Information (Details) Sheet http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails Nature of Business - Additional Information (Details) Details 33 false false R34.htm 999026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 34 false false R35.htm 999027 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details) Details 35 false false R36.htm 999028 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyParentheticalDetails Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details) Details 36 false false R37.htm 999029 - Disclosure - Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details) Sheet http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details) Details 37 false false R38.htm 999030 - Disclosure - Business Combination - Additional Information (Details) Sheet http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails Business Combination - Additional Information (Details) Details 38 false false R39.htm 999031 - Disclosure - Bayer License Agreement - Additional Information (Details) Sheet http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails Bayer License Agreement - Additional Information (Details) Details 39 false false R40.htm 999032 - Disclosure - Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details) Sheet http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details) Details 40 false false R41.htm 999033 - Disclosure - Restructuring - Additional Information (Details) Sheet http://vincerx.com/role/RestructuringAdditionalInformationDetails Restructuring - Additional Information (Details) Details 41 false false R42.htm 999034 - Disclosure - Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details) Sheet http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details) Details 42 false false R43.htm 999035 - Disclosure - Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details) Details 43 false false R44.htm 999036 - Disclosure - Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details) Sheet http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details) Details 44 false false R45.htm 999037 - Disclosure - Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details) Sheet http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details) Details 45 false false R46.htm 999038 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 46 false false R47.htm 999039 - Disclosure - Available-For-Sale Securities - Summary of Available For Sale Securities (Details) Sheet http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails Available-For-Sale Securities - Summary of Available For Sale Securities (Details) Details 47 false false R48.htm 999040 - Disclosure - Available-For Sale Securities - Additional Information (Details) Sheet http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails Available-For Sale Securities - Additional Information (Details) Details 48 false false R49.htm 999041 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://vincerx.com/role/BalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 49 false false R50.htm 999042 - Disclosure - Balance Sheet Details - Summary of Other Current Assets (Details) Sheet http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails Balance Sheet Details - Summary of Other Current Assets (Details) Details 50 false false R51.htm 999043 - Disclosure - Balance Sheet Details - Summary Of Property Plant And Equipment (Details) Sheet http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails Balance Sheet Details - Summary Of Property Plant And Equipment (Details) Details 51 false false R52.htm 999044 - Disclosure - Balance Sheet Details - Summary Of Accrued Expenses (Details) Sheet http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails Balance Sheet Details - Summary Of Accrued Expenses (Details) Details 52 false false R53.htm 999045 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 53 false false R54.htm 999046 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details) Sheet http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details) Details 54 false false R55.htm 999047 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) Sheet http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) Details 55 false false R56.htm 999048 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Activity (Details) Sheet http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails Stockholders' Equity - Schedule of Restricted Stock Activity (Details) Details 56 false false R57.htm 999049 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 57 false false R58.htm 999050 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 58 false false R59.htm 999051 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails Stock-Based Compensation - Schedule of Stock Option Activity (Details) Details 59 false false R60.htm 999052 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details) Sheet http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details) Details 60 false false R61.htm 999053 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details) Sheet http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details) Details 61 false false R62.htm 999054 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details) Sheet http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details) Details 62 false false R63.htm 999055 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details) Sheet http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details) Details 63 false false R64.htm 999056 - Disclosure - Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details) Sheet http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details) Details 64 false false R65.htm 999057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 65 false false R66.htm 999058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) Sheet http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails Income Taxes - Schedule of Deferred Tax Assets (Details) Details 66 false false R67.htm 999059 - Disclosure - Income Taxes - Schedule of Income Tax Contingencies (Details) Sheet http://vincerx.com/role/IncomeTaxesScheduleOfIncomeTaxContingenciesDetails Income Taxes - Schedule of Income Tax Contingencies (Details) Details 67 false false R68.htm 999060 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 68 false false R69.htm 999061 - Disclosure - Insider Trading Arrangements - Additional Information (Details) Sheet http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails Insider Trading Arrangements - Additional Information (Details) Details 69 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - d739497d10k.htm 9, 3832 d739497d10k.htm vinc-20231231.xsd vinc-20231231_cal.xml vinc-20231231_def.xml vinc-20231231_lab.xml vinc-20231231_pre.xml g739497g02c90.jpg g739497g18j79.jpg g739497g28l72.jpg g739497g44r00.jpg g739497g48u85.jpg g739497g58u95.jpg g739497g60m33.jpg g739497g61b65.jpg g739497g67a65.jpg g739497g74b32.jpg g739497g74z96.jpg g739497g78d87.jpg g739497g82i65.jpg g739497g93f68.jpg g739497g93n77.jpg g739497g98w03.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d739497d10k.htm": { "nsprefix": "vinc", "nsuri": "http://vincerx.com/20231231", "dts": { "inline": { "local": [ "d739497d10k.htm" ] }, "schema": { "local": [ "vinc-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "vinc-20231231_cal.xml" ] }, "definitionLink": { "local": [ "vinc-20231231_def.xml" ] }, "labelLink": { "local": [ "vinc-20231231_lab.xml" ] }, "presentationLink": { "local": [ "vinc-20231231_pre.xml" ] } }, "keyStandard": 278, "keyCustom": 53, "axisStandard": 24, "axisCustom": 1, "memberStandard": 42, "memberCustom": 16, "hidden": { "total": 8, "http://fasb.org/us-gaap/2023": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 215, "entityCount": 1, "segmentCount": 63, "elementCount": 622, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 647, "http://xbrl.sec.gov/dei/2023": 41, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://vincerx.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://vincerx.com/role/ConsolidatedBalanceSheets", "longName": "1002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesIssued", "us-gaap:PreferredStockSharesOutstanding", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R4": { "role": "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "PAsOn12_31_2021", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R6": { "role": "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows", "longName": "1006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "P10_01_2023To12_31_2023", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://vincerx.com/role/NatureOfBusiness", "longName": "999001 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999002 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://vincerx.com/role/BusinessCombination", "longName": "999003 - Disclosure - Business Combination", "shortName": "Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://vincerx.com/role/BayerLicenseAgreement", "longName": "999004 - Disclosure - Bayer License Agreement", "shortName": "Bayer License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:BayerLicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:BayerLicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://vincerx.com/role/Restructuring", "longName": "999005 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://vincerx.com/role/FairValueMeasurement", "longName": "999006 - Disclosure - Fair Value Measurement", "shortName": "Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://vincerx.com/role/AvailableForSaleSecurities", "longName": "999007 - Disclosure - Available-For-Sale Securities", "shortName": "Available-For-Sale Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://vincerx.com/role/BalanceSheetDetails", "longName": "999008 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://vincerx.com/role/CommitmentsAndContingencies", "longName": "999009 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://vincerx.com/role/StockholdersEquity", "longName": "999010 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://vincerx.com/role/StockBasedCompensation", "longName": "999011 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholders", "longName": "999012 - Disclosure - Net Loss per Share Applicable to Common Stockholders", "shortName": "Net Loss per Share Applicable to Common Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://vincerx.com/role/IncomeTaxes", "longName": "999013 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "999014 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "999015 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://vincerx.com/role/RestructuringTables", "longName": "999016 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://vincerx.com/role/FairValueMeasurementTables", "longName": "999017 - Disclosure - Fair Value Measurement (Tables)", "shortName": "Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://vincerx.com/role/AvailableForSaleSecuritiesTables", "longName": "999018 - Disclosure - Available-For-Sale Securities (Tables)", "shortName": "Available-For-Sale Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://vincerx.com/role/BalanceSheetDetailsTables", "longName": "999019 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://vincerx.com/role/CommitmentsAndContingenciesTables", "longName": "999020 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://vincerx.com/role/StockholdersEquityTables", "longName": "999021 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://vincerx.com/role/StockBasedCompensationTables", "longName": "999022 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersTables", "longName": "999023 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables)", "shortName": "Net Loss per Share Applicable to Common Stockholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://vincerx.com/role/IncomeTaxesTables", "longName": "999024 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails", "longName": "999025 - Disclosure - Nature of Business - Additional Information (Details)", "shortName": "Nature of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:NatureOfOperations", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:NatureOfOperations", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "999026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:ClassOfWarrantOrRightOutstanding", "div", "vinc:PrivateWarrantLiabilityPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "vinc:LiquidityAndGoingConcernPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R35": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails", "longName": "999027 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PreferredStockValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022_ScenarioPreviouslyReportedMembersrtRestatementAxis", "name": "us-gaap:PreferredStockValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "vinc:ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R36": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyParentheticalDetails", "longName": "999028 - Disclosure - Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Impact of Restatement on The Balance Sheet of The Company (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails", "longName": "999029 - Disclosure - Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details)", "shortName": "Summary of Significant Accounting Policies - Summary of Tabular Form of Impact of Restatement on The Income Statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OperatingExpenses", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2022To12_31_2022_ScenarioPreviouslyReportedMembersrtRestatementAxis", "name": "us-gaap:OperatingExpenses", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "vinc:DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R38": { "role": "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails", "longName": "999030 - Disclosure - Business Combination - Additional Information (Details)", "shortName": "Business Combination - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "vinc:BusinessCombinationShareIssueRatio", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "vinc:BusinessCombinationShareIssueRatio", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails", "longName": "999031 - Disclosure - Bayer License Agreement - Additional Information (Details)", "shortName": "Bayer License Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DateOfLicenceAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vinc:BayerLicenseAgreementTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "vinc:DateOfLicenceAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "vinc:BayerLicenseAgreementTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails", "longName": "999032 - Disclosure - Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details)", "shortName": "Restructuring - Schedule Of Accrued Restructuring and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis", "name": "us-gaap:RestructuringReserveCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R41": { "role": "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "longName": "999033 - Disclosure - Restructuring - Additional Information (Details)", "shortName": "Restructuring - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "P06_04_2022To06_04_2022", "name": "vinc:PercentageOfEmployeesReduction", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P06_04_2022To06_04_2022", "name": "vinc:PercentageOfEmployeesReduction", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "longName": "999034 - Disclosure - Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "shortName": "Fair Value Measurement - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_CashEquivalentsMemberusgaapFairValueByAssetClassAxis", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R43": { "role": "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "999035 - Disclosure - Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurement - Summary of Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "longName": "999036 - Disclosure - Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details)", "shortName": "Fair Value Measurement - Summary of Changes in Level 3 Warrant liabilities measured at fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantsMemberusgaapClassOfWarrantOrRightAxis", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_WarrantsMemberusgaapClassOfWarrantOrRightAxis", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R45": { "role": "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "longName": "999037 - Disclosure - Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details)", "shortName": "Fair Value Measurement - Summary of Fair Value Of Private Warrants was Re-measured Based on the Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R46": { "role": "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails", "longName": "999038 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_DebtSecuritiesMemberusgaapFairValueByAssetClassAxis_MarketableSecuritiesMemberusgaapFinancialInstrumentAxis", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R47": { "role": "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "longName": "999039 - Disclosure - Available-For-Sale Securities - Summary of Available For Sale Securities (Details)", "shortName": "Available-For-Sale Securities - Summary of Available For Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "longName": "999040 - Disclosure - Available-For Sale Securities - Additional Information (Details)", "shortName": "Available-For Sale Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "PAsOn12_31_2023_AvailableforsaleSecuritiesMemberusgaapFinancialInstrumentAxis", "name": "us-gaap:MarketableSecurities", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_AvailableforsaleSecuritiesMemberusgaapFinancialInstrumentAxis", "name": "us-gaap:MarketableSecurities", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "vinc:DisclosureOfAvailableForSaleSecuritiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://vincerx.com/role/BalanceSheetDetailsAdditionalInformationDetails", "longName": "999041 - Disclosure - Balance Sheet Details - Additional Information (Details)", "shortName": "Balance Sheet Details - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails", "longName": "999042 - Disclosure - Balance Sheet Details - Summary of Other Current Assets (Details)", "shortName": "Balance Sheet Details - Summary of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis", "name": "vinc:ClinicalRelatedVendorPrepayments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R51": { "role": "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "longName": "999043 - Disclosure - Balance Sheet Details - Summary Of Property Plant And Equipment (Details)", "shortName": "Balance Sheet Details - Summary Of Property Plant And Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "vinc:DisclosureOfBalanceSheetDetailsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails", "longName": "999044 - Disclosure - Balance Sheet Details - Summary Of Accrued Expenses (Details)", "shortName": "Balance Sheet Details - Summary Of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "longName": "999045 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "P12_23_2020To12_23_2020", "name": "vinc:DateOfLeaseAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P12_23_2020To12_23_2020", "name": "vinc:DateOfLeaseAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails", "longName": "999046 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details)", "shortName": "Commitments and Contingencies - Summary of Quantitative Information About the Company's Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails", "longName": "999047 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)", "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ContractualObligationDueInSecondYear", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ContractualObligationDueInSecondYear", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails", "longName": "999048 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Activity (Details)", "shortName": "Stockholders' Equity - Schedule of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "PAsOn12_31_2022_RestrictedStockMemberusgaapAwardTypeAxis", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021_RestrictedStockMemberusgaapAwardTypeAxis", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R57": { "role": "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "longName": "999049 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R58": { "role": "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "longName": "999050 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R59": { "role": "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails", "longName": "999051 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R60": { "role": "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails", "longName": "999052 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details)", "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R61": { "role": "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails", "longName": "999053 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details)", "shortName": "Stock-Based Compensation - Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R62": { "role": "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails", "longName": "999054 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details)", "shortName": "Net Loss per Share Applicable to Common Stockholders - Schedule of Earnings Per Share Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails", "longName": "999055 - Disclosure - Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details)", "shortName": "Net Loss per Share Applicable to Common Stockholders - Schedule of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R64": { "role": "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails", "longName": "999056 - Disclosure - Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details)", "shortName": "Income Taxes - Schedule of Income (Loss) before Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "999057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails", "longName": "999058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)", "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true, "unique": true } }, "R67": { "role": "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeTaxContingenciesDetails", "longName": "999059 - Disclosure - Income Taxes - Schedule of Income Tax Contingencies (Details)", "shortName": "Income Taxes - Schedule of Income Tax Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R68": { "role": "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "longName": "999060 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "unique": true } }, "R69": { "role": "http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails", "longName": "999061 - Disclosure - Insider Trading Arrangements - Additional Information (Details)", "shortName": "Insider Trading Arrangements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "P10_01_2023To12_31_2023", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d739497d10k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r665" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Net amortization of discounts on marketable securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r98" ] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonus", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued benefits", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 14.0 }, "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails", "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total Accrued Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25" ] }, "vinc_AccruedManufacturingClinicalTrialAndRelatedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "AccruedManufacturingClinicalTrialAndRelatedCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Manufacturing Clinical Trial And Related Current", "terseLabel": "Accrued manufacturing, clinical trial and related", "documentation": "Accrued manufacturing clinical trial and related current." } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Salaries, Current", "terseLabel": "Accrued payroll", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r644" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r44", "r143", "r514" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r31", "r32", "r87", "r149", "r510", "r528", "r532" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r14", "r32", "r403", "r406", "r452", "r523", "r524", "r781", "r782", "r783", "r792", "r793", "r794" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r718" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r82", "r665", "r881" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r361", "r362", "r363", "r543", "r792", "r793", "r794", "r860", "r882" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r724" ] }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForErrorCorrectionDomain", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Error Correction, Type [Domain]", "documentation": "Type of error correction." } } }, "auth_ref": [ "r179", "r180", "r181", "r185", "r186", "r187", "r188" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r61", "r62", "r327" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "vinc_AggregateMilestonePaymentsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "AggregateMilestonePaymentsPayable", "crdr": "credit", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Milestone Payments Payable", "terseLabel": "Aggregate milestone payments Payable to Bayer", "documentation": "Aggregate milestone payments payable." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r688", "r700", "r710", "r736" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r691", "r703", "r713", "r739" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r724" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r731" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r695", "r704", "r714", "r731", "r740", "r744", "r752" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r750" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r356", "r364" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r199" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r37" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r37" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r121", "r145", "r171", "r206", "r216", "r218", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r396", "r400", "r423", "r506", "r582", "r665", "r677", "r825", "r826", "r869" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r139", "r152", "r171", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r396", "r400", "r423", "r665", "r825", "r826", "r869" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "verboseLabel": "Total cash equivalents and marketable securities", "terseLabel": "Total cash equivalents and marketable securities", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r72" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r682", "r683", "r696" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r682", "r683", "r696" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r682", "r683", "r696" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r222", "r261", "r505" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Gross Unrealized Gain", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r803" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "negatedLabel": "Gross Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r804" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r223", "r261", "r500", "r798" ] }, "us-gaap_AvailableforsaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableforsaleSecuritiesMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-Sale Securities [Member]", "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r125" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r747" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r748" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r743" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r743" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r745" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r744" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r744" ] }, "vinc_BalanceSheetDetailsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BalanceSheetDetailsAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Details [Abstract]", "terseLabel": "Details Of Balance Sheet Details [Abstract]", "documentation": "Abstract." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails", "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails", "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r69", "r70" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Details Of Balance Sheet Details [Abstract]" } } }, "auth_ref": [] }, "vinc_BaseAmountForDeterminingDailyVolumeWeightedAveragePricePerShare": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BaseAmountForDeterminingDailyVolumeWeightedAveragePricePerShare", "crdr": "credit", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Base Amount For Determining Daily Volume Weighted Average Price Per Share", "terseLabel": "Base amount for determining daily volume weighted average price per share", "documentation": "Base amount for determining daily volume weighted average price per share." } } }, "auth_ref": [] }, "vinc_BasicAndDilutedEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BasicAndDilutedEarningsPerShareAbstract", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Basic And Diluted Earnings Per Share [Abstract]", "verboseLabel": "Denominator:", "documentation": "Basic and diluted earnings per share." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "vinc_BayerLicenseAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BayerLicenseAgreementAbstract", "lang": { "en-us": { "role": { "label": "Bayer License Agreement [Abstract]", "documentation": "Bayer license agreement." } } }, "auth_ref": [] }, "vinc_BayerLicenseAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BayerLicenseAgreementLineItems", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Bayer License Agreement [Line Items]", "documentation": "Bayer license agreement." } } }, "auth_ref": [] }, "vinc_BayerLicenseAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BayerLicenseAgreementTable", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Bayer License Agreement [Table]", "documentation": "Bayer license agreement." } } }, "auth_ref": [] }, "vinc_BayerLicenseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BayerLicenseAgreementTextBlock", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreement" ], "lang": { "en-us": { "role": { "label": "Bayer License Agreement [Text Block]", "terseLabel": "Bayer License Agreement", "documentation": "Bayer license agreement." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails", "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r392", "r658", "r659" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails", "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r67", "r68", "r392", "r658", "r659" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r392" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://vincerx.com/role/BusinessCombination" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r117", "r393" ] }, "vinc_BusinessCombinationShareIssueRatio": { "xbrltype": "pureItemType", "nsuri": "http://vincerx.com/20231231", "localname": "BusinessCombinationShareIssueRatio", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination Share Issue Ratio", "terseLabel": "Business combination share issue ratio", "documentation": "Business combination share issue ratio." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r34", "r141", "r642" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r35" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r35", "r120" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34", "r96", "r168" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r96" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r777", "r878" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r141" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal depository insurance coverage amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r722" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r171", "r193", "r194", "r196", "r198", "r204", "r205", "r251", "r288", "r290", "r291", "r292", "r295", "r296", "r300", "r301", "r304", "r307", "r314", "r423", "r536", "r537", "r538", "r539", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r570", "r591", "r609", "r632", "r633", "r634", "r635", "r636", "r760", "r787", "r796" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r147", "r148", "r204", "r300", "r301", "r302", "r304", "r307", "r312", "r314", "r536", "r537", "r538", "r539", "r654", "r760", "r787" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementTables", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementTables", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "vinc_ClassOfWarrantOrRightExcludesTheWarrantsPostBusinessCombinationToRemoveCashlessExerciseProvisionShares": { "xbrltype": "sharesItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ClassOfWarrantOrRightExcludesTheWarrantsPostBusinessCombinationToRemoveCashlessExerciseProvisionShares", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant Or Right Excludes The Warrants Post Business Combination To Remove Cashless Exercise Provision Shares", "documentation": "Class of warrant or right excludes the warrants post business combination to remove cashless exercise provision shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "definitionGuidance": "Class of warrants exercised", "terseLabel": "Class of warrents exercised", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "No of Warrants outstanding", "terseLabel": "No of Warrents outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "vinc_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right Redemption Threshold Consecutive Trading Days", "verboseLabel": "Class of warrant or right redemption threshold consecutive trading days", "terseLabel": "Class of warrant or right redemption threshold consecutive trading days", "documentation": "Class of Warrant or Right Redemption Threshold Consecutive Trading Days." } } }, "auth_ref": [] }, "vinc_ClassOfWarrantOrRightRedemptionThresholdTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ClassOfWarrantOrRightRedemptionThresholdTradingDays", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right Redemption Threshold Trading Days", "verboseLabel": "Class of warrant or right redemption threshold trading days", "terseLabel": "Class of warrant or right redemption threshold trading days", "documentation": "Class of Warrant or Right Redemption Threshold Trading Days." } } }, "auth_ref": [] }, "vinc_ClassOfWarrantOrRightUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ClassOfWarrantOrRightUnitsOutstanding", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Units Outstanding", "verboseLabel": "No of Warrants outstanding", "documentation": "Class of warrant or right units outstanding." } } }, "auth_ref": [] }, "vinc_Classofwarrantorrightexercisedduringtheperiod": { "xbrltype": "sharesItemType", "nsuri": "http://vincerx.com/20231231", "localname": "Classofwarrantorrightexercisedduringtheperiod", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "ClassOfWarrantOrRightExercisedDuringThePeriod", "terseLabel": "ClassOfWarrantOrRightExercisedDuringThePeriod", "documentation": "Class of warrant or right exercised during the period." } } }, "auth_ref": [] }, "vinc_ClinicalRelatedVendorPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ClinicalRelatedVendorPrepayments", "crdr": "debit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Clinical Related Vendor Prepayments", "terseLabel": "Clinical related vendor prepayments", "documentation": "Clinical related vendor prepayments." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r723" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r723" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r394" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "verboseLabel": "Commercial paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r105", "r671", "r672", "r673", "r674" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r28", "r76", "r507", "r569" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r104", "r280", "r281", "r638", "r822" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConversionBasis", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Conversion Basis", "terseLabel": "Common stock conversion", "documentation": "Description of basis for conversion of convertible common stock." } } }, "auth_ref": [ "r148" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r792", "r793", "r860", "r880", "r882" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r570" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r81", "r570", "r588", "r882", "r883" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value; 120,000,000 shares authorized; 21,407,510 shares and 21,242,884 shares issued and outstanding as of December 31, 2023 and 2022, respectively", "terseLabel": "Common stock - $ 0.0001 par value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r509", "r665" ] }, "vinc_CommonStockWarrantLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "CommonStockWarrantLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrant Liabilities Current", "verboseLabel": "Common stock warrant liabilities", "documentation": "Common stock warrant liabilities current." } } }, "auth_ref": [] }, "vinc_CommonStockWarrantLiabilitiesRestatesMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "CommonStockWarrantLiabilitiesRestatesMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrant Liabilities Restates [Member]", "terseLabel": "Common Stock Warrant Liabilities Restates [Member]", "documentation": "Common Stock Warrant Liabilities Restates [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r728" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r727" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r729" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r726" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "terseLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r33", "r154", "r156", "r161", "r501", "r520" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income or Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r79", "r129" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "totalLabel": "Total", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r790" ] }, "us-gaap_ContractualObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Four", "definitionGuidance": "Year ended December 31, 2026", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Two", "definitionGuidance": "Year ended December 31, 2024", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Three", "definitionGuidance": "Year ended December 31, 2025", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFiscalYearMaturityAbstract", "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r791" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r655", "r657", "r879" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "vinc_CurrentAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "CurrentAssetMember", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current asset [Member]", "terseLabel": "Current asset [Member]", "documentation": "Current asset." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current tax expense", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r116", "r382", "r386", "r789" ] }, "vinc_DailyVolumeWeightedAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DailyVolumeWeightedAveragePricePerShare", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Daily Volume Weighted Average Price Per Share", "terseLabel": "Daily volume weighted average price per share", "documentation": "Daily volume weighted average price per share." } } }, "auth_ref": [] }, "vinc_DateOfLeaseAgreement": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DateOfLeaseAgreement", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Date Of Lease Agreement", "terseLabel": "Duration of lease agreement", "documentation": "Date of lease agreement." } } }, "auth_ref": [] }, "vinc_DateOfLeaseCommencement": { "xbrltype": "dateItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DateOfLeaseCommencement", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Date of Lease Commencement", "terseLabel": "Date of lease Commencement", "documentation": "Date of lease commencement." } } }, "auth_ref": [] }, "vinc_DateOfLicenceAgreement": { "xbrltype": "dateItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DateOfLicenceAgreement", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Date of Licence Agreement", "terseLabel": "Date of licence agreement with Bayer", "documentation": "Date of licence agreement." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available For Sale Securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r42", "r669", "r884" ] }, "vinc_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Capitalized Research And Development", "terseLabel": "Capitalized research and development", "documentation": "Deferred tax assets capitalized research and development." } } }, "auth_ref": [] }, "vinc_DeferredTaxAssetsDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DeferredTaxAssetsDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "Deferred tax assets depreciation and amortization." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "vinc_DeferredTaxAssetsNetValuationAllowances", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred income tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r377" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "Research and development credit", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r66", "r858" ] }, "vinc_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Lease Liability", "terseLabel": "Lease liability", "documentation": "Deferred tax assets lease liability." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Net deferred taxes", "terseLabel": "Deferred tax assets valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r857" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "vinc_DeferredTaxAssetsNetValuationAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DeferredTaxAssetsNetValuationAllowances", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net Valuation Allowances", "totalLabel": "Deferred tax assets, net of valuation allowances", "documentation": "Deferred tax assets liabilities before valuation allowances." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r66", "r858" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax carry forward", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r65", "r66", "r858" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Stock-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r66", "r858" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r66", "r858" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "vinc_DeferredTaxAssetsNetValuationAllowances", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: Valuation allowances", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r378" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Total deferred income tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r63", "r857" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Right of use asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r66", "r858" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities", "verboseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation Expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r43" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r208" ] }, "vinc_DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Abstract]", "documentation": "Disclosure in tabular form of impact of restatement on the income statement." } } }, "auth_ref": [] }, "vinc_DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementLineItems", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Line Items]", "documentation": "Disclosure in tabular form of impact of restatement on the income statement." } } }, "auth_ref": [] }, "vinc_DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementTable", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Table]", "documentation": "Disclosure in tabular form of impact of restatement on the income statement." } } }, "auth_ref": [] }, "vinc_DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureInTabularFormOfImpactOfRestatementOnTheIncomeStatementTableTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Impact Of Restatement On The Income Statement [Table Text Block]", "terseLabel": "Summary of Tabular Form of Impact of Restatement on The Income Statement", "documentation": "Disclosure in tabular form of impact of restatement on the income statement" } } }, "auth_ref": [] }, "vinc_DisclosureOfAvailableForSaleSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureOfAvailableForSaleSecuritiesTextBlock", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecurities" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Available For Sale Securities [Text Block]", "terseLabel": "Available-For-Sale Securities", "documentation": "Disclosure of available for sale securities." } } }, "auth_ref": [] }, "vinc_DisclosureOfBalanceSheetDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureOfBalanceSheetDetailsLineItems", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Balance Sheet Details [Line Items]", "terseLabel": "Disclosure Of Balance Sheet Details [Line Items]", "documentation": "Disclosure of balance sheet details." } } }, "auth_ref": [] }, "vinc_DisclosureOfBalanceSheetDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureOfBalanceSheetDetailsTable", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Balance Sheet Details [Table]", "terseLabel": "Disclosure Of Balance Sheet Details [Table]", "documentation": "Disclosure of balance sheet details." } } }, "auth_ref": [] }, "vinc_DisclosureOfBalanceSheetDetailsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "DisclosureOfBalanceSheetDetailsTextBlock", "presentation": [ "http://vincerx.com/role/BalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure OF Balance Sheet Details [Text Block]", "terseLabel": "Balance Sheet Details", "documentation": "Disclosure of balance sheet details." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://vincerx.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r325", "r329", "r357", "r358", "r360", "r661" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://vincerx.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "verboseLabel": "Summary of Fair Value of the Company's warrant liabilities", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r10", "r56" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "terseLabel": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r682", "r683", "r696" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r682", "r683", "r696", "r732" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r682", "r683", "r696", "r732" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r717" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r680" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per common share, basic", "terseLabel": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r162", "r179", "r180", "r182", "r183", "r185", "r191", "r193", "r196", "r197", "r198", "r202", "r412", "r413", "r502", "r521", "r646" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per common share, diluted", "terseLabel": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r162", "r179", "r180", "r182", "r183", "r185", "r193", "r196", "r197", "r198", "r202", "r412", "r413", "r502", "r521", "r646" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Loss per Share of Common Stock", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r37", "r38" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholders" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share Applicable to Common Stockholders", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r190", "r199", "r200", "r201" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "verboseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r425" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Income taxes provision (benefit)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r370" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r173", "r370", "r388" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r856", "r859" ] }, "vinc_EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent": { "xbrltype": "percentItemType", "nsuri": "http://vincerx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Warrants Percent", "terseLabel": "Change in fair value of warrant liabilities", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable Change in fair value of warrant liabilities." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Research and development", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r856", "r859" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal tax benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r856", "r859" ] }, "vinc_EmergingGrowthCompanyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "EmergingGrowthCompanyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Emerging Growth Company Policy [Text Block]", "terseLabel": "Emerging Growth Company", "documentation": "Emerging growth company." } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Employee Benefits and Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock based compensation", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r359" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Amotization period of unrecognized stock based compensation", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r359" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Workforce Reduction [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Stock Option [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "vinc_EmployeeStockPurchasePlanAnnualIncreaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://vincerx.com/20231231", "localname": "EmployeeStockPurchasePlanAnnualIncreaseShares", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan Annual Increase Shares", "terseLabel": "Employee stock purchase plan annual increase shares, shares", "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase shares." } } }, "auth_ref": [] }, "vinc_EmployeeStockPurchasePlanAnnualIncreaseSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://vincerx.com/20231231", "localname": "EmployeeStockPurchasePlanAnnualIncreaseSharesPercentage", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan Annual Increase Shares Percentage", "terseLabel": "Employee stock purchase plan annual increase shares percentage", "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase percentage." } } }, "auth_ref": [] }, "vinc_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r679" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r679" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r759" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r679" ] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Incorporation date", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r757" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r679" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r679" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r679" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r679" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r758" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r136", "r158", "r159", "r160", "r174", "r175", "r176", "r178", "r186", "r188", "r203", "r252", "r255", "r315", "r361", "r362", "r363", "r383", "r384", "r402", "r403", "r404", "r405", "r406", "r407", "r411", "r426", "r427", "r428", "r429", "r430", "r431", "r452", "r523", "r524", "r525", "r543", "r609" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r725" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r688", "r700", "r710", "r736" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r685", "r697", "r707", "r733" ] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Error Correction, Type [Axis]", "documentation": "Information by type of error correction." } } }, "auth_ref": [ "r179", "r180", "r181", "r185", "r186", "r187", "r188" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r731" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 7.0 }, "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "verboseLabel": "Change in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r7" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementTables", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r415", "r416", "r421" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementTables", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r415", "r416", "r421" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://vincerx.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Assets Measured on Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r72", "r119" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r72", "r73" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r72", "r74", "r75" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r297", "r317", "r318", "r319", "r320", "r321", "r322", "r416", "r459", "r460", "r461", "r652", "r653", "r655", "r656", "r657" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "terseLabel": "Liability Class", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r73", "r118" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r415", "r416", "r418", "r419", "r422" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://vincerx.com/role/FairValueMeasurement" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurement", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r414" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r297", "r317", "r322", "r416", "r459", "r655", "r656", "r657" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r297", "r317", "r322", "r416", "r460", "r652", "r653", "r655", "r656", "r657" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r297", "r317", "r318", "r319", "r320", "r321", "r322", "r416", "r461", "r652", "r653", "r655", "r656", "r657" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://vincerx.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r72", "r119" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r297", "r317", "r318", "r319", "r320", "r321", "r322", "r459", "r460", "r461", "r652", "r653", "r655", "r656", "r657" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r414", "r422" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "negatedLabel": "Change in fair value", "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r420" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17", "r20" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://vincerx.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Level 3 Warrant liabilities measured at fair value", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17", "r20" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r20", "r72" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes unrealized gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r420" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value Measurement", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r11", "r22" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r298", "r312", "r408", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r519", "r651", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r811", "r812", "r813", "r814" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r424" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r692", "r704", "r714", "r740" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r692", "r704", "r714", "r740" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r692", "r704", "r714", "r740" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r692", "r704", "r714", "r740" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r692", "r704", "r714", "r740" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r92", "r593" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r90" ] }, "us-gaap_GovernmentAssistanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceAmount", "crdr": "credit", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Amount", "verboseLabel": "German grant income", "documentation": "Amount of government assistance recognized." } } }, "auth_ref": [ "r434" ] }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistancePolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Policy Text Block]", "terseLabel": "German Grant Income", "documentation": "Disclosure of accounting policy for government assistance." } } }, "auth_ref": [ "r433", "r435" ] }, "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance." } } }, "auth_ref": [ "r434" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Grants Receivable, Current", "terseLabel": "Grant receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r780" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r682", "r683", "r696" ] }, "vinc_ImpactOfRestatementOnTheBalanceSheetOfTheCompanyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ImpactOfRestatementOnTheBalanceSheetOfTheCompanyAbstract", "lang": { "en-us": { "role": { "label": "Impact Of Restatement On The Balance Sheet Of The Company [Abstract]", "documentation": "Impact of restatement on the balance sheet of the company." } } }, "auth_ref": [] }, "vinc_ImpactOfRestatementOnTheBalanceSheetOfTheCompanyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ImpactOfRestatementOnTheBalanceSheetOfTheCompanyLineItems", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Impact Of Restatement On The Balance Sheet Of The Company [Line Items]", "documentation": "Impact of restatement on the balance sheet of the company." } } }, "auth_ref": [] }, "vinc_ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTable": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTable", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Impact Of Restatement On The Balance Sheet Of The Company [Table]", "documentation": "Impact of restatement on the balance sheet of the company." } } }, "auth_ref": [] }, "vinc_ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ImpactOfRestatementOnTheBalanceSheetOfTheCompanyTableTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Impact Of Restatement On The Balance Sheet Of The Company [Table Text Block]", "terseLabel": "Summary of Impact of Restatement on The Balance Sheet of The Company", "documentation": "Impact of restatement on the balance sheet of the company." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r172", "r387" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Total", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r88", "r123", "r206", "r215", "r217", "r219", "r503", "r516", "r648" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r172", "r387" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r267", "r272", "r594" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r272", "r594" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://vincerx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r173", "r366", "r371", "r374", "r380", "r385", "r389", "r390", "r391", "r541" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r157", "r368", "r369", "r374", "r375", "r379", "r381", "r535" ] }, "us-gaap_IncomeTaxUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Uncertainties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows", "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes", "verboseLabel": "Provision for income tax", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r36" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "vinc_IncreaseDecreaseInGrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "IncreaseDecreaseInGrantsReceivable", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Grants Receivable", "negatedLabel": "Grant receivable", "documentation": "Increase decrease in grants receivable." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid and other current assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r6" ] }, "vinc_IncreaseDecreaseinLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "IncreaseDecreaseinLeaseLiabilities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase DecreaseIn Lease Liabilities", "verboseLabel": "Lease liabilities", "documentation": "Increase decrease in lease liabilities." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r695", "r704", "r714", "r731", "r740", "r744", "r752" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r750" ] }, "vinc_InsiderTradingArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "InsiderTradingArrangementsAbstract", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Abstract]", "documentation": "Insider trading arrangements." } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r684", "r756" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r684", "r756" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r684", "r756" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r163", "r166", "r167" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "verboseLabel": "Interest income", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r93", "r207" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r555", "r556", "r557", "r558", "r559", "r615", "r617", "r619", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r669" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r555", "r556", "r557", "r558", "r559", "r615", "r617", "r619", "r622", "r623", "r624", "r625", "r627", "r628", "r629", "r630", "r631", "r669" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "terseLabel": "Annual lease rent", "totalLabel": "Total operating lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r441", "r664" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "verboseLabel": "Summary of Quantitative Information About the Company's Operating Leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r865" ] }, "us-gaap_LeaseDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseDepositLiability", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease Deposit Liability", "terseLabel": "Lease Deposit Liability", "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease." } } }, "auth_ref": [ "r450" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r440" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r449" ] }, "vinc_LesseeOperatingSubLeaseRentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LesseeOperatingSubLeaseRentAmount", "crdr": "debit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Sub Lease Rent Amount", "terseLabel": "Lessee, operating sub lease, rent amount", "documentation": "Lessee operating sub lease rent amount." } } }, "auth_ref": [] }, "vinc_LesseeOperatingSubLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LesseeOperatingSubLeaseTermOfContract", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Sub Lease Term Of Contract", "terseLabel": "Lessee Operating Sub Lease Term Of Contract", "documentation": "Lessee operating sub lease term of contract." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r171", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r397", "r400", "r401", "r423", "r568", "r647", "r677", "r825", "r869", "r870" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r86", "r122", "r512", "r665", "r788", "r815", "r864" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r140", "r171", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r397", "r400", "r401", "r423", "r665", "r825", "r869", "r870" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities fair value disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r72" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "vinc_LicenceFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LicenceFeePaid", "crdr": "debit", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Licence Fee Paid", "terseLabel": "Licence fee paid to Bayer", "documentation": "Licence fee paid." } } }, "auth_ref": [] }, "vinc_LicenceFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LicenceFeePayable", "crdr": "credit", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Licence Fee Payable", "verboseLabel": "Licence fee payable to Bayer", "documentation": "License fee payable." } } }, "auth_ref": [] }, "vinc_LifesciHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LifesciHoldingsLlcMember", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "LifeSci Holdings LLC [Member]", "terseLabel": "LifeSci Holdings LLC [Member]", "documentation": "LifeSci holdings LLC." } } }, "auth_ref": [] }, "vinc_LiquidityAndGoingConcernPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "LiquidityAndGoingConcernPolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity And Going Concern Policy [Policy Text Block]", "terseLabel": "Liquidity and Going Concern", "documentation": "Liquidity and going concern." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r282", "r283", "r284", "r287", "r823", "r824" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r282", "r283", "r284", "r287", "r823", "r824" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r77", "r778" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r778" ] }, "vinc_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "MarketableSecuritiesMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Member]", "documentation": "Marketable securities member." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r78" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Net unrealized gain (loss) on marketable securities", "verboseLabel": "Unrealized gain (loss) on marketable securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r91" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails", "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r324", "r486", "r522", "r560", "r561", "r616", "r618", "r620", "r621", "r626", "r639", "r640", "r650", "r654", "r660", "r666", "r827", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r723" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r723" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r862" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r862" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r862" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r862" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r862" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r417" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "vinc_MilestonePaymentsPayablePerLicencedProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "MilestonePaymentsPayablePerLicencedProduct", "crdr": "credit", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Milestone Payments Payable Per Licenced Product", "terseLabel": "Milestone payments payables per licenced product to Bayer", "documentation": "Milestone payments payable per licenced product \n." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails", "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r324", "r486", "r522", "r560", "r561", "r616", "r618", "r620", "r621", "r626", "r639", "r640", "r650", "r654", "r660", "r666", "r827", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r743" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r828" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r751" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r724" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://vincerx.com/role/NatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r126", "r134" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r165" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r165" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r98", "r124", "r138", "r153", "r155", "r160", "r171", "r177", "r179", "r180", "r182", "r183", "r187", "r188", "r195", "r206", "r215", "r217", "r219", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r413", "r423", "r518", "r590", "r607", "r608", "r648", "r675", "r825" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r723" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r692", "r704", "r714", "r731", "r740" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r721" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r720" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r731" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r751" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r751" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://vincerx.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r21" ] }, "vinc_NumberOfConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "NumberOfConsecutiveTradingDays", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Consecutive Trading Days", "terseLabel": "Number of consecutive trading days", "documentation": "Number of consecutive trading days." } } }, "auth_ref": [] }, "vinc_NumberOfTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "NumberOfTradingDays", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Trading Days", "terseLabel": "Number of trading days", "documentation": "Number of trading days." } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OpenTaxYear", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Open Tax Year", "terseLabel": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r372" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "terseLabel": "Operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r206", "r215", "r217", "r219", "r648" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r442", "r664" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "definitionGuidance": "Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2022", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r439", "r445" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use assets, net", "definitionGuidance": "Operating Right of Use Assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r437" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r785" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted-average discount rate\u2014operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r448", "r664" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term\u2014operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r447", "r664" ] }, "vinc_OperatingLossCarryForwardExpirationYear": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "OperatingLossCarryForwardExpirationYear", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carry Forward Expiration Year", "terseLabel": "Operating loss carry forward expiration year", "documentation": "Operating Loss Carry Forward Expiration Year." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r65" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r64" ] }, "vinc_OptionOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "OptionOutstandingMember", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Option Outstanding [Member]", "terseLabel": "Option Outstanding [Member]", "documentation": "Option outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "vinc_Other": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "Other", "crdr": "debit", "calculation": { "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other", "terseLabel": "Other", "documentation": "Other." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 22.0 }, "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails", "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "totalLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r151", "r665" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r69", "r71" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "definitionGuidance": "Net foreign currency translation gain (loss)", "verboseLabel": "Cumulative translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r69", "r71" ] }, "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenseDisclosureNonoperatingAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Expense, Nonoperating [Abstract]", "verboseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r95" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r723" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r690", "r702", "r712", "r738" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r693", "r705", "r715", "r741" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r693", "r705", "r715", "r741" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r719" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r271", "r784" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r799" ] }, "vinc_PayrollTaxRefundReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PayrollTaxRefundReceivableCurrent", "crdr": "debit", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Payroll Tax Refund Receivable Current", "terseLabel": "Payroll tax refund receivable", "documentation": "Payroll tax refund receivable current." } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r722" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r722" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r721" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r731" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r724" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r720" ] }, "vinc_PercentageOfEmployeesReduction": { "xbrltype": "percentItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PercentageOfEmployeesReduction", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Of Employees Reduction", "terseLabel": "Percentage of employees reduction", "documentation": "Percentage of employees reduction." } } }, "auth_ref": [] }, "vinc_PercentageOfTheEarnoutSharesToBeIssuedToTheShareholdersOfTheAcquireeCompany": { "xbrltype": "percentItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PercentageOfTheEarnoutSharesToBeIssuedToTheShareholdersOfTheAcquireeCompany", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Of The Earnout Shares To Be Issued To The Shareholders Of The Acquiree Company", "terseLabel": "Percentage of the earnout shares to be issued to the shareholders of the acquiree company", "documentation": "Percentage of the earnout shares to be issued to the shareholders of the acquiree company." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r80", "r300" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r570" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r80", "r300" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r80", "r570", "r588", "r882", "r883" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "definitionGuidance": "Preferred stock, $0.0001 par value; 30,000,000 shares authorized, none issued and outstanding as of December 30, 2023 and 2022", "verboseLabel": "Preferred stock - $ 0.0001 par value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r508", "r665" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r150", "r265", "r266", "r643" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "vinc_PrivateWarrantLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PrivateWarrantLiabilityPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Private Warrant Liability [Policy Text Block]", "verboseLabel": "Private Warrant Liability", "documentation": "Private Warrant Liability." } } }, "auth_ref": [] }, "vinc_PrivateWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PrivateWarrantMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementTables", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Private Warrant [Member]", "verboseLabel": "Private Warrants [Member]", "terseLabel": "Private Warrants [Member]", "documentation": "Private warrant." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales and maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock from employee stock plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r138", "r153", "r155", "r164", "r171", "r177", "r187", "r188", "r206", "r215", "r217", "r219", "r251", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r395", "r398", "r399", "r413", "r423", "r503", "r517", "r542", "r590", "r607", "r608", "r648", "r662", "r663", "r676", "r783", "r825" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r101", "r142", "r515" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "verboseLabel": "Total property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r504", "r515", "r665" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r8", "r130", "r133", "r513" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary Of Property Plant And Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property plant and equipment, useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "vinc_PublicWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "PublicWarrantMember", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Public Warrant [Member]", "verboseLabel": "Public Warrant [Member]", "terseLabel": "Public Warrant [Member]", "documentation": "Public warrant." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r719" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r719" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails", "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r316", "r324", "r352", "r353", "r354", "r462", "r486", "r522", "r560", "r561", "r616", "r618", "r620", "r621", "r626", "r639", "r640", "r650", "r654", "r660", "r666", "r669", "r818", "r827", "r872", "r873", "r874", "r875", "r876" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails", "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails", "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r316", "r324", "r352", "r353", "r354", "r462", "r486", "r522", "r560", "r561", "r616", "r618", "r620", "r621", "r626", "r639", "r640", "r650", "r654", "r660", "r666", "r669", "r818", "r827", "r872", "r873", "r874", "r875", "r876" ] }, "vinc_ReclassificationOnAccountOfErrorsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ReclassificationOnAccountOfErrorsPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification On Account Of Errors [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Reclassification on account of errors." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r685", "r697", "r707", "r733" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "terseLabel": "Related Party", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r323", "r453", "r454", "r563", "r564", "r565", "r566", "r567", "r587", "r589", "r614" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "terseLabel": "Related Party", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r323", "r453", "r454", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r563", "r564", "r565", "r566", "r567", "r587", "r589", "r614", "r868" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r855" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r365" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r64" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "definitionGuidance": "Revision of Prior Period, Adjustment [Member]", "presentationGuidance": "Restatement Adjustment [Member]", "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r174", "r175", "r176", "r185", "r186", "r202", "r411", "r412", "r761", "r762", "r763", "r764", "r765", "r768", "r769" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r137", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r202", "r253", "r254", "r384", "r410", "r411", "r412", "r413", "r436", "r451", "r452", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r686", "r698", "r708", "r734" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r687", "r699", "r709", "r735" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r694", "r706", "r716", "r742" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r137", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r202", "r253", "r254", "r384", "r410", "r411", "r412", "r413", "r436", "r451", "r452", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r777", "r786" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]", "verboseLabel": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r37" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://vincerx.com/role/Restructuring" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r268", "r269", "r271", "r274", "r279" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring costs expected to be incurred through the year", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r270", "r273", "r276", "r278" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring", "verboseLabel": "Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r7", "r275", "r276", "r819" ] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringChargesMember", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Member]", "verboseLabel": "Restructuring [Member]", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r102", "r103" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r270", "r271", "r276", "r277" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r276", "r277", "r278" ] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r779", "r820", "r821" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r83", "r109", "r511", "r527", "r532", "r540", "r571", "r665" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r174", "r175", "r176", "r178", "r186", "r188", "r252", "r255", "r361", "r362", "r363", "r383", "r384", "r402", "r404", "r405", "r407", "r411", "r523", "r525", "r543", "r882" ] }, "vinc_RevisionOfPreviouslyReportedConsolidatedFinancialStatementsAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vincerx.com/20231231", "localname": "RevisionOfPreviouslyReportedConsolidatedFinancialStatementsAccountingPolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revision of Previously Reported Consolidated Financial Statements Accounting Policy [Policy Text Block]", "terseLabel": "Revision of Previously Reported Consolidated Financial Statements", "documentation": "Revision of previously reported consolidated financial statements accounting policy." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r446", "r664" ] }, "vinc_RosedaleParkLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "RosedaleParkLlcMember", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Rosedale Park LLC [Member]", "terseLabel": "Rosedale Park LLC [Member]", "documentation": "Rosedale park, LLC." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r751" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://vincerx.com/role/InsiderTradingArrangementsAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r751" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "verboseLabel": "Stock issued per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "presentationGuidance": "Scenario Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r137", "r174", "r176", "r177", "r178", "r179", "r180", "r188", "r202", "r384", "r410", "r411", "r412", "r436", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r765", "r766", "r767", "r768", "r795", "r816", "r817", "r861", "r866", "r867" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary Of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Potential Common Stock Outstanding that was excluded from the Computation of Diluted Net Loss Per Share of Common Stock", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r67", "r68", "r392" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://vincerx.com/role/NatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://vincerx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Net Deferred Tax Assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Earnings Per Share, Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r797" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://vincerx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r112" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://vincerx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://vincerx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income (Loss) before Provision for Income Taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r789" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Summary of Other Current Assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://vincerx.com/role/BalanceSheetDetailsSummaryOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Restructuring Type [Axis]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r276", "r277", "r278" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://vincerx.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Accrued Restructuring and Accrued Expenses", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r45", "r46" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails", "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://vincerx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r58" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://vincerx.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Valuation Model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r111" ] }, "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]", "terseLabel": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms", "documentation": "Represents settlement terms for the group of mandatorily redeemable securities, including the description and the details of all terms for each outstanding financial instrument and each settlement option." } } }, "auth_ref": [ "r9", "r15", "r47" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r107", "r108", "r109", "r146", "r147", "r148", "r204", "r300", "r301", "r302", "r304", "r307", "r312", "r314", "r536", "r537", "r538", "r539", "r654", "r760", "r787" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r678" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r681" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r209", "r210", "r211", "r212", "r213", "r214", "r220", "r649" ] }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date", "terseLabel": "Share based compensation arrangement by share based payment award, discount from market price", "documentation": "Discount rate from fair value on offering date that participants pay for shares." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r341", "r342" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted Average", "periodStartLabel": "Beginning balance, Weighted Average", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r341", "r342" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Shares", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted Average", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield (per share)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Volatility (annual)", "terseLabel": "Volatility (annual)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free rate", "terseLabel": "Risk-free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails", "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r326", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Options cancelled, Stock Options", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r340" ] }, "vinc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Intrinsic Value", "terseLabel": "Options vested and exercisable, Aggregate Intrinsic Value", "documentation": "Share based compensation arrangement by share based payment award options forfeitures in period total intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted, Stock Options", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r337" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, Stock Options", "periodStartLabel": "Outstanding, Stock Options", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r333", "r334" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Weighted Average Exercise Price", "periodStartLabel": "Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r333", "r334" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options vested and exercisable, Stock Options", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable, Weighted Average Exercise Price (in years)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://vincerx.com/role/RestructuringAdditionalInformationDetails", "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityScheduleOfRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Options exercised, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r338" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r337" ] }, "vinc_ShareBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ShareBasedPaymentsMember", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Payments [Member]", "terseLabel": "Share Based Payments [Member]", "documentation": "Share based payments." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "definitionGuidance": "Stock price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "vinc_ShareRedemptionTriggerPrice": { "xbrltype": "perShareItemType", "nsuri": "http://vincerx.com/20231231", "localname": "ShareRedemptionTriggerPrice", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Redemption Trigger Price", "verboseLabel": "Share redemption trigger price", "terseLabel": "Share redemption trigger price", "documentation": "Share redemption trigger price." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails", "http://vincerx.com/role/StockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsAndRestrictedStockAwardsUsingBlackScholesOptionValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Option term (years)", "terseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r351" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "definitionGuidance": "Outstanding, Outstanding, Weighted Average Remaining Contractual Life (in years)", "verboseLabel": "Outstanding, Outstanding, Weighted Average Remaining Contractual Life (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r110" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and exercisable, Weighted Average Remaining Contractual Life (in years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r350" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Fair value of restricted stock", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock expressed as a percentage of its fair value", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued price per warrant", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]", "terseLabel": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument", "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur." } } }, "auth_ref": [ "r9", "r15" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "terseLabel": "Short-term marketable securities [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r629", "r630", "r631", "r641" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r99", "r169" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r135", "r146", "r147", "r148", "r171", "r193", "r194", "r196", "r198", "r204", "r205", "r251", "r288", "r290", "r291", "r292", "r295", "r296", "r300", "r301", "r304", "r307", "r314", "r423", "r536", "r537", "r538", "r539", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r570", "r591", "r609", "r632", "r633", "r634", "r635", "r636", "r760", "r787", "r796" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r30", "r136", "r158", "r159", "r160", "r174", "r175", "r176", "r178", "r186", "r188", "r203", "r252", "r255", "r315", "r361", "r362", "r363", "r383", "r384", "r402", "r403", "r404", "r405", "r406", "r407", "r411", "r426", "r427", "r428", "r429", "r430", "r431", "r452", "r523", "r524", "r525", "r543", "r609" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/RestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r174", "r175", "r176", "r203", "r487", "r534", "r554", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r587", "r589", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r670" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement Of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/RestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r174", "r175", "r176", "r203", "r487", "r534", "r554", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r587", "r589", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r670" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r689", "r701", "r711", "r737" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock issued during period shares employee stock purchase plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r16", "r80", "r81", "r109" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, Shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r16", "r80", "r81", "r109" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "negatedLabel": "Stock Issued During Period, Shares, Reverse Stock Splits", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r16" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock from employee stock plans, Shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r16", "r80", "r81", "r109" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://vincerx.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised, Stock Options", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r80", "r81", "r109", "r338" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Stock issued during period value employee stock purchase plans", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r16", "r80", "r81", "r109" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock from employee stock plans", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r59", "r80", "r81", "r109" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://vincerx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets", "http://vincerx.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfImpactOfRestatementOnTheBalanceSheetOfTheCompanyDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r84", "r85", "r100", "r572", "r588", "r610", "r611", "r665", "r677", "r788", "r815", "r864", "r882" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://vincerx.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r106", "r170", "r299", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r315", "r409", "r612", "r613", "r637" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sublease Income", "terseLabel": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r444", "r664" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r432", "r455" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://vincerx.com/role/BayerLicenseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r432", "r455" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://vincerx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Schedule of Income Tax Contingencies", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r13", "r114", "r115" ] }, "vinc_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "vinc_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r730" ] }, "vinc_TaxCreditCarryForwardExpirationYear": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "TaxCreditCarryForwardExpirationYear", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carry Forward Expiration Year", "terseLabel": "Tax credit carry forward expiration year", "documentation": "Tax credit carry forward expiration year." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r64" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r722" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r729" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r750" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r752" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vincerx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails", "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r298", "r312", "r408", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r519", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r811", "r812", "r813", "r814" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r753" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r754" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r752" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r752" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r755" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r753" ] }, "vinc_TwentyThousandTwentyPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "TwentyThousandTwentyPlanMember", "presentation": [ "http://vincerx.com/role/StockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Twenty Thousand Twenty Plan [Member]", "terseLabel": "Twenty Thousand Twenty Plan [Member]", "documentation": "Twenty thousand twenty plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://vincerx.com/role/RestructuringScheduleOfAccruedRestructuringAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r270", "r271", "r276", "r277" ] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. government agency securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r877" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://vincerx.com/role/AvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails", "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. government treasuries [Member]", "verboseLabel": "U.S. government treasuries [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r645", "r655", "r657", "r877" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r749" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r367", "r373" ] }, "vinc_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Decrease Resulting From Current Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increase Decrease Resulting From Current Period Tax Positions", "documentation": "Unrecognized tax benefits, increase decrease resulting from current period tax positions." } } }, "auth_ref": [] }, "vinc_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://vincerx.com/20231231", "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://vincerx.com/role/IncomeTaxesScheduleOfIncomeTaxContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Decrease Resulting From Prior Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increase Decrease Resulting From Prior Period Tax Positions", "documentation": "Unrecognized tax benefits, increase decrease resulting from prior period tax positions." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r39", "r40", "r41", "r127", "r128", "r131", "r132" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://vincerx.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r376" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vincerx.com/role/CommitmentsAndContingenciesSummaryOfQuantitativeInformationAboutTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "verboseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r443", "r664" ] }, "vinc_VinceraPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VinceraPharmaMember", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails", "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vincera Pharma [Member]", "terseLabel": "Vincera Pharma [Member]", "documentation": "Vincera pharma." } } }, "auth_ref": [] }, "vinc_VolumeWeightedAveragePriceAxis": { "xbrltype": "stringItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VolumeWeightedAveragePriceAxis", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Volume Weighted Average Price [Axis]", "documentation": "Volume weighted average price." } } }, "auth_ref": [] }, "vinc_VolumeWeightedAveragePriceDomain": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VolumeWeightedAveragePriceDomain", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Volume Weighted Average Price [Domain]", "documentation": "Volume weighted average price." } } }, "auth_ref": [] }, "vinc_VolumeWeightedAveragePriceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VolumeWeightedAveragePriceOneMember", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Volume Weighted Average Price One [Member]", "terseLabel": "Volume Weighted Average Price One [Member]", "documentation": "Volume weighted average price one." } } }, "auth_ref": [] }, "vinc_VolumeWeightedAveragePriceThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VolumeWeightedAveragePriceThreeMember", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Volume Weighted Average Price Three [Member]", "terseLabel": "Volume Weighted Average Price Three [Member]", "documentation": "Volume weighted average price three." } } }, "auth_ref": [] }, "vinc_VolumeWeightedAveragePriceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "VolumeWeightedAveragePriceTwoMember", "presentation": [ "http://vincerx.com/role/BusinessCombinationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Volume Weighted Average Price Two [Member]", "terseLabel": "Volume Weighted Average Price Two [Member]", "documentation": "Volume weighted average price two." } } }, "auth_ref": [] }, "vinc_WarrantExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://vincerx.com/20231231", "localname": "WarrantExpirationTerm", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Expiration Term", "terseLabel": "Warrant expiration term", "documentation": "Warrant expiration term." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfPotentialCommonStockOutstandingThatWasExcludedFromTheComputationOfDilutedNetLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r667", "r668", "r671", "r672", "r673", "r674" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfFairValueOfPrivateWarrantsWasReMeasuredBasedOnTheAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "verboseLabel": "Dividend yield (per share)", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r419" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrant expiration term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r863" ] }, "vinc_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vincerx.com/20231231", "localname": "WarrantsMember", "presentation": [ "http://vincerx.com/role/FairValueMeasurementSummaryOfChangesInLevel3WarrantLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "verboseLabel": "Warrant [Member]", "documentation": "Warrants [Member]." } } }, "auth_ref": [] }, "vinc_WarrentsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://vincerx.com/20231231", "localname": "WarrentsExpirationDate", "presentation": [ "http://vincerx.com/role/StockholdersEquityAdditionalInformationDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrents Expiration Date", "verboseLabel": "Warrents expiration date", "terseLabel": "Warrants expiration date", "documentation": "Warrents Expiration Date." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/NetLossPerShareApplicableToCommonStockholdersScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted average common shares outstanding, diluted", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r192", "r198" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://vincerx.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://vincerx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTabularFormOfImpactOfRestatementOnTheIncomeStatementDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r191", "r198" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "45", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481679/480-10-45-2A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r760": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" } } } ZIP 108 0001193125-24-081994-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-081994-xbrl.zip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�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ˈ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

X\'5%RC+/K ]'ZPZ6YU[53SXLK8RZ6E3S-Q]L7!0<6W9NO1MGP<.<=T_U"K M*],L%51?CM1M:T,CN^U24GOB3-.IZ9;*KB_'=C.:71APE[#W+RQ:4RL.EDM? MSC]63-8QY#"L?GNA4/> M8$_#6YSKK(SS+7Z><=47-Q/@@TP7T&TO4^[_E>3.K[:X:%GM0=NE(),[OW1\DW9?)<1''\'RB>[([]512" MT91E6[PAUYQYA"5W'^5&]WP==(,&-C@=].6A2;]'AGNAMQ'HL!^9ND;31RI$ MM#SR_Q'D3\LJ$YK(;)2\O!$)EW,6IJ/[BWAM;F59:N6J<\^R^\-D\A45;^DD MC=/9PN ^OX.O$W>/\P%0+C$OHES@6>'@%/BJI$M%:,]5<5.>WCH&.+^).3CK MBS'!&;DUKERH%!Q=[?=$*9K>MAR< 9^[]835NFVAN!Q=R0-$<%[O:NAVTB!& MNZP*WN<=G1\=],6ZTO+PUTO!T15]/W1"._KEE;A$@,T1>K[,>=[&Y>AN'9YI MNN_")YD0Z2.Y:ZIRZ0![:9FP9\:[')^CFW9X]F\^24#SO*8""&HS&0V KU'= MZ8 2HJ-;_3ZHP3L*"S0A:6EJ:,%V92XAX&V!2R60(_3V%GL;)-7PW],8T\2L MD99J(*S/Y01L?G"G"1J0CNY]X97A*]I I^&M?)31TI?WY%UI>+NB M=)6[#NR1F^-9@,EH;2PD1J'NIG/1URE5T"]@/9[7E3)UE4QO/]1?9!'M2OE% MWV8T ;\I]E;UE1)M,6%@-XJ_=.#&XJ:.7OFH+/(B2"8T6O^FI5^APS;-<.O. M7V@JKB<=B3^E]:5)3Y)1YL/))&)@[I)IFLWIA_8C/M_Q*AZ//Q;"#G--]B9: MC92[]LQ\%1%XGFMRF8'W+L&2*^F:J;GZ%-<8'^_#-KS"JT1Y5.B]]95_P0M9 MCGM(A/:,LH\HQ (9305@<^)2D(O_I+WO=/D9+''HO:]*%<3:XUX 4#[[DN!( M7X/L.U[[\2!Z)N.*#SU5H"1Y#6I3/X,V:;FG;%,UC(7@K2=^Q66 SLR6J8PW MZU!YG!_LP263?JG1R\!;G_TM =;.E;H6C+FSC>-/O(<]R828">+ICN9^9V7DLG! M+N^*M YS<^E-F&IW'(N5R4 .;:6B;-N6._P(HI@,IMLT>PZJYXY57!AYD>[- MN_*^&!AY]949GR>G@-N+[4[J#+D&M3DJX .TC?1-MA$:J-X&,7%_3#XY 9ZH MK8BKB4GD%-ITWSK?,A<6O5S\3HKB[CZ1"03XS.IB!=/A\]:(Z^.M(9,ZM+%6 MIQ(=W!ZN!.&M>?8JG<_)NX0@?@S>4:9=E(3EN1R 7X:TPZQ8BS1B\#VOR[?G MEXPNYPL+T[V\$A<,<-RO+O7#1!:.3** 2O(EQ1]/B%BNTNP]S8)E(-;A#&&Y MH=Q*>ZQ;XZ+<)]\&K5HU$%);5M:N%BH&%UE>*"KK<>$ 6WBZ7;B,Q.$J*@W4 ML\3P#4W*&*GL[R:7AU;M<.D!FV\<'+9JHO8W%,TVS"T9SM.L(%D.KM*\H"8- MBVL275-,?&? 7K\U&9=<^-46@:O0-%"WQ$K@7[(TSS=39M36(T%;7(K -L$. M%4DI U<1;GS0)$W^-.NVN!2!C89PFK0I@\:19Z SF*D\$*I2J'7WO]D$EQJP M8;!5S=%#=Q6[ID?>+#UYGMB)_\I9MTF#.O)?.0.VO=E(OZ'_RID\)U__3R(M M^*^< =O'K(BKY;]R)C5N_>V_TKW_REE?'%OER@+AOW(FM:IYX+_BUB'A%#K+ MN(LI28?/VY>&OCHDG()G\]:I1$<.":?RQ-L>^,.L1B,^:.2!T1-HTZI<.OMV M#4WYUIQ>M1+QUH$%\*KG'-AJ[V 9JXG:VU>'HA@!"J40%>=CQC\CU[DTHH8: M9EM/]]JV9UT&,8GX_/R&2&9S:JQR8\B2A.T0?4]NE])5H?(_7AW>N[)&8?F' M[""C-#NMB_%^ AWZS*4HLRJ)D+05C0I XUMWZ:"J0KLP^:UR7=Q7XUM96K)MCJ098O\.] M5?'=DR\0MM3F$%D5+A*@N]8:S(FG43T\1_;9'C&NM7#(*W&Q &\A]:29D[V- MRY&E$XCNW;52:WN05>$B 39XFE F)EN/"_2I7;UE6V4/L*K/I0!D>&P\?=?$ MZLBVZ)3Q*UPD"H.8;U]^Q[OF-'O,T#L+82YE6E>/HP:Z0ZU)D(!EK45N9FCQQLP,WXM@#HRWCDEF"XS M,A+I'SEZ2#N#$Z*VP/@=%XN"8=L"^4"4%^9B 'HQX813$W"N'EZE11#WQ9ST MF*7O*"L6C[A(,4PF-_\NHW>RDG1O59)VQ<"@I*W+/90K76Q=!*<#+!;DOUABB#&IS&0$?6>T9%6N&%6!OO0CE M,L(?U5JJ#&IS&0&[V%B1::D/(JS^.NR561(5>%>#$=Y&G^0GO0U+7HE+!-B3 MV(HZ,?LF$+WUW",9W4I\$EC)Q22:BZ@&E<4Q=!HR!W1K\?7+32[/B@K/^%]K MCO$_QD\D1Y]D?=_X.\9W?'C8G[>@]59P":1^>:J94"8=AELE.$8@6Y1$W!). MMGO<+X\P#2M?@\]H7LZ5O&R4X3B!+NRD0M_E1M)K1U:FCMB)$CT[U3(<)]"! MQ88=<:\=V8=Z=.I07;"95^;+]+X?1 5X787?Z9%*T$?V==2!5N2B 7;=MZ'0 M4@FV4'H<2R<,RWG)?,@JSI7XYQA1NI()#P%#?R\5B$)57'V"BQOXO6)SI7(O MC\:!>*"#7D@Q/J!:UP&X&I/. /A0U>(4M('150 =L.B44IC?/[,2C2Y^7Q'20Z1F.<"[6/F)&)^QI+,(&3@$B"OPO@,[QQH)5[H<*V'Y[?S.T5VF"<9A M3O)F>2X,Z+FS,<?N(*N-_ N^<:8A8/.A5 O_?1 MS^5K'DTB? E01M&T^D=;! @"=6%5%B:C5@_-Y"5R ]!'/\(XWZ M@Y7=Y.&HOC(6$; GGH8]">6&P/Q^/Q]=Q:0=_+N%L0B '2]MZ=*37D4&^IRT=\$@3@?>C68]'M WI;V, M_G Z ![3>M+,R=[&!?K"U,VCQHCZ3T*GO3M);PE>8*)68H%-Y:=GBJ;2Q=.1(5G5X@QCW_9+5GP)X;CR_H.:/1FP M7&6(795AH/LV/2HYE&/P/('=Z!V1A++)C");KNX+U89'7(/%/C@&MD+78U4+ MR?/<EXM71: G/E^C9!TRBA=VI?RFA"-N(. MUM-[A#N+5DB>RU<*Y@5E\]&4B$05A=BH,M_: V<%K+'86J)K+7U;"_0^88D- MYVDIWSAI*W+@7LW4ML@DE/IB?L+08@+M+@G3N3+FRT9!CM_+*5F&1,*D+Y8E MJJ'7Z#W-H\)D=R4LSZ4!?/_78,6?P88^R-C2)^B_*_>6;;]_B%GU41XP7UV!BZ._MW&:55.'RI%3 M"]C8W#)LCU[QP3)!D[ODYC-\(_&+;M/,_@*H0:M!WYWO13:8BU M@MCOGX("/:(L5+\WM&V*"Q$HY4#+2J/$Z\H/2* U?3"OWI8DF"^/L+>QA$.8 M4-FM8AG$H]Z2 M9Q2FR83TTQ;A5G4&"_B<5Y<*\3BV@NW(W-K,\Z!%17EYB[+Z>K*JS>0%? #I M2DUV43LRUO962V[3,BO>:JO)NCJ3&/"YHRL]$:C^EDSX_I?$<@MQ4:EO5*/V^.7I7JTS#071U&X-'2[4 MM>/S7JTM6JB.S-_2]:3MXR4-2/"6QKC;.8E^62S6,;^?$)91%&*M9!$.PB+Z MP 6Z/U.RCAD<&3<+8FZ/CTZ[]:M92^_Y#>OK)=::"7%O0DG.1T)&S*/T<'ZY M6)?A!_;ACR";F.>W:_@-*B#H5"D2SL3CT3UTOR/I,$#ZU'<;Y1AV8!5WT*+: M@F ;U;L$C]>2TD$C@KR\! 3)R.O!C94G"3[.E94U"MAZ5WW?M6[BT ME^7"\E@0P$_U#'@2$ZS X_>M-7E8E29F-]8[9<='Y\ QCQ2\B(F48/#[AKFV M_]/Q(702J7KSK1C(GM_(^N'.='P(O$43ZT:W[DQ4"'ZGO''FSG1\"+VG:Y-D M2WPM7'C#B/Y6L=^+DF62H\GF?#N2SS*"%O)D-\6LVI!5F7'U)<8WQ^=G@. M'06CYFJI@^0J<4[WD69%R,B/&=*?PK1UF7R 3^DZ[LP9%V-SE4_'FGO)1/P[ MO0H*'O&A8!ZHYV%!408+^!1L+GS!9*P"Y2H)3K-QFJ/PUUGZ\=L$16R(XA_6 M(Q/_8WR/9D%\0^+MRQ)M"TK1%0?E81K:_-*]R>$"B1B0AY-7_ A-P]"ZCZDO:C15N8B M@G["J6=00KT%0(D7A;7=IGL=X :.QSA@J7ZU%RKB"EP4T%ADQ#M M08*AY4619AJO%J.P3PZA7^;5F[G%0"3\>6#.,;Y!W[H19-"!K:]B,M3$;?=? M0AV8->9F_AZG"X2H5CZ66?A&0COCSJLWOYIJ'"_PHBGC0+ 7-L8CX:]C"TV# M&T>*\-X@^(6P_!C^I7^C^V01&@FEOK@V/2X[2;%17XM\6!9O:1;]B50OX]45 MQT?G_;A,%E$FV_;H 4G(]L5Q:!/B8Y"-,NIV.Z%/0QY11E$;DRYK8 P>R: A M^6I@$B7PQ4E(I.>CLLB+("&6',LA7ZF)I0.=!<#%F-]!).';%T-6Q:W:8GI7 MU,)2 39D6?.L12/AN"/_()<B%*_V?R%1(BO_IVD3'Q(BW^AX@F%Z2S1S ZM?9-Y^OFV>VA?'!(= M]<7-JC4!L5 "MVG&?T7*J=+8==L11I]OFR(@&4E4W)=GF$+G2K-]M:XJ<[;T M;OTU124AWL-GFE=D4&0Y!H+'B_K5A;02%8O/&VP9'@G-OCSD9.>&NSPO\426 MX7G18&,MK<.$ OSBVIID/1P)Q_[D2!=.6BR>'I84"DEJE@CE5T$N61P? $YJ@.>W82Q;-9BBCPT-V_:6H M0K">'/AR_C%&(V$.UF5/J)@5(+AR3F(,O60!V:]'Z/ MHT(=,\NJ)?94QY?EO2E(B9:8&RVAPZ_O7!L9VG,4U<9'Y] );1M?GNW D1#= MD>E.,7/CY6@]@[V@;*Z:N'<*C\$#:MM/VA(0$H9\L;%I9J#-+*#$(/V BM'T M-LVF*"I*7*;^%*YOFYY/CWQ9WMW#ENB65X:]5WU4WM?M$$0;4:T;1V!NOP>, M,%]F-"CA2+39%W].Y;!FO\=CF%_MU9X6=QIBXO/MBJHF1HF*^.(%6GDA9'R1 M(:G"1.+;AE:+1D*PM;D2[!I#J=C2UPJUIP-YB^SIPX%W-UU-T4HTR!>?40E^ MNE)*X=MKC[H])LV!=QN69E@EFN.+)^ICEH8(3?);+$@BA" )\5Q;,2$H_-L, EB9/<_B-JU0U).OW!+ MIEM%M]"?*P@AOMR=4OXLW]"[+ MHVG?");%R<4)=!K &A<@]@ E9#=WZNPD_#@K-ME?/7:TLF-H56Q^)[.I$[*!(N]-Q(8V.)7L,T1"\#NY3=V(#Q1] MGP(^+.E0,[?5>]#\-9(=X9!,V+_T$1_4M1C@?L5[6'(@V.X9 M@@%-7--YP([S,^@7@N8$&L-QE+:F^W =-=,.G1V>]R=(77<+IU@*CI+$ ,2T MVX=T182$?J4KXFJAN*9L2PB.LM)TKXD;$RV[D-4&UY/6X883Z%B*;1(MUBT# MB3A*9^/VPBK/BHJ2X'^M%03_8_Q$)"99GS;^SF%"!U;L<&&2P'>4Q,;1/&!" MKW2T;Y7@&('N"27BEG"RW6-7"6NZH>5K\!G-R[F2F(TR'"C0);]4ZKOD2'KM M*D--1_1$B9Z>:AD&%,H^:D./N-?^)I?1[@1D&X%[@_B)S1LG2\O1P5]HT6Q! M=*ZRW_0@-$'P'A5!O'+OQ2Q0Y[;;DCCS+F^ES1XUF+5%A0A]5^]0%\3*5E\L MKK+U[%M('Y.C81MQEHX&T):OMG6U??'U**E1KW2Z_V&JC@;0.P5OM5\MTU[F MDI)>@ R3I"3^.V&&\&_84H;QA40A9M)GSS6;X_&]'T,MN5%2HG M6L,% GREWR-=60O$]T1;=65*?++2,BF(6^W7(/N."OJ:8S3%F&EL"6&XQ1<9]WIDF-EURD0K_QJE?[ 7URDM:K%*<*#/^]JU MWE4.&?G-,HQ%7<.=L#'N_[D79F25_C403-.WA]#!DYN.O748V]4 ;'&*%'R- M&;\.]L( T^(4OBMQ'[:J>W$Q K!5E5Z96/O>L*WJ3>*A K/PN<-D M0FX$2$#HEY3\BJ]7Y-3;NEZ;=H'MS/K^/!1:VZVEZ>AIJ?^VAJT8TLLMFRS5 M5\<]8'SMA1-O-W.]D3 =O;CMMZU":M44GH+;&@;N>D'9@\ZW!#\46A"HJZ?. M?5T,=");2@5\,%AUA-L4]L+/OLT!45.HKAZ8PT6+;RZX'1, W,"PZ@KWCMN+ MEW_M#HV:8G7UO+^O*\9>'1\._[X/"C/YK/.$2/@X_/NK-*'N<640DZ2/A[IQTVUO&)%_B4T6D&!=!5Z M/8/\/4;^$FYE0()U%8EA@J81B_+PI8PF+&R21R/%>DV625;[$*87G:3T0V?G M[?VX:D'>L($KP,\]E9GJ#DLH2O(H-$H$W,8W&2E_G^Z;BL]5J(WZYWE)0):F MT"MYO9?V/1K[2*NZ'7Z=L;"OIP@(0;866@/ZE>368C7,\W+.)/0M)VO;35Y$ M\VKZ[XV'E3E>!Y_PZI=%9"6D?V#AP+[E>&JXC(/P._X4[D?.RI,6: >^IA,4 M__T<<^.IWJD?J_9*$RJZTKHE4OM1.E)/@;WD'6F!XS7;7'9[\(*SSLY>+""^ MNV_K^*;]*&,%V&[>OD:W*[N_Z/-/E8!^3S%U41P5BZ>6XKZ9?YWR=+8'&4N[ MFK650@1-@M@O97^*\N^W&4)X.X^P5A5=JKKHVXPC8+\R?Q1=*4+/GY.V,2%< M1Q_1!)\*(6;TZK<91WN_9^E$A(XR:O;.XN FO4GWM@-=1X?)Y"H.\CR:1NP7 M=\EME 1)& 7Q,Y8L,K4EN/T0U>?3LV[GN#9RV1B%?7*<.V< O62WI N2N:U5 M,?IM7+A+\ 2'5B*]7\I?G31848O)!=HMKE7&Q5IF(A._C^T2A-KTP,IZ3#; M=SHFW%FQOH7-[Q,LR62%Y?F&)^5K]('B])U Y0%BM=E\#6HS.0%[/IDQ*=8" M&XQ^'_.^H 1E08R!#B?S*(G( EQ$'\A4&XSJ4UF= YO/FNB#'%DH,76-"I.+YQU&SE!M&'.V?"P&$#E MDH;*X!(:S^"V UVDS;7E$5;\6+:MO ](#S1YR0'&\4Y?'^/ MHY ,NI?T:IW%Y2V-,9Z\,KJ#C+C!KNIA^40AV0E&<4F,H)U;]+8[9&";DU4A MG!X<#CH=NI@&MOS>JV.B;I2C'3T!WC)JI2@>7F(@CNQ*=;<($C?3+>6V4#6; MZCS^&K!5P)+.>@ =F83 =H);CI8L=-AHRO%3T%6W:L5XMFR)BQ!H[:U'MGC\ MUP;NMUE)N&Y:K%&T/!<&T'6&2RW0P//;;+0-CLO*@FU>@PL$R#S0)M\[ 'V] M**^YC7Y,\4>*B&;;7A:JS'HO;T'Q1Y#??(9QB;M"$H>^O"%R#"D+?FKF$MSZ M_D8*QCW8C!\ 77D/,3D3(N'H SVCL,RB(D(;?&R0L0W"_*[;Q8>8J(#C'FMY MU%U7.Y6$W_?4#45QN1 WH+GG;O&KE) ML>NJ,@D!>_UTH0$VNB<0#^B12F)S86\,*WLAZ?6:JCB#".R88\R#P+2BP^7W M">F/@-CK"^W-Z48YAAW83%:34S6@/;@37[\=-KL.WR[/3H+06X2&[&J0^7X/ MWG!%,[D-=_4)1A1T<@R/-IR[DO/\2KR9.(;SM$Q49@LG[3-9 Q_=+\(DJQL#U?>@EFJ89>LS2CRC''[M-LTJ%[LUYZXXQ?C"%28E9 M&;TC'AV;=;C2R:]1DF)J%\M'?\-DLMG*S;]+_.>OJ'A+\5\^ILH8(\*R&HIG^#46= M1KE8@0_^^Z&J.R+UV]Y80P(WGUBV&&:4!-F";G(>4OS7I, X8A8VCY+E5I5- MO\J)Z<5K(M]UW5[FKFRG)%X=^ [T9CI%(=F9K_Y*7K$3Q^PDC.*(/0< VG[B MSJR# 1AO$X6UQL<=;^5,Y#HL;M&$/* A#S!*W(?%1F'5U7GSUK%$>K&M4] E M<2AQA=WO[9>)&.C#'CS'DG<]<67X-]0L6;-8K+W8?K6B4FK0H!LDR7V:":IU M6)/)?Y9LL1U-^54%L<"$2&@+<]K^^.+X].(8V!9FJ3GM",!S1U<#<>"]%=ZO ME+C8:[Q\)BI^5=QPCC+_$$GA=CZ SJ+:XLQ51Q1^7S*;2&54O*%L]2N\SR=; M?_F,YZII.M9/@"\[6U0V(^Q^WWJ;B.'JC3Q*O,-')X8'%QKF.2KR50AM\MCP M!\NITDC9++Z$N>V%R: 5Q;.6@Z,[^5XIHWLKX_.3H'-JS4<^JH388X/3[)FD',1E!_'?\9+41 MFR*97*($3:/"2EV,&Z52A4ZEZ$Q[[&'WT8M=L.;BWH31$L1PGF9%]"?]I\RR M9M,&/K,?'QX?0P=MME2"!C =F2;BMOB^"MXCO/DC48V,+5LU6V)WD@-@TZD; M[BW ^FT^V$%^ESQF:8CRW-H0:ML46X6A\W6X6B],P?I]T#=8)@G^[ .1;&[# M,,S*(&ZXW1 TR$W#P,>6%O<:2LR@'O&F"\\]"G#K4?!*4\L8KS*;U1AFW^8( M.V1MN9 #30A?,G4 ,7$%+,9].3A4\(BIM<_SN6V^ Z+6ZK; Q/)]=.'99M$: MG,0 =6"L A=,!1(T(Z$@6YNM,>Y="*)A;%.=GI(N3CSCN!Y""='VID;PL;Y< MHLB#4UO;LK@N7>M.5FECO#4RZ]!)=,"?L()BK&3C$B6S2FA;P_5=W0:76W^6 M?1V]-OJAQ"O1$W-+8<-%H24]L58*+I'^K \N-6 -3D*WN8UPD^X7\!5BM2): M7CB.CP_Z0/^!@8_Y)Y)\Q0$D9P;W]Q/[Z17N.O)S3Z MD,6MO; B.W\/N@VR_2W)5CD&<,<,;N,D-7CO^^+?KI&P>"AIH3FZO'^GR1R> MBR K7!V?)%W'\LB(D><:L?\^H;R,R=@AS[\><2\REE@"5WE,\TCF#^7Z$URB M?7&VLU*6]F31QS<2=8!>E1D1?[N:)?T(EV=?_(>ZT2T#:?C]=L+I.G5Q>@X< M ;&U=8I!<^0"P-:IFV0"M/4;3B81PW"73--LOC^/;0?=/K:5^YWIPC%K:F(D M?7XD.Y"Z/1OA\MM7DQR4CH@I/$^A86H!>L";'[OC9;N/<8I>%)[NUX-@+50_?!/"LJ;.-_K9G&_Q@_D2MQR2J[\7=V&7<"?.:ML;!* M4#AR![1^*U*?)>FXVRK!,0)M@23BEG"RW>/&+GJ=TO(U2J)Y.5<2LU&& P4R M)DBEODN.I->N'.LZHB?XU--3+<.! NU";.@1]]J5SYLC>IR8:>\-$D08U,8K M@[\F/&-\C9W9>G)"1/EC$$W43DV[A>FS+F@?1F.N-*?$752-7=>@/5KY5>T* M(G]>Q2_Q%%2K*XZ)9Q_4I.V(=D.$KOS:^O(^J8;;XOG)V2&T4;XAV4I<$HI] ML03MOLO81KN,QJ7-IF/;%)THSWI[0#52C=J8)6H#^PYU5QBW3!AX>HM8;*U_ MH4"1QM&H.GOW QWFHB;Q]8!*V.[(T"1A>_-"RXII@ZK\=1>PV;\)RU8@)0S; M/U>%609J!<=2Q(@ZAHYDTG!>UT&3N&!8V[WZLK$37F[;AIX0M$ ONB^ 'ZZX MWOYIH$ITPQ=G+"RM!".43/^"4MR>!>RGVGS [^*1,-GVQD*/PUUGZ\1L*)WP8A).U]N-_C)_* M& T.7D\&^/O#">8=36[C8";HLZ(T[R>05,A*H+ER$FTXQ&J M95-:GB,'2L7@?GR*D+40*U.X"_F-=.XUR-%__?\!4$L! A0#% @ O'E] M6$;M#^!?M ( 06H9 \ ( ! &0W,SDT.3=D,3!K+FAT M;5!+ 0(4 Q0 ( +QY?5CFWLVW=@( () 1 " 8RT M @!D-S,Y-#DW9&5X,C$Q+FAT;5!+ 0(4 Q0 ( +QY?5AE!JO^9@, *<' M 1 " 3&W @!D-S,Y-#DW9&5X,C,Q+FAT;5!+ 0(4 Q0 M ( +QY?5B#934P2@< +,9 1 " <:Z @!D-S,Y-#DW M9&5X,S$Q+FAT;5!+ 0(4 Q0 ( +QY?5CSSA6W2 < *H9 1 M " 3_" @!D-S,Y-#DW9&5X,S$R+FAT;5!+ 0(4 Q0 ( +QY?5BA MG(05C00 $X/ 1 " ;;) @!D-S,Y-#DW9&5X,S(Q+FAT M;5!+ 0(4 Q0 ( +QY?5A5ZH2PBP0 $4/ 1 " 7+. M @!D-S,Y-#DW9&5X,S(R+FAT;5!+ 0(4 Q0 ( +QY?5B@**+U1A< "9M M 1 " 2S3 @!D-S,Y-#DW9&5X.30NWX *RR 1 " >G1!P!G-S,Y-#DW9S8Q8C8U+FIP M9U!+ 0(4 Q0 ( +QY?5A+##]=JG4 .(E 0 1 " =-0 M" !G-S,Y-#DW9S8W838U+FIP9U!+ 0(4 Q0 ( +QY?5@PJ#AJ,>@ !WL M 1 " :S&" !G-S,Y-#DW9SCDV+FIP9U!+ 0(4 Q0 ( +QY?5@KD-?9CI< $;2 1 M " 75;"@!G-S,Y-#DW9S 1 " 3+S"@!G-S,Y-#DW9S@R:38U+FIP M9U!+ 0(4 Q0 ( +QY?5@A_6J*3)H ,5# 0 1 " 51A M"P!G-S,Y-#DW9SDS9C8X+FIP9U!+ 0(4 Q0 ( +QY?5BU7^&>+. &T_ M 0 1 " <_["P!G-S,Y-#DW9SDS;C&M#0!V:6YC+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0 ( +QY?5CE M)K1<) T !FR 5 " 6S"#0!V:6YC+3(P,C,Q,C,Q7V-A M;"YX;6Q02P$"% ,4 " "\>7U8\@+X:@!$ !3.@0 %0 M@ '#SPT =FEN8RTR,#(S,3(S,5]D968N>&UL4$L! A0#% @ O'E]6-(W M$TX2> Y2X' !4 ( !]A,. '9I;F,M,C R,S$R,S%?;&%B M+GAM;%!+ 0(4 Q0 ( +QY?5B\K_PW2V *M+!@ 5 " M 3N,#@!V:6YC+3(P,C,Q,C,Q7W!R92YX;6Q02P4& !T '0 Q!P N>P. # end XML 110 d739497d10k_htm.xml IDEA: XBRL DOCUMENT 0001796129 2023-12-31 0001796129 2022-12-31 0001796129 2022-01-01 2022-12-31 0001796129 2023-01-01 2023-12-31 0001796129 2021-01-01 2021-01-05 0001796129 2020-12-23 2020-12-23 0001796129 2023-01-31 0001796129 2021-01-01 2021-12-31 0001796129 2023-06-30 0001796129 2024-03-26 0001796129 2020-12-31 0001796129 2022-06-04 2022-06-04 0001796129 2022-07-01 2022-07-31 0001796129 2023-10-01 2023-12-31 0001796129 2021-12-31 0001796129 srt:RestatementAdjustmentMember 2022-04-01 2022-06-30 0001796129 srt:RestatementAdjustmentMember 2023-07-01 2023-09-30 0001796129 srt:RestatementAdjustmentMember 2023-04-01 2023-06-30 0001796129 srt:RestatementAdjustmentMember 2023-01-01 2023-03-31 0001796129 srt:RestatementAdjustmentMember 2022-10-01 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-07-01 2022-09-30 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceTwoMember 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceOneMember 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceThreeMember 2023-12-31 0001796129 srt:MaximumMember 2023-12-31 0001796129 srt:MinimumMember 2023-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-12-31 0001796129 vinc:PrivateWarrantMember 2023-12-31 0001796129 us-gaap:PrivatePlacementMember 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:LifesciHoldingsLlcMember 2023-12-31 0001796129 vinc:PrivateWarrantMember us-gaap:CommonStockMember 2023-12-31 0001796129 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel2Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel1Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001796129 us-gaap:DomesticCountryMember 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001796129 us-gaap:ComputerEquipmentMember 2023-12-31 0001796129 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001796129 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001796129 us-gaap:OtherCurrentAssetsMember 2023-12-31 0001796129 us-gaap:DebtSecuritiesMember vinc:MarketableSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember 2023-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001796129 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0001796129 us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0001796129 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001796129 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001796129 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001796129 vinc:OptionOutstandingMember 2022-01-01 2022-12-31 0001796129 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestructuringChargesMember 2022-01-01 2022-12-31 0001796129 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001796129 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001796129 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-01-01 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-01 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001796129 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2022-01-01 2022-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-01-01 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-12-31 0001796129 vinc:PrivateWarrantMember 2022-01-01 2022-12-31 0001796129 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-01-01 2022-12-31 0001796129 srt:MaximumMember 2022-12-31 2022-12-31 0001796129 srt:MinimumMember 2022-12-31 2022-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2021-05-31 0001796129 us-gaap:RestrictedStockMember 2020-05-31 0001796129 us-gaap:RestrictedStockMember vinc:VinceraPharmaMember 2020-05-31 2020-05-31 0001796129 us-gaap:RestrictedStockMember 2020-05-31 2020-05-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2020-05-31 2020-05-31 0001796129 us-gaap:RestrictedStockMember 2019-07-31 2019-07-31 0001796129 us-gaap:RestrictedStockMember 2019-07-01 2019-08-31 0001796129 vinc:PrivateWarrantMember 2021-12-31 0001796129 vinc:PublicWarrantMember 2021-12-31 0001796129 vinc:PrivateWarrantMember 2021-01-01 2021-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001796129 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceThreeMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceTwoMember 2023-01-01 2023-12-31 0001796129 vinc:VinceraPharmaMember vinc:VolumeWeightedAveragePriceOneMember 2023-01-01 2023-12-31 0001796129 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001796129 vinc:OptionOutstandingMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestructuringChargesMember 2023-01-01 2023-12-31 0001796129 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001796129 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001796129 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001796129 vinc:PrivateWarrantMember 2023-01-01 2023-12-31 0001796129 vinc:PublicWarrantMember 2023-01-01 2023-12-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-01-01 2023-12-31 0001796129 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-01-01 2023-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-01-01 2023-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001796129 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001796129 vinc:EmployeeStockPurchasePlanMember 2023-01-01 2023-12-31 0001796129 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001796129 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001796129 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001796129 us-gaap:OtherAssetsMember 2023-01-01 2023-12-31 0001796129 vinc:CurrentAssetMember 2023-01-01 2023-12-31 0001796129 vinc:ShareBasedPaymentsMember 2023-01-01 2023-12-31 0001796129 vinc:TwentyThousandTwentyPlanMember 2023-01-31 0001796129 vinc:PublicWarrantMember 2023-01-31 0001796129 vinc:PrivateWarrantMember 2023-01-31 0001796129 vinc:PrivateWarrantMember vinc:LifesciHoldingsLlcMember 2023-01-31 0001796129 vinc:PrivateWarrantMember vinc:RosedaleParkLlcMember 2023-01-31 0001796129 vinc:PrivateWarrantMember us-gaap:CommonStockMember 2023-01-31 0001796129 us-gaap:OtherCurrentAssetsMember 2023-01-31 0001796129 vinc:PublicWarrantMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member vinc:CommonStockWarrantLiabilitiesRestatesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001796129 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001796129 us-gaap:ComputerEquipmentMember 2022-12-31 0001796129 us-gaap:OtherCurrentAssetsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001796129 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-12-31 0001796129 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001796129 srt:RestatementAdjustmentMember 2022-12-31 0001796129 us-gaap:RetainedEarningsMember 2021-12-31 0001796129 us-gaap:CommonStockMember 2021-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001796129 us-gaap:RestrictedStockMember 2021-12-31 0001796129 us-gaap:RestrictedStockMember 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001796129 us-gaap:RetainedEarningsMember 2022-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001796129 us-gaap:CommonStockMember 2022-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2021-12-31 0001796129 us-gaap:EmployeeSeveranceMember 2022-12-31 0001796129 us-gaap:CommonStockMember 2023-12-31 0001796129 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001796129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001796129 us-gaap:RetainedEarningsMember 2023-12-31 0001796129 vinc:WarrantsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 iso4217:USD shares utr:Day pure utr:Year iso4217:EUR utr:Month iso4217:USD shares false FY 0001796129 CA 10-K true 2023-12-31 --12-31 2023 false 001-39244 Vincerx Pharma, Inc. DE 83-3197402 260 Sheridan Avenue, Suite 400 Palo Alto 94306 650 800-6676 Common Stock, $0.0001 par value per share VINC NASDAQ No No Yes Yes Non-accelerated Filer true true false false true false false 23000000 21413389 Portions of the registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120 days of December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> P2Y http://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLoss http://fasb.org/us-gaap/2023#MarketableSecuritiesUnrealizedGainLoss http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost WithumSmith+Brown, PC East Brunswick, New Jersey 100 12782000 11663000 72000 70000 0 40796000 51000 134000 1044000 1372000 784000 1929000 14733000 55964000 2201000 3064000 125000 177000 1158000 81000 18217000 59286000 2497000 4065000 1755000 3923000 1162000 1024000 191000 144000 5605000 9156000 1340000 2412000 50000 50000 6995000 11618000 0.0001 0.0001 30000000 30000000 0 0 0 0 0 0 0.0001 0.0001 120000000 120000000 21407510 21407510 21242884 21242884 2000 2000 170324000 166647000 8000 -26000 -159112000 -118955000 11222000 47668000 18217000 59286000 13636000 18885000 28973000 49837000 0 2469000 42609000 71191000 -42609000 -71191000 47000 -6303000 1251000 664000 1248000 1240000 2452000 8207000 -40157000 -62984000 -40000 69000 74000 -74000 -40123000 -62989000 -1.89 -1.89 -3 -3 21295 21295 21029 21029 21057 2000 156311000 -21000 -55971000 100321000 186 280000 280000 10056000 10056000 69000 69000 -74000 -74000 -62984000 -62984000 21243 2000 166647000 -26000 -118955000 47668000 165 114000 114000 3563000 3563000 -40000 -40000 74000 74000 -40157000 -40157000 21408 2000 170324000 8000 -159112000 11222000 -40157000 -62984000 52000 54000 3563000 10056000 863000 885000 47000 -6303000 630000 292000 -1228000 3158000 -328000 -200000 1077000 -1372000 -1568000 1046000 -2168000 208000 -934000 -738000 0 50000 -40453000 -59604000 11821000 42978000 53321000 2400000 41500000 -40578000 114000 280000 114000 280000 -40000 71000 1121000 -99831000 11733000 111564000 12854000 11733000 0 0 0 0 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Nature of Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 4), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense, and distribute a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s business operations, and those of third parties with whom the Company conducts business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and by economic, business and political events, including inflation and the wars in Ukraine and Israel. The extent to which these factors could continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on the Company’s current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations. </div> 2018-12-19 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). They include the accounts of Vincerx and its wholly-owned subsidiaries, VNRX Corp., Vincerx Pharma GmbH and Vincerx Pharma Australia Pty Limited. All intercompany accounts and transactions have been eliminated.</div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, the Company had approximately $12.8 <div style="display:inline;">million in cash and cash equivalents. The Company has incurred recurring operating losses and negative cash flows from operating activities since its inception and expects to continue to incur operating losses and negative cash flows in the future. Based on current business plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early third quarter 2024, although this estimate is based on plans and assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Accordingly, the Company will need to raise additional capital through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other </div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">sources, and such additional capital may not be available on favorable terms or at all, particularly in light of the current economic and market conditions. Market volatility resulting from pandemics or other epidemics, inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain the listing on The Nasdaq Capital Market of the Company’s common stock, and other factors could also adversely impact the Company’s ability to raise additional capital. The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on the Company’s financial condition and the ability to pursue its business strategy, and the Company may have to reduce its workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail its business operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40),</div> the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. In light of the Company’s existing cash resources and current and expected operating losses and negative cash flows, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">w<div style="letter-spacing: 0px; top: 0px;;display:inline;">ill</div></div> need additional capital prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the issuance of its consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, the Company has concluded that these circumstances and the uncertainties associated with its ability to obtain additional capital raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business, and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revision of Previously Reported Consolidated Financial Statements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified an error in the computation of stock-based compensation that resulted in an overstatement of stock-based compensation of approximately $2.4 million for the year ended December 31, 2022. This error resulted from the erroneous inclusion of unvested forfeited awards that should have been excluded in the calculation of stock-based compensation. As a result, net loss for the year ended December 31, 2022 and the balances of accumulated deficit and additional paid in capital at December 31, 2022 were also overstated. The error did not impact the Company’s cash flows from operating activities, financing activities and investing activities. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Management assessed the materiality of this presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250,<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-style: normal; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Changes and Error Corrections</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>(“ASC 250”). Based on this assessment, management concluded that this error did not have a material impact on the prior period stated above. However, the amount of the prior period error in 2022 would have been material to the consolidated financial statements for fiscal year 2023 if the correction of the error was recognized in fiscal year 2023 or left uncorrected. Therefore, the Company has revised the prior</div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">period financial statements impacted for this error. The impact of the revision on the 2022 consolidated financial statements is as follows:</div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> <br/></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 65%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance Sheet</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in-capital</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169,030</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,647</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,955</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except per share amounts)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Statement of Operations and Comprehensive Loss</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,574</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73,574</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71,191</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,367</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr> <td style="vertical-align:top"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Comprehensive loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,372</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,989</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.11</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.11</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.00</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);">—</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the revision on quarterly unaudited consolidated financial statements is as follows<div style="letter-spacing: 0px; top: 0px;;display:inline;">:</div> stock-based compensation expense for the second and third quarters of 2022 were overstated by approximately $2.2 million and $0.3 million, respectively<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, and understated by approximately $0.1 million in the fourth quarter of 2022.</div></div> Stock-based compensation for the first <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>n<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> second quarters of 2023 were understated by approximately $0.3 million <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>n<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> $0.4 million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> respectively<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, and overstated by approximately $0.7 million in the third quarter of 2023</div></div>. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">c<div style="letter-spacing: 0px; top: 0px;;display:inline;">onsolidated </div></div>financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">nce </div>and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain previously reported financial information has been reclassified to conform to the current period presentation. The impact of reclassifications was not significant to the prior year’s overall presentation. These reclassifications had no effect on the reported results of operations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash represents cash deposits with a financial institution in support of the Company’s corporate credit card program. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generally invests its excess cash in money market funds and investment grade short-term to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities or long-term marketable securities on the consolidated balance sheets. Marketable securities with a maturity date greater than 90 days and less than one year at each consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year, if any, are classified as long-term. All of the Company’s marketable securities are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income on the consolidated statements of operations and comprehensive loss. The cost of securities sold is determined using specific identification. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates whether declines in the fair values of its marketable securities below their amortized cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the marketable security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company’s strategy and intentions for holding the marketable security. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. </div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. There has been no impairment loss as of December 31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1—Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Warrant Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023 and 2022, there were 3,295,000 private warrants to purchase common stock outstanding. As of December 31, 2020, there were 10,133,767 warrants outstanding, consisting of 6,563,767 public warrants (which included 2,744,586 public warrants constituting part of the units) and 3,570,000 private warrants. Each unit consisted of one share of common stock and one public warrant exercisable for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one share of common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each public warrant entitled the registered holder to purchase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> (1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants, provided that such redemption rights could not be exercised during the first 12 months following the closing of the Business Combination unless the sales price of the Company’s common stock had been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the public and private warrants under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post Business Combination, these private warrants could be transferred to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-permitted</div> transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on the Company’s common stock, these private warrants fail the indexation guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> This conclusion excludes the 500,000 private warrants held by LifeSci </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since these private warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. </div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The</div> Company adopted FASB ASC Topic 842, “Leases” (“ASC 842”), using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 840, “Leases”. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease liabilities and their corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 9). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components (e.g., common area maintenance, consumables). The fixed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed contract consideration (including any consideration related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-components)</div> must be allocated based on the respective relative fair values to the lease components and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as a single operating segment. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses research and development costs as operating expenses as incurred. These expenses include acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses for which there is no alternative future use, salaries for research and development personnel, consulting fees, product development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, clinical trial costs, and other fees and costs related to the development of the technology. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> including stock options and restricted shares, based on estimated fair values recognized over the requisite service period. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. No awards have been issued with a market condition or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-standard</div> terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risk profiles, volatility, capital intensity and market growth patterns and drivers. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are recorded in accordance with ASC 740, “Income Taxes” (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit (“R&amp;D Credit”) carryforwards. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2023 and 2022, the Company had no liability for income tax associated with uncertain tax positions. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There was no income tax interest or penalties incurred in 2023 or 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">German Grant Income </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 958, the</div> Company recognizes grant income in the period when the underlying eligible expenses are incurred. The German government grant program provides for tax refunds or direct reimbursements of eligible <div style="-sec-ix-hidden:hidden107884737;display:inline;">research expenses</div> of up to 1.0 million euros per year over a period of six years. The grant was approved in 2022 and is retroactive to 2021. Grant income for the years ended December 31, 2023 and 2022 has been recorded in other income (expense), net on the consolidated statements of operations and comprehensive loss. The corresponding receivable is included within current assets and other assets, $1.0 million and $1.0 million, respectively, at December 31, 2023 on the consolidated balance sheet depending upon expectations for collection within twelve months of the balance sheet date. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation and Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements are presented in U.S. dollars. The functional currency for the Company’s foreign subsidiaries is the local currency. Expenses, gains and losses for this entity are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities are translated using exchange rates in effect at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company’s consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in the functional currency are recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Income or Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is equal to net loss, net foreign currency translation gain (loss), and net unrealized gain (loss) on marketable securities as presented in the accompanying consolidated statements of operations and comprehensive loss. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share of Common Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported losses for all periods presented, all potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, Financial Accounting Standards Board (“FASB”) issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2023-07</div> “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-07</div> requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. The Company expects to adopt this guidance on January 1, 2025 on a retrospective basis and has yet to assess the impact to the consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2023-09</div> “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-09</div> requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. The Company expects to adopt this guidance on January 1, 2025. The Company expects the adoption of this standard to result in increased disclosures in its notes to consolidated financial statements. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). They include the accounts of Vincerx and its wholly-owned subsidiaries, VNRX Corp., Vincerx Pharma GmbH and Vincerx Pharma Australia Pty Limited. All intercompany accounts and transactions have been eliminated.</div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, the Company had approximately $12.8 <div style="display:inline;">million in cash and cash equivalents. The Company has incurred recurring operating losses and negative cash flows from operating activities since its inception and expects to continue to incur operating losses and negative cash flows in the future. Based on current business plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into early third quarter 2024, although this estimate is based on plans and assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. Accordingly, the Company will need to raise additional capital through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other </div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">sources, and such additional capital may not be available on favorable terms or at all, particularly in light of the current economic and market conditions. Market volatility resulting from pandemics or other epidemics, inflation and other economic and market conditions, the wars in Ukraine and Israel, the inability to maintain the listing on The Nasdaq Capital Market of the Company’s common stock, and other factors could also adversely impact the Company’s ability to raise additional capital. The failure to raise additional capital as and when needed or on acceptable terms would have a negative impact on the Company’s financial condition and the ability to pursue its business strategy, and the Company may have to reduce its workforce or delay, reduce the scope of, suspend, or eliminate one or more preclinical programs, clinical trials, or future commercialization efforts, or curtail its business operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40),</div> the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. In light of the Company’s existing cash resources and current and expected operating losses and negative cash flows, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">w<div style="letter-spacing: 0px; top: 0px;;display:inline;">ill</div></div> need additional capital prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the issuance of its consolidated financial statements, and such additional capital may not be available as and when needed on acceptable terms or at all. As a result, the Company has concluded that these circumstances and the uncertainties associated with its ability to obtain additional capital raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that its audited consolidated financial statements are issued. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business, and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div> 12800000 <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revision of Previously Reported Consolidated Financial Statements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified an error in the computation of stock-based compensation that resulted in an overstatement of stock-based compensation of approximately $2.4 million for the year ended December 31, 2022. This error resulted from the erroneous inclusion of unvested forfeited awards that should have been excluded in the calculation of stock-based compensation. As a result, net loss for the year ended December 31, 2022 and the balances of accumulated deficit and additional paid in capital at December 31, 2022 were also overstated. The error did not impact the Company’s cash flows from operating activities, financing activities and investing activities. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Management assessed the materiality of this presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250,<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-style: normal; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Changes and Error Corrections</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>(“ASC 250”). Based on this assessment, management concluded that this error did not have a material impact on the prior period stated above. However, the amount of the prior period error in 2022 would have been material to the consolidated financial statements for fiscal year 2023 if the correction of the error was recognized in fiscal year 2023 or left uncorrected. Therefore, the Company has revised the prior</div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">period financial statements impacted for this error. The impact of the revision on the 2022 consolidated financial statements is as follows:</div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> <br/></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 65%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance Sheet</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in-capital</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169,030</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,647</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,955</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except per share amounts)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Statement of Operations and Comprehensive Loss</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,574</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73,574</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71,191</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,367</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr> <td style="vertical-align:top"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Comprehensive loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,372</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,989</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.11</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.11</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.00</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);">—</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the revision on quarterly unaudited consolidated financial statements is as follows<div style="letter-spacing: 0px; top: 0px;;display:inline;">:</div> stock-based compensation expense for the second and third quarters of 2022 were overstated by approximately $2.2 million and $0.3 million, respectively<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, and understated by approximately $0.1 million in the fourth quarter of 2022.</div></div> Stock-based compensation for the first <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>n<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> second quarters of 2023 were understated by approximately $0.3 million <div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>n<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> $0.4 million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> respectively<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, and overstated by approximately $0.7 million in the third quarter of 2023</div></div>. </div> 2400000 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 65%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance Sheet</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock - $ 0.0001 par value</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in-capital</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169,030</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166,647</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(121,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,955</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,668</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 65%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders’ equity</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,286</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align: bottom; width: 65%;"></td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> 0.0001 0 0 0 0.0001 2000 0 2000 169030000 -2383000 166647000 -26000 -26000 -121338000 2383000 -118955000 47668000 0 47668000 59286000 0 59286000 <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"> <tr> <td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December 31, 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revision</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Revised</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except per share amounts)</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Statement of Operations and Comprehensive Loss</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73,574</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,383</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73,574</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71,191</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,303</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">664</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,240</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,367</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr> <td style="vertical-align:top"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Comprehensive loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (65,372</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> (62,989</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.11</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.11</div></td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(3.00</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">) </td> </tr> <tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding, basic and diluted</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);">—</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">  </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">21,029</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> 73574000 -2383000 71191000 -73574000 2383000 -71191000 -6303000 0 -6303000 664000 0 664000 1240000 0 1240000 8207000 0 8207000 -65367000 2383000 -62984000 -65372000 2383000 -62989000 -3.11 -3.11 -0.11 -0.11 -3 -3 21029 21029 0 0 21029 21029 2200000 300000 100000 300000 400000 700000 <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">c<div style="letter-spacing: 0px; top: 0px;;display:inline;">onsolidated </div></div>financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experie<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">nce </div>and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain previously reported financial information has been reclassified to conform to the current period presentation. The impact of reclassifications was not significant to the prior year’s overall presentation. These reclassifications had no effect on the reported results of operations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company. </div> 250000000 <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash represents cash deposits with a financial institution in support of the Company’s corporate credit card program. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generally invests its excess cash in money market funds and investment grade short-term to intermediate-term fixed income securities. Such investments are included in cash and cash equivalents, short-term marketable securities or long-term marketable securities on the consolidated balance sheets. Marketable securities with a maturity date greater than 90 days and less than one year at each consolidated balance sheet date are classified as short-term. Marketable securities with a maturity date greater than one year, if any, are classified as long-term. All of the Company’s marketable securities are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income on the consolidated statements of operations and comprehensive loss. The cost of securities sold is determined using specific identification. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates whether declines in the fair values of its marketable securities below their amortized cost are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the marketable security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company’s strategy and intentions for holding the marketable security. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred. </div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. There has been no impairment loss as of December 31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies fair value accounting for all financial assets and liabilities measured on a recurring and nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, used to determine the fair value of its financial instruments. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1—Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Warrant Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023 and 2022, there were 3,295,000 private warrants to purchase common stock outstanding. As of December 31, 2020, there were 10,133,767 warrants outstanding, consisting of 6,563,767 public warrants (which included 2,744,586 public warrants constituting part of the units) and 3,570,000 private warrants. Each unit consisted of one share of common stock and one public warrant exercisable for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one share of common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each public warrant entitled the registered holder to purchase <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> (1/2) of a share of common stock at a price of $11.50 per whole share of common stock, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of the initial public offering of LSAC or the consummation of a business combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private warrants are identical to the warrants underlying the units except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants, provided that such redemption rights could not be exercised during the first 12 months following the closing of the Business Combination unless the sales price of the Company’s common stock had been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the notice of redemption), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the public and private warrants under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that certain of the private warrants do not meet the criteria to be classified in stockholders’ equity. Because post Business Combination, these private warrants could be transferred to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-permitted</div> transferee and become public warrants (i.e., become subject to redemption and no longer have a cashless exercise feature), the settlement value of the private warrants is dependent, in part, on the holder of these private warrants at the time of settlement. Because the holder of an instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on the Company’s common stock, these private warrants fail the indexation guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> This conclusion excludes the 500,000 private warrants held by LifeSci </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Holdings LLC, which were amended in connection with the Business Combination to remove the cashless exercise provision and include a redemption provision, as described above. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since these private warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations and comprehensive loss at each reporting date. The estimated fair value of the private warrants is determined with Level 3 inputs using Black-Scholes and Monte Carlo simulations. </div> </div> 3295000 3295000 10133767 6563767 2744586 3570000 11.5 11.5 500000 500000 500000 500000 20 P20D P30D 2025-03-05 P5Y 500000 <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The</div> Company adopted FASB ASC Topic 842, “Leases” (“ASC 842”), using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 840, “Leases”. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease liabilities and their corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment (see Note 9). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components (e.g., common area maintenance, consumables). The fixed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed contract consideration (including any consideration related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-components)</div> must be allocated based on the respective relative fair values to the lease components and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as a single operating segment. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses research and development costs as operating expenses as incurred. These expenses include acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development expenses for which there is no alternative future use, salaries for research and development personnel, consulting fees, product development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, clinical trial costs, and other fees and costs related to the development of the technology. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> including stock options and restricted shares, based on estimated fair values recognized over the requisite service period. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"></div><div></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options granted is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures when they occur. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. No awards have been issued with a market condition or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-standard</div> terms. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimate for volatility is based on an average of the historical volatilities of the common stock of several entities with characteristics similar to those of the Company. Since these comparable companies operate in the same industry segment, the Company expects that it would share similar characteristics, such as risk profiles, volatility, capital intensity and market growth patterns and drivers. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are recorded in accordance with ASC 740, “Income Taxes” (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss carryforwards and research and development tax credit (“R&amp;D Credit”) carryforwards. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such determination was made. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2023 and 2022, the Company had no liability for income tax associated with uncertain tax positions. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There was no income tax interest or penalties incurred in 2023 or 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">German Grant Income </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 958, the</div> Company recognizes grant income in the period when the underlying eligible expenses are incurred. The German government grant program provides for tax refunds or direct reimbursements of eligible <div style="-sec-ix-hidden:hidden107884737;display:inline;">research expenses</div> of up to 1.0 million euros per year over a period of six years. The grant was approved in 2022 and is retroactive to 2021. Grant income for the years ended December 31, 2023 and 2022 has been recorded in other income (expense), net on the consolidated statements of operations and comprehensive loss. The corresponding receivable is included within current assets and other assets, $1.0 million and $1.0 million, respectively, at December 31, 2023 on the consolidated balance sheet depending upon expectations for collection within twelve months of the balance sheet date. </div> 1000000 1000000 1000000 <div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation and Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements are presented in U.S. dollars. The functional currency for the Company’s foreign subsidiaries is the local currency. Expenses, gains and losses for this entity are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities are translated using exchange rates in effect at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company’s consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in the functional currency are recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Income or Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is equal to net loss, net foreign currency translation gain (loss), and net unrealized gain (loss) on marketable securities as presented in the accompanying consolidated statements of operations and comprehensive loss. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share of Common Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted earnings per share adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. As the Company has reported losses for all periods presented, all potentially dilutive securities including stock options and warrants, are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, Financial Accounting Standards Board (“FASB”) issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2023-07</div> “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-07</div> requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments in the update and all existing segment disclosures in Topic 280. The Company expects to adopt this guidance on January 1, 2025 on a retrospective basis and has yet to assess the impact to the consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2023-09</div> “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-09</div> requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. This guidance requires prospective application and permits retrospective application to prior periods presented. The Company expects to adopt this guidance on January 1, 2025. The Company expects the adoption of this standard to result in increased disclosures in its notes to consolidated financial statements. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Business Combination </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, on December 23, 2020, the Company consummated the Business Combination, with Legacy Vincera Pharma surviving the merger as a wholly-owned subsidiary of the Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Business Combination, each share of Legacy Vincera Pharma Common Stock was canceled, and the Legacy Holders received (i) 0.570895 shares of common stock, for each share of Legacy Vincera Pharma Common Stock held by them immediately prior to the effective time of the Business Combination and (ii) certain rights to Earnout Shares after the closing of the Business Combination. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Holders are entitled to receive Earnout Shares if the daily volume-weighted average price of the Company’s common stock equals or exceeds the following prices for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30 trading-day period</div> following the closing of the Business Combination: (1) during any such trading period prior to the 42 month anniversary of the closing of the Business Combination, upon achievement of a daily volume-weighted average price of at least $20.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; (2) during any such trading period prior to the six year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $35.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share; and (3) during any such trading period prior to the eight year anniversary of the closing, upon achievement of a daily volume-weighted average price of at least $45.00 per share, such number of shares of the Company’s common stock as equals the quotient of $20.0 million divided by the Closing Price Per Share. A total of 90.6% of (rounded to the nearest whole share) of the Earnout Shares then earned and issuable shall be issued to the Legacy Holders on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a pro-rata basis</div> based on the percentage of the number of shares of Vincera Pharma Common Stock owned by them immediately prior to the closing of the Business Combination, and the remaining Earnout Shares that would otherwise have been issuable shall not be issuable to the Legacy Holders but in lieu thereof the number of authorized shares available for issuance under the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) shall be automatically increased by an equivalent n<div style="letter-spacing: 0px; top: 0px;;display:inline;">u</div>mber of shares of the Company’s common stock. </div> 0.570895 P20D P30D 20 20000000 35 20000000 45 20000000 0.906 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">4. Bayer License Agreement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 7, 2020, Legacy Vincerx Pharma entered into the Bayer License Agreement, which became effective on December 23, 2020 upon the closing of the Business Combination. Pursuant to the Bayer License Agreement, Legacy Vincerx Pharma has an exclusive, worldwide, royalty-bearing license under certain Bayer patents <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and know-how to</div> develop, use, manufacture, commercialize, sublicense and distribute (i) a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug platform, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-TEFb</div> inhibitor compound, and (ii) a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of the Business Combination, the Company paid Bayer a $5.0 million upfront license fee on January 5, 2021. During 2022 and 2023, the Company recorded $1.0 million in development milestones payable to Bayer in connection with the Company’s IND filings for VIP236 and VIP943, respectively. Each of these milestone obligations were expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company achieves all of the development and commercial sales milestones for license products under the Bayer License Agreement for each of the countries and disease indications, the Company would be obligated to pay milestone payments that range from $110.0 million to up to $318.0 million per licensed product, and upon successful commercialization of at least five licensed products, the Company could be required to pay aggregate milestone payments in excess of $1 billion. In addition to milestone payments, the Company is also required to pay Bayer under the Bayer License Agreement ongoing royalties in the single digit to low double-digit percentage range on net commercial sales of licensed products. </div> 2020-10-07 5000000 1000000 1000000 110000000 318000000 1000000000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">5. Restructuring </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June 4, 2022, the Board of Directors of the Company approved a strategic plan to prioritize and focus its resources on certain of its enitociclib </div>clinical studies and its next generation bioconjugation platform and streamline and realign its resources to support these prioritized studies. This plan included a reduction of the Company’s full-time employees by 33% and other cost reduction measures. Affected employees were offered separation benefits, including severance payments, payments to cover premiums for continuation of healthcare coverage for a limited period and in some cases vesting acceleration on certain outstanding stock options. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred approximately $2.5 million of severance and related expenses during 2022, which includes approximately $0.5 million of stock-based compensation expense related to the acceleration of stock options to certain affected employees. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity in the accrued restructuring balance, included within accrued expenses on the consolidated balance sheet, was as follows for the year ended December 31, 2022 (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:47%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Restructuring<br/> liabilities at<br/> January 1, 2022</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Charges</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Cash payments</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Restructuring<br/> liabilities at<br/> December 31, 2022</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Workforce reduction</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,022</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,022</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect to incur additional restructuring charges or cash expenditures associated with this restructuring. </div> 0.33 2500000 500000 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity in the accrued restructuring balance, included within accrued expenses on the consolidated balance sheet, was as follows for the year ended December 31, 2022 (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:47%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Restructuring<br/> liabilities at<br/> January 1, 2022</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Charges</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Cash payments</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Restructuring<br/> liabilities at<br/> December 31, 2022</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Workforce reduction</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,022</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,022</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> </table> 0 2022000 2022000 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Fair Value Measurement </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash Equivalents:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,682</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,682</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,233</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,233</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,915</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,914</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash Equivalents:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,266</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,266</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,032</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,032</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents and marketable securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 3,271</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,319</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,590</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no marketable securities at December 31, 2023. The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly. There were no transfers of assets between Level 1, Level 2, or Level 3 during the years ended December 31, 2023 and 2022. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the warrant liability for the private warrants at December 31, 2023 and 2022 was determined using Level 3 inputs. Inherent in a Monte Carlo options pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on its historical volatility for a time period that approximates the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div> yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. There were no changes to the number of private warrants underlying the Level 3 financial instruments during the year ended December 31, 2023. There were no transfers between Level 1, 2, or 3 during the years ended December 31, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (in thousands). </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:85%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – January 1, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,447</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107884743;display:inline;">Change</div> in fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,303</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – December 31, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">144</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107884742;display:inline;">Change</div> in fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – December 31, 2023</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">191</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2023 and 2022 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option term (years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility (annual)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90.9</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.2</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield (per share)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (amounts in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash Equivalents:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,682</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,682</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,233</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,233</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,915</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   999</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,914</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash Equivalents:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,266</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,266</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,496</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,032</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,032</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents and marketable securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 3,271</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,319</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,590</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 4682000 0 0 4682000 6233000 0 0 6233000 0 999000 0 999000 10915000 999000 0 11914000 2266000 0 0 2266000 0 4496000 0 4496000 0 3032000 0 3032000 0 15587000 0 15587000 1005000 0 0 1005000 0 16069000 0 16069000 0 8135000 0 8135000 3271000 47319000 0 50590000 0 <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:63%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   — </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">   144</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 0 0 191000 191000 0 0 191000 191000 0 0 144000 144000 0 0 144000 144000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2023 and 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (in thousands). </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:85%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – January 1, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,447</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107884743;display:inline;">Change</div> in fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,303</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – December 31, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">144</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107884742;display:inline;">Change</div> in fair value</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance – December 31, 2023</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">191</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 6447000 6303000 144000 -47000 191000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2023 and 2022 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:65%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/> December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option term (years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility (annual)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90.9</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.2</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield (per share)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> 1.18 1.02 11.5 11.5 P2Y P3Y 0.909 0.737 0.042 0.041 0 0 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">7. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-For-Sale</div></div> Securities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All marketable securities were considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at December 31, 2022. There were no marketable securities at December 31, 2023.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2022 are summarized in the table below (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gain</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Loss</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,608</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,007</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,105</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,149</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,869</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,796</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, some of the Company’s marketable securities were in an unrealized loss position. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All marketable securities were considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at December 31, 2022. There were no marketable securities at December 31, 2023.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s marketable securities by major security type at December 31, 2022 are summarized in the table below (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:54%"></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gain</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Loss</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,608</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,587</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasuries</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,007</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,105</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate debt securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,149</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,869</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,796</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 0 15608000 0 21000 15587000 1007000 0 2000 1005000 16105000 0 36000 16069000 8149000 0 14000 8135000 40869000 0 73000 40796000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">8. Balance Sheet Details </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other current assets consist of the following at December 31, 2023 and 2022 (in thousands): </div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Clinical related vendor prepayments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">407</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,560</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll tax refund receivable</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">369</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">784</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,929</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net consist of the following at December 31, 2023 and 2022 (in thousands): </div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Useful Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5 years</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5 years</div></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property, plant and equipment, net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was approximately $52,000 and $54,000 for the years ended December 31, 2023 and 2022, respectively. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"></div> <div></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the components of accrued expenses at December 31, 2023 and 2022, respectively (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued bonus</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,042</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued benefits</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">918</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued manufacturing, clinical trial and related</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">505</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">661</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other current assets consist of the following at December 31, 2023 and 2022 (in thousands): </div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:12%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Clinical related vendor prepayments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">407</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,560</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payroll tax refund receivable</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">369</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">784</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,929</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 407000 1560000 250000 0 127000 369000 784000 1929000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net consist of the following at December 31, 2023 and 2022 (in thousands): </div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto;text-indent: 0px;"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Useful Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5 years</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5 years</div></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property, plant and equipment, net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">177</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> </table> 236000 236000 P5Y 20000 20000 P3Y P5Y 256000 256000 131000 79000 125000 177000 52000000 54000000 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the components of accrued expenses at December 31, 2023 and 2022, respectively (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:66%"></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued bonus</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,042</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued benefits</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">918</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued manufacturing, clinical trial and related</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">505</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">661</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 332000 297000 0 2042000 918000 923000 505000 661000 1755000 3923000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Commitments and Contingencies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 23, 2020, the Company entered into a five-year term lease agreement which commenced on January 1, 2021. In April and May, 2021, the lease was amended to include additional space. The annual rent expense is approximately $1.2 million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December 31, 2023, the Company had operating lease liabilities of approximately $2.5 million and right of use assets of approximately $2.2 million, which were included in the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company’s strategic plan and workforce reduction (see <div style="letter-spacing: 0px; top: 0px;;display:inline;">N</div>ote 5), the Company has consolidated its leased office space at its corporate headquarters location. Effective July 2022, the Company subleased substantially all of its unused office space for a term of 18 months at a base rent of $50,000 per month. The Company has not been legally released from its primary obligations under the original lease and subsequent amendments and, therefore, continues to account for the original lease according to Accounting Standard Codification (“ASC”) Topic 842, “Leases.” The Company records both fixed and variable payments received from the sublessee in its consolidated statements of operations and comprehensive loss on a straight-line basis as an offset to rent expense. Such payments received in the years ended December 31, 2023 and 2022 were $0.6 million and $0.3 million, respectively. The Company also received a $50,000 deposit, recorded as a noncurrent liability in the consolidated balance sheet at December 31, 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes quantitative information about the Company’s operating leases (dollars in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended</div></div></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease expense</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other information</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,270</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,048</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease liabilities</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term—operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate—operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, future minimum payments during the next three years are as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:87%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,320</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2026</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,720</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less present value discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(218</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,502</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> P5Y 2021-01-01 1200000 2500000 2200000 P18M 50000000 600000 300000 50000000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes quantitative information about the Company’s operating leases (dollars in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended</div></div></td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease expense</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,196</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other information</div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,270</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,048</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease liabilities</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term—operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate—operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> 1196000 1196000 0 0 1196000 1196000 1270000 1048000 0 0 P2Y P2Y10M24D 0.08 0.08 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, future minimum payments during the next three years are as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:87%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,320</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ended December 31, 2026</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,720</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less present value discount</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(218</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,502</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 1320000 1372000 28000 2720000 218000 2502000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stockholders’ Equity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s Certificate of Incorporation authorizes the issuance of 120,000,000 shares of common stock, $0.0001 par value per share and 30,000,000 shares of undesignated preferred stock, $0.0001 par value per share. As of December 31, 2023 and 2022, there were 21,407,510 shares and 21,242,884 shares of common stock outstanding, respectively, and no shares of preferred stock outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2021, 275,000 private warrants were exercised for approximately $3.2 million. No private warrants were exercised during the years ended December 31, 2023 and December 31, 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December 31, 2023 and 2022, 161,668 shares and 183,366 shares, respectively, were issued pursuant to the Company’s Employee Stock Purchase Program (“ESPP”) (see Note 11) for approximately $112,000 and $278,000 in proceeds, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Shares </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between July and August 2019, Legacy Vincera Pharma issued 471,850 shares (826,510 shares prior to the effects of the Merger) of restricted stock at par value to certain management persons. All amounts owed for the issuance of these restricted shares were settled in cash in July 2020. The grant date fair value of this restricted stock was approximately $6,000. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2020, Legacy Vincera Pharma issued an additional 173,552 shares (304,000 shares prior to the effects of the Merger) of restricted stock at a fair value of $0.07 per share in exchange for services. Pursuant to these restricted share agreements, the term vesting represents the expiration of the Company’s repurchase right for the underlying shares. As of December 31, 2023, there was approximately $1,600 of unrecognized stock-based compensation related to restricted stock that will be amortized in 0.4 years.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock activity for the years ended December 31, 2023 and 2022 is presented below:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:57%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/> Grant Date Fair<br/> Value per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at January 1, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">182,686</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.045</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115,684</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at December 31, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67,002</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.065</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48,940</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at December 31, 2023</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,062</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.103</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, there were 3,295,000 private warrants to purchase common stock outstanding. After the redemption described above, no public warrants remained outstanding at December 31, 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private warrants are identical to the previously outstanding public warrants except that (i) each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share and (ii) such private warrants will be exercisable for cash (even if a registration statement covering the shares of common stock issuable upon exercise of such private warrants is not effective) or on a cashless basis, at the holder’s option (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to remove the cashless exercise provision), and will not be redeemable by the Company (except with respect to 500,000 of the private warrants held by Rosedale Park, LLC and 500,000 of the private warrants held by LifeSci Holdings LLC, which were amended to include a redemption provision substantially identical to that of the public warrants; provided, however, that such redemption rights may not be exercised during the first 12 months following the closing of the Business Combination unless the last sales price of the Company’s common stock has been equal to or greater than $20.00 per share for any 20 trading days within a 30 trading day period ending on the third business day prior to the date on which notice of redemption is given), in each case so long as they are still held by the initial purchasers or their affiliates. The private warrants purchased by Rosedale Park, LLC, will expire on March 5, 2025, provided that once the private warrants are not beneficially owned by Chardan Capital Markets, LLC or any of its related persons anymore, the private warrants may not be exercised five years following the completion of the Business Combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The previously outstanding public warrants and the private warrants issued to LifeSci Holdings LLC that were amended as described above were determined to be equity classified in accordance with ASC 815, Derivatives and Hedging. The remaining private warrants were determined to be liability classified in accordance with ASC 815, Derivatives and Hedging (see Note 6). </div> 120000000 0.0001 30000000 0.0001 0.0001 21407510 21242884 0 0 275000 3200000 0 0 161668 183366 112000 278000 471850 826510 6000 173552 304000 0.07 1600 P0Y4M24D <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock activity for the years ended December 31, 2023 and 2022 is presented below:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:57%"></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/> Grant Date Fair<br/> Value per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at January 1, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">182,686</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.045</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(115,684</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at December 31, 2022</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67,002</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.065</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(48,940</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Nonvested at December 31, 2023</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,062</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.103</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 182686 0.045 115684 0 67002 0.065 48940 0 18062 0.103 3295000 0 each private warrant is exercisable for one share of common stock at an exercise price of $11.50 11.5 500000 500000 500000 500000 20 P20D P30D 2025-03-05 P5Y <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Stock-Based Compensation </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Incentive Plans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the stockholders approved the 2020 Plan, which became effective upon the closing of the Business Combination on December 23, 2020. As of December 31, 2023, the Company had 5,600,152 shares of common stock reserved for issuance under the 2020 Plan. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Plan allows for the grant of stock options and rights to acquire restricted stock to employees, directors and consultants of the Company. The terms and conditions of specific awards are set at the discretion of the Company’s board of directors. Options granted under the 2020 Plan expire no later than 10 years from the date of grant. Unvested common shares obtained upon early exercise of options are subject to repurchase by the Company at the original issue price. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock option activity under the Plan is as follows (amounts in thousands, except per share amount): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/> Options</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,562</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.89</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.87</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(262</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,219</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options vested and exercisable at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is based on the grant-date fair value. The Company recognizes compensation expense for all stock-based awards on a straight-line basis over the requisite service period of the awards, which is generally the option vesting term of either <div style="-sec-ix-hidden:hidden107884290;display:inline;">two</div> or three years. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, the Company had stock-based compensation of approximately $0.7 million related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 0.6 years. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted average assumptions were used as inputs to the Black-Scholes option valuation model in determining the estimated grant-date fair value of the Company’s stock options granted during the years ended December 31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:77%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.90</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility (annual)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield (per share)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized in the accompanying consolidated statements of operations and comprehensive loss for stock option awards is as follows (amounts in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:76%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,712</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,988</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,851</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,621</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total stock-based compensation expense</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,563</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,056</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) became effective in May 2021 upon stockholder approval and is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. 200,000 of the Company’s authorized but unissued or reacquired shares of common stock have been reserved for issuance under the ESPP, plus an additional number of shares to be reserved annually on the first day of each fiscal year from January 1, 2022 through January 1, 2031, equal to the least of (i) one percent (1%) of the outstanding shares of the Company’s common stock on such date, (ii) 500,000 shares, or (iii) a lesser amount determined by the compensation committee or the Company’s board. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP consists of a series of offerings of purchase rights to eligible employees, each with a duration of not more than 12 months and purchase dates every six months. The purchase price cannot, under the terms of the ESPP, be less than 85% of the fair market value per share of the Company’s common stock on either the offering date or on the purchase date, whichever is less. If the fair market value of a share of the Company’s common stock on any purchase date within a particular offering period is less than or equal to the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, 241,484 shares of common stock were reserved for future issuance under the ESPP. Shares issued under the ESPP were 161,668 and 183,366 shares for the years ended December 31, 2023 and 2022, respectively. The Company recorded approximately $133,000 and $278,000 of stock-based compensation expense for the years ended December 31, 2023 and 2022, respectively, related to the ESPP. </div> 5600152 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock option activity under the Plan is as follows (amounts in thousands, except per share amount): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr> <td style="width:58%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/> Options</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,509</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,562</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.89</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.87</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.22</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options cancelled</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(262</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,219</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.1</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options vested and exercisable at December 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.25</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 3408 18.74 P10Y 2509000 3.3 2000 0.82 1562000 15.89 4353 10.87 P8Y7M6D 1131000 1.22 3000 0.82 262000 11.74 5219 8.74 P8Y1M6D 134000 3628000 11.25 P7Y9M18D 73000 P3Y 700000 P0Y7M6D <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted average assumptions were used as inputs to the Black-Scholes option valuation model in determining the estimated grant-date fair value of the Company’s stock options granted during the years ended December 31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:77%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.90</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility (annual)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield (per share)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> 0.9 3.3 P5Y7M6D P5Y9M18D 0.895 0.851 0.04 0.028 0 0 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized in the accompanying consolidated statements of operations and comprehensive loss for stock option awards is as follows (amounts in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:76%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,712</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,988</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,851</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,621</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total stock-based compensation expense</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,563</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,056</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 1712000 4988000 1851000 4621000 0 447000 3563000 10056000 200000 0.01 500000 0.15 0.85 241484 161668 183366 133000 278000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Net Loss per Share Applicable to Common Stockholders </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of loss per share for the years ended December 31, 2023 and 2022, respectively (amounts in thousands, except per share number): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Numerator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Denominator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding, basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share, basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.89</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3.00</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,219</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,532</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,715</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of loss per share for the years ended December 31, 2023 and 2022, respectively (amounts in thousands, except per share number): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Numerator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Denominator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding, basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,029</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share, basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.89</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3.00</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> -40157000 -62984000 21295 21295 21029 21029 -1.89 -1.89 -3 -3 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the potential common stock outstanding that was excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:78%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the years ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,219</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,295</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,532</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,715</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 5219000 4353000 3295000 3295000 18000 67000 8532000 7715000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no provision for income taxes for the years ended December 31, 2023 and 2022. The Company has no current tax expense from losses and no deferred expense from the valuation allowance. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,281</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,708</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,876</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,276</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"> <tr> <td style="width: 77%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/>December 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal tax benefit</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.7</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.1</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23.6</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22.9</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income taxes provision (benefit)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company’s net deferred tax assets as of December 31, 2023 and 2022, are as follows (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,475</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,198</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,734</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credit</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,231</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,635</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accruals and reserves</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,004</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowances</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,748</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,360</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowances</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(526</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(644</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(526</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(644</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred taxes</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The Company’s valuation allowance increased by $9.4 million and $12.9 million for the years ended December 31, 2023 and 2022, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the U.S. must be amortized over a five-year period and over a fifteen-year period if incurred outside the U.S. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $59.2 million and $0.7 million, respectively. The federal net operating loss carryforwards can be carried forward indefinitely, with certain limitations. A portion of the state net operating loss carryforwards will expire beginning in 2039, if not utilized. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2023, the Company also has Federal and California research and development credits of $2.6 million and $1.1 million, respectively. The federal tax credit carryforwards will expire beginning in 2039, if not utilized. The state tax credit carryforwards do not expire. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity related to the Company’s gross unrecognized tax benefits (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:88%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2021</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">518</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to prior year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to current year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2022</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">979</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to prior year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to current year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2023</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,238</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits, if recognized, would not have an impact on the Company’s effective tax rate due to the valuation allowance. The Company does not expect a significant change to its unrecognized tax benefits over the next twelve months. The Company files income tax returns in the United States, California and Germany jurisdictions and is not currently under examination by federal, state or local taxing authorities for any open tax years. The tax years 2019 through 2023 remain open to examination by the major taxing authorities. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. The Company records interest related to uncertain tax positions as interest, and any penalties are recorded as income tax expense in its consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Utilization of net operating losses and tax credit carryforwards may be limited by the “ownership change” rules, as defined in Section 382 of the Internal Revenue Code (any such limitation, a “Section 382 limitation”). Similar rules may apply under state tax laws. The Company has not performed an analysis to determine whether an “ownership change” occurred from inception to December 31, 2023. If a change <div style="display:inline;">in</div> ownership were to have occurred, additional net operating loss and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> “Income Taxes”, prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company’s income tax return and also provides guidance on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-recognition,</div> classification, interest and penalties, accounting in interim periods, disclosure, and transition.</div> 0 0 0 0 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/> December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,281</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58,708</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,876</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,276</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,157</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(62,984</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> -35281000 -58708000 -4876000 -4276000 -40157000 -62984000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"> <tr> <td style="width: 77%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/>December 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2023 </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal tax benefit</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.7</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.5</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.1</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23.6</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22.9</td> <td style="white-space:nowrap;vertical-align:bottom">%) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income taxes provision (benefit)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> 0.21 0.21 0.001 0.007 0 0.02 0.02 -0.007 0.005 -0.001 -0.236 -0.229 0 0 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company’s net deferred tax assets as of December 31, 2023 and 2022, are as follows (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr> <td style="width:72%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,475</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,235</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,198</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,734</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,314</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credit</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,231</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,635</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accruals and reserves</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,274</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,004</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowances</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,748</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,360</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowances</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">644</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(526</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(644</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred income tax liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(526</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(644</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred taxes</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 15475000 9639000 5235000 5025000 0 4198000 14734000 7314000 2231000 1635000 137000 471000 462000 722000 38274000 29004000 37748000 28360000 526000 644000 526000 644000 526000 644000 0 0 9400000 12900000 59200000 700000 P2039D 2600000 1100000 P2039D <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity related to the Company’s gross unrecognized tax benefits (amounts in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr> <td style="width:88%"></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2021</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">518</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to prior year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to current year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2022</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">979</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to prior year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase/decrease due to current year positions</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2023</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,238</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 518000 -164000 625000 979000 0 259000 1238000 2019 2023 false false false false

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ţ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end GRAPHIC 24 g739497g74z96.jpg GRAPHIC begin 644 g739497g74z96.jpg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end GRAPHIC 25 g739497g78d87.jpg GRAPHIC begin 644 g739497g78d87.jpg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